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DepartmentName, Degree
ABU-HASABALLAH, KHAMIS, PHD Psychiatry
ADAMS, NANCY, MD Medicine/Nephrology
AFFLECK, GLENN, PHD Community Medicine
ALBERT, DAVID, PHD Psychiatry
ALBERTSEN, PETER, MD Surgery
ALESSI, SHEILA, PHD Psychiatry
ALLEN, HOLLY, MD BAYSTATE MEDICAL CENTER: 
MA, USA
PEDIATRIC ENDOCRINOLOGY
ARIAS, ALBERT, MD Psychiatry
ARMELI, STEPHEN, PHD PACE UNIVERSITY: NY, USA
ARNOLD, ANDREW, MD Medicine
ASTUR, ROBERT, PHD HARTFORD HOSPITAL: CT, USAOLIN CENTER
AZIZ, KHALID, MD Medicine
BABOR, THOMAS, PHD Community Medicine
BAUER, LANCE, PHD Psychiatry
BENMAMOUN, CHOUKRI, MD Microbial Pathology
BONA, ROBERT, MD Medicine/Hem-Onc
BONKOVSKY, HERBERT, MD Medicine/Gasteroenterology
BOXER, REBECCA, MD Medicine/Geriatrics
BRUNO, RICHARD, PHD,RD UCONN STORRS: CT, USANUTRITIONAL SCIENCES
BURKI, NAUSHERWAN K, MD Medicine/Pulmonary Medicin
BURLESON, JOSEPH, PHD Behavioral Sciences
CABRAL, CYNTHIA, BS Dental-Students
CALHOUN, VINCE, MD YALE UNIVERSITY: CT, USAPSYCHIATRY
CAMPBELL, WINSTON, MD Obstetrics/Gynecology
CAPRIGLIONE, ANTOINETTE, MD NEW BRITAIN GENERAL 
HOSPITAL: CT, USA
OB/GYN
CARROLL, CHRISTOPHER, MD CONNECTICUT CHILDREN'S 
MEDICAL: CT, USA
PEDIATRICS
CARROLL, KATHLEEN, PHD YALE UNIVERSITY: CT, USAPSYCHIATRY
CHAKRABORTY, NITYA G, PHD Medicine
CHERNIACK, MARTIN, MD Occupational/Environmental
CILLESSEN, ANTONIUS, PHD UCONN, STORRS: CT, USAPSYCHOLOGY
CLARK, ROBERT, MD Immunology
CLOUTIER, MICHELLE, MD Pediatrics
COBB, RICHARD, MD Diagnostic Imaging
CONNER, TAMLIN, PHD Psychiatry
CONWAY, JUDITH, ARNP CANCER CENTER
COONEY, JUDITH, PHD YALE UNIVERSITY: CT, USAPSYCHIATRY
COONEY, NED, PHD YALE UNIVERSITY: CT, USAPSYCHIATRY
COVAULT, JONATHAN, MD,PHD Psychiatry
CRANFORD, JAMES, PHD UNIVERSITY OF MICHIGAN: MI, 
USA
SUBSTANCE ABUSE RESEARCH
DAMATO, KATHRYN L, MS Oral Diagnosis
DANNENBERG, ANDREW J, MD CORNELL UNIVERSITY: NY, USAGASTROENTEROLOGY/HEPATOLOG
DAVENPORT, MARSHA, MD UNIVERSITY OF NORTH 
CAROLINA: NC, USA
PEDIATRICS
DECKERS, PETER, MD Surgery
DEHART, TRACY, PHD LOYOLA: IL, USAPSYCHOLOGY
DEMARTINIS, NICHOLAS, MD Psychiatry
DIECKHAUS, KEVIN, MD Medicine/Infectious Diseas
DIPASQUALE, CHRIS, PHD UCONN - STORRS: CT, USAKINESIOLOGY
DONGARI-BAGTZOGLOU, ANNA, 
DDS,PHD
Periodontology
DORSKY, DAVID, MD Infectious Disease
PERSONNEL ROSTER
*Current CAP, -Previous CAP, + Minority
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DOUGLAS, KARA R, BS GCRC
DOWSETT, ROBERT J, MD Radiation Oncology
DRAZINIC, CAROLYN, MD Psychiatry
DUCK, KIM, PHD Surgery
DUFFY, VALERIE, PHD UCONN, STORRS: CT, USAALLIED HEALTH SCIENCES
ELSHEICKA, HANY, MD Center for Microbial Patho
ESAYAG-TENDLER, BEATRICE, MD Medicine
ESTRADA, ELIZABETH, MD CONNECTICUT CHILDREN'S 
MEDICAL: CT, USA
PEDIATRICS
FANG, MIN, MD,PHD Genetics & Dev. Biology
FEDER, HENRY, MD Medicine/Family Medicine
FEINN, RICHARD, PHD Psychiatry
FISHER, JEFFREY D, PHD UCONN - STORRS: CT, USAPSYCHOLOGY
FORD, JULIAN, PHD Psychiatry
FORMAKER, BRADLEY, PHD Oral Health & Diagnostics
FORTINSKY, RICHARD, BA Center on Aging
FRANK, MARION, DMD Oral Diagnosis
FREILICH, MARTIN A, DDS Prosthodontics
FRESTON, JAMES, MD Medicine
FRIEDLAND, GERALD, MD YALE UNIVERSITY: CT, USAPSYCHIATRY
GELERNTER, JOEL, MD YALE UNIVERSITY: CT, USAPSYCHIATRY
GOLDBERG, JON, PHD Biomaterials
GRAVELEY, BRENTON, PHD Genetics and Developmental
GREENSTEIN, ROBERT, MD Pediatrics/Genetics
GRILLE, MICHAEL, BS GCRC
GUNTHERT, KATHLEEN, PHD AMERICAN UNIVERSITY: DC, USAPSYCHOLOGY
GUTMAN, CHARLES, MD BRIGHAM & WOMENS HOSPITAL: 
MA, USA
CNTR FOR NEUROLOGICAL IMG
HAGER, DAVID, MD Medicine/Cardio-Pulmonary
HEGDE, UPENDRA, MD Medicine
HERMAN, AREY, BA Psychiatry
HERNANDEZ-AVILA, CARLOS, MD Psychiatry
HESSELBROCK, VICTOR, PHD Psychiatry
HETTINGER, THOMAS, PHD Oral Health & Diagnostic
HULL, DAVID, MD HARTFORD HOSPITAL: CT, USASURGERY
HUSSAIN, NAVEED, MD Pediatrics
IOANNIDOU, EFFIE, DDS Periodontology
ISOGNA, KARL, MD YALE UNIVERSITY: CT, USAINTERNAL MEDICINE
JOSEPH, CHERIAN, MD Medicine/Geriatrics
KADDEN, RONALD M, PHD Psychiatry
KAMINER, YIFRAH, PHD Psychiatry
KAPLAN, RICHARD, PHD Psychiatry
KAPTUCH, JUSTIN, BS GCRC
KELLY, JOHN R, DDS,DSC Oral Rehab, Biomaterials
KENNY, ANNE, MD Center on Aging
KERSTETTER, JANE, PHD UCONN - STORRS: CT, USANUTRITION
KING, ANDREA, PHD UNIVERSITY OF CHICAGO: IL, 
USA
DEPT OF PSYCHIATRY
KINGSBURY, JEFFREY, DDS,MD Oral & Maxillofacial Surge
KNOX, ISABELLA, MD Pediatrics
KOZLAK, SCOTT, BS GCRC
KRANZLER, HENRY, MD Psychiatry
KRAUSE, PETER, MD Pediatrics
KREUTZER, DONALD L, PHD Pathology
KUCHEL, GEORGE, MD Center on Aging
KURTZMAN, SCOTT, MD Surgery
LALANDE, MARC, MD Genetics & Develop Biology
LALLA, RAJESH, BDS,PHD Oral Diagnosis
LAMBRECHT, RICHARD, PHD Pharmacology & Toxicology
LAMMI, KEEFE, PHD UCONN, STORRS: CT, USANUTRITION
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LEVINE, JOEL, MD Medicine
LEWIS, COURTLAND, MD Orthopedics
LI, ZIHAI, MD,PHD Ctr for Immunotherapy
LITT, MARK, PHD Behavioral Sci & Comm Hlth
LORENZO, JOSEPH, MD Medicine
MADEJ, OLGA, BA GCRC
MALCHOFF, CARL, MD,PHD Medicine/Endocrinology
MALCHOFF, DIANA, PHD Medicine
MANSOOR, GEORGE, MD Medicine/Hypertension
MARKS, LAWRENCE, PHD PIERCE FOUNDATION 
LABORATORY: CT, USA
GENERAL MEDICINE
MARTIN, ISHMAEL, MD Pulmonary
MAYER, BRUCE, PHD Genetics & Dev. Biology
MCELHANEY, JANET, MD Immunology
MEIERS, JONATHAN, DDS Prosthodonics
MENZOIAN, JAMES, MD CTR FOR CLIN CARE IMPROV
MEYER, JOHN, MD,PHD Occupational Medicine
MIRZA, FARYAL, MD Medicine
MOFFITT, KATHIE H, PHD Psychiatry
MOHLER, WILLIAM, PHD Genetics & Dev. Biology
MOYO, VICTOR, MD Medicine/Oncology
MUKHERJI, BIJAY, MD Medicine
NELLISSERY, MAGGIE, MD Psychiatry
NICHOLS, FRANK, PHD Oral Health & Diag Science
NICHOLS, GINGER, MS Human Genetics
O'CAMPO, PATRICIA, PHD U OF TORONTO, CANADAMATERNAL/CHILD HEALTH
ONCKEN, CHERYL, MD Medicine
ONYIUKE, HILARY, MD Neurosurgery
PACHTER, LEE, MD INSTITUTE OF LIVING: CT, USAPEDIATRICS
PANZER, VICTORIA, MD Neurology
PAPPAGALLO, MARIANN, MD Pediatrics
PARHAM, KOUROSH, MD Surgery
PEARLSON, GODFREY, MD INSTITUTE OF LIVING: CT, USAPSYCHIATRY
PENDRYS, DAVID, DDS,PHD Behavioral Sci & Comm Hlth
PETERSON, DOUGLAS, DMD,PHD Oral Diagnostics
PETRY, NANCY, PHD Psychiatry
PHULWANI, PRIYA, MD CONNECTICUT CHILDREN'S 
MEDICAL: CT, USA
MEDICINE/ENDOCRINOLOGY
PIERUCCI, AMIRA, PHD Psychiatry
PILBEAM, CAROL, MD,PHD Medicine
PRESTWOOD, KAREN, MD Medicine
PROTIVA, PETR, MD GASTEROENTEROLOGY
RADOLF, JUSTIN, MD Microbial Pathogenesis
RAISZ, LAWRENCE G, MD Medicine/Endocrinology
RAJAN, THIRUCHANDURAI V, MD,PHD Pathology
REICHENBERGER, ERNST, PHD Biostructure and Function
REYNOLDS, JENNIFER, MD Center for Microbial Patho
REZAIE, TAYEBEH, PHD Surgery
ROPER, NITIN, BS GCRC
ROSENKRANTZ, TED S, MD Pediatrics
ROSSON, ROBERT, MD Medicine
ROUNSAVILLE, BRUCE, MD YALE UNIVERSITY: CT, USAPSYCHIATRY
RUBIN, KAREN, MD CONNECTICT CHILDREN'S 
MEDICAL: CT, USA
PEDIATRICS
SALAZAR, JUAN, MD Pediatrics
SALERMO, EDWARD, MD Medicine/Pulmonary
SANDERS, MARILYN, MD Pediatrics
SARFARAZI, MANSOOR, PHD Surgery
SCHRAMM, CRAIG, MD Pediatric Pulmonary
SCOTT, DENISE, BS HOWARD UNIVERSITY: DC, USAGENETICS
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SECOR, ERIC, MD Immunology
SEIP, RICHARD, PHD HARTFORD HOSPITAL: CT, USAPREVENTIVE CARDIOLOGY
SHAFER, DAVID, DMD Behavioral Sci & Comm Hlth
SILVERMAN, DAVID I, MD Medicine
SMARADOTTIR, AGNES, MD Medicine/Hem-Onc
SMILOWITZ, HENRY, MD Diagnostic Imaging & Thera
SMITH, JOANNE, MD Medicine
SONIS, STEPHEN T, DMD,DMSC DANA FARBER CANCER 
INSTITUTE: MA, USA
ORAL & MAXILLOFACIAL SURGE
SPIRO, JEFFREY, MD Surgery
SPORN, JONATHAN, MD ST. FRANCIS HOSPITAL: CT, USACANCER CENTER
SQUIER, RACHEL, DSC,DMD Prosthodontics
STEINBERG, KAREN, PHD Psychiatry
STEVENS, MICHAEL, PHD HARTFORD HOSPITAL: CT, USAOLIN CENTER
STEVENS, RICHARD G, PHD Community Medicine
SULLIVAN, BRIDGET, MD UCONN - STORRS: CT, USAALLIED HEALTH SCIENCES
SULLIVAN, TAMI, PHD YALE UNIVERSITY: CT, USAFAMILY VIOLENCE RESEARCH A
SWEDE, HELEN, PHD Community Medicine
TANEV, KALOYAN, MD Psychiatry
TANNENBAUM, SUSAN, MD Medicine/Hem-Onc
TAXEL, PAMELA, MD Medicine
TAYLOR, ROBERT, MD HOWARD UNIVERSITY: DC, USAPHARMACOLOGY
TENNEN, HOWARD, PHD Community Medicine
THAPAR, MANISH, MD Internal Medicine
THOMPSON, PAUL, MD HARTFORD HOSPITAL: CT, USAPREVENTIVE CARDIOLOGY
THRALL, ROGER, PHD Medicine/Pulmonary
TROJIAN, THOMAS, MD ST. FRANCIS HOSPITAL: CT, USAMEDICINE/FAMILY MEDICINE
TURNER, GARY, MD NEW BRITAIN GENERAL 
HOSPITAL: CT, USA
OB/GYN
VIDWANS, ANIRUDDHA, MD Pediatrics
WAGNER, JULIE, PHD Behavioral Sci & Comm Hlth
WALSH, KEVIN, BA GCRC
WALSH, STEPHEN J, SCD Ctr for Biostatistics
WARFIELD, SIMON, PHD BRIGHAM & WOMEN'S 
HOSPITAL: MA, USA
RADIOLOGY
WARREN, NICHOLAS, PHD Occupational Medicine
WAYNIK, ILANA, MD Pediatrics
WEIGERT, JEAN, MD WOMEN'S IMAGING: CT, USARADIOLOGY
WEINER, SCOTT, MD NEW BRITAIN GENERAL 
HOSPITAL: CT, USA
OB/GYN
WHALEN, GILES F, MD Surgery
WHITAKER, CHARLES, MD Medicine/Neurology
WHITE, WILLIAM, MD Medicine/Hypertension
WIKEL, STEPHEN, PHD Microbial Pathogenesis
WILLIAMS, CARLA, PHD HOWARD UNIVERSITY: DC, USAMEDICINE
WINOKUR, ANDREW, MD Psychiatry
WOLFSON, LESLIE, MD Medicine/Neurology
YIGIT, SEVKET, MD CONNECTICUT CHILDREN'S 
MEDICAL: CT, USA
PEDIATRICS
ZAKKO, LIAM, BA GCRC
ZARFOS, KRISTEN, MD Surgery
ZUCKER, AARON, MD CONNECTICUT CHILDREN'S 
MEDICAL: CT, USA
PEDIATRICS
6/27/2008   9:32:04AM 5
REPORT PD:  04/01/2007-03/31/20085M01RR006192-14 Final
0051 51PROTOCOL:SPID: RESEARCHTYPE:  
COGASHORT TITLE:
LONG TITLE: Collaborative Study on the Genetics of Alcoholism
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 21  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 9/1/1993
 3,175Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryHESSELBROCK, VICTOR PHD
PsychiatryBAUER, LANCE PHD
SUBPROJECT DESCRIPTION:
The primary goal of the Collaborative Study on the Genetics of Alcoholism (COGA) is the elucidation of the genes responsible 
for susceptibility to alcohol dependence. The COGA project, initiated in 1987, is a large scale family study of alcoholism being 
conducted at six sites nationwide. The initial clinical assessment has been completed on over 1800 probands and their biological 
relatives (total N= 12,800) and a five-year follow-up is underway.
SUBPROJECT PROGRESS:
This report covers the period from April 1, 2007 to March 31, 2008 for the Collaborative Study on the Genetics of Alcoholism 
(COGA) Participating Center at the University of Connecticut School of Medicine, Department of Psychiatry. This report covers 
the period of time devoted to completing activities related to data collection and phenotyping/data analyses.
Specific Aims for the current grant period include: 
• To identify additional susceptibility and protective genes for alcohol dependence and related phenotypes within regions that 
provides evidence for linkage. 
• To localize regions of linkage with newly generated, novel intermediate phenotypes related to behavioral impulsivity. 
• To test in a prospective study of adolescents and young adults whether a variety of genes, including genes currently identified 
(such as Gamma-Aminobutyric Acid A receptor Alpha 2 (GABRA2) and Alcohol Dehydrogenase (ADH)), contribute to the risk for 
alcohol dependence and related disorders and predict the onset of psychopathology in adolescents and young adults. 
• To develop multivariate phenotypes, based upon data collected across domains of data, for use in genetic analyses. 
• To examine new statistical methods for use in developing typologies of alcohol dependence. 
• To provide cross-sectional and longitudinal characterization of probands and family members in relation to different phenotypes, 
including an examination of the stability of diagnoses and phenotype stability over time. 
Data Collection and Phenotyping Studies / Results
Personnel - Some staff changes have occurred over the past year. Phlebotomy services continued to be provided by Ms. Pam 
Ferzacca, who also performs the necessary laboratory/sample preparation work. Backup assistance, when necessary, continues to be 
provided by staff from the General Clinical Research Center (GCRC) of the School of Medicine. 
Ms. Carmel Bourgoin provides secretarial support to the project and Ms. Shirley Crall continued as the study's administrative 
assistant. Data entry and data management duties over the past year remain the responsibility of the research technician's 
[Kathryn Hayden, James Plouffe, and Jesse Wagner]. During the past year, Ms. Kathryn Hayden and Jesse Wagner served as the 
UConn site's interviewers. Ms. Cheryl McCarter was also available on an 'as needed' basis. 
Each person is fully trained on the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA-II), C-SSAGAs, and 
SUBPROJECT DESCRIPTIONS
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neuropsychological testing protocols. Ms Hayden and McCarter served as the primary SSAGA/C-SSAGA editors. 
James Plouffe served as the site's ERP technician and will continue in that capacity. Jesse Wagner, who was hired during this grant 
year, will also serve as a backup Enterprise Resource Planning (ERP) technician. 
Dr. Lance Bauer continues as the investigator responsible for the electrophysiological portion of the study protocol. 
Dr. Victor Hesselbrock continues as the site principal investigator. 
Michie Hesselbrock, Ph.D. continues on the project part-time to assist with data analyses and other COGA related activities at the 
UConn COGA site. She is knowledgeable regarding multivariate analyses and assists with the development of conceptual and 
statistical phenotypes described in the renewal application. 
Dr. M. Hesselbrock recently retired as a Professor at the University of Connecticut School of Social Work. Christine Ohannessian, 
Ph.D. is an associate professor in the Department of Human Development, University of Delaware will continue to assist with the 
data analysis of the child and adolescent data sets. Her particular interests are in peer relations and family relations as mediators 
and moderators of the susceptibility for developing alcoholism among offspring at high risk for alcohol use disorders. She will focus 
on developing structural equation models (SEM) of 'risk' as proposed in the renewal application. 
Dr. Ohannessian currently is supported by a NIAAA-funded K01 career development award that began Sept 1, 2005; part of her 
activities involves SEM analyses of the COGA adolescent data sets.
The scope of work proposed for FY19 was completed. During the past year, the UCONN site devoted much of its efforts to 
recruitment of 13-22 year old subjects from previously assessed families for a baseline assessment as proposed in the new grant. As 
in the past, productivity from the UCONN site has been very good; with 365 subjects having completed the new assessment 
battery. Data entry still lags somewhat, given the project was one FTE short staffed fro much of the year; that vacancy was filled 
by Jesse Wagner.  We will catch up with the recruitment of subjects now that Mr Wagner is fully trained.
As of May 11, 2007, across all three previous waves of data collection, the UConn site had conducted 3078 adult SSAGA wave I-III 
interviews, 742 child and adolescent interviews, 1723 DNAs, 1515 cell lines, and 1481 ERPs representing 245 families. This 
sample includes 46.3% males and 53.7% females; 67.92% are Caucasian (no Hispanic), 26.95% are African-American, 3.2% are 
Hispanic, and 0.5%% belong to other ethnic groups, rates similar to the population prevalence rates of the greater Hartford 
metropolitan area. UConn has contributed 964 biochemistries, 569 neuropsychological test batteries, and 1513 personality tests to 
the Masterfile (#153). Data entry with respect to the SSAGA, C-SSAGA, and FHAM for waves I-III is now complete. 
 Study Findings/Novel Clinical Phenotypes - Specific Aims of the Novel Phenotype component include: 1). To identify and test 
both conceptual and multivariate phenotypes of alcohol dependence susceptibility among all available offspring (12-25 year olds) 
in the COGA sample and at regular two year follow-up intervals thereafter. 2). To test and develop models of "Risk" for 
susceptibility to heavier drinking and alcohol-related problems including alcohol dependence among 12-22 year old COGA subjects. 
3.) To provide a cross-sectional and longitudinal phenotypic characterization of alcohol dependence among adult probands and 
their adult biological family members using the clinical assessment and neurophysiologic data to examine factors related to the 
onset and maintenance of drinking, recovery from alcohol dependence, and other aspects of the course of illness. During the 
current year, our efforts have continued to focus on phenotype development in both the adult and in the child/adolescent data sets. 
The analysis of clinical phenotypes of African - Americans in the sample has continued in collaboration with Drs. Denise Scott, 
Robert Taylor and colleagues at Howard University School of Medicine. It is well known that patterns of alcohol use, abuse and 
dependence are often found to vary widely among ethnic groups. Using information from samples obtained at Howard University, 
the sequence and progression of alcohol related life events were investigated in this sample of African Americans and compared 
with findings from the predominantly caucasian COGA sample. The sequence and mean age of appearance of alcohol-related life 
events were similar for this sample of 224 African-American men and women. Arguments while drinking was the first alcohol 
related event to emerge at about 20 years of age. Using alcohol in larger amounts than intended developed next, followed by 
interference with functioning in multiple life areas such as problems with work or school. The onset of alcohol dependence 
occurred about 26 years of age, and persistent or recurrent physical or psychological problems emerged around age 27 years. The 
first initiation of seeking help from a health professional occurred at about 31 years of age. While there were similarities in the 
progression of alcohol related life problems between the African American and the Caucasian samples, the frequency of symptom 
endorsement for most problems was significantly higher in the Caucasian sample. Work has also continued to examine several 
possible intermediate outcomes related to the development of alcohol dependence in both the COGA adult and adolescent samples. 
Recent literature has suggested that age of initiation of alcohol use, intoxication and binge drinking may be important predictors of 
alcohol use problems in adolescence and young adulthood. Adult Binge Drinking and Alcohol Dependence - In the adult SSAGA, 
there is not a question that directly corresponds to the current definition of "binge drinking", ie 5 or more drinks per occasion etc. 
Since the SSAGA was initially developed in 1989, it contains the older definition of binge drinking - the question reads "Have you 
ever gone on binges or bender when you kept on drinking for 2 days or more without sobering up except for sleeping?". It is not 
the same as asking 'have you ever had 5+ drinks in a 24 hr period'. When this SSAGA question is used from the wave II data set, we 
find that N=1039 persons with a lifetime DSM-IV diagnosis of alcohol dependence answered this question positively. For 56% of 
this N=1039, binge drinking first occurred about the same time or after the onset of DSM-IV alcohol dependence For the 44% 
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(n=457) whose binge drinking preceded the onset of alcohol dependence, 303 (66%) had an onset of alcohol dependence within 5 
years of first binging and 23% had an onset of alcohol dependence within 10 years of onset of binging. Adolescent Alcohol Use, 
including Binging - About 65% (736/1130) of the COGA teens in wave II have tried alcohol (including a sip), with a wide range of 
ages for this first experience, ranging from 1 - 17 years old. The modal age of first use is 13, with the median of 12-13 years old. 
Only 42.5% of the sample (480/1130) have ever had a whole standard drink of alcohol. In the wave II adolescent sample, the 
C-SSAGA-A did not have a question that specifically asks 'have you ever consumed 5+ drinks in one occasion, etc." Instead we 
asked several different questions about what is the largest number of drinks consumed at one time for each grade in school 
beginning in the sixth grade and going through the 12th grade. The C-SSAGA-A also asked how often this maximum amount was 
consumed during that year in school. The C-SSAGA-A also asked the adult SSAGA MAX drinks question, a question about how 
many times that the person had at least 3+ drinks in a 24 hr period and the age at which this first occurred. Since COGA was 
surveying adolescents as young as 12, setting the bar at 3+ drinks per occasion seemed appropriate. Only 5 twelve year old subjects 
reported having ever consumed 5+ drinks in a 24 hr period at any time in their life and only 1 reported doing this more than once. 
The largest number of drinks ever consumed in a 24 hour period and the lifetime frequency of occurrence of this maximum 
consumption was examined by age. Only 7/278 (2.5%) thirteen year olds reported ever having consumed 5+ drinks in a 24 hr 
period; of this number, 3 consumed this amount only 1-2 times in their lifetime. Only 17/221 (7.7%) fourteen year olds reported 
having ever consumed drinking 5+ in a 24hr period. Of this number 11 did so on only 1-2 occasions. At age 15, 60/238 (25%) 
subjects reported a history of consuming 5+ drinks in a 24 hr period. Of this number, only 11 reported doing so on 1-2 occasions. 
At age 16, 74/224 (33%) subjects reported a history of consuming 5+ drinks in a 24 hr period. Only 12 reported doing so on one or 
more occasions. At age 17, 111/219 (51%) subjects reported drinking 5+ drinks in a 24 hr period. Only 7 reported doing so on 1-2 
occasions. Thus, the data seem to show that the number of teens binge drinking (5+ drinks in 24 hr period) increases with age 
across the adolescent years along with the frequency of occasions of binge drinking. An initial analysis indicates that the best 
predictors of 'binge drinking' are beginning regular alcohol use before age 13 and a history of conduct disorder or oppositional 
defiant disorder. Parental alcoholism [either one or both parents] does not add to the prediction. Adolescent Binging and Alcohol 
Dependence - Among the COGA adolescents aged 13-17 years old, alcohol dependence is rare. The prevalence of DSM-III-R 
alcohol dependence is 5.2% (N=59; 59/1130); DSM-IV alcohol dependence is even more rare with a prevalence rate of 2.5% (28; 
28/1130). For those 28 adolescents with a DSM-IV diagnosis of alcohol dependence, 18 (64%) experienced their first binge and the 
onset of alcohol dependence with one year or less of each other. For the remainder, the time between first binge and onset of 
alcohol dependence was either 2 yrs (7.1%), 3 yrs (10.7%, 4 years (7.1%) or 5 years (10.7%). 
Significance 
The present study provides a fertile database for the identification of clinical and genetic factors related to the risk and 
development of alcohol dependence. Both association and linkage studies continue to be performed. The influence of age at 
interview, gender, ethnic/socio-demographic factors, and clinical characteristics on the transmission of alcoholism continue to be 
examined in this large cross-national database, including an emphasis on externalizing behavior/disinhibition. Further, the database 
has shown itself to be an excellent resource for studying the development of alcohol-related problems among individuals at high 
genetic risk for alcohol dependence. A multiwave data set has been obtained on children (ages 7-12 yrs.) and adolescents (ages 
13-17 yrs.) at baseline and at five-year intervals. The data collected in waves I-III and the wave IV data to be collected will provide 
very fertile databases for the identification of personal, genetic, and environmental factors and their interaction related to the 
vulnerability for and development of alcohol dependence. The clinical assessment battery to be used in this next wave of data 
collection has been almost totally automated using CATI and electronic or web-based methods for data collection. The adolescent 
and young adult COGA subjects to be assessed in the new grant period have been identified and their assessment continues on 
schedule, with a good follow-up rate. The follow-up data will provide useful information on the characterization of the disorder 
over time, including studies of gene-gene interaction and gene - environment interplay. In the coming year, we will continue to 
examine the influence of certain psychosocial mediator/moderator variables that affect the initiation and maintenance alcohol use 
in the adolescent sample, with some emphasis on the role of peer and family relations on the initiation of drinking behavior among 
young adolescents. Genetic association and linkage studies will be performed, using the initial, follow-up, and combined databases. 
Phenotypes based upon standardized diagnostic systems and novel phenotypes developed from information taken from all aspects 
of the clinical assessment battery are being used in the search for alcohol dependence susceptibility genes.
Plans for 2008-2009 
Personnel - The UConn site anticipates no vacancies in staffing and no personnel changes are anticipated for the coming year. 
Subject recruitment - The UConn site will actively pursue recruiting for the wave IV assessment period. During the current year, 
UCONN staff has been aggressively locating subjects from the current UCONN sample for this wave of data collection, and many 
subjects have been scheduled for testing. These efforts are likely to leave the UCONN site on schedule to meet its revised 
recruitment goals. 
Phenotyping analyses - In the coming year, an emphasis will continue to be placed on the examination of certain psychosocial 
mediator/moderator variables that affect alcohol use in the adolescent sample, with some emphasis on the role of psychological 
and environmental factors as predictors of the initiation of drinking behavior among young adolescents [with Drs. Ohannessian and 
M Hesselbrock]. In addition, genetic association and linkage studies will be performed [in conjunction with the COGA Genetic 
Analysis committee], using the initial, follow-up, and combined databases with a focus on both qualitative and quantitative 
externalizing behavior phenotypes. Our initial genetic findings in the adult sample will continue to be examined using more refined 
phenotypes associated with adolescent drinking behavior (versus alcohol diagnoses such as abuse or dependence).  We will also 
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continue our efforts in relation to examining gene-environment interplay. Specific genes of interest that may have etiological 
relevance include GABRA2, CHRM2 and the taste receptor gene, TAS16. The adult / parent sample has just undergone a genome 
wide association study (GWAS) through the NIH's Center for Inherited Diseases Research (CIDR).  In the coming year, as 
examination of these findings increase, there are likely to be more candidate genes and SNPs identified as possible susceptibility 
genes for alcohol dependence and related conditions that can be explored in the offspring sample described above now being 
examined prospectively.
Human Subjects - There have been no changes in the study protocol since last submission. No subjects have been withdrawn due to 
untoward consequences of participating in the COGA protocol. In order to comply with the new Health Insurance Portability and 
Accountablity Act (HIPAA) regulations, a  HIPPA Authorization form has been developed and put into place and the Informed 
Consent Form (ICF) modified accordingly. Both the HIPAA Authorization form and the ICF have been approved for use by the 
UConn Institutional Review Board (IRB), and all UCONN site staff and investigators have up-to-date IRB certifications.
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0060 60PROTOCOL:SPID: RESEARCHTYPE:  
Primary Cortisol ResistanceSHORT TITLE:
LONG TITLE: Primary Cortisol Resistance
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 2/27/1998
 50Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/EndocrinologyMALCHOFF, CARL MD, PHD
SUBPROJECT DESCRIPTION:
It is our general hypothesis that primary cortisol resistance is a treatable cause of sexual precocity, hypertension, and in women, 
hirsutism and menstrual irregularities.  There are two specific hypotheses of the studies proposed here.  First, we predict that 
selected clinical, biochemical, and ligand binding measurements are sensitive and specific markers for primary cortisol resistance.  
Second, we predict that the sexual precocity of primary cortisol resistance can be successfully and safely treated with 
dexamethasone.  Once we understand in detail the clinical and biochemical presentations of this disorder, then we will be able to 
efficiently screen larger potentially affected populations to determine the frequency of cortisol resistance and to identify 
potentially treatable individuals.
SUBPROJECT PROGRESS:
There is a total of 19 subjects enrolled since initiation of this study. For the current report period, no new subjects have been 
enrolled.
There are no proposed changes in recruitment plans at this time. In addition, there are no unexpected safety concerns concerns to 
report.  This study closed in the General Clinical Research Center (GCRC) on 09/06/2007.
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0231 231PROTOCOL:SPID: RESEARCHTYPE:  
Familial Papillary Thyroid CarcinomaSHORT TITLE:
LONG TITLE: Familial Papillary Thyroid Carcinoma
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 2/27/1998
 120Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/EndocrinologyMALCHOFF, CARL MD, PHD
MedicineARNOLD, ANDREW MD
MedicineESAYAG-TENDLER, BEATRICE MD
MedicineMALCHOFF, DIANA PHD
SurgerySARFARAZI, MANSOOR PHD
SurgeryWHALEN, GILES F MD
SUBPROJECT DESCRIPTION:
Identification of genes that cause human tumors provides important insight into the mechanisms of tumorogenesis.  Inherited 
malignancies provide an opportunity to identify these pathogenetic genes, since powerful positional cloning methodologies will 
identify the gene of interest.  Because there are relatively few multigeneration familial papillary thyroid carcinoma (fPTC) 
kindreds, genetic linkage methodologies with positional cloning have not yet been used to investigate fPTC.  The purpose of 
this proposal is to use linkage analysis as the first step in positional cloning of the fPTC susceptibility gene.
SUBPROJECT PROGRESS:
The long term goal is identification of the gene(s) causing familial papillary thyroid carcinoma.  We are currently sequencing gaps 
in the human genome project within the minimal region of the 1q21 containing the gene and sequencing candidate genes.  Large 
new families are being categorized as to linkage region.
In the last year we have added 14 new subjects for a total of 96 subjects in all.
No changes in recruitment, no unexpected safety concerns, no new interim data, no changes in protocol.
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0253 253PROTOCOL:SPID: RESEARCHTYPE:  
Smoking and Pregnancy - CAPSHORT TITLE:
LONG TITLE: Smoking and Pregnancy - CAP
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/26/1997
 100Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineONCKEN, CHERYL MD
Obstetrics/GynecologyCAMPBELL, WINSTON MD
PsychiatryKRANZLER, HENRY MD
SUBPROJECT DESCRIPTION:
The aim of this study is to evaluate the effects of maternal smoking on measures of fetal well-being and to determine whether 
smoking cessation with nicotine replacement can lessen these effects.
SUBPROJECT PROGRESS:
A paper of the final results of this study was submitted to Obstetrics and Gynecology this last year but rejected.  We are 
resubmitting the paper to Journal of Maternal-Fetal medicine within the next month.
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0268 268PROTOCOL:SPID: RESEARCHTYPE:  
Complication of Hemophilia and Serum Testing and StorageSHORT TITLE:
LONG TITLE: Universal Data and Serum Specimen Collection System for Hemophilia.
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  9  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 2/1/1999
 90Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/Hem-OncBONA, ROBERT MD
SUBPROJECT DESCRIPTION:
   The primary congenital bleeding disorders are hemophilia A and B, which affect approximately 1 in 5,000 males and von 
Willebrand's Disease which affects 1 in 100 men and women.  Several plasma proteins called factors are necessary for normal 
blood clotting.  Persons with hemophilia are either missing a particular factor in their blood that is essential to the clotting 
process or the protein is present but does not work.  Without this factor, bleeding into muscles, joints, and internal organs often 
occurs without any noticeable trauma.  The treatment of a bleeding episode involves the replacement of the missing protein 
through intravenous administration of factor concentrate which is derived from, or contains components of human blood.  The 
frequent bleeding and the necessary intravenous administration of blood products to control the bleeding are responsible for the 
two most severe complications of hemophilia: 1) development of chronic joint disease from repeated bleeding into major joints; 
and 2) infection with viral, blood-borne disease such as hepatitis and human immunodeficiency virus (HIV).
About three-fourths of all persons with hemophilia in the US receive some of their treatment from federally-sponsored, 
specialized hemophilia treatment centers (HTCs).  The Center for Disease Control and Prevention (CDC) provides support to 
these treatment centers for programs designed to prevent complications of hemophilia.
The Universal Data and Serum Specimen Collection System will extend CDC's collaboration with the HTCs by assisting with the 
analysis of a uniform set of clinical data which are used to monitor the extent of complications in congenital bleeding disorders 
in the US.  Specific measurements will be used to evaluate the degree of joint disease.  In addition, serum will be tested for the 
presence of blood borne pathogens.  The remainder of each serum specimen will be used by the CDC to establish a serum bank 
for possible future use in evaluating the safety of blood products.  Information from this system will be used to assess the safety 
of the blood supply and to develop and monitor the effectiveness of interventions designed to address the mandate from 
congress which is to reduce or prevent the complications of hemophilia.
SUBPROJECT PROGRESS:
Number of subjects enrolling during the report period and since initiation of the study: 
During the above report period, (1) one new study subject was enrolled as a participant, (2) one pediatric study patient had an 
annual follow-up visit and (3) 4 adult study subjects had an annual follow-up visit. For CCMC study participants: the General 
Clinical Research Center (GCRC) processes the blood specimens and sends out the specimens. For adult patients: GCRC will draw 
the blood specimens, process the specimens and send them to the study site laboratory. 
Study subjects are enrolled as participants or refusals. The study is being conducted at University of Connecticut Health Center 
(UCHC) and the Connecticut Children's Medical Center (CCMC). When the patients/subjects come in for a scheduled visits, they 
are invited to participate in the study. If a patient is already in the study, they are invited to continue to participate or refuse to 
participate in the study at their annual visit.
Any changes in recruitment plans that might be needed: None 
Unexpected safety concerns and their resolution: None 
Interim data and outcomes if appropriate: The study is ongoing. 
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Any proposed changes made or anticipated in the protocol. None at this time.
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0279 279PROTOCOL:SPID: RESEARCHTYPE:  
NSABP Treatment B21SHORT TITLE:
LONG TITLE: NSABP B21 Node Negative Clinical Occult Breast Cancer - Tamoxifen/Radiation
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/1/1989
 10Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
Patients eligible for this study must have had a lumpectomy with tumor-free specimen margins and axillary node dissection with 
pathologically-negative axillary nodes.  The largest tumor diameter, by pathological examination of the resected specimen, 
must be < 1 cm.  If the pathologic tumor size is indeterminable from the report, then the maximum clinical and mammographic 
tumor sizes must both be < 1 cm.  If a tumor pathologically consists of both an invasive component and an intraductal 
component, then the maximum diameter of both components when measured together must be < 1 cm.  Finally, patients are 
eligible if a carcinoma pathologically < 1 cm in size is detected in association with a benign lesion of any size.  Patients in this 
study will be randomly assigned to one of three groups:  lumpectomy and breast radiation plus placebo, lumpectomy and breast 
radiation plus tamoxifen, or lumpectomy, tamoxifen and no breast radiation.
SUBPROJECT PROGRESS:
This study was terminated here at the University of Connecticut Health Center on 06-20-2007. 
There were no changes to protocol, no safety concerns, no publications
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0282 282PROTOCOL:SPID: RESEARCHTYPE:  
NSABP BI-65 NSABP BI-65SHORT TITLE:
LONG TITLE: NSABP BI-65 Menstrual Cycle in Surgical Treatment of Breast Cancer
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 9/4/1998
 10Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
The purpose of this study is to evaluate whether the timing of breast cancer surgery during a woman's menstrual cycle affects 
her ultimate outcome- namely, the likelihood of recurrence or death.  While some reports have indicated that women operated 
on during certain times of their menstrual period are at higher risk of recurrence of breast cancer, most studies have not found 
any difference in results regardless of when breast cancer surgery is performed.  Thus, it remains standard procedure to perform 
breast cancer surgery as soon as a woman has been informed of her options and she is ready to proceed.
SUBPROJECT PROGRESS:
There is one subject on long term follow up for this study, one patient is deceased as of 04/03/2007. There have been no safety 
concerns, no publications, there have been no changes to the protocol. This study remains closed to accrual, there is no 
recruitment plan.
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0286 286PROTOCOL:SPID: RESEARCHTYPE:  
NSABP B-27SHORT TITLE:
LONG TITLE: NSABP B-27 A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin Cyclophosphamide) 
(AC) to Preoperative AC Followed by Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed 
by Postoperative Docetaxel in Patients with Operable
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/30/1996
 10Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
The primary aim of this study is to determine whether four cycles of preoperative or postoperative Taxotene given after for 
cycles of preoperative Adriamycin; (A) and cyclophosphamide (C) (AC) will more effectively prolong disease-free survival 
(DFS) and survival (S) than do four cycles of preoperative AC alone.  The study will also evaluate the effect of the 
administration of preoperative Taxotene after preoperative AC with respect to clinical and pathologic loco-regional tumor 
response and conservation.  Women with palpable, operable carcinoma of the breast diagnosed by age, clinical tumor size, and 
clinical nodal status, then randomized to one of three groups.  Group I will receive four cycles of preoperative A and C given at 
60 mg/m2 and 500 mg/m2, respectively, every 21 days followed by surgery (lumpectomy and exillary node dissection, or 
modified radical mastectomy).  Group II will receive four cycles of preoperative AC as in group I, followed by four cycles of 
preoperative Taxotere at 100 mg/m2 as a 1-hour infusion every 21 days followed by surgery.  Group III will receive four cycles 
as AC as in groups I and II, followed by surgery and by four cycles of postoperative Taxotere, as in group II.  Beginning on the 
first day of administration of their assigned chemotherapy, all three groups will receive tamoxifen at 20 mg p.o. once daily for 
5 years.  In all three groups, tumor measurements will be obtained after each cycle of preoperative chemotherapy.  Assessment 
of response will be performed after completion of all preoperative chemotherapy and before surgery.  For patients in group II, 
an additional assessment of response will be performed after completion of AC chemotherapy.  Patients in groups I and II who 
undergo lumpectomy will receive postoperative radiotherapy after their recovery from surgery.  Patients in group III who 
undergo lumpectomy will receive postoperative radiotherapy after their recovery from the fourth cycle of postoperative 
Taxotere.
SUBPROJECT PROGRESS:
3 patients are in long term follow-up and have no evidence of disease, no Adverse Events, no new primaries and begin seen 
annually for follow up.  4 patients have expired due to progression of disease. Please note that The Hospital of Central 
Connecticut is not under our Institutional Review Board umbrella for this study. There have been no unexpected safety concerns. 
There have been no publications that have cited the General Clinical Research Center.
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0290 290PROTOCOL:SPID: RESEARCHTYPE:  
NSABP P-2: STARSHORT TITLE:
LONG TITLE: NSABP P-2: Study of Tamoxifen and Raloxifene (STAR) for the prevention of breast cancer.
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  58  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 9/1/1999
 60Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase III-IV
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
CANCER CENTER ST. FRANCIS HOSPITAL, CT USASPORN, JONATHAN MD
SUBPROJECT DESCRIPTION:
In the P-1 study, tamoxifen was shown to prevent the development of invasive and in situ breast cancer.  Raloxifene has shown 
to be an effective drug for the prevention of osteoporosis.  It was observed in the Multiple Outcomes of Raloxifene Evaluation 
(MORE) trial that there were fewer breast cancers in the group of patients that had taken raloxifene compared to the controls.  
This study will determine if raloxifene is either more or less effective than tamoxifen in reducing the incidence of invasive 
breast cancer in postmenopausal women who are at increased risk for the disease.  A secondary goal is to determine whether 
raloxifene reduces the endometrial cancer rate compared to tamoxifen.
SUBPROJECT PROGRESS:
No new participants were enrolled this past year. study is closed to enrollment -58 women were randomized to STAR at the 
University of Connecticut Health Center (UCHC) 
-no changes in recruitment plan 
-no unexpected safety concerns 
-unblinded -amendment was passed to allow women to change from open label tamoxifen to open label raloxifene; 1 participant 
chose to crossover
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0292 292PROTOCOL:SPID: RESEARCHTYPE:  
Cutaneous Immune Response in Lyme Disease and Secondary SyphilisSHORT TITLE:
LONG TITLE: Cutaneous Immune Response in Lyme Disease and Secondary Syphilis
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 28  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/1/1999
 100Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Microbial PathogenesisRADOLF, JUSTIN MD
PediatricsSALAZAR, JUAN MD
SUBPROJECT DESCRIPTION:
Venereal syphilis is a chronic inflammatory disorder driven by the persistence of its etiologic agent Treponema pallidum. 
Though the immune/inflammatory response at sites of local treponemal infection may ultimately underlie the development of 
both protective immunity and clinical manifestations, these local cellular processes have yet to be characterized in humans using 
the tools of contemporary cellular and molecular immunology. The components of T. pallidum that induce these potentially 
deleterious inflammatory processes also remain poorly characterized. Our understanding of cellular immunity in syphilis is 
further compromised by our currently limited knowledge concerning the interactions between syphilis and human 
immunodeficiency virus (HIV) infection. Accordingly, the proposed research has three Specific Aims. In Specific Aim 1, we will 
perform immunocytochemical analysis of skin biopsies and flow cytometry analysis of leukocytes in suction blisters to 
characterize cutaneous cellular immune processes in HIV- and HIV+ patients with secondary syphilis. Data from these studies 
will be correlated with our in vitro research involving immune effector cell activation by T. pallidum and treponemal 
lipoproteins. In Specific Aim 2, we will use the same immunocytochemical and flow cytometric approaches to characterize the 
cutaneous inflammatory response to synthetic analogs (lipopeptides) of T. pallidum lipoproteins. These experiments are an 
outgrowth of our hypothesis that T. pallidum lipoproteins are major inflammatory mediators during syphilitic infection. 
Building upon our observation that T. pallidum lipoprotein analogs induce HIV gene expression in vitro, the experiments in 
Specific Aim 3 will elucidate the mechanisms which underlie this phenomenon.  A principal long-term objective of this research 
is to elucidate the immune/inflammatory events during syphilitic infection which engender both clinical manifestations and 
protective immunity. An equally important objective is to obtain cellular and molecular data which will complement our 
emerging understanding of the interactions between syphilis and HIV infection, including the potential for syphilis to serve as a 
co-factor for HIV transmission and for HIV infection to alter the clinical course of syphilis.
SUBPROJECT PROGRESS:
The number of subjects enrolled during the reporting period is 34. 
The number of subjects enrolled since the initiation of the study is 372. 
There have been no unexpected safety concerns during this reporting period
Specific Aim One.  To further characterize the innate immune responses elicited by treponemal lipoproteins in human skin 
(already completed and closed enrollment).  
Specific Aim Two. To further characterize the cutaneous immune response to T. pallidum in secondary syphilis lesions (already 
completed and published).  
Specific Aim Three.  To elucidate immune cell responses to T. pallidum and B. burgdorferi or its constituents (manuscript in 
preparation) 
Specific Aim Four.  To study how T. pallidum and B. burgdorferi or its constituents activate macrophages following uptake into 
phagosomal vacuoles (ongoing using blood samples from healthy volunteers).
Studies related to Specific Aim and Two are now completed and have been published.  Work on Specific Aim Two is also completed 
and has been accepted for publication.  Given our successes at the Cali site and the unanticipated wealth of new information 
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obtained from combined analysis of blood and skin blister fluids, Dr. Salazar has expanded the scope of this work and has obtained 
independent funding and Institutional Review Board (IRB) approval to continue his research activities in Cali.  Studies for Specific 
Aims Three and Four will continue at the University of Connecticut Health Center (UCHC) and will use the isolated peripheral 
blood mononuclear cells (PBMC) system to assess monocyte, T cell, and dendritic cell responses to live spirochetes and spirochetal 
components. to elucidate the mechanisms and signaling pathways elicited during uptake by macrophages of Borrelia burgdorferi and 
opsonized T. pallidum.
        No changes in the protocol are anticipated.
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0303 303PROTOCOL:SPID: RESEARCHTYPE:  
The effects of nicotine on bone turnover in older womenSHORT TITLE:
LONG TITLE: The effects of nicotine on bone turnover in older women
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/1/1999
 160Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineONCKEN, CHERYL MD
PSYCHIATRY YALE UNIVERSITY, CT USACOONEY, JUDITH PHD
MedicinePRESTWOOD, KAREN MD
Medicine/EndocrinologyRAISZ, LAWRENCE G MD
SUBPROJECT DESCRIPTION:
This study will enroll 150 subjects (smokers, postmenopausal women)to evaluate the effects of smoking cessation with either 
nicotine replacement or placebo on markers of bone resorption and formation.
SUBPROJECT PROGRESS:
 Two papers have been published off this data set.  We are analyzing the body composition data and hope to have another paper 
submitted this year.
6/27/2008   9:32:04AM 21
REPORT PD:  04/01/2007-03/31/20085M01RR006192-14 Final
0322 322PROTOCOL:SPID: RESEARCHTYPE:  
Circadian Blood Pressure ProfileSHORT TITLE:
LONG TITLE: The circadian blood pressure profile, its reproducibility and its relationship to sympathetic nervous system 
activity, circadian physical activity, sleep quality and novel markers of hypertensive organ damage.
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/1/2000
 150Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
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NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/HypertensionWHITE, WILLIAM MD
SUBPROJECT DESCRIPTION:
About 20-30% of essential hypertensive patients will have less than the normal (15-20% of awake blood pressure) decline in 
blood pressure during sleep. This higher than normal sleep blood pressure has been observed during ambulatory blood pressure 
monitoring and such patients have been termed "non-dippers" to distinguish them from patients with a normal sleep blood 
pressure decline, "dippers".  Patients with nondipping sleep blood pressure are continuously exposed to higher blood pressure 
levels. This persistent hypertension is likely to be injurious to the endothelium and other organs susceptible to the ill effects of 
hypertension. Indeed, preliminary studies indicate that nondipper hypertensives have more evidence of hypertensive organ 
damage. The present study will therefore examine some important issues regarding the criteria for dipper and nondipper 
categories of blood pressure, the reproducibility of such categorization and the effects of daytime and sleep activity on the 
decline of blood pressure during sleep. The study will also compare sympathetic nervous system activity, salt sensitivity, and 
insulin resistance measures in relation to the extent of sleep blood pressure reduction. Finally, endothelial function, retinal 
vascular structure and left ventricular mass will be compared in dippers and non-dippers.
The project will recruit 150 newly diagnosed and untreated hypertensive subjects to eliminate the effects of drug treatment on 
blood pressure profiles. After an initial 2-week period when the presence of hypertension will be confirmed by clinic blood 
pressure readings, patients will undergo 2 separate 24-hour ambulatory blood pressure and electronic activity monitoring sessions 
about 1-2 weeks apart. During these two periods, awake and sleep sympathetic nervous system activity will be evaluated using 
plasma and urinary catecholamines. Sleep quality will be measured using a questionnaire and actigraphy derived indices of sleep 
quality. During the next two weeks and while remaining untreated, all patients will undergo endothelial function studies (B-mode 
ultrasound), retinal vascular structure assessment (high-resolution retinal photography), and left ventricular mass estimation 
(echocardiography). In the latter two years of the project, salt sensitivity and its relation to dipper and nondipper blood 
pressure profiles will be studied. 
The reproducibility of the dipper and nondipper categorization will be examined in relation to the effects of sleep and daytime 
activity, sleep quality, and sympathetic nervous system activity. Direct comparisons between dipper and nondipper groups will 
be made in salt sensitivity, insulin resistance, and sympathetic nervous system activity. This study will provide information that 
will be important if clinical trials targeting nocturnal blood pressure are to be designed.
SUBPROJECT PROGRESS:
The study did not recruit any new patients during the reporting period, as recruitment was completed in June of '05. There have 
been no safety concerns. The study closed in the General Clinical Research Center (GCRC) on 06/05/2007.
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LONG TITLE: Dendritic Type Antigen Presenting Cell (APC) -Based Vaccine for Prostate Cancer
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MedicineCHAKRABORTY, NITYA G PHD
MedicineMUKHERJI, BIJAY MD
MedicineTAXEL, PAMELA MD
SUBPROJECT DESCRIPTION:
The overall goal of this study is to develop an effective form of active specific immunotherapy for prostate cancer based on the 
fundamental principles of T lymphocyte activation and molecular mechanism of antigen processing and presentation.  The 
project is based upon the hypothesis that antigen presenting cells (APC) grown from prostate cancer patients will be able to 
successfully present the prostate specific membrane antigen derived peptides to cytotoxic T lymphocyte (CTL) precursors to 
induce a specific CTL response in in vitro co-cultures.  The idea is to develop an in vitro model system consisting of prostate 
cancer patients who are human leukocyte antigen (HLA) A2+ and who have very high levels of serum prostate specific antigen 
(PSA).  The question is whether or not it is possible to induce a peptide specific CTL response in vitro, by presenting one of 
four PSA gene derived epitopes, exhibiting binding motif for HLA A2 molecules, on autologous APC.
SUBPROJECT PROGRESS:
It was not possible to enroll any subjects during the reporting period due to some questions raised by the Institutional Review Board 
(IRB) about our recruitment procedure. We have recently got the final approval from IRB, which is valid until May 15 2009. 
Although there are no safety concerns, the IRB needed some clarification of the protocol too. In between we were able to do 
cytokine enzyme linked immunosorbent assay (ELISA) with some frozen culture medium collected from a previous study's case 
samples. These will help us for our (near) future publication.
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SUBPROJECT DESCRIPTION:
Prior to the development of this new procedure, sentinel lymph node dissection (SLND), the only way to identify if the tumor 
had spread to the nodes in the armpit was to remove all the lymph nodes from the armpit.  Numerous studies have shown that 
removing all of the lymph nodes does not affect survival even though the cancer may come back under the arm.  It is possible 
that removal of the lymph nodes from the middle and lower areas of the armpit (Level I and II) is no better than removing just 
the sentinel lymph node(s).  In 1995, Giuliano et al. conducted a study comparing a SLND with immunohistochemistry (IHC) to 
routine axillary lymph node dissection (ALND).  SLND detected nodal metastases in 42% of all patients, and of these, 45% had 
micrometastases.  The main objectives of this study are: 1) to estimate the prevalence and to evaluate the prognostic 
significance of sentinel node micrometastases detected by IHC, 2) to estimate the prevalence and to evaluate the prognostic 
significance of bone marrow micrometastasis detected by immunocytochemistry (ICC) for the first 3600 women, 3) to evaluate 
the hazard rate for regional recurrence in women whose sentinel nodes are negative by hematoxylin and eosin (H&E) staining, 
and 4) to provide a mechanism for identifying women whose sentinel nodes contain metastases detected by H&E so that these 
women can be considered candidates for Study Z001.  Women with clinical T1 or T2 NO MO breast cancer will undergo 
breast-conserving therapy (BCT), bilateral iliac crest bone marrow aspirations, and sentinel lymph node dissection (SLND).  
When a sentinel node is not identified during the SLND, an ALND is performed.  Patients who have no sentinel lymph node 
metastasis by H&E will not have an ALND.  Patients with evidence of metastatic disease in the sentinel node may be eligible for 
registration and randomization to Study Z0011.
SUBPROJECT PROGRESS:
The 9 patients enrolled at the University of Connecticut Health Center (UCHC) are all alive and disease free.  They are in the long 
term follow-up. There have been no safety concerns, no unanticipated problems, no changes to protocol. 
This study is closed to accrual; there is no longer a recruitment plan. There are no unexpected safety concerns and no anticipated 
changes to the protocol. There have been no publications that have cited the General Clinical Research Center (GCRC).
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Behavioral Sci & Comm HlthPENDRYS, DAVID DDS, PHD
SUBPROJECT DESCRIPTION:
Prostheses placed over dental implants are generally made with a metal substructure supporting either a ceramic veneer or resin 
with artificial plastic teeth.  The use of fiber composite technology in the creation of a metal-free implant prosthesis may solve 
many of the problems associated with this metal alloy substructure such as corrosion, toxicity, complexity of fabrication, high 
cost and esthetic deficiencies.
Glass fiber-reinforced composites (FRCs) have been developed which have the potential to make an esthetic implant prosthesis 
substructure utilizing a simple, time-efficient technique.  Laboratory and clinical research evaluating FRC prostheses used to 
restore and replace teeth have shown that these materials exhibit excellent mechanical properties and can form a chemical bond 
to resin-based veneer materials.  Additionally, these FRC materials have the potential to be used to make a single visit, 
chairside-fabricated provisional tooth replacement bonded to an adjacent anterior tooth prior to implant loading.
SUBPROJECT PROGRESS:
No participants were enrolled for study A & B during the above time period.  There have been seven 2 year follow up visits and 
sixteen 3 year follow up visits for studies A & B.  
No participants have been enrolled or have had follow up visits for study C during the above time period.  
There have been no unexpected safety concerns and no changes made to the protocol.
There have been no publications during the above-mentioned time period.
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PsychiatryKRANZLER, HENRY MD
PSYCHIATRY YALE UNIVERSITY, CT USAGELERNTER, JOEL MD
PsychiatryHERNANDEZ-AVILA, CARLOS MD
PsychiatryHESSELBROCK, VICTOR PHD
PSYCHIATRY YALE UNIVERSITY, CT USAROUNSAVILLE, BRUCE MD
SUBPROJECT DESCRIPTION:
Cocaine dependence (CD) has been shown in twin and family studies to have a genetic contribution.  This is a multi-center study 
recruiting affected sibling pairs and other nuclear family members.  A genome scan will make it possible to identify regions 
containing genes that influence risk of CD.
SUBPROJECT PROGRESS:
We recruited 265 participants for this study between 4/1/07 and 3/31/08. We have recruited 940 total subjects in the study since its 
initiation. We continue to recruit probands and controls in addition to our previous recruitment of sibling pairs and family trios. 
A Certificate of Confidentiality was issued for the period 6/1/06 to 3/31/11  (Certificate No. DA-06-186 is on file with 
Institutional Review Board (IRB)).  We were previously covered under a certificate that was awarded to Yale University for the 
original study involving sibling pairs. A waiver/alteration of informed consent for phone screening phase only; phone script was 
changed to reflect change in payment from $75 to $100. 
Breath alcohol readings are now done to ensure that participants are able to give informed consent. Following an extensive trial 
period with Solutions in Surveys(SIS), the company we had hired to aid in our control recruitment, we decided to terminate our 
relationship with SIS. We have continued control recruitment on our own.
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PsychiatryKRANZLER, HENRY MD
PSYCHIATRY YALE UNIVERSITY, CT USAGELERNTER, JOEL MD
PsychiatryHESSELBROCK, VICTOR PHD
PSYCHIATRY YALE UNIVERSITY, CT USAROUNSAVILLE, BRUCE MD
SUBPROJECT DESCRIPTION:
Opioid dependence (OD) risk has been shown by both twin and family studies to have a genetic component.  This study is being 
conducted at UConn and Yale, where small nuclear families (SNFs) containing affected sibling pairs are being recruited.  A 
genome scan will make it possible to identify chromosomal regions containing genes that influence risk of OD.
SUBPROJECT PROGRESS:
We recruited 184 participants for this study between 4/1/07 and 3/31/08. We have recruited 767 subjects in the study since its 
initiation. Subject payment has changed from $75 to $100 for cases and from $50 to $75 for control subjects. We continue to 
recruit cases and controls in addition to our previous recruitment of sibling pairs and family trios. 
A waiver to consent for the phone screening phase only was approved as well as minor changes to the phone screen itself. Breath 
alcohol reading is also now evaluated to ensure that participants are able to give informed consent. The protocol has been changed 
so that control subjects are now being recruited as matches to the affected subjects as opposed to simply recruiting a control sample 
of convenience.
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PsychiatryKADDEN, RONALD M PHD
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PsychiatryPETRY, NANCY PHD
SUBPROJECT DESCRIPTION:
The overall goal of this research is to improve treatment outcome for marijuana-dependent individuals.  The study will attempt 
to enhance abstinence over the levels obtained in prior research by combining contingency management with Motivational 
Enhancement Therapy and Cognitive Behavior Therapy (MET/CBT), providing voucher-based reinforcement for abstinence.  
This combined intervention will be compared to three other interventions: MET/CBT-only, contingency-management-only, 
and a control group that receives supportive case management only.  Recruitment of 260 marijuana-dependent participants will 
occur over a three-year period.  They will be randomly assigned to one of the four interventions.  All treatments will be 
individual, manualized, and provided on an outpatient basis for 9-sessions.  Pretreatment assessments will provide baseline data 
against which to compare treatment outcomes.  Follow-up assessments, at three-month intervals for one year following 
treatment, will evaluate marijuana and other drug/alcohol use, and psychosocial functioning in several domains.  It is anticipated 
that the intervention combining contingency management and MET/CBT will result in the best outcomes, and that the 
contingency management and MET/CBT interventions by themselves will each be superior to supportive case management.
SUBPROJECT PROGRESS:
- Number of subjects enrolling during the report period and since initiation of the study  
       During the report period:   67
       Since initiation of the original study:  330 (MTP2=250 + MTP3=80)
   - Any changes in recruitment plans that might be needed    None
   - Unexpected safety concerns and their resolution      None
   - Interim data and outcomes if appropriate      None at this stage
   - Any proposed changes made or anticipated in the protocol
The following modifications were reviewed and approved by the IRB on 6/6/07:
Revisions to protocol, informed consent form, and Treatment Manual to extend reinforcement-for-attendance from 2 weeks to 3 
weeks in the group that is to eventually receive reinforcement for marijuana-free urine specimens.
      No other changes to the protocol are anticipated at this time.
A competitive-renewal application for this project was funded in September 2006, and General Clinical Research Center (GCRC) 
support for the renewal period was approved in October 2006. After a start-up period for development of the Research and 
Treatment manuals, for programming the Interactive Voice Response (IVR) system, and for therapist training and treatment of 
training cases, the first Main Phase cases were recruited in March 2007. In the current reporting period a total of 67 participants 
were recruited and randomized to the three treatment conditions. 
After a slow start, recruitment rates have recently averaged somewhat greater than 1.5 subjects per week, which puts us on track to 
recruit the projected number of 75 in the coming project-year.  Thus far, 38 participants have completed the treatment phase of 
the project, and follow-up assessments have begun at the 5-, 8-, and 11-month follow-up points.  There are no safety concerns, 
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SUBPROJECT DESCRIPTION:
SELECT is a Phase III, double blind, placebo-controlled clinical trial designed to assess the effect of selenium and vitamin E 
(individually and in combination) on the incidence of prostate cancer as determined by routine clinical management.  The 
accrual goal is 32,400 healthy men nationwide who are 55 years old or older (age 50 years or older for African-American men).  
Study duration will be twelve years with a five-year uniform accrual period.  Participants will receive study supplements from the 
time of their randomization until the end of the trial period, between seven and twelve years depending upon when the 
participant was randomized.
SUBPROJECT PROGRESS:
No new participants were enrolled in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) in the report period. Two 
participants moved out of the area and transferred out to other SELECT sites. 
# since initiation of trial: 60 
Any changes in recruitment plans that might be needed: N/A, enrollment to the study is closed 
Unexpected safety concerns and their resolution: In the report period, the Southwest Oncology Group (SWOG) sent us a prepared 
Fact Sheet regarding a new finding of risks associated with excessive multivitamin use.  The Fact Sheet was submitted to the IRB 
and subsequent to approval was distributed to enrolled participants, who signed a document acknowledging receipt and who were 
given a copy of the document. 
Interim data and outcomes if appropriate: N/A - study is in data collection phase 
Any proposed changes made or anticipated in the protocol: None known
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SUBPROJECT DESCRIPTION:
The primary aims of the study are 1) to compare the cardiotoxicity of four cycles of Adriamycin and Cyclophosphamide (AC) 
followed by four cycles of Taxol, with that of the same chemotherapy regimen plus Herceptin, in patients with operable, 
histologically node-positive breast cancer which overexpresses the HER2 protein; and 2)to determine whether, in this patient 
population, four cycles of AC followed by four cycles of Taxol and weekly Herceptin for one year is more effective in 
prolonging survival than four cycles of AC followed by four cycles of Taxol.
SUBPROJECT PROGRESS:
All have completed study and are in long term follow-up only.
The Hospital of Central Connecticut (THOCC):  Four patients were enrolled at this site.  Three are alive and well without adverse 
events (AEs), new primaries, or recurrence.  The fourth patient had new lung cancer primary in 03/12/07 and is being treated 
accordingly.  The patient did not have AEs or recurrence related to breast cancer.
The University of Connecticut Health Center (UCHC):  Five patients were enrolled at this site.  One patient expired due to 
metastatic disease.  One other patient moved to Washington DC and has been lost to follow-up.  The other patient with metastatic 
disease to the brain had surgery on 8/31/07 for a left cerebellar tumor and is now in follow-up.  The last two patients are alive and 
well without AEs, new primaries, or recurrence.
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SUBPROJECT DESCRIPTION:
The primary aim of this study is to compare the relative efficacy of Fluorouracil (5-FU) + Leucovorin (LV) + Oxaliplatin 
(FLOX) with that of 5-FU + LV in prolonging disease-free survival among patients who have undergone a potentially curative 
resection of a stage II or III carcinoma of the colon.  The secondary aim of the study is to compare the relative efficacy of 
FLOX with that of FL in prolonging Survival (S).
SUBPROJECT PROGRESS:
Local Report:
University of Connecticut Health Center (UCHC): As of 2/13/08 One patient is alive with 3rd recurrence for which the patient is 
receiving non-study treatment.  No long-term toxicity noted.
The Hospital of Central Connecticut (THOCC): As of 2/13/08, 5 patients are alive and well with no adverse events (AE's), no new 
primaries and no recurrence of disease.
6/27/2008   9:32:04AM 32
REPORT PD:  04/01/2007-03/31/20085M01RR006192-14 Final
0381 381PROTOCOL:SPID: RESEARCHTYPE:  
MalariaSHORT TITLE:
LONG TITLE: Study of the Human Malaria Parasite Plasmodium Falciparum
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 12  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 2/1/2001
 17Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Microbial PathologyBENMAMOUN, CHOUKRI MD
Center for Microbial PathoELSHEICKA, HANY MD
Center for Microbial PathoREYNOLDS, JENNIFER MD
SUBPROJECT DESCRIPTION:
Malaria is by far the world's most important tropical parasitic disease.  It causes clinical illness in 300 million to 500 million 
people, 1.5 million to 2.7 million of whom die.  Sub-saharian Africa remains the most malarious region in the world with ninety 
percent of cases and deaths, mostly among children, In this region, about 30% of outpatient consultations and up to 20% 
hospital admissions are due to malaria.  This causes major disturbance in economic and social development.  Malaria cases in the 
United States are linked to international tourism with about one thousand cases diagnosed and treated each year.  Since the 
mid-1950's malaria prophylaxis has relied mostly on chloroquine because of its effectiveness and, notably its low cost.  
Chloroquine resistance has become widespread in different parts of the world.  Mefloquine and quinine have been used 
extensively in areas of resistance to chloroquine, and proguanil for prophylaxis and treatment, but resistance to these drugs is 
becoming a substantial problem.  The need for more efficacious and less toxic agents, particularly rational drugs that exploit 
pathways and targets unique to the parasite, is therefore acute.  
Plasmodium falciparum is an important intraerythrocytic protozoan pathogen, responsible for the most severe form of human 
malaria.  The parasite undergoes a number of developmental stages in the human host and multiplies asexually in the red blood 
cell to effect its clinical symptoms and lethal outcome.
Research in my laboratory focuses on how the malaria parasite responds to changing environmental conditions.  Maintaining 
the parasite in culture is an essential step in our research toward understanding the basic biology of this parasite and future 
development of a vaccine or new antimalarial drugs. The GCRC supports the study by by drawing blood and transporting the 
sample to the research lab.
SUBPROJECT PROGRESS:
 1. Number of Subjects enrolled during the reported period: 8 subjects (15 blood draws)
2.  Number of Subjects enrolled since intiation of the study: 35 subjects (144 blood draws)
3. Any changes in recruitment plans that might be needed: No
4. Unexpected safety concerns and their resolution: None
5.Interim data and outcomes if appropriate: None
6.Any proposed changes made or anticipated in the protocol. Enrollment was increased from 10 to 35 and was approved on 
4/19/07.
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SUBPROJECT DESCRIPTION:
Currently, patients whose primary breast cancer demonstrated estrogen receptors, receive five years of anti-estrogen treatment 
with tamoxifen.  This has been standard care for many years.  There is no data supporting more than five years of tamoxifen 
use, in fact at least one study showed worse results with more than five years of tamoxifen.  There is no treatment offered to 
patients beyond this other than close observation.  Exemestane is a new aromatase inhibitor, i.e. a drug that interferes with the 
metabolism of steroid hormones.  The primary aim of this randomized, placebo-controlled, double-blind clinical trial is to 
determine whether oral administration of exemestane, for 2 years, in postmenopausal patients with estrogen-receptor-positive 
(ER+) and/or progesterone-receptor-positive (PgR+) breast cancer (CT 1-3 cNO-1 MO) who have completed 5 years of 
tamoxifen therapy, will prolong disease-free survival and overall survival when compared with placebo.  To be eligible, patients 
must have completed approximately 5 years of adjuvant tamoxifen therapy (either 10 mg po twice a day or 20 mg po daily), be 
disease free, and have been resected by lumpectomy and axillary node dissection or by modified radical mastectomy.  Eligible 
patients may have received either adjuvant or neoadjuvant chemotherapy at the time of their breast cancer diagnosis.  
Following stratification by nodal status, patients will be randomized to receive either exemestane 25 mg po daily or placebo, for 
2 years.  Another aim of this study is to evaluate the effect of tamoxifen withdrawal on bone and to determine if exemestane 
has any additional effects on the rate of bone loss resulting from tamoxifen withdrawal.  Data for fractures, height, and total 
serum alkaline phosphatase will be collected on the entire study population.
SUBPROJECT PROGRESS:
University of Connecticut Health Center (UCHC) - 3 patients were enrolled into this study.  All 3 patients are doing well.  2 
patients are off study, one continues with Long Term Follow Up only. At last follow up (11-12-2007) patient was seen by Dr. Ann 
Waitzman and is alive and well. 
The Hospital of Central Connecticut (THOCC) report: 2 patients enrolled since initiation of trial.
One patient is deceased as of April 2006.
One patient was last seen 5/17/07 by Dr. Fallon, is still on treatment, no adverse events (AEs), recurrence, or new primaries. (Dr. 
Fallon). Receiving Exemestane (as approved by the Food and Drug Administration (FDA) on October 5, 2005); not receiving any 
experimental treatment.
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0400 400PROTOCOL:SPID: RESEARCHTYPE:  
NSABP-B34SHORT TITLE:
LONG TITLE: NSABP B34 A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early Stage Breast 
Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen of No Therapy
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 1/21/2002
 10Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
This phase III prospective randomized, double-blind, placebo-controlled trial in women with early-stage breast cancer that will 
evaluate the worth of clodronate, a second-generation bisphosphonate.  Bisphosphonates have been shown to block the 
breakdown of bones, and in one small open label study, had a beneficial effect on bone metastases in patients with breast cancer.  
This study's primary aim is to determine whether 1600 mg/day of clodronate administered for 3 years, whether alone or in 
addition to adjuvant chemotherapy and/or hormonal therapy will improve disease-free survival.  This study will also evaluate 
whether adjuvant clodronate results in a reduction in the incidence of skeletal metastasis, skeletal-related morbidity, 
non-skeletal metastases, and an improvement in relapse-free survival and overall survival.  To qualify for this trial, women must 
have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy.  Patients 
will be stratified according to age, nodal status and estrogen receptor (ER) and or progesterone receptor (PgR) receptor status.  
Patients must have no evidence of metastatic disease. The administration of adjuvant chemotherapy and/or tamoxifen will be at 
the discretion of the investigator.  The exact regimen, dose and duration will be at the discretion of the investigator and is not 
part of the study.  It is the addition of either clodronate or placebo that is the subject of this study.
SUBPROJECT PROGRESS:
Locally: the University of Connecticut Health Center (UCHC) accrued 3 patients. All are alive and well and have not had 
recurrence. The Hospital of Central Connecticut (THOCC) accrued 2 patients. One is alive and well. The other patient is deceased 
as of 11/27/2007.
There have been 3 unexpected safety concerns with this study; however, they involved patients who were not enrolled in the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) B34 study. There are no proposed changes to the protocol at this 
time. The Institutional Review Board (IRB) adverse event (AE) computer system reference numbers are: 3000, 3001, 3002.
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0410 410PROTOCOL:SPID: RESEARCHTYPE:  
Testosterone Effects on Bone and Frailty in Men with OsteoporosisSHORT TITLE:
LONG TITLE: Testosterone Effects on Bone and Frailty in Men with Osteoporosis
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/15/2001
 150Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NY CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Center on AgingKENNY, ANNE MD
SurgeryALBERTSEN, PETER MD
MedicinePRESTWOOD, KAREN MD
SUBPROJECT DESCRIPTION:
Attention to osteoporosis has largely emphasized women's health, and little attention has focused on the diagnosis and 
prevention of osteoporotic fractures in men. And yet the disease is also an important problem in men. Testosterone levels 
decline with advancing age, and severe testosterone deficiency is associated with low bone mass and fracture. Several 
epidemiologic studies suggest that low testosterone is associated with low bone mass in older men, but this finding is not 
consistent. Men with hip fracture are found to be testosterone deficient more often than control subjects. Among men over age 
70 with testosterone levels below the young normal range, we found differences in bioavailable testosterone accounted for 20% 
of the variance in femoral neck bone mineral density (FN BMD) values. Additional predictors of FN BMD in this population 
included body mass index and physical activity, two described  parameters of frailty.
Based on these data, testosterone supplementation may be important for bone health and frailty in older men. We will test the 
hypothesis that testosterone supplementation can increase bone mineral density in older men with hip fracture. We will also 
evaluate the effects of testosterone on physical health and frailty.
SUBPROJECT PROGRESS:
The study is closed to recruitment. We are in the data analysis phase. We require continued support while preparing manuscripts.
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0413 413PROTOCOL:SPID: RESEARCHTYPE:  
The Effect of Risedronate on Bone Turnover and Bone Mass in Older Men ReceivingSHORT TITLE:
LONG TITLE: The Effect of Risedronate on Bone Turnover and Bone Mass in Older Men Receiving Neoadjuvant Therapy 
for Prostate Cancer
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 36  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/15/2001
 60Total # pts expected for entire study:
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Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineTAXEL, PAMELA MD
SurgeryALBERTSEN, PETER MD
Medicine/EndocrinologyRAISZ, LAWRENCE G MD
SUBPROJECT DESCRIPTION:
This proposal will examine a therapeutic intervention with risedronate in a population of men at high risk for bone loss. 
Carcinoma of the prostate gland is the most commonly diagnosed cancer in U.S. men, and is the second leading cause of cancer 
death. Over the last decade, more and more men are being treated with hormonal suppression therapy for locally advanced 
disease. Recent studies have shown that such hormonal suppression with Luteinizing Hormone Releasing Hormone (LHRH) 
agonists leads to rapid bone loss and increased risk of osteoporotic fractures (1). The increased incidence of hip fractures and 
other fragility fractures in older men is a major public health issue. Hip fractures are costly, increase mortality and significantly 
compromise the independence and quality of life of the survivors. The potential for compounding this problem in men treated 
with hormonal suppression for locally advanced prostate carcinoma is the rationale for this study.
SUBPROJECT PROGRESS:
There were 6 more subjects enrolled in the above time period.  We closed the study for recruitment in the above time period. The 
data is currently being analyzed by a statistician and manuscript preparation is underway.
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0417 417PROTOCOL:SPID: RESEARCHTYPE:  
Transdermal vs Oral Estrogen Therapy on Adolescents with Turner's SyndromeSHORT TITLE:
LONG TITLE: Effect of transdermal vs oral estrogen therapy on achieving near final adult height and near peak bone mass 
in growth hormone treated adolescents with Turner Syndrome
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 12/20/2001
 24Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PEDIATRICS CONNECTICUT CHILDREN'S MEDICAL, 
CT USA
YIGIT, SEVKET MD
PEDIATRIC ENDOCRINOLOGY BAYSTATE MEDICAL CENTER, MA USAALLEN, HOLLY MD
PEDIATRICS UNIVERSITY OF NORTH CAROLINA, NC 
USA
DAVENPORT, MARSHA MD
PEDIATRICS CONNECTICT CHILDREN'S MEDICAL, CT 
USA
RUBIN, KAREN MD
SUBPROJECT DESCRIPTION:
Estrogen replacement in Turner Syndrome (TS) is accomplished most commonly using estrogen preparations. Based on 
preliminary data we hypothesize that transdermal vs. oral estradiol will have more favorable effect on near final adult height 
(FAH) and near peak bone mass (PBM) in growth hormone (GH) treated adolescents with TS. The aim of the study is to 
evaluate the effect of transdermal vs. oral estrogen on growth and bone mass and their correlation with growth factor levels, 
markers of bone turnover and sex steroid levels. This 2 year selectively randomized prospective study involves two treatment 
groups: equivalent doses of oral vs. transdermal estradiol in combination with standard growth hormone therapy. The TS 
adolescents ages 12-15 years will be selectively randomized to each group by bone age. Estrogen dose will be gradually increased 
every 6 months over the two years in both groups mimicking normal puberty. With a sample size of 12 in each group and test 
significance level of 0.05, we will have an 80% power to detect a 25% difference in growth of two groups. There is no 
preliminary data in terms of bone mass to evaluate sample size estimation for signigicant difference between two groups. 
Statistical analysis of outcome measures will be done with repeated measures analysis of variance.
SUBPROJECT PROGRESS:
4 subjects were enrolled in the study.  There was no study activity in the reporting period.  The study was terminated in the General 
Clinical Research Center (GCRC) on 12/25/07.
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0426 426PROTOCOL:SPID: RESEARCHTYPE:  
The SMART StudySHORT TITLE:
LONG TITLE: A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (SMART) 
for Human Immunodeficiency Virus (HIV) Positive Patients
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 7  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: Y
START DATE: 11/4/2002
 10Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/Infectious DiseasDIECKHAUS, KEVIN MD
PSYCHIATRY YALE UNIVERSITY, CT USAFRIEDLAND, GERALD MD
SUBPROJECT DESCRIPTION:
The purpose of this study is to compare the long-term clinical consequences of two strategies of antiretroviral (AR) 
management for the Human Immunodeficiency Virus (HIV): (1) the drug conservation (DC)  strategy, a strategy aimed at 
conserving drugs through episodic use of antiretroviral treatment for the minimum time to maintain CD4+cell count x 250 
cells/mm^3   -versus- (2)  the viral suppression (VS) strategy, a strategy aimed at suppressing viral load as much as possible, 
immediately following randomization and throughout follow-up, irrespective of CD4+cell count. 
The primary objective is to compare the DC group with the VS group for the following: 
-Survival
-Incidence of major cardiovascular and metabolic complications
-Incidence of serious disease progression events
-Combined endpoint of clinical disease progression, major cardiovascular and metabolic complications, or death
-Grade 4 adverse events
-Self-reported changes in body appearance
-Prevalence at selected time points of multi-drug resistant (MDR) HIV, and rate of developing MDR HIV
-Adherence to antiretroviral treatment, averaged over follow-up
-Disease progression, death, and other outcomes
SUBPROJECT PROGRESS:
Seven subjects were enrolled, none within this reporting period. The study closed on July 11,2007.  No further follow-up is planned. 
Data from the trial has been presented and published.  A final paper was published in the New England Journal of Medicine 
355:2283-2296, 2006, which was reported in last year's annual report.
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0428 428PROTOCOL:SPID: RESEARCHTYPE:  
NSABP B-31.1: Cardiac Function and Patient Characteristic CorrelationSHORT TITLE:
LONG TITLE: NSABP B-31.1: A Study to Determine the Correlation of Cardiac Function with Patient Characteristics and 
Blood Markers in Women Enrolled in NSABP B-31
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 2/1/2002
 10Total # pts expected for entire study:
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NANCILLARIES ONLY
Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
This is a companion study to NSABP B31.  This study, NSABP B-31.1, is designed to determine the usefulness of  echo 
cardiography (ECHO) in addition to multi gated acquisition (MUGA) scan in the monitoring of patients' cardiac function. This 
study offers an excellent opportunity to assess more subtle  effects of Herceptin on cardiac function and serum markers. More 
sensitive and precise measures of Herceptin's cardiac effects may provide important information for early detection and risk 
stratification of a patient's cardiac characteristics, which in turn may allow the application of preventive measures. 
The primary aim of this companion study is to evaluate Herceptin-associated abnormalities via  echo cardiographic ally 
obtained parameters that indicate diastolic dysfunction and correlate these abnormalities with baseline patient characteristics to 
determine whether such correlations predict which patients are at greatest risk of developing cardiac dysfunction when treated 
with Adriamycin and cyclophosphamide (AC), followed by Taxol plus Herceptin as part of NSABP B-31. 
The secondary aim of this companion study is to determine whether abnormal levels of brain  natriuretic peptide (BNP), 
troponin- T (TnT), troponin-I (TnI), tumor necrosis factor-alpha (TNF- cx), interleukin-1 beta (IL-1fJ), or interleukin-6 
(IL-6) correlate with echocardiographic  abnormalities that reflect myocardial damage in patients receiving AC followed by 
Taxol with Herceptin and whether any of these blood markers can serve as early predictors of cardiac dysfunction in this 
adjuvant setting. 
The tertiary aim of this companion study is to evaluate the concordance of left ventricular ejection fraction (L VEF) results 
measured by MUGA and by ECHO. 
The changes in echocardiographic parameters and blood markers will be compared longitudinally in B-31 group 2 patients who 
will receive Herceptin as well as compared laterally with group 1 patients who will not receive Herceptin. Because this research 
is exploratory in nature, none of  the results obtained from a patient's ECHOs or blood markers will be made known to the 
patient  or her investigator. The data analysis will be descriptive and numerous possible relationships will be considered.   A total 
of 220 B-31 patients will be enrolled. Patients enrolled in B-31.1 are subject to all eligibility criteria defined in NSABP B-31.
SUBPROJECT PROGRESS:
1 patient was accrued at The Hospital of Central Connecticut (THOCC).  She is alive and well, no recurrences, Adverse Events 
(AE's) or new primaries.
The progress notes for this reporting period remain the same as those from the last: 1 patient enrolled, who is in long term 
follow-up and doing well. This study is closed to accrual therefore there is no recruitment plan at this time. There are no 
anticipated changes to the protocol and no unexpected safety concerns. 
There are no publications that have cited the General Clinical Research Center (GCRC).
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0439 439PROTOCOL:SPID: RESEARCHTYPE:  
Dendritic Cells (DC) CrosstalkSHORT TITLE:
LONG TITLE: DC-Th Crosstalk in Cytotoxic T Lymphocytes (CTL) Responses to Mart-1
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/25/2002
 12Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineMUKHERJI, BIJAY MD
MedicineCHAKRABORTY, NITYA G PHD
MedicineHEGDE, UPENDRA MD
SUBPROJECT DESCRIPTION:
The major goal of this proposal is to test the hypothesis that Crosstalk in Cytotoxic T Lymphocytes (CTL) response against 
human thioacetamide acid (TAA) induced by Dendritic Cells (DC)-based stimulation is subject to regulation by DC-Th 
cross-talks.  A better understanding of the rules of the engagement of DC-Th cross-talks that govern the generation and the 
control of anti-TAA CTL response will have a major impact in DC-based vaccine design.
SUBPROJECT PROGRESS:
This study is in the process of competitive renewal.  We did not recruit any subject in the last year.  We were conducting analysis  
and going through renewal preparation.
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0442 442PROTOCOL:SPID: RESEARCHTYPE:  
HALT-C TrialSHORT TITLE:
LONG TITLE: The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C)
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 23  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/7/2002
 45Total # pts expected for entire study:
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Phase III-IV
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/GasteroenterologyBONKOVSKY, HERBERT MD
MedicineAZIZ, KHALID MD
SUBPROJECT DESCRIPTION:
The purpose of this study is to conduct a randomized, controlled trial to determine if long-term interferon therapy can 
reasonably reduce the risk of histologic progression to cirrhosis, decompensated liver disease and/or hepatocellular carcinoma in 
patients with chronic hepatitis C and advanced fibrosis or cirrhosis who failed to respond to previous interferon therapy.
Specific aims:  1) To determine if 4 years of interferon therapy will prevent progression of advanced fibrosis to cirrhosis in 
patients with chronic hepatitis C who failed previous interferon treatment; 2) to determine if 4 years of interferon therapy, in 
patients with cirrhosis secondary to chronic hepatitis C who failed previous interferon treatment, will a) reduce the risk of 
developing hepatic decompensation; b) reduce the need for hepatic transplantation; c) reduce the risk of developing 
hepatoceullar carcinoma; and 3) To determine if 4 years of interferon therapy will improve the quality of life in patients with 
advanced fibrosis or cirrhosis secondary to chronic hepatitis C who failed previous interferon treatment.
Approximately 1200 patients (at all centers) who meet the inclusion/exclusion criteria will be entered into a Lead-in 
Phase.  They will be treated with a combination of Peginterferon alfa-2a and ribavirin for a period of 24 weeks.  Patients who 
have no detectable Hepatitis C Virus (HCV)Ribonucleic Acid (RNA) at week 20 will continue on combination therapy until week 
48.  Patients who do not clear virus will be randomized 50:50 at week 24 to receive either Peginterferon alfa-2a alone or  no 
further therapy for the next three and a half years.  Both randomized groups will be monitored quarterly during these 42 months 
and biopsies will be obtained at 24 and 48 months after the start of the Lead-in Phase.  An estimated 800 patients will be 
evaluable at the conclusion of the trial.
SUBPROJECT PROGRESS:
Enrollment closed in 2003. We enrolled 37 patients. The target for enrollment was exceeded and nationally there were 1382 
patients enrolled in the study. The Halt-C Trial was extended until October 2009 to add an observational period of time in which 
to gather further data on the natural history of hepatitis C.  All patients finished study drug as of January 2007 and most are now in 
the Halt-C extension/observational part of the trial. The Data Safety Monitoring Board (DSMB) last met in June, 2007, and voted 
unanimously to continue the Halt-C Trial. There were no safety concerns identified.  A total of 11 patients continue to be seen 
every six months at the University of Connecticut Health Center's (UCHC) General Clinical Research Center (GCRC).  Other 
patients have died or been transplanted, have moved away, have elected to leave the study, or have elected to have continuing 
follow-up performed at another clinical center.  
The main results of the Trial are that long-term, low-dose pegylated interferon is NOT of benefit in patients with advanced 
chronic hepatitis C.  Rather, it is important for us to find better ways of treating and curing the chronic viral infection.  This result 
was presented in Nov, 2007, at the annual meeting of the American Association for the Study of Liver Diseases, and the full paper 
describing the results has been submitted to The New England Journal of Medicine.  We anticipate final acceptance of a revised 
version, but this cannot yet be guaranteed.  There have been a number of publications that have appeared or been accepted during 
2007--2008, all of which have cited the University of CT Health Center's GCRC, and all of which have already been transmitted to 
the Administrative Office of the GCRC [Lisa Godin and Lesley Mancini].
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0445 445PROTOCOL:SPID: RESEARCHTYPE:  
Feasibility of SH2 Domain ProfilingSHORT TITLE:
LONG TITLE: Feasibility of Src Homology 2 (SH2) Domain Profiling as a Molecular Diagnostic Tool for Patients
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 6/20/2002
 60Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Genetics & Dev. BiologyMAYER, BRUCE PHD
SurgeryDECKERS, PETER MD
SurgeryKURTZMAN, SCOTT MD
SurgeryZARFOS, KRISTEN MD
SUBPROJECT DESCRIPTION:
There is a need for molecular diagnostic tools that will allow the classification of tumors beyond what is currently possible using 
standard techniques.  Ideally markers will be identified that will have prognostic value (correlate with response to particular 
treatments, for example).  Expression profiling using cDNA microarrays is now being tested for this purpose, but is at present 
cumbersome, costly, and is unlikely to give any information about the molecular defects in the tumor cell.  We are developing a 
novel molecular diagnostic technique based on the profile of proteins in a tumor sample that bind to certain protein domains 
known to play an important role in signal transduction.  In preliminary experiments this technique can identify different 
binding profiles in hematological malignancies, suggesting it may be a valuable molecular diagnostic tool.  The resulting profiles 
may also be informative about the molecular defects in a particular tumor.  To date we have not tested the method on solid 
tumor samples.  We propose to test this technique on samples of breast cancers available at the UCHC to establish the 
feasibility of implementation on a larger scale. Ultimately, if the technique is sufficiently robust and reproducible, we will 
correlate profiling data with patient information to determine whether the interaction profiling provides information with 
prognostic value.
SUBPROJECT PROGRESS:
No new patients were enrolled in this study in the past year. Because of ongoing difficulties in recruiting subjects, and changing 
research priorities, this study was officially closed on 3/31/08.
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0448 448PROTOCOL:SPID: RESEARCHTYPE:  
Soy and IsoflavonesSHORT TITLE:
LONG TITLE: The Effect of Soy Protein and Isoflavones on Bone on Older Women
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 7/16/2002
 160Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
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NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Center on AgingKENNY, ANNE MD
NUTRITION UCONN - STORRS, CT USAKERSTETTER, JANE PHD
SUBPROJECT DESCRIPTION:
Osteoporosis is a disease that primarily affects older women in the United States.  Epidemiological studies report decreased hip 
fracture incidence in Asian countries where the population ingests larger amounts of soy than is contained in the average US 
diet. Recent data suggest that soy intake is correlated with bone mineral density in Asian women.  Soy foods are rich sources of 
isoflavones and these compounds may be responsible for the health benefits of soy.  Although epidemiological and preliminary 
cross-sectional data suggest that soy may be beneficial to bone (1,2), few well-controlled clinical trials have been completed to 
adequately test this theory.  Many women in the United States are demanding more 'natural' treatments for chronic diseases and 
a substantial proportion of women are already consuming more soy products or using isoflavone supplements.  However, it is 
unclear if these practices are beneficial to postmenopausal women.  We hypothesize that isoflavones and soy protein will have a 
beneficial effect on bone in older women compared to control protein.  Further, we hypothesize that there will be an additional 
benefit to bone in women who receive soy protein plus isoflavones compared to control protein or soy protein alone.  In order 
to test these hypotheses we propose an 1-year nutrition intervention study in women over age 65 years in which the main 
outcome measures will be biochemical markers of bone turnover, quality of life, bone mineral density.
SUBPROJECT PROGRESS:
The study was completed in August 2005. 99 women completed. Presently we are analyzing data and preparing manuscripts. There 
were no safety concerns. There is no interim data. We will still need General Clinical Research Center (GCRC) support for ongoing 
laboratory analysis and statistical assistance.
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0453 453PROTOCOL:SPID: RESEARCHTYPE:  
Diabetes, Depression, & Coronary Heart DiseaseSHORT TITLE:
LONG TITLE: Pilot Study of the Relationship Between Diabetes, History of Depression, and Coronary Heart Disease 
(CHD) in Post-Menopausal Women
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 36  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 7/12/2002
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Behavioral Sci & Comm HlthWAGNER, JULIE PHD
PREVENTIVE CARDIOLOGY HARTFORD HOSPITAL, CT USASEIP, RICHARD PHD
PREVENTIVE CARDIOLOGY HARTFORD HOSPITAL, CT USATHOMPSON, PAUL MD
SUBPROJECT DESCRIPTION:
Diabetes and depression both independently put women at increased risk for coronary heart disease (CHD).  Thus, a better 
understanding of how these risk factors interact is crucial to our understanding of heart disease in women.  One hypothesized 
mechanism for the depression-diabetes-CHD relationship is the Hypothalamic-Pituitary-Adrenal (HPA) axis and cortisol 
production.  Currently, no data have been published that look at these variables in concert.  Thus, it is unclear if they each 
convey an individual risk that becomes additive when combined, or if they interact to convey multiplicative risk.  
The study being proposed is a cross sectional study of depression, diabetes, and CHD risk in women.  The research design is a 
2X2 factorial design.  The sample will consist of 80 age-matched postmenopausal women.  The independent variables are 1) 
presence of a history of depression (yes or no), and 2) T2DM status (yes or no).  The dependent variables are salivary cortisol 
levels, lipids (total cholesterol, HDL subfractions, and triglycerides), waist-to-hip ratio, brachial artery flow mediated dilation, 
hemostatic indicator (vWF), inflammatory marker (c-reactive protein), microalbuminuria, and blood pressure. Variables that 
will be controlled for include BMI (Bone Mass Index), lipid lowering agents, beta blockers, ACE inhibitors, antihypertensive 
agents, and history of smoking, physical activity, and alcohol use. 
Three hypotheses will be tested: 1) There will be a main effect for diabetes, such that participants with diabetes will show higher 
WHR, blood pressure, vWf, C-Reactive Protein (CRP), dyslipidemia, microalbuminuria, and more impaired endothelium 
dependent brachial reactivity (EDBR) than those without diabetes; 2) There will be a main effect for history of depression, such 
that participants a positive history will show higher WHR, blood pressure, vWf, CRP, microalbuminuria, more impaired EDBR, 
and a flatter cortisol pulsatile circadian rhythm than those with a negative history; 3) there will be an interaction between 
history of depression and diabetes, such that participants with both diabetes and positive history of depression will show higher 
WHR, blood pressure, vWf, CRP, and more impaired EDBR, than those with only history of depression or diabetes.
SUBPROJECT PROGRESS:
From 4/1/2007 until 3/31/2008, 18 women enrolled. One was found to be ineligible during the first visit and excluded from 
participation, for a total of 17 eligible participants during this period. Since initiation of the study, 150 subjects have enrolled and 
122 have been eligible and able to fully participate (25 women were excluded from the study after an Informed Consent Form (ICF) 
was collected and during first visit data collection). This was because it was discovered during first visit that they did not meet set 
criteria to complete the study. Three withdrew from the study due to health reasons (unrelated to the study). 
Modifications to the project approved by IRB this year include:  1) Hartford Hospital (HH) was removed as a collaborator on this 
study due to changes in their staff and inability to run subjects.  All references to HH were removed.  Dr. Paul Thompson was 
removed as a co-investigator. 2) Dr. Mallareddy completed her fellowship and is no longer employed by the University of 
Connecticut Health Center (UCHC).  Dr. White (currently a co-investigator) took over her study responsibilities, 3) A change in 
protocol adding a mental stress challenge, additional flow mediated dilation assessments, and additional blood samples, 4) Change in 
Protocol for subset of participants for an Expressive Writing Intervention***the General Clinical Research Center (GCRC) HAS 
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THIS UNDER A SEPARATE STUDY NUMBER 657, 5) Changes have been made to the ICF and protocol to reflect the above 
modifications. A separate ICF, Part B has been submitted for the Expressive Writing Intervention. This ICF is part of GCRC study 
657.  There were no unexpected safety concerns for this study
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0459 459PROTOCOL:SPID: RESEARCHTYPE:  
Inhaled Nitric OxideSHORT TITLE:
LONG TITLE: Inhaled Nitric Oxide for the Prevention of Chronic Lung Disease
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  6  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/1/2002
 20Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PediatricsPAPPAGALLO, MARIANN MD
PediatricsKNOX, ISABELLA MD
PediatricsROSENKRANTZ, TED S MD
PediatricsSANDERS, MARILYN MD
PediatricsVIDWANS, ANIRUDDHA MD
SUBPROJECT DESCRIPTION:
Inhaled nitric oxide (iNO) therapy is a safe and effective treatment for term newborns with persistent pulmonary hypertension 
of the newborn and hypoxemic respiratory failure.  However, little is known about the potential role of iNO in premature 
newborns with respiratory failure.  The premature newborn is particularly susceptible to the adverse effects of ventilator-induced 
lung injury, oxygen toxicity, and lung inflammation which contribute to the development of chronic lung disease (CLD).  
Despite treatment with exogenous surfactant and steroids, CLD remains a major cause of morbidity and mortality in premature 
newborns.  Moreover, there is increasing evidence that steroid treatment causes long-term adverse neurodevelopmental and 
cardiopulmonary sequelae.  
Early clinical observations suggest that low-dose iNO improves oxygenation and decreases the need for mechanical ventilator 
support in the premature infant.  In addition to its effects on gas exchange, recent laboratory and clinical observations suggest 
that iNO may also act as a lung-specific anti-inflammatory treatment and reduce the contribution of lung inflammation to the 
evolution of acute and chronic lung injury in premature infants.
SUBPROJECT PROGRESS:
There were a total of six patients enrolled at this site since initiation of this study. It is a multi-center study. Enrollment is 
complete and the study is now in the follow-up phase. One patient was lost to follow-up so we are following a total of five patients.  
During the report period, we will see the infants at their age three visits.  One final visit will be done as part of the study at age four 
and one half.   There are no changes anticipated to the protocol nor have there been any unexpected safety concerns identified. 
No interim data available.  There have been no publications submitted from this site.  There have been publications from the 
primary site referencing the study.
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0461 461PROTOCOL:SPID: RESEARCHTYPE:  
Effects of Oral Estradiol Therapy on OsteoclastogenesisSHORT TITLE:
LONG TITLE: The Acute Effects of Oral Estradiol Therapy on Osteoclastogenesis in Hypogonadal Older Men and 
Women: A Pilot Study
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 9  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 3/6/2003
 124Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineTAXEL, PAMELA MD
MedicineLORENZO, JOSEPH MD
Medicine/EndocrinologyRAISZ, LAWRENCE G MD
SUBPROJECT DESCRIPTION:
Our understanding of the mechanisms by which estrogens regulate bone cells are incomplete.  This process is important because 
estrogen loss by women after menopause and probably in hypogonadal men produces a relatively rapid decrease in bone mass 
and predisposes susceptible individuals to the development of the disease osteoporosis.  This translational project is the result of 
a collaboration between basic and clinical scientists at the University of Connecticut Health Center (UCHC) whose work focuses 
on the identification of the mechanisms by which human beings develop the disease osteoporosis.  Our specific goal in this pilot 
project is to examine the differences in cellular and molecular changes that occur in the bone marrow of sex steroid-replete and 
deficient older men and postmenopausal women in response to estrogen, as preliminary data in mice demonstrates the 
importance of this hormone.  
In preliminary work we have found that ovariectomy in mice is rapidly followed by an increase in the ability of bone marrow 
cells to differentiate into osteoclasts, the cells that mediate bone resorption.  This finding suggests that regulates the ability of 
hematopoietic precursor cells to differentiate into osteoclasts, a process that has not been adequately examined.  Since increased 
rates of bone resorption appear to be the earliest known effects of estrogen withdrawal on the human skeleton, a better 
understanding of this process may lead to more effective therapies for the treatment of osteoporosis in both men and women.  
Specific Aim 1:Examine the osteoclastogenic potential of each of these three groups of older men by evaluation of bone 
marrow aspirates both before and after treatment with Estrogen (E2).
Specific Aim 2: Examine parameters of B-lymphocyte lineage development and osteoclast formation in cells from bone marrow 
including markers of B-lymphocyte lineage development, and the percentage of early and mature B-lymphocytes in the bone 
marrow before and after E2 treatment.  These studies will also evaluate the ability of fractionated (CD19+ and CD19-) bone 
marrow cells to form osteoclasts-like cells in vitro with and without treatment with receptor activator of NF-kappa B-ligand 
(RANKL) and monocyte- colony stimulating factor (M-CSF).  
Specific Aim 3: Examine the expression in the bone marrow of factors known to influence osteoclast formation including 
messenger ribonucleic acid (RNA) for RANKL, receptor activator of NF-kappa B (RANK), osteoprotegerin (OPG), M-CSF and 
the M-CSF receptor (c-Fms). We will also measure protein levels of RANK and c-Fms by flow cytometry.
SUBPROJECT PROGRESS:
Study is not actively recruiting
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0466 466PROTOCOL:SPID: RESEARCHTYPE:  
Nicotine Replacement Treatment (SNAP) Nicotine ReplacementSHORT TITLE:
LONG TITLE: Nicotine Replacement Treatment for Pregnant Smokers
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 214  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 12/2/2002
 266Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineONCKEN, CHERYL MD
SUBPROJECT DESCRIPTION:
Although medications are first-line treatment for smoking cessation in adults (1), and 30-40% of obstetricians prescribe or 
recommend over-the-counter nicotine replacement therapies for smoking cessation during pregnancy (2,3), little information 
on the efficacy or safety of these products is available for pregnant smokers. We propose a randomized, placebo-controlled, 
clinical trial to assess the utility of nicotine gum for smoking cessation during pregnancy.  Subjects for this trial will be recruited 
from a large prenatal clinic in Hartford, Connecticut.  This clinic serves an indigent population with a smoking rate of 29%.  In 
addition to testing the efficacy and safety of the intervention, we will examine predictors of response among the women and we 
will conduct an analysis of maternal genetic factors that can augment the adverse effects of smoking on the fetus.  
The specific aims of this study are:  to compare the efficacy of nicotine gum or a matching placebo for smoking cessation 
among pregnant smokers.  To examine whether nicotine versus placebo gum reduces the number of cigarettes smoked per day 
by pregnant smoker; to evaluate the safety of nicotine gum for smoking cessation during pregnancy.  Specifically, we will 
compare nicotine gum with placebo on overall nicotine exposure (as measured by salivary cotinine), overall tobacco exposure 
(as measured by exhaled carbon monoxide and urinary alkaloids), and birth weight at the time of delivery; to identify factors 
that determine which subjects benefit the most from the use of nicotine replacement therapy for smoking cessation during 
pregnancy; and to examine the interaction between maternal smoking and allelic variation at two genetic loci (CYP1A1 and 
GSTT1) on birth weight in a racially diverse sample of pregnant smokers.  As an exploratory aim we will also evaluate the 
interaction between smoking cessation and allele variations of other selected phase I and II genes of drug metabolism on birth 
weight.
SUBPROJECT PROGRESS:
Since the initiation of the study we have had approximately 33 subjects enrolled in the pilot study and have randomized 
approximately 194 subjects enrolled in the randomized trial. A paper has been written and sent to Obstetrics and Gynecology for 
publication.  We are awaiting a review. 
The genetics substudy continues to run. We have recruited approximately 380 smokers and 200 never smokers.  We also received 
de-identified samples from Duke University (about 140 new id's) depending on how many of these deoxyribonucleic acid (DNA) 
samples are useable, we are getting close to the goal of 565 pregnant smokers.  We plan to recruit until Jan 2008 and conduct 
follow-ups until July 2009.
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0467 467PROTOCOL:SPID: RESEARCHTYPE:  
Smoking CessationSHORT TITLE:
LONG TITLE: Smoking Cessation and Bone Remodeling in Adolescents
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/23/2002
 120Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineONCKEN, CHERYL MD
SUBPROJECT DESCRIPTION:
Adolescent smoking rates are higher than among adults.  High teenage smoking rates are due to increased smoking initiation 
rates in young persons and low success rates of adolescent smoking treatment programs.  Low success rates may result from 
treatments focusing on the long-term health risks of smoking, and adolescents being less concerned about these risks.  In order 
to optimize smoking treatment in adolescents, the Centers for Disease Control recommends that programs emphasize the 
immediate health benefits of smoking cessation (i.e., improved lung function, whiter teeth, better smelling breath).  
Unfortunately, these health benefits may not be meaningful enough for adolescents to quit smoking.  Other potentially 
persuasive benefits of smoking cessation, such as the effects of smoking cessation on bone remodeling, have yet to be fully 
explored.  This information holds promise to be beneficial for smoking treatment (especially in adolescent boys) if it can be 
presented in terms of maximal bone strength and height potential.  It also may provide useful information on the effects of 
smoking cessation for osteoporosis prevention and treatment, which may motivate the public health community to invest more 
dollars to combat the epidemic of teenage smoking.  The specific aims of this study are to determine the effects of smoking 
cessation on biochemical markers of bone turnover in adolescents and to elucidate the potential mechanisms by which smoking 
could affect bone turnover by measuring plasma cotinine concentrations and hormone profiles.
SUBPROJECT PROGRESS:
All subjects have been enrolled. There have been no new subjects enrolled in the report period. We plan to analyze the data this 
year. No unexpected safety concerns--this is a low risk study. No publications to date.
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0468 468PROTOCOL:SPID: RESEARCHTYPE:  
Genetics of Alcohol DependenceSHORT TITLE:
LONG TITLE: Genetics of Alcohol Dependence (Family Controlled Linkage Disequilibrium Studies in Alcoholism )
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 3  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/23/2002
 900Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryKRANZLER, HENRY MD
PsychiatryCONNER, TAMLIN PHD
PsychiatryDRAZINIC, CAROLYN MD
SUBPROJECT DESCRIPTION:
The only specific genes known to affect risk for alcohol dependence (AD) are some of those coding enzymes important for 
ethanol metabolism. Promising linkage regions have been identified in two genome scans, but for genetically heterogeneous 
disorders (like AD), strategies that rely purely on linkage in the absence of disequilibrium for gene localization are likely to be 
insufficient for gene discovery. Linkage disequilibrium (LD) studies, using methods such as the transmission-disequilibrium test 
(TDT) (Spielman et al., 1993), provide a possible solution, and delineation of the properties of these methods has been the 
subject of many recent studies. These methods address the gene localization shortcomings of linkage designs.
LD studies are complementary to conventional linkage approaches, but to be applied, they require specialized clinical materials, 
collected under rigorous ascertainment conditions. Our proposed sample will be recruited through affected probands and not 
conditioned on affection of more than one family member (although making use of multiple affecteds when available), and will 
be more representative of alcoholism in the target population than samples recruited based on multiple affecteds in each family. 
We will increase our chance of success by applying a novel approach to sample collection: we will specifically target the 
African-American (AA) population, a recently admixed population.
Extensive regions of LD in AA populations have been demonstrated by Lautenberger et al. (2000); our data support LD to >7 
cM in AAs recruited in Connecticut. While most project resources will be allocated to sample collection, we will also study a 
series of markers mapped to regions showing statistically significant linkage to AD in prior studies, and we will seek new markers 
in these regions and candidate loci.
SUBPROJECT PROGRESS:
We recruited 3 participants for this study between 3/31/07 and 4/1/08. We recruited a total of 967 subjects (261 control and 706 
affected individuals) in the study since its initiation. The study was closed to enrollment 4/2007.  Data anaysis still continues and 
we are in the process of applying for renewal.
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0469 469PROTOCOL:SPID: RESEARCHTYPE:  
Lower-Cost HIV Contingency ManagementSHORT TITLE:
LONG TITLE: Lower-Cost (Human Immunodeficiency Virus) HIV Contingency Management in a Group Setting
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 4  0  0
 0  0  0
 0  0  0
Offsite Visits  84  0  0
AIDS: Y
START DATE: 10/24/2002
 172Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryPETRY, NANCY PHD
PSYCHIATRY YALE UNIVERSITY, CT USACARROLL, KATHLEEN PHD
Medicine/Infectious DiseasDIECKHAUS, KEVIN MD
SUBPROJECT DESCRIPTION:
Voucher contingency management (CM) interventions are efficacious in enhancing retention in treatment and reducing drug 
use, but they have not been implemented widely in community-based programs.  A lower-cost CM procedure, that provides 
opportunities to win prizes ranging in value from $1 to $100, shows efficacy in retaining substance abusers in an HIV drop-in 
center (Petry et al., 2001), as well as in reducing substance use in traditional, community-based treatment programs (Petry et 
al., 2000; Petry & Martin, in press).  
The purpose of this study is to evaluate the efficacy of this CM technique in enhancing attendance, reducing drug use, and 
improving health among clients attending (Human Immunodeficiency Virus) HIV drop-in centers.  Specifically, 172 clients will 
be randomly assigned to one of two 6-month treatment conditions: standard 12-step oriented group treatment, or CM group 
treatment.  In the CM group, clients earn the chance to win prizes for submitting clean urine specimens and for complying with 
steps toward their treatment goals.  Activities related to improving health will be emphasized, such as attending medical 
appointments, recording daily medication consumption, getting prescriptions filled, and attending medication adherence support 
groups.  Group attendance, drug use, medical problems and services received, and risky drug use and sexual behaviors will be 
measured pre-treatment, at months 3 and 6, and at 9- and 12-month follow-up evaluations. 
Compared to the control condition, we expect that those assigned to the CM condition will show greater retention in treatment, 
reductions in drug use, improvements in health, and decreases in risk behaviors.  This study represents an important extension 
of our previous and ongoing work in low-cost CM in that it involves a specific population of substance abusers (HIV-positive), 
expands our work to non-traditional, community-based settings (drop-in centers), and implements the CM approach in a group 
(rather than individual) format.
SUBPROJECT PROGRESS:
Total Enrollment: 172
Past Year Enrollment: 0
No changes in recruitment plans are needed (enrollment is complete).
• No unexpected safety concerns have occurred.
• Interim data and outcomes are not available.
• No changes were made to the protocol and none are anticipated.
• Results not yet published as study is ongoing.
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through March 31, 2009?  No, study is completed
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0470 470PROTOCOL:SPID: RESEARCHTYPE:  
Mu-Opioid Receptor Polymorphism and HPASHORT TITLE:
LONG TITLE: Examination of the Dose Effect of a Functional Polymorphism at the Mu-Opioid Receptor Locus 
(OPRM1) and Hypothalamic-Pituitary-Adrenal (HPA) Axis Activation
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/17/2002
 20Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
NY CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase II-III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryCOVAULT, JONATHAN MD, PHD
PsychiatryDEMARTINIS, NICHOLAS MD
PsychiatryKRANZLER, HENRY MD
SUBPROJECT DESCRIPTION:
Individuals with the variant form of the A118G (Asn40Asp) polymorphism in exon 1 of the m-opioid receptor gene (genetic 
locus OPRM1) appear to have a greater cortisol response to opioid blockade after naloxone administration. This study will 
examine whether there is a dose-effect relationship between the presence of the variant Asp40 allele and HPA axis activation 
by opioid blockade. Additionally, we will examine the relationship between Asn40Asp alleles and measures of anxiety, distress, 
and cardiovascular reactivity following the naloxone challenge. 
METHODS:  The study will employ a balanced, within-subject design involving two test days over a period of 3-7 days to 
examine cortisol response to intravenous naloxone (125 mcg/kg) or placebo in 36 healthy subjects (12 subjects in each of the 
three genotypic groups: Asn40 homozygotes, heterozygotes and Asp40 homozygotes).  Deoxyribonucleic acid (DNA), isolated 
from whole blood will be POlymerase chain reaction (PCR)-amplified and genotyped using artificial restriction sites, restriction 
enzyme digestion and agarose gel size fractionation. Plasma cortisol will be measured at 15-minute intervals over 120 minutes 
post infusion.
SUBPROJECT PROGRESS:
1) Number of subjects enrolled during the report period:  none.  Since initiation of study:  43.  
2) Planned changes in recruitment plans: The study has been closed for enrollment since November 2005, the last subject ended 
participation in December 2005. 
 
3) Unexpected safety concerns and their resolution:  None occurred.
4) Interim data:  The OPRM1 Asn40Asp was unexpectedly found to associate with cortisol reponse only in subjects of 
European-American heritage.  Large differences in genetic background may have large effects even on biologically functional 
genetic variants such as the Asn40Asp coding polymorphism.  The results of this analysis have been published during the past year. 
5) Proposed changes made or anticipated in the protocol:  None.
6) Continued GCRC support requested - We request the GCRC protocol remain active with the potential request for additional 
genotyping of the study participants at additional candidate loci related to regulation of the Hypothalamic-pituitary-adrenal (HPA) 
axis.
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0471 471PROTOCOL:SPID: RESEARCHTYPE:  
Discovery and Assessment of Genetic and EnvironmentSHORT TITLE:
LONG TITLE: Discovery and Assessment of Genetic and Environmental Factors that Influence Severity and Progression 
of Hepato-Biliary Pancreatic Disease and Cancerµ-Opioid Receptor Polymorphism and 
Hypothalamic-Pituitary-Adrenal (HPA) Axis Activation
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 1  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/4/2002
 1,000Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
GASTEROENTEROLOGYPROTIVA, PETR MD
PsychiatryABU-HASABALLAH, KHAMIS PHD
PsychiatryCOVAULT, JONATHAN MD, PHD
SUBPROJECT DESCRIPTION:
Host genetic, acquired factors and environmental influences affect the development, severity, progression, and outcome of 
many chronic diseases, including hepato-biliary-pancreatic diseases.  To facilitate the discovery of new genetic factors that 
influence development or progression of chronic diseases, we need to develop tissue and Deoxyribonucleic acid (DNA) banks and 
correlate results of polymorphisms and mutational analyses (genotypes) with patient and clinical characteristics (phenotypes).  
To provide the necessary databases for such studies, we need to build-up clinical databases and tissue and DNA banks.  This 
project is designed to accomplish this for patients with hepato-biliary diseases seen at UConn who will be undergoing liver 
biopsies for reasons unrelated to this study.  We expect the database and specimen repository thus developed will allow us to 
perform important and informative new analyses, and will form the basis for new grant and contract applications in the future.  
It will serve as a paradigm for other studies in other diseases and disorders.  The potential is great for studies of the kind.  We 
need support from the GCRC cores in order to get these initiatives off to a successful start.
SUBPROJECT PROGRESS:
There were no subjects enrolled during the report period. There are a total of 142 subjects enrolled.  There are no changes to 
recruitment at this time there are no unexpected safety concerns at this time there have been no publications at this time
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0477 477PROTOCOL:SPID: RESEARCHTYPE:  
SH2 ProfilingSHORT TITLE:
LONG TITLE: Feasibility of Src Homology 2 (SH2) Profiling as a Molecular Diagnostic Tool for Patients with 
Hematological Malignancies
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 12/10/2002
 40Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Genetics & Dev. BiologyMAYER, BRUCE PHD
Medicine/Hem-OncBONA, ROBERT MD
Ctr for ImmunotherapyLI, ZIHAI MD, PHD
SUBPROJECT DESCRIPTION:
There is a need for molecular diagnostic tools that will allow the classification of tumors beyond what is currently possible using 
standard techniques.  Ideally, markers will be identified that will have prognostic value (correlate with response to particular 
treatments, for example).  Expression profiling using Complementary Deoxyribonucleic acid (cDNA) microarrays is now being 
tested for this purpose, but is at present cumbersome, costly, and is unlikely to give any information about the molecular defects 
in the tumor cell.  We are developing a novel molecular diagnostic technique based on the profile of proteins in a tumor sample 
that bind to certain protein domains known to play an important role in signal transduction.  In preliminary experiments this 
technique can identify different binding profiles in similar tumor types, suggesting it may be a valuable molecular diagnostic tool.  
The resulting profiles may also be informative about the molecular defects in a particular tumor.  We propose to test this 
technique on samples from hematopoietic malignancies available at the UConn Health Center to establish the feasibility of 
implementation on a larger scale. Ultimately, if the technique is sufficiently robust and reproducible, we will correlate profiling 
data with patient information to determine whether the interaction profiling provides information with prognostic value.
SUBPROJECT PROGRESS:
No patients were enrolled in the past year, and a total of 57 have been enrolled over the course of the study to date. In 
consultation with General Clinical Research Center (GCRC) staff and leadership, we have decided to transfer coordination of this 
study to the Neag Cancer Center. This will make more sense in terms of logistics, as Cancer Center staff and nurses are on the 
appropriate wards continuously and can identify and consent subjects more easily. 
This study was closed in the GCRC as of 3/31/08.
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0478 478PROTOCOL:SPID: RESEARCHTYPE:  
IronSHORT TITLE:
LONG TITLE: The Role of Iron, Hemochromatosis Gene (HFE) Mutations, and Polymorphisms of other Genes in Chronic 
Hepatitis C (CHC)
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 1/9/2003
 2,400Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
GASTEROENTEROLOGYPROTIVA, PETR MD
PsychiatryCOVAULT, JONATHAN MD, PHD
Pharmacology & ToxicologyLAMBRECHT, RICHARD PHD
Ctr for BiostatisticsWALSH, STEPHEN J SCD
SUBPROJECT DESCRIPTION:
The success of the human genome project provides the promise of a new era in understanding and modifying human disease.  It 
seems both likely and feasible that, during the next generation, we will identify the major host genes and their genetic 
variations, which modulate susceptibility to and severity of disease and responsiveness to medical therapies.  To translate this 
promise into reality will require careful clinical characterizations of different patient phenotypes, coupled with determination of 
genotypes (genetic variations), gene expression information Messenger Ribonucleic Acid (mRNA's by microarrays, etc.), and 
information about translation of mRNA's into proteins (proteomics).  A few studies have already identified genotypes that 
predict with greatly improved accuracy susceptibility to chronic vascular or neoplastic diseases and/or severity and outcome of 
these diseases.  This project will take full advantage of the samples and clinical data obtained through the landmark HALT-C 
Trial, in order to develop a similar body of knowledge for chronic hepatitis C (CHC).  
The long-term goal of this program is to ascertain the major genetic variations that predispose patients to develop advanced 
CHC and/or lack of responsiveness to (Interferon) IFN-based treatment.  We will concentrate our efforts on variations in 
selected genes, which in previous smaller studies, have been shown to predict severity of CHC and/or responsiveness to IFN 
treatment.  Specifically, we will delineate the role of iron, HFE gene mutations, and/or polymorphisms in other selected genes 
or gene promoters on the production and progression of CHC.  Our major hypotheses are that hepatic iron, mutations of the 
HFE gene associated with human leukocyte antigen (HLA)-linked hereditary hemochromatosis (HHC), and/or selected 
polymorphisms in other genes, are important host factors that influence the progression of chronic hepatitis C to cirrhosis, 
decompensation, and hepatocellular carcinoma and/or the response of CHC to IFN-based therapies.  
The specific aims of this project are:
To determine whether there is a direct correlation between progression of chronic hepatitis C (i.e., the major endpoints of the 
HALT-C Trial) and hepatic or total body iron content and/or the presence of the HFE gene mutations (C282Y, H63D, S65C) 
associated with HHC;
To determine whether there are correlations between progression of chronic hepatitis C and polymorphisms of the 
angiotensinogen promoter (Ang-P), apolipoprotein E (apo-E) genotype, the interleukin-I0 promoter (IL-10-P), microsomal 
epoxide hydrolase (mEH), transforming growth factor-beta (TGF), or the tumor necrosis factor-alpha promoter (TNF-P);
To explore whether there are significant interactions among mutations of HFE, polymorphisms of other genes, and patients' 
responses to therapy or long-term outcomes; and 
To determine whether the frequencies of these genetic variations differ significantly among subjects in the HALT-C Trial vs 
other subjects with less advanced CHC, or control subjects without CHC, matched for age, sex, and ethnicity.
SUBPROJECT PROGRESS:
There were no subjects enrolled during the current report period. There were 282 subjects enrolled since initiation.
There are no changes in recruitment plans that might be needed or unexpected safety concerns at this time.
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Data analysis going on currently.
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SUBPROJECT DESCRIPTION:
Oral mucositis refers to inflammatory, erythematous, erosive or ulcerative lesions of the oral mucosa seen in 60-90% of 
patients undergoing radiation therapy for head and neck cancer to fields involving the oral cavity. These lesions are painful, 
compromise nutrition and become secondarily infected. Hospitalization is required for pain control and nutritional support in 
approximately 15% of cases. Further, severe oral mucositis can necessitate interruptions in radiation therapy thus 
compromising cancer therapy. No agent is currently available to prevent oral mucositis or reduce its severity.
Available evidence implicates inflammatory responses to radiation therapy and to products of colonizing microorganisms in the 
pathogenesis of oral mucositis. The use of anti-inflammatory agents in oral mucositis has not been well-studied. However, the 
limited available data using non-steroidal anti-inflammatory drugs (NSAIDS) indicates that this is a promising approach. The use 
of celecoxib, a selective Cyclooxygenase-2 (COX-2) inhibitor, in radiation-induced oral mucositis has not been previously 
studied. Celecoxib offers several potential advantages in this setting as compared to conventional NSAIDS.
This pilot study is intended to generate preliminary data in preparation for submission to extramural funding sources. This 
randomized, double-blind, placebo-controlled pilot study will evaluate celecoxib in ten subjects at high risk for developing 
radiation-induced oral mucositis. Subjects will be randomized to 200 mg bid celecoxib or placebo (both by mouth) in a 1:1 ratio. 
They will be asked to use the study medication daily starting 5 days before the first day of radiation therapy until 3 days after 
the end of radiation therapy. The primary endpoint will be the investigator's evaluation of severity of oral mucositis using the 
Oral Mucositis Assessment Scale (OMAS). OMAS scores will be compared between the two groups to assess the impact of 
celecoxib on mucosal injury. The secondary endpoint will be evaluation of pain severity using the severity subscale of the Brief 
Pain Inventory. Additional assessments will include evaluation of 1. medications used for pain management 2. normalcy of diet  
3. type, dose, duration and fields of radiation therapy and 4. mucosal injury using the World Health Organization (WHO) and 
Common Toxicity Criteria (CTC) mucositis scales. 
Further, 2 mm punch biopsies of the oral mucosa will be obtained from consenting subjects in both groups at four time-points. 
Levels of selected enzymes, prostanoids and receptors involved in the cyclooxygenase pathway will be measured. In addition, a 
10 ml blood sample will be obtained from subjects in both groups at four time-points. These blood samples will be used to 
measure levels of selected prostanoids generated via the cyclooxygenase pathway and of selected cytokines that induce COX-2 
expression. Comparison between the two groups will allow assessment of the role of the cyclooxygenase pathway in radiation 
mucositis and the impact of celecoxib. Correlations will be examined between levels of prostaglandins whose synthesis is 
mediated by COX-2 and mucosal injury and pain in radiation-induced oral mucositis. 
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This line of research could lead to the development of an agent to prevent or reduce the severity of oral mucositis. This would 
substantially decrease morbidity in these patients. In addition, it may also improve patient prognosis by avoiding breaks in 
cancer therapy.
SUBPROJECT PROGRESS:
Number of subjects enrolling during the report period: 3 and since initiation of the study: 10 
Any changes in recruitment plans that might be needed: None 
Unexpected safety concerns and their resolution: None 
Interim data and outcomes if appropriate: None 
Any proposed changes made or anticipated in the protocol: Currently, only patients who receive head and neck radiation therapy 
with concurrent chemotherapy are eligible for the study. We have submitted a protocol modification request to the Institutional 
Review Board (IRB) to allow patients who are receiving head and neck radiation therapy without concurrent chemotherapy to also 
be eligible for the study.
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SUBPROJECT DESCRIPTION:
The long-term goal of this study is to understand the molecular mechanisms of neoformation of dermal  tissue in fibrotic 
diseases. To achieve this goal we study hereditary keloid formation. Keloids are benign tumors of the skin or cornea caused by 
overactivity of fibroblasts during abnormal wound repair. The relatively large number of familial cases of keloid formation 
makes it possible to propose a genetic approach for the identification of a gene responsible for increased cell proliferation and 
extracellular matrix expression. We perform genome wide screening and linkage analysis of suitably large families afflicted with 
the autosomal dominant form of hereditary keloid formation. Subsequently we identify and analyze the chromosomal loci.  We 
have identified  possible disease gene loci and are now in the process of establishing high resolution maps of the keloid loci.  
Additional families need to be identified and recruited to verify and further characterize the loci. These families will be tested for 
co-localization. Suitable families that do not co-localize to an existing locus will be used for genome wide screening.
SUBPROJECT PROGRESS:
Total number of patients enrolled as of 3/31/2008: 685
Current Year Enrollment: 124
Changes in recruitment plans: No changes needed. 
Unexpected safety concerns and their resolution: None 
Interim data and outcomes: 
-We have enrolled 124 subjects during the reporting period. 
-The General Clinical Research Center (GCRC)-sponsored pilot project for recruitment in Nigeria is highly successful. 
-Preliminary mapping has been performed with a pilot grant from the GCRC.
Proposed changes made or anticipated in the protocol:
- We tested the families for consistency using Combined DNA Index System(CODIS) markers and for exclusion or linkage to 
published keloid loci on chromosomes 7 and 2.
-Hepatocyte Growth Factor (HGF) was tested for mutations.
We will need to test more families for consistency in the coming period.
Publications: None
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SUBPROJECT DESCRIPTION:
Glaucoma is an optic neuropathy that affects over 67 million people worldwide. This condition has broad clinical manifestation, 
possibly resulting from a significant genetic heterogeneity that exists within this group. Glaucoma is divided into many clinical 
subtypes, ranging from onset at birth to very late in life. The most common form, Primary Open Angle Glaucoma (POAG) has 
a prevalence of about 1% of a predominantly white population over 40 years of age. Several genetic loci have been identified 
for POAG but so far only mutations in Myocilin gene are predominantly reported in juvenile-onset and certain other 
adult-onset cases. 
Recently, we identified a gene that is primarily involved in a subgroup of Adult-Onset POAG, commonly known as Normal 
Tension Glaucoma (NTG). This gene that we named Optineurin (for "Optic Neuropathy Inducing" protein; OPTN) is mutated 
in 16.7% of our hereditary NTG families. This gene maps to the GLC1E locus on 10p14 and has 13 coding exons that encodes 
for a protein with 577 amino acids (~66-kDa). Our OPTN protein studies showed co-localization with Golgi, secretion into 
aqueous humor and expression in many ocular and non-ocular tissues. Cloning of both mouse and monkey genes showed very 
similar patterns of Messenger Ribonucleic Acid (mRNA) and protein expression to human OPTN. It has also been shown by 
other investigators that OPTN interacts with Ad E3-14.7K, Huntington, TFIIIA, RAB8 and 2 other unknown kinases. 
Although existing evidence suggests that OPTN, through its interaction with other proteins may be utilizing TNF-á or 
Fas-Ligand pathways to mediate apoptosis, inflammation or vasoconstriction, as yet there is no clear indication on how OPTN 
mutations lead to either NTG or POAG. Therefore, as an initial step towards understanding the function of this gene and its 
protein products we propose to do the following: 1)-Screen a large number of glaucoma patients for OPTN mutations by 
SSCP/DHPLC and Automated Deoxyribonucleic acid (DNA) sequencing to establish a firm genotype/phenotype correlation. 
This specific aim will be done as a main part of this GCRC protocol. In a complementary study we plan to: 2)-Identify 
promoter, its transcription start points, binding sites, regulatory elements and to study its activity and expression patterns; 3)
-Use OPTN as "bait" and search for new interacting proteins by a Yeast Two Hybrid System and to search for protein motifs 
that are important for OPTN function; 4)-Determine ultracellular localization of OPTN in normal and glaucomatous eyes by 
immunogold labeling; 5)-Study specific sites of localization of OPTN in normal and glaucomatous eyes by 
immunohistochemistry and to determine its potential differential expression patterns; and 6)-Use In Situ hybridization to study 
developmental expression patterns of OPTN in mouse embryos. 
At the conclusion of this investigation, it is anticipated that our study will provide essential information that one day may 
contribute to the design of innovative drug intervention in this group of optic neuropathies.
SUBPROJECT PROGRESS:
During the last year a total of 180 blood samples were processed by the General Clinical Research Center (GCRC) Molecular Core 
Laboratory for Deoxyribonucleic Acid (DNA) extraction. Most of these were re-extraction of samples from patients that recruited 
into the study in the prior years. 
The number of participating patients has generally been much less than expected. There have been no changes to our active 
recruitment of these patients for this study. However, despite the fact that our clinical collaborators are still actively recruiting 
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patients for this study, the numbers of patients that volunteered for this study have been limited. There has been no safety concern 
on any of the patients recruited during this time. The samples obtained and processed during the prior years will be analyzed 
together with other samples that have been processed in our laboratory. We have not made any changes to our protocols and 
anticipate that no changes are necessary to our current protocol for the upcoming year of this study.
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SUBPROJECT DESCRIPTION:
In the US, heavy drinking occurs commonly and is associated with a variety of alcohol-related problems. Available treatments 
for problem drinking have limited efficacy.  This proposal is for a 12-week, placebo-controlled trial of naltrexone (50 mg 
orally) in 200 problem drinkers.  Problem drinkers are those individuals whose drinking puts them at risk of a variety of 
psychosocial and medical problems, including alcohol dependence, but who are not physically dependent on alcohol.  They are 
estimated to comprise up to 20% of the general population.  The study will employ a factorial design in which the effects of 
medication (naltrexone vs. placebo), schedule of medication administration (i.e., daily vs. targeted), and the interaction of these 
factors on drinking behavior will be examined.  Targeted administration refers to the use of medication to cope with anticipated 
high-risk drinking situations.  The primary outcome measures will be drinking days and heavy drinking days.  Secondary 
outcomes will include alcohol-related problems and biological measures of alcohol consumption (i.e., serum Gamma glutamyl 
transpeptidase (GGTP) and Carbohydrate-Deficient Transferrin CDT).  
The study will extend the results of a recently completed 8-week trial of targeted naltrexone in early problem drinkers.  That 
study showed a significant advantage of naltrexone over placebo on heavy drinking days and for targeted administration on daily 
drinking.  The effects of targeted administration diminished substantially over time, apparently due to the schedule that was used 
for targeted medication administration.  
In the proposed study, the targeted medication schedule has been modified, the sample size increased, the duration of treatment 
lengthened and a pharmacogenetic analysis added to examine the effect of allelic variation at candidate loci on the response to 
naltrexone.  The daily monitoring of mood, desire to drink, perceived self-efficacy, and drinking behavior will make it possible 
to examine in depth the processes by which the study variables exert their effects.  
Daily monitoring will be performed using automated telephone interviews, with in-person follow-up evaluations conducted at 3 
and 6 months post-treatment to provide a measure of the durability of treatment effects.  A pharmacogenetic analysis based on 
preliminary evidence showing that a functional polymorphism in the gene encoding the mu-opiate receptor (OPRM1) affects 
response to naltrexone will serve to explore an important source of variation in the response to naltrexone treatment.  
Exploratory analyses involving other the gene encoding the delta opioid receptor (OPRD1) will also be conducted.  Careful 
evaluation of the study hypotheses will provide important information on the efficacy and mechanism of the effects of targeted 
naltrexone in problem drinkers.  This study will allow us to model effects across multiple levels of analysis in an effort to apply 
novel genetic findings to understanding the psychopharmacological mechanisms underlying the therapeutic effects of 
naltrexone in problem drinkers.
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SUBPROJECT PROGRESS:
A total of 8 subjects were enrolled during the report period (a total of 192 since initiation of the study).  Subject enrollment began 
in January 2003 and was completed in May 2007.  Of the 192 subjects enrolled, 29 subjects were excluded and were not randomized 
to receive study drug (due to meeting exclusionary criteria, having out-of-range bloodwork results, or deciding not to participate).  
A total of 163 subjects were randomly assigned to receive either naltrexone or placebo, administered on either a daily or a targeted 
basis.  Of the 163 subjects randomized to study treatment, 138 (85%) completed treatment and 25 (15%) withdrew early (5 due to 
medication side effects, 7 due to lack of efficacy, and 13 due to other issues unrelated to study medication).  The last treatment was 
delivered in August 2007 and the last follow-up assessment was completed in March 2008.  
Follow-up data at 3 and 6 months post-treatment are available for 142 (87%) and 138 (85%) of patients, respectively There were 
no unexpected safety concerns associated with this study. This study used interactive voice response technology (IVR) for daily 
data collection, with support from the General Clinical Research Center (GCRC). Compliance with the daily reporting of moods, 
events, drinking, and medication usage approached 90% of days for subjects while in the study, and was about 80% for all possible 
days, suggesting that data analysis will be able to proceed as planned. 
Changes made in the protocol during the report period include the following: 1) addition of a statistician co-investigator (Grace 
Chan); 
2) due to a letter from the Office of Human Research Protections (OHRP), the study protocol was reviewed and modified (where 
necessary) to cover the Deoxyribonucleic Acid (DNA)/genetic testing aspects of the study (including: an explanation of the 
purpose of the DNA testing aspects of this research study and a description of the DNA tests to be run on the collected samples; a 
description of any foreseeable risks and discomforts to the subjects regarding DNA testing; a description of any benefits to the 
subject or others that may reasonably be expected from the DNA testing; and a statement describing the extent to which the 
confidentiality of these records/samples identifying the subject will be maintained; 
3) the protocol was modified to explain that DNA samples and phenotypic datasets will be de-identified before any examination of 
genetic markers for risk of alcohol dependence is resumed (and a notification will be sent to the IRB once all DNA samples and 
phenotypic data are completely de-identified); 
4) protocol language was modified to reflect that women who become pregnant are withdrawn from the study; 
5) removal of a co-investigator (Carlos Hernandez-Avila).  There have been no recent publications associated with this study since 
data analysis is ongoing.
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SUBPROJECT DESCRIPTION:
Lyme disease is the most frequently reported tick-borne infection in the United States. People who live in areas that are 
endemic for Lyme disease are often repeatedly exposed to bites of uninfected as well as infected Ixodes ticks and recurrent 
episodes of this infection have been reported. We found that about 14% of people experiencing Lyme disease on Block Island, 
Rhode Island suffered recurrent infection and that subsequent episodes of infection were associated with fewer symptoms than 
the initial infection. It is unclear whether a similar rate of recurrence and a milder clinical outcome during recurrent episodes 
occur at endemic mainland sites. It is also unclear what prevents the majority of people from experiencing either initial 
infection or recurrent infection when they are repeatedly exposed to Borrelia burgdorferi-infected ticks. Although immunity 
against the causative pathogen probably helps limit recurrence, immune responses directed against the tick vector also may help 
prevent initial and repeated infections. Our first two objectives are to compare frequency and clinical outcomes of recurrent 
Lyme disease on Block Island and at mainland sites in southern New England and New York. Our third objective is to examine 
relationships among immune responses to I. scapularis salivary gland proteins and protection against the development of 
primary and recurrent B. burgdorferi infections. In particular, we propose three specific aims.
1. Determine whether the frequencies of primary and recurrent Lyme disease differ among residents of Block Island, RI and of 
southern New England and New York. 
2. Determine whether the acute symptoms of repeated episodes of Lyme disease are less severe than the initial episode of Lyme 
disease.
3. Determine whether immune factors directed against the tick Ixodes scapularis are protective against B. burgdorferi 
transmission and whether they correlate inversely with the incidence of primary and recurrent Lyme disease. 
This proposed body of work will provide a basis for understanding the frequency and clinical outcome of recurrent Lyme disease 
and how immune factors directed against the tick vector may limit the incidence of recurrent Lyme disease and other tick-borne 
infections.
SUBPROJECT PROGRESS:
1. The number of subjects enrolled during the report period was 290.
2. The number of subjects enrolled since initiation of the study has been 2587.
3. No changes in recruitment plans have been needed.
4. There have been no unexpected safety concerns.
5. Interim data and outcomes have been summarized in the papers and regional/national talks listed below.
6. There were no proposed changes to the protocol during the reporting period; however, we are planning to submit National 
Institute of Health (NIH) grants for babesiosis and Lyme disease diagnostic studies and a babesia immunity study during the next 
reporting period. These will be collaborative studies with investigators from other universities. We plan to initiate pilot studies as 
part of these studies this summer.
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SUBPROJECT DESCRIPTION:
Temporomandibular joint dysfunction (TMD)is a widespread chronic pain condition. A number of psychosocial treatments for 
TMD have been developed that have been successful for a majority of patients. The mechanisms by which these treatments 
achieve their effects, however, are not well specified. The general goal of the current study is to evaluate the cognitive, 
behavioral, and physiological mechanisms of treatment to discover what accounts for treatment gains in this disorder. To do 
this we will deliver to patients a brief cognitive-behavioral treatment designed to maximize adaptive cognitions and behaviors, 
while periodically monitoring their pain, thoughts, feelings, and coping behaviors using an experience sampling paradigm. 
Specifically the aims are as follows:
1.  To evaluate the effects on TMD patients' pain and psychosocial functioning of a brief treatment that combines a standard 
splint therapy with a focused cognitive-behavioral program (STD+CBT) intended to maximize coping self-efficacy and 
minimize catastrophization in response to specific pain-related circumstances. 
    H1. It is hypothesized that patients exposed to the brief cognitive behavior treatment will have better outcomes than will a 
group of patients given a standard conservative treatment based on splint therapy without cognitive-behavioral treatment.        
2.  To determine what situational factors and dispositional factors are predictive of general adaptation and pain perception 
following TMD treatment. 
    H2. It is expected that both dispositional factors, and situational factors measured four times daily, will play a role in 
predicting adaptation and pain following treatment.
3.  To determine specifically what moods, cognitions and coping behaviors are changed as a result of treatment. 
    H3. It is predicted that patients in the STD+CBT treatment will exhibit increased numbers of specific coping behaviors, 
improved mood, higher self-efficacy for pain control, and decreased frequency and intensity of catastrophization as measured in 
real time, as compared to STD patients, and that these changes will be associated with treatment outcome.
4.  To determine what effects treatment per se may have on measures of physiological stress and cell-mediated immunity. 
    H4. It is expected that, at the follow-up points, subjects in the STD+CBT group will have lower levels of plasma cortisol and 
lower levels of proinflammatory cytokines than will the STD subjects.
5.  To determine whether changes in treatment-related situational process variables such as self-efficacy are associated with 
changes in cortisol and cytokine levels, suggesting that psychosocial treatments act partly by altering HPA axis and 
cell-mediated inflammatory processes. 
    H5. It is hypothesized that changes in number of coping behaviors used and changes in situational self-efficacy and 
catastrophization will be correlated with changes in cortisol and cytokine levels from pre-to post-treatment.
The results may indicate what classes of variables need to be addressed to enhance treatment for TMD sufferers, and start to 
pinpoint the true active mechanisms accounting for improvement in TMD treatment. If these mechanisms can be successfully 
identified it would have implications for the development of more effective treatment programs for TMD and for related 
disorders.
SUBPROJECT PROGRESS:
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100 subjects have been enrolled, 12 since last progress report. Enrollment is now completed. 87% have provided posttreatment 
data, 80% have provided 6-month data, and 87% have provided 9-month data.  There are no safety concerns. There are no 
interim data or outcomes available at this time. No publications have been prepared to date, but two are in preparation. One 
scientific presentation was made in March 2008. The General Clinical Research Center (GCRC) was cited as a contributor to this 
talk.
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SUBPROJECT DESCRIPTION:
The primary objectives of this study are:  to compare the combination of 2 NRTIs plus a protease inhibitor (PI) versus 2 
Nucleoside Reverse Transcriptase (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) as initial therapy, 
followed by second-line therapy if failure occurs, in terms of their effects on a long-term virologic endpoint and to compare two 
different viral load criteria for switching from first-line to second-line therapy in HIV Antiretroviral Naive Children > 30 Days 
and < 18 years of age.
SUBPROJECT PROGRESS:
Pediatric Acquired Immune Deficiency Syndrome (AIDS) Clinical Trial Group (PACTG) 390 (Version 3.0) has had a total 
enrollment of  two subjects at the Connecticut Children's Medical Center since the initiation of the study. Both of these subjects 
have discontinued study participation as of Nov. 2007 due to the overall PACTG Site closure at Connecticut Children's Medical 
Center.  The closing was due to non-refunding of the site.  
This study has been closed to accrual.  
There have been no unexpected safety concerns reported by The PACTG 390 team.
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NSABP B-35SHORT TITLE:
LONG TITLE: NSABP B-35: A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with 
Ductal Carcinoma in situ (DCIS) Undergoing Lumpectomy with Radiation Therapy
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Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
This Phase III randomized, double-blind study will evaluate the effectiveness of anastrozole compared to tamoxifen in 
preventing the subsequent occurrence of breast cancer (local, regional and distant recurrences, and contralateral breast cancer) in 
postmenopausal women with primary ductal carcinoma in situ (DCIS) treated with lumpectomy and breast radiation.  In 
addition, this study will compare adjuvant anastrozole to tamoxifen in terms of time to invasive breast cancer, ipsilateral 
recurrence, contralateral breast cancer, other non-breast second primary cancers, osteoporotic fractures, disease-free survival, 
and overall survival.  Also, B-35 will ascertain the effects of anastrozole on patients' symptoms and quality of life as compared 
to tamoxifen.  Analysis will include an endpoint based on survival time adjusted for the quality of life experienced.
SUBPROJECT PROGRESS:
Local Report:
University of Connecticut Health Center (UCHC): 5 patients were enrolled.  Four patients are receiving study medication and are 
doing well with no evidence of disease.  One patient discontinued study drug because of the side effects she was experiencing but did 
not withdraw her consent and is continuing with the quality of life questionnaire.  This patient is alive and doing well.
The Hope Clinic: 2 patients were enrolled:  One patient is still receiving study and doing well, was last seen on 04/21/2008.  One 
patient drug was discontinued because she developed tuberculosis, which was unrelated to the study medication.  This patient is also 
doing well
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Center on AgingKENNY, ANNE MD
Center on AgingKUCHEL, GEORGE MD
Genetics & Dev. BiologyMOHLER, WILLIAM PHD
SUBPROJECT DESCRIPTION:
 Although frailty has been difficult to define, Fried and her colleagues have established criteria for frailty based on physical ad 
psychological characteristics.  These characteristics include unintentional weight loss (10 or more pounds per year), 
self-reported exhaustion, weakness as measured by grip strength, slow walking speed, and low physical activity (Fried et al., 
2001).  With a framework to examine frailty, we propose to explore more fully the pathophysiology of sarcopenia in frail and 
non-frail older individuals.  In Frontera et al. 2000 and Balagopal et al. 1997, the authors hypothesized that sarcopenia largely 
results from the decreased ability for the replacement of dysfunctional contractile proteins within the myofilament lattice. 
Exploiting the signal in Second Harmonic Imagine Microscopy (SHIM), which is derived from and sensitive to the local density 
and alignment of contractile proteins within muscle sarcomeres, this new mode of non-linear laser-scanning microscopy will 
allow quantitative analysis of both the histology and molecular structure of completely native, intact muscle tissue.  Thus far, 
few studies to date have provided extensive and quantitative ultrastructural examination of muscle from very old individuals 
(Frontera et al. 2000).  Fiatarone Singh and colleagues, reported data outlining aspects of muscle damage in frail elders using 
electron microscopy, which has limitations in comparison to SHIM.
SUBPROJECT PROGRESS:
The study to assess the differences in high resolution muscle imaging in frail and non-frail individuals and correlate the changes to 
clinical outcomes is ongoing. Preliminary data suggest that there may be measurable differences in muscle morphology in frail and 
non-frail adults or at least correlations with physical performance measures. We have worked in the last year to better objectively 
quantify the output from the high resolution imaging. We now believe we should compare samples from young and old adults. We 
have recruited 6 subjects (3 M, 3F) within the last year. The samples and data has been analyzed and we are again working out 
methodology issues with the SHG. We may need to recruit another 6 individuals once this methodology issue has been resolved. We 
have had no unexpected safety concerns. No further changes in protocol have been made. There have been no publications from 
the work but preliminary data was presented at the 2004 meeting (May) of the American Geriatrics Society in Washington, DC. 
We request further General Clinical Research Center (GCRC) support for the project while we continue to work through the 
laboratory methods and prepare to biopsy a final 6 subjects.
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Center on AgingKENNY, ANNE MD
Medicine/GeriatricsBOXER, REBECCA MD
Medicine/Cardio-PulmonaryHAGER, DAVID MD
ImmunologyMCELHANEY, JANET MD
SUBPROJECT DESCRIPTION:
Background:  Congestive heart failure (CHF) is common in those defined as frail. CHF may increase bone and muscle loss, due to 
either pathophysiology or treatment. In this study we set out to evaluate bone mineral density (BMD), and muscle mass in an 
older population with congestive heart failure compared with healthy aged matched controls.  
Methods: Subjects were recruited from a university CHF clinic if ejection fraction (EF) was 40%. Healthy controls were recruited 
from the community. Participants were assessed for level of frailty with the 5-step frailty phenotype(1) including self reported 
weight loss, grip strength, energy level, walk time, and physical activity. Lean tissue masses, appendicular skeletal muscle 
mass/height2 (ASM/Ht2) and bone mineral density were assessed by dual x-ray absorptiometry.  
Results: There were 83 subjects; 60 with CHF (43M,17W), 23 (15M,8W) healthy age matched controls. The mean age of CHF 
men was 76.5+8.9 and women 77.7+12.2, control men 76.8+9.0, control women 78.1+10.6. NYHA classification was class I 
and II n=35; III and IV n= 25 and mean EF was 28.9+8.0. Frailty phenotype score for CHF was 28.3% (n=17) not frail, 45% 
(n=27) pre-frail, and 26.7% (n= 16) frail compared to controls 47.8% (n=11) not frail, 52.1% (n=15) pre-frail, and 0% frail. 
Sarcopenia was present in 12.5% women and 20.9% men with CHF, and 12.5% women and 26.7% men of controls. In separate 
regression models of femoral neck (fnBMD) and ASM/Ht2, the variables of age and gender were significant (age p=0.007; 
p<0.00) and gender p=0.031, p<0.001) but the diagnosis of CHF was not. Regressions of fnBMD and ASM/Ht2, controlling for 
age and sex, showed a significant relationship with frailty score (p= 0.02) and EF (p=0.03) for fnBMD. There was no 
relationship with frailty score or EF with ASM/Ht2.  
Conclusion:  Older age, female gender, frailty score and ejection fraction all predict low fnBMD although the diagnosis of CHF 
does not. Age and female gender were also related to ASM/Ht2, but frailty and EF were not. This work suggests that CHF 
severity may affect BMD and that individuals with CHF and frailty should be evaluated for osteoporosis. In this cohort of older 
adults, with CHF, sarcopenia was not related to CHF or frailty status.
SUBPROJECT PROGRESS:
The study recruited 83 individuals, 23 controls and 60 individuals with heart failure. No safety concerns were noted during the 
active phase of the trial. We are presently closed for recruitment but are actively analyzing data. We continue to use the services 
of the General Clinical Research Center (GCRC) statisticians for the project. Three manuscript preparations have been published 
from this work.  
One manuscript  in Osteoporosis International. Kenny AM, Boxer R‡, Walsh S, Hager HD, Raisz LG. Femoral Bone Mineral 
Density in Patients with Heart Failure.Osteoporos Int. 2006;17(9):1420-7. Epub 2006 Jun 13. American Journal of Geriatric 
Cardiology Boxer R,Walsh S, Wang Z, Hager WD, Kenny AM Use of the Frailty Phenotype and 6-Minute Walk Test to Define a 
Syndrome of Pre-Frailty in Older Adults with Heart Failure. Journal of Cardiac Failure Boxer R,Walsh S, Wang Z, Hager WD, 
Kenny AM The Association of Vitamin D and Inflammation with the 6-Minute Walk and Frailty in Patients with Heart Failure 
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Due to critiques from one of the papers, we will be extending the project to identify whether participants are alive and for those 
living, to reassess frailty status. This project received Institutional Review Board (IRB) approval and will begin data collection this 
summer.
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Biostructure and FunctionREICHENBERGER, ERNST PHD
SUBPROJECT DESCRIPTION:
Craniometaphyseal dysplasia (CMD) is a monogenic craniotubular bone disorder, which is characterized by deposition of highly 
mineralized bone matrix in the cranium and face, whereas long bones exhibit flared metaphyses of decreased bone density. 
Diaphyses appear normal. Cherubism is a disorder of excessive bone degradation which affects only maxillar and mandibular 
bones. Excessive bone resorption occurs first in the cyst-like cavities of the mandible. Bone in the cavities is replaced by soft 
fibrous tissue. Jaw bones progressively resorb until in more severe cases only an outer shell of cortical bone remains. The soft 
stromal tissue proliferates and causes characteristic facial features. Isolated aplasia cutis congenita (ACC) manifests in congenital 
skin defects which are typically on the scalp, and the underlying cranial bone can be absent. Patients with trichodentoosseous 
syndrome (TDO) present with curled hair, enamel hypoplasia and hypocalcification of teeth, increased bone density of the skull 
and subtle undertubulation of long bones.  
All of the above disorders occur as autosomal dominant (AD) traits, but also sporadically, and in the case of CMD, ACC, and 
cherubism also in an autosomal recessive (AR) fashion. Disease genes for the AD form of the disorders have been identified. 
However, there are a number of patients who did not have mutations in the known disease genes.  The AD form of CMD is 
caused by mutations in ANK (Reichenberger et al., 2001), AD cherubism by mutations in SH3BP2 (Ueki et al., 2001), and TDO 
by a deletion in DLX3 (Price et al., 1998). 
Our goal is to identify additional mutations in these genes which could help to explain the mode of action of the mutations 
during pathogenesis. We also attempt to identify and recruit families which do not map to the known loci and perform 
genome-wide screening, especially for cherubism and ACC.
SUBPROJECT PROGRESS:
Total number of patients enrolled as of 3/31/2008: 382
Current Year Enrollment: 12
Changes in recruitment plans that might be needed: None 
Unexpected safety concerns and their resolution: None 
Interim data and outcomes: Research in the past year was directed on the analysis of mouse models for the human disorders 
Cherubism and Craniometaphyseal Dysplasia. Recruitment of human subjects is still ongoing. We will test human specimen for 
results which we gained from studies in an animal system. Deoxyribonucleic Acid (DNA) samples from ACC patients will be 
subjected to genome-wide screening and linkage analysis. Recruitment efforts will be increasing in the future. 
Proposed changes made or anticipated in the protocol: 
We used Luminex instrument to test samples for Tumor Necrosis Factoy-alpha (TNFalpha). In the future we would like to test 
more samples for TNF-alpha and Interleukin 6 (IL-6). Supplies will be provided by Reichenberger laboratory.
Publications (with mention of the General Clinical Research Center): None
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PsychiatryPETRY, NANCY PHD
PsychiatryALESSI, SHEILA PHD
SUBPROJECT DESCRIPTION:
In our research evaluating contingency management (CM) that provides opportunities to win prizes, we have noted that the 
efficacy of CM may be dependent on the status of the individual as they initiate treatment. Patients who begin treatment with a 
cocaine-positive urinalysis result tend to drop out of treatment prematurely and to continue using while in treatment.  CM 
interventions have been efficacious in reducing drug use in this subgroup, and the effects were magnitude dependent.  However, 
we have thus far only tested up to a maximum of $250 in prizes, and larger magnitudes may further improve outcomes.  One 
purpose of this proposal is to examine the efficacy of an enhanced CM procedure, in which increased frequencies of prize 
winnings are provided during initial periods of abstinence.  Cocaine-dependent patients beginning treatment with a 
cocaine-positive urine sample (N=120) will be randomly assigned to one of three conditions: (a) standard, non-CM treatment, 
(b) standard treatment plus CM with an expected probability of winning about $250 in prizes, or  (c) standard treatment plus 
CM with an expected probability of winning about $560 in prizes.  
We have also found that patients who present to treatment with cocaine-negative samples generally remit negative samples 
throughout their time in treatment, regardless of whether they received a non-CM or a CM treatment contingent upon 
abstinence. Thus, we will also conduct a parallel study that will assess whether simply reinforcing attendance at treatment 
enhances retention and improves long-term outcomes in this subgroup. Cocaine-dependent patients (N=330) initiating 
treatment with a cocaine-negative urine sample will be randomly assigned to one of three conditions: (a) standard treatment 
without CM or (b) standard treatment plus CM with an expected probability of winning about $250 worth of prizes contingent 
upon cocaine abstinence, or (d) standard treatment plus CM with an expected probability of winning about $250 worth of prizes 
contingent upon treatment attendance. Together, these studies will address the conditions under which lower and higher cost 
prize CM procedures may improve outcomes of cocaine-dependent patients
SUBPROJECT PROGRESS:
Total Enrollment: 437
Past Year Enrollment: 63
• No changes in recruitment plans are needed.
• No unexpected safety concerns have occurred.
• Interim data and outcomes are not available.
• No changes were made to the protocol and none are anticipated. 
• Results not yet published as study is ongoing.
Do you wish to continue to receive General Clinical Research Center (GCRC) resources for the period April 1, 2008 through March 
31, 2009?  Yes
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Medicine/GeriatricsJOSEPH, CHERIAN MD
SUBPROJECT DESCRIPTION:
Fracture risk as measured by low Bone Mineral Density (BMD), is found to be genetically determined. Family history of hip 
fracture predicts osteoporotic fracture independently from bone mass. It is unclear whether many genes, each with small effects 
or small number of genes with somewhat larger effects are responsible for the genetic contribution determining BMD. 
Inheritance of BMD at the hip has been estimated to be between 70-85%. Nevertheless, many factors play a role in predicting 
the development of a fracture including bone mass, as well as the quality, and geometry of the bone architecture.
Potential candidate genes, which may contribute to the development of osteoporosis include genes coding for bone matrix 
proteins, adhesion molecules and ligands, hormones and their receptors, as well as enzymatic pathways (e.g. Aromatase, Matrix 
Metalloproteinases (MMPs)). Although many genetic studies have already been done, further work needs to be done looking for 
a candidate gene with major effect on molecular or cellular mechanism underlying osteoporosis.
Research Hypothesis: We propose that individuals with a higher mean CATT (cytosine, adenine, thymine,thymine)repeats in 
the Mif gene will have lower bone mineral density than individuals with lower mean CATT repeats.
SUBPROJECT PROGRESS:
The study is now closed to recruitment. There were no changes to recruitment plans. There were no reported adverse effects or 
safety concerns. Analysis and work to obtain access to a national database to obtain adequate sample size is ongoing. 
Preliminary analysis follows: The distribution of Macrophage Migration Inhibitory Factor (Mif) genotype are as follows: 5,5 
genotype were 5/86 (5.81%); 5,non 5 genotype present in 26 (30.2%); and non 5, non 5 present in 55 (63.9%) participants. The 
mean femoral neck Bone Mineral Density (BMD) for those with any 5 allele (low expressing genotype) was 0.89 ± SD 0.13 and for 
group with no 5 allele (high expressing genotype) was 0.84 ± SD 0.13 difference of 0.06 in bone density. (p= 0.063). There was no 
significant contribution of CATT genotype to femoral neck bone density (F 1.64, P=0.204.) when adjusted for age, gender, and 
Body Mass Index. 
Conclusions: In this preliminary pilot study, no difference was seen in femoral neck bone density between individuals with low- and 
high-expressing Mif alleles once potentially confounding variables were controlled. A larger sample cohort will be required to 
adequately address the study hypothesis. The data was presented at the 2004 annual meeting of the Society for Bone and Mineral 
Research. No publications from the data are available to date. We are presently attempting to expand the work with collaborators 
in Europe to assess similar issues in a large population based study. If this can be accomplished, manuscript preparation will begin. 
Continuing General Clinical Research Center (GCRC) resources are required for continued data analysis and manuscript preparation.
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ImmunologyMCELHANEY, JANET MD
Medicine/Cardio-PulmonaryHAGER, DAVID MD
SUBPROJECT DESCRIPTION:
Aging causes a decline in cell-mediated immunity (CMI) and is associated with a tremendous increase in the late-life morbidity 
from influenza infections. Vaccination can prevent influenza illness but current vaccines are only 50-60% effective in the over 
65 population (versus 90% in younger adults). Even with this limited efficacy, influenza vaccination is a cost-saving 
intervention due to the reduction in hospitalization for acute respiratory illness and congestive heart failure (CHF). This 
proposal outlines a strategy to advance the basic science of influenza learned from studies in the aged mouse model, to 
application in a very high-risk population of older adults with CHF. Identifying age and CHF-related changes in the innate and 
adaptive immune responses to influenza and influenza vaccination, is imperative to the development of new vaccines or 
adjuvant therapies for improved prophylaxis in older people.
The long-range goal of this project is to use translational methodology to determine the mechanism by which age and 
disease-related factors increase the risk of influenza and diminish vaccine efficacy.  The objective of this application is to 
characterize protective immunologic responses, compare the level of immunity in different risk groups, and finally define the 
level of laboratory measures that predict outcomes of illness in older people.  In the process, clinical and laboratory measures 
will be developed as individual and population indicators of how risk for influenza illness is altered by vaccination and including 
clinical trials of new vaccines. 
The central hypothesis of the application is that the level of granzyme B (Grz B) in influenza-specific cytotoxic T 
lymphocytes (CTL) predicts risk for influenza illness.  Grz B levels decrease with advancing age and functional decline due to a 
dysregulation of T-cell function that is not reversed by vaccination with killed influenza virus.  The rationale for the proposal is 
that older adults with CHF have a very high-risk for serious complications of influenza and suggests that the senescent immune 
response to influenza is further compromised in the presence of CHF.  Influenza attack rates are higher and vaccine efficacy is 
lower in this population.  CHF in older adults thus provides a model for studying immunologic responsiveness that can be linked 
to clinical outcomes.  Very high-risk groups of older adults who continue to suffer disabling consequences of influenza due to 
poor responses to current killed-virus vaccines can then be targeted for new prophylaxis strategies. Recent studies have 
highlighted the role of Toll-like receptors (TLR) in the transition from innate to adaptive immune responses. TLR recognize 
pathogen-associated molecular patterns (PAMP) and stimulate cytokine production by a number of cells including Th type 1 
(Th1), creating the necessary microenvironment to stimulate effector mechanisms such as CTL.  In viral infections, it is 
critical that the transition from the innate to adaptive immune response activates cytotoxic T-lymphocytes (CTL) to kill 
virus-infected host cells.  The methodology derived from this work will be critical for screening new vaccines for immunologic 
responsiveness prior to expensive, large clinical trials.  In the interim, it will be possible to combine vaccination with the use of 
antiviral drugs in those very high-risk groups with poor responses to current vaccines.
SUBPROJECT PROGRESS:
Total number of subjects enrolled: 585
Number of subjects enrolled since last reporting period: 158
Changes in recruitment plan: no changes in recruitment plan at this time
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Unexpected safety concerns and their resolution: no unexpected safety concerns occurred this past year
The study in question has three aims: 
1) Establish causal relationships between changes in T-cell function and outcomes of influenza illness through a prospective study 
of older adults including those with congestive heart failure (CHF) and acute coronary syndromes (ACS). The hypothesis is that 
granzyme B (Grz B) is a key mediator of protection against influenza illness and is stimulated by a Th1 response to vaccination. 
With a defined threshold level of protection for GrzB and demonstrated low Th1 response (IFN-gamma:IL-10 ratio) to influenza, 
the next step is to determine the effect of different chemokines and cytokines on the response to influenza. The analysis is 
designed to produce a model of influenza risk based on prospectively measured GrzB and cytokine levels and the effect of clinical 
factors.
 
2) Elucidate mechanisms that alter the immune response to influenza and are associated with increased risk of influenza. The 
hypothesis is that influenza risk increases with the loss of the costimulatory molecule, CD28, and Grz B in influenza virus-specific 
CTL. A new hypothesis is that CD4+CD8+ T-cells become the reservoir for influenza-specific memory CTL with aging. FACS 
analysis will identify the cellular determinants that correspond to protection versus vaccine failure using the threshold level of 
GrzB as a correlate of protection following influenza vaccination. Similarly, microarray analysis will characterize the differences in 
gene expression with a protective vs. failed response to vaccination. The hypothesis that activation-induced cell death (AICD) 
determines the Th1:Th2 response has been abandoned due to recent evidence that T-cells must be conditioned in vitro to exhibit 
AICD. Thus, the effect of AICD is not a testable hypothesis under the ex vivo conditions of our assays.
3) Aim 3 has been modified to an alternate approach to enhancing the CTL response to influenza in older adults using 
costimulatory molecules. Our previous results suggest that efficacy in older adults may be improved with vaccines targeted to the 
CTL response.  The hypothesis is that costimulatory molecules, 4-1BB ligand and CD70, will specifically increase the response to 
influenza-peptide CTL epitopes in older adults. FACS analysis will evaluate the virus-specific CTL frequency in virus or 
peptide-stimulated PBMC. Testing of heat shock proteins as potential vaccine adjuvants has been deferred until testing of 
co-stimulatory molecules has been completed.
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SUBPROJECT DESCRIPTION:
Oral candidiasis is perhaps the most frequent opportunistic infection associated with an immunocompromised host. The most 
important immune cell type in the defense against Candida is the neutrophil (PMN). Although these cells are considered 
important in the resistance to and eradication of fungi, expression of these functions requires activation by soluble proteins 
known as cytokines. In the immunocompromised host these molecules are more likely to be derived from cells of non-immune 
origin, such as epithelial cells. The purpose of this study is to test the activation of neutrophil anti-fungal functions in response 
to cytokines secreted by oral epithelial cells.
SUBPROJECT PROGRESS:
Since the initiation of the study we enrolled 18 subjects. During the last report period, we did not recruit any subjects. Recruited 
human subjects at the General Clinical Research Center (GCRC) provide the blood/neutrophils used in in vitro experiments. We 
expect to recruit 10-15 subjects during the next year of funding by the National Institute of Health (NIH) (RO1 was just renewed). 
There are no unexpected concerns or changes in the protocol. There were no publications related to human subjects during the last 
period.
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0528 528PROTOCOL:SPID: RESEARCHTYPE:  
Fabry RegistrySHORT TITLE:
LONG TITLE: Fabry Registry
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 8  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/20/2003
 40Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase IV
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/NephrologyADAMS, NANCY MD
Medicine/Hem-OncBONA, ROBERT MD
Diagnostic ImagingCOBB, RICHARD MD
Pediatrics/GeneticsGREENSTEIN, ROBERT MD
OrthopedicsLEWIS, COURTLAND MD
Medicine/EndocrinologyRAISZ, LAWRENCE G MD
MedicineSILVERMAN, DAVID I MD
Medicine/NeurologyWHITAKER, CHARLES MD
SUBPROJECT DESCRIPTION:
The Fabry Registry is an ongoing, observational database that tracks the natural history and outcomes of patients with Fabry 
disease. Participation is open to all physicians managing patients with Fabry disease. Physicians are encouraged to collaborate, 
share observations, and generate hypotheses for evaluation, as well as assist in the collection of clinical data in an effort to guide 
and assess future therapeutic interventions.
SUBPROJECT PROGRESS:
The Fabry Registry was not discontinued as noted in the prior report, but was transferred to a new principal investigator Nancy 
Day Adams, MD in September 2007.  She completed the Institutional Review Board (IRB) renewal with the help of the General 
Clinical Research Center (GCRC) staff and was officially accepted by Genzyme as a Registry physician in November 2007.  
Registry visits have been performed in the GCRC and also during routine clinical follow-up nephrology visits, with data entry via 
the GCRC computers.  A single new patient has been enrolled in the Registry during the above time frame, and two additional 
patients identified by 3/31/08.  Anticipated enrollment of these two will occur in the current study period.  They have affected 
relatives who may participate.  Activity during this current year should be greater than in 07-08. 
No local publications have resulted from the registry to date.  The International Registry has published two studies during this 
period.
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, 
Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP. Females with Fabry disease frequently have 
major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab. 2008 Feb;93 (2):112-28. 2007 Nov 26.
Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C; on behalf of the Fabry Registry. Nephropathy in males 
and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. 
Nephrol Dial Transplant. 2008 Jan 9 [Epub ahead of print].
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0529 529PROTOCOL:SPID: RESEARCHTYPE:  
Gaucher RegistrySHORT TITLE:
LONG TITLE: Gaucher Registry
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 8  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/20/2003
 40Total # pts expected for entire study:
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Phase IV
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Pediatrics/GeneticsGREENSTEIN, ROBERT MD
Medicine/NephrologyADAMS, NANCY MD
Medicine/Hem-OncBONA, ROBERT MD
Diagnostic ImagingCOBB, RICHARD MD
OrthopedicsLEWIS, COURTLAND MD
Medicine/EndocrinologyRAISZ, LAWRENCE G MD
MedicineSILVERMAN, DAVID I MD
Medicine/NeurologyWHITAKER, CHARLES MD
SUBPROJECT DESCRIPTION:
The Gaucher Registry is an ongoing, post-marketing, observational database that tracks outcomes of routine clinical practice for 
patients with Gaucher disease. Not all patients in the Registry are on Enzyme Replacement Therapy (ERT). All physicians 
participating in the Registry are considered members of the International Collaborative Gaucher Group (ICGG).  Data collected 
from ICGG physicians will represent Gaucher disease practice patterns under common clinical conditions.  Thus, the data 
collected by this international, collaborative Registry will provide information to better characterize the natural history and 
progression of Gaucher disease, as well as the clinical responses of patients whose physicians have prescribed ERT.
SUBPROJECT PROGRESS:
Since our last report on this project, there have been no new subjects enrolled. We continue to collect Registry data on 19 subjects. 
There are no changes in recruitment plans. There were no unexpected safety concerns and no major adverse events. There is no 
interim data to report nor outcomes to report. The participation of the principal investigator will end 6/30/07 and the funding is 
completed as of 12/31/06 with a no cost extension through 6/30/07.
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0530 530PROTOCOL:SPID: RESEARCHTYPE:  
Gleevec ResistanceSHORT TITLE:
LONG TITLE: Study of the Mechanisms of Gleevec Resistance in Chronic Myelogenous Leukemia (CML) CML Patients
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 1  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/16/2003
 44Total # pts expected for entire study:
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Genetics & Dev. BiologyFANG, MIN MD, PHD
Ctr for ImmunotherapyLI, ZIHAI MD, PHD
SUBPROJECT DESCRIPTION:
Cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common cancers in the U.S..  While 
they both arise from the epidermis, these cancers differ dramatically in biological behavior and their underlying gene expression 
patterns have not been compared. We thus examined Messenger Ribonucleic Acid (mRNA) transcript levels in these 
malignancies as well as in psoriasis, a benign epidermal hyperplasia. Transcript expression patterns distinguish these disorders 
and identify differentially expressed genes. Among these is Egr-1, whose epidermal expression is consistently decreased in BCC 
and SCC but is elevated in psoriasis. Our preliminary data indicated that Egr-1 inhibits accelerated growth of benign and 
malignant epidermal cells in association with suppression of Cdc25A expression.  We would like to confirm this finding and 
further investigate whether the phosphorylation status and kinase activity of Cdk2, a downstream target of Cdc25A, are 
affected.  We hypothesize that gene expression profiling can differentiate epidermal hyperproliferative diseases and identify a 
role for Egr-1 in preventing uncontrolled epidermal growth.
SUBPROJECT PROGRESS:
Number of subjects enrolled during the report period and since initiation of the study TOTAL NUMBER OF PATIENTS 
ENROLLED:15 
Current Year Enrollment: 0
 
Any changes in recruitment plans that might be needed No Unexpected safety concerns and their resolution No Interim data and 
outcomes if appropriate Interim findings: Sequence analysis has shown mutations in samples from patients with Gleevec resistance. 
The hypothesis remains sound and continuation of the investigation is justified by the data obtained so far.  However, the system 
stopped working for unclear reasons.  The core lab has trouble amplifiying products for sequencing.  Still trouble shooting.  Any 
proposed changes made or anticipated in the protocol No Publications N/A
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0531 531PROTOCOL:SPID: RESEARCHTYPE:  
Sertraline PharmacotherapySHORT TITLE:
LONG TITLE: Sertraline Pharmacotherapy for Alcoholism Subtypes
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 184  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/29/2003
 160Total # pts expected for entire study:
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NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryKRANZLER, HENRY MD
PsychiatryCOVAULT, JONATHAN MD, PHD
PsychiatryDEMARTINIS, NICHOLAS MD
PsychiatryHERNANDEZ-AVILA, CARLOS MD
PsychiatryNELLISSERY, MAGGIE MD
MedicineONCKEN, CHERYL MD
Community MedicineTENNEN, HOWARD PHD
SUBPROJECT DESCRIPTION:
During the past decade, the pharmacotherapy of alcoholism has received increasing attention both from National Institute on 
Alcohol Abuse and Alcoholism (NIAAA)and the pharmaceutical industry.  However, despite the Federal Drug Administration 
(FDA)approval of naltrexone for relapse prevention, medications are still not widely used to treat the disorder.  This contrasts 
sharply with the treatment of nicotine dependence, for example, as well as other psychiatric disorders.  In an effort to broaden 
the options for pharmacotherapy of alcoholism, this proposal will examine the effects of sertraline, a selective serotonin 
reuptake inhibitor (SSRI), for the treatment of alcohol dependence.  The study is based on evidence that, although SSRI therapy 
is not appropriate for all alcoholics (Kranzler et al. 1996a, Pettinati et al. 2000), there exists a substantial subgroup with the 
disorder (i.e., Type A or later-onset alcoholics) for whom SSRI's appear to exert a clinically important effect.  Since sertraline is 
well tolerated and among the most widely prescribed psychotropic medications in the world, a prospective demonstration of its 
efficacy could have a broad influence on the treatment of alcohol dependence.  Consequently, this study will examine the safety 
and efficacy of sertraline, the mechanism and duration of those effects and the best method for subtyping alcoholics to identify 
individuals for whom the medication is most likely to produce a clinically important reduction in drinking behavior.
SUBPROJECT PROGRESS:
A total of 30 subjects were enrolled during the report period (a total of 123 since initiation of the study).  As of 3/31/08, a total of 
112 subjects had been randomized to receive treatment with either sertraline or placebo. We plan to run a recruitment ad 
specifically targeting individuals with early onset alcohol dependence, due to a difficulty in recruiting individuals in that group.  
There have been no unexpected safety concerns associated with this study.  Interim outcomes data are not available at this time. 
This study uses interactive voice response technology (IVR) for daily data collection, with support from the General Clinical 
Research Center (GCRC). The overall completion rate for IVR calls exceeds 87% among subjects while in treatment and 68% for 
all subject days. There have been no recent publications associated with this study since data collection is ongoing. Changes made in 
the protocol during the report period were: 1) Removal of a co-investigator (Carlos Hernandez-Avila) and addition of a new 
co-investigator (Carolyn Drazinic); 2) due to a letter from the Office of Human Research Protections (OHRP), the study protocol 
and consent form were reviewed and modified (where necessary) to cover the Deoxyribonucleic Acid (DNA)/genetic testing aspects 
of the research study (including: an explanation of the purpose of the DNA testing aspects of this research study and a description 
of the DNA tests to be run on the collected samples; a description of any foreseeable risks and discomforts to the subjects regarding 
DNA testing; a description of any benefits to the subject or others that may reasonably be expected from the DNA testing; a 
statement describing the extent to which the confidentiality of records/samples identifying the subject will be maintained); 3) the 
protocol and consent form were modified to explain that DNA samples will be kept in the laboratory until the study ends and that 
samples will then be de-identified (Due to the protocol and consent form modifications made for items #2 and 3, subjects who were 
active in the treatment phase of the study were re-consented at their next regularly scheduled appointment with the revised 
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consent form once it was IRB-approved.  Prior to that, the research nurse reviewed the information regarding the DNA aspects of 
the study with active subjects and documented the discussion and date of discussion in subject's progress notes.  Subjects were then 
asked to sign the revised consent form at their next visit once it was IRB-approved); 4) The IRB-approved consent form has 
always stated (since this study was originally IRB-approved), "My DNA will be studied to identify specific genetic markers that 
might influence my risk of alcohol dependence or my response to sertraline treatment."  For consistency with the IRB-approved 
consent form, the protocol was updated to mention this specific aim of the study.
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0535 535PROTOCOL:SPID: RESEARCHTYPE:  
The Effects of Oral Estrogen and Progesterone on the ACL and ATSHORT TITLE:
LONG TITLE: The Effects of Supplemental Estrogen and Progesterone on the Anterior Cruciate Ligament (ACL) and 
Achilles Tendon (AT)
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 54  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/25/2003
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MEDICINE/FAMILY MEDICINE ST. FRANCIS HOSPITAL, CT USATROJIAN, THOMAS MD
KINESIOLOGY UCONN - STORRS, CT USADIPASQUALE, CHRIS PHD
SUBPROJECT DESCRIPTION:
Anterior cruciate ligament (ACL) tears are a major health risk for female athletes. Early degenerative arthritis of the knee is 
more likely to develop in women with ACL tears as compared to their uninjured counterparts. ACL tears normally produce 6 - 
12 months of disability after the injury. The National Collegiate Athletic Association Injury Surveillance Survey data identifies 
that female college athletes have a 3 - 8 times higher rate of ACL tears compared to males. ACL tears produce immediate and 
delayed disability in women.
Little is known about modifiable risk factors in the prevention of ACL tears. Discovering these factors has been identified as a 
major goal by the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS) and the Office of Research on 
Women's Health. There are a number of proposed risk factors for instance a proposed association between ACL tears and the 
menstrual cycle. Over the menstrual cycle, changes are seen in the ACL measurements. The fluctuation of estrogen levels are 
proposed to be the cause of the changes in the ACL properties. Muscle-tendons complexes, including the Achilles tendon (AT), 
provide additional stability to the knee joint. These secondary restraints play an important role in the stability of the knee. 
Estrogen and progesterone affect the collagen content of tendons and ligaments (like the ACL and AT). Some investigators 
have recommended oral contraceptives, which prevents the estrogen spike, in order to prevent injury. These recommendations 
are premature since ACL risk factors have not been thoroughly studied and any current recommendations for the use of oral 
contraceptives are from retrospective studies with small sample sizes.
Further, prospective, adequately powered, studies are needed to define the affects of supplemental hormones such as oral 
contraceptives (OCP) on the stretch and strain properties of the ACL. Previous studies quantifying the change in ACL laxity 
measurements across the menstrual cycle while a woman is on OCPs do not exist. 
The specific aims of the proposed research project are first, to identify the affects of a monophasic OCPs on ACL 
measurements across the menstrual cycle. The secondary aim of the proposed research project is to identify the affects of 
monophasic OCPs on tendon extensibility across the menstrual cycle. Lastly, the proposed project will be used as preliminary 
data for a cross-over study investigating the change in ACL measurements with and without OCPs in an RO3 or RO1 
application to NIAMS, which will carry out a more comprehensive evaluation on the risk factors for ACL tears.
SUBPROJECT PROGRESS:
We are near completion of the study and we will soon start analysis of blood samples. The Institutional Review Board (IRB) has 
approved the study through January 2009. 
We have 17 total completed subjects with 6 new since 4/1/2007. We have tried newspaper, broadcast e-mail, and other methods of 
recruitment but only get responses from the Broadcast E-mail message. There have been no unexpected safety concerns. No injury 
to participants has occurred. We have no interim data since the blood work is being batched analysized at end of study. We will 
need to request an extension to the time frame. We have recruited 18 but 17 completed. One stopped due to time commitment. 
We are planning to have the lab analyze the bloods. No publications from this study have occurred, yet.
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0536 536PROTOCOL:SPID: RESEARCHTYPE:  
Effects of Aripiprazole on Subjective and Physiological Responses to AlcoholSHORT TITLE:
LONG TITLE: Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol
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Outpatient
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TOTALS A B D
 0  0  0
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AIDS: N
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PsychiatryKRANZLER, HENRY MD
PsychiatryCOVAULT, JONATHAN MD, PHD
PsychiatryHERNANDEZ-AVILA, CARLOS MD
MedicineONCKEN, CHERYL MD
PsychiatryPIERUCCI, AMIRA PHD
SUBPROJECT DESCRIPTION:
A. 1. Specific Aims:
To study the effect of aripiprazole on behavioral effects (i.e., sedative/hypnotic, anxiolytic, stress-reducing properties) and 
physiological effects (i.e., blood pressure, heart rate, psychomotor task performance) of a moderate dose of alcohol in 20 
healthy subjects with no history of alcohol abuse or dependence. Genetic analysis will also provide preliminary information on 
allelic association both to alcohol response in healthy individuals and as control data for studies of individuals affected with 
alcohol and/or drug dependence. 
2. Hypothesis:
Aripiprazole is a new atypical antipsychotic with a unique receptor binding profile that combines partial agonist activity at D2 
and 5-HT1A receptors and potent antagonism at 5-HT2A receptors. Based on this profile of activity, we hypothesize that 
aripiprazole will reduce the pleasurable, stimulating, and anxiolytic effects of alcohol, but not its effects on blood pressure and 
heart rate. An evaluation of this hypothesis may help to elucidate the neuropsychopharmacology of alcohol and may suggest a 
novel approach to the pharmacotherapy of alcohol dependence.
SUBPROJECT PROGRESS:
A total of 49 subjects were enrolled since the initiation of the study. This study has been closed to enrollment since December 
2006 and is currently under secondary data analysis.  Due to enrollment closure, there have not been any changes in recruitment 
plans.  Further, there have not been any unexpected safety concerns within this report period.  
During the report period, a protocol modification to address Deoxyribonucleic Acid (DNA) testing and DNA sample storage was 
Institutional Review Board (IRB) approved on 12/10/07.  In response to a recent letter from office for human research protections 
(OHRP), the study protocol was modified to address the DNA/genetic testing aspects of the study.  Therefore, the following 
elements were fully addressed in the protocol:
'b7 An explanation of the purpose of the DNA testing aspects of this research study and a description of the DNA test to be run 
on the collected samples
'b7 A description of any foreseeable risks and discomforts to the subjects regarding DNA testing
'b7 A description of any benefits to the subject or others that may reasonably be expected from the DNA testing
'b7 A statement describing the extent, if any, to which the confidentiality of these records/samples identifying the subject will be 
maintained.
The protocol was also modified to explain that all DNA samples and data sets will be completely de-identified in order to conduct 
the genetic analysis as planned.  Genetic analyses will not be conducted with the samples until the de-identification is complete.  A 
notification will be sent to the IRB once all DNA samples and phenotypic data are completely de-identified.  
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Additional genotyping is anticipated (use of the General Clinical Research Center (GCRC) Core lab), suggesting 28 samples with 10 
markers each.
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0542 542PROTOCOL:SPID: RESEARCHTYPE:  
Effect of Letrozole on bone markers and blood pressureSHORT TITLE:
LONG TITLE: Short term Effects of Letrozole on Bone Markers and Vascular Indices in Postmenopausal Women after 
Completion of Tamoxifen Therapy for Primary Breast Cancer
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 3  0  0
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Offsite Visits  0  0  0
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MedicineMIRZA, FARYAL MD
Medicine/OncologyMOYO, VICTOR MD
Medicine/Hem-OncTANNENBAUM, SUSAN MD
MedicineTAXEL, PAMELA MD
SUBPROJECT DESCRIPTION:
Studies using aromatase inhibitors (AI) have recently demonstrated improved disease free survival after five years of tamoxifen 
therapy for early stage breast cancer in postmenopausal women. AI are a class of compounds that inhibit the synthesis of 
estrogens from androgens by blocking aromatase, a cytochrome P450 enzyme, which catalyzes the peripheral conversion of 
androgens to estrogens, thereby reducing the tissue and plasma concentration of estradiol to below castrate levels. 
We hypothesize that with suppression of estradiol, letrozole, the most potent aromatase inhibitor, will cause a significant 
increase in markers of bone resorption and bone formation, along with an increase in baseline blood pressure and loss of 
nocturnal dipping of blood pressure. The following specific aims will be studied:
To determine the effects of letrozole on sex hormone levels and the relationship of change in sex hormone levels to the change 
in bone markers.  
To determine the change in markers of bone resorption and formation. 
To examine the effects of letrozole on 24 hr ambulatory blood pressure monitoring and office blood pressure.
To determine change in parameters of neurocognitive function with letrozole therapy.
This will be a 12 week, open label pilot study evaluating women with primary breast cancer, who have completed five years of 
tamoxifen treatment and are opting to choose letrozole as treatment in consultation with their oncologist. The patients will 
serve as their own controls.
SUBPROJECT PROGRESS:
There are 12 subjects enrolled so far since initiation of the study. 2 subjects did not complete the study and one withdrew due to the 
time commitment involved.
There were no subjects enrolled during the period of 4/1/07 to 3/31/08, although 2 of the subjects previously enrolled were active 
during the above study period.
A significant increase in the blood pressures as measured by 24 hour ambulatory blood pressure monitoring has been seen in the 8 
subjects who have completed the study.
Measurement of the hormones of the renin angiotensin system including measurement of serum aldosterone, renin levels, 
angiotensin converting enzyme level and angiotensin 1 levels are anticipated to be added to the protocol to help understand the 
pathogenesis of the increase in blood pressure with aromatase inhibitor therapy.
An oral abstract has been accepted for presentation at the Endocrine Society Annual meeting in San Francisco in June 2008. The 
General Clinical Research Center (GCRC)  has been cited in the abstract.
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0548 548PROTOCOL:SPID: RESEARCHTYPE:  
Chronic Recidivist Alcohol-Dependent PatientsSHORT TITLE:
LONG TITLE: Contingency Management for Chronic Recidivist Alcohol-Dependent Patients
Inpatient
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Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
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 0  0  0
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AIDS: N
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PsychiatryPETRY, NANCY PHD
Community MedicineBABOR, THOMAS PHD
PsychiatryKADDEN, RONALD M PHD
SUBPROJECT DESCRIPTION:
In a pilot study from our previous granting period, we demonstrated the efficacy of a relatively low-cost contingency 
management (CM) procedure for retaining alcohol-dependent patients in treatment and reducing alcohol as well as other drug 
use (Petry et al., 2000).  This study will extend use of these procedures to chronic recidivist alcohol-dependent patients and 
evaluate their efficacy for reducing in-patient detoxification services.  Specifically, 116 alcohol-dependent patients who have 
received 4 or more alcohol detoxifications in a calendar year will be randomly assigned to one of two 6-month treatment 
conditions: standard case management treatment, or standard case management treatment plus CM.  In the CM condition, 
patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment 
goals, such as attending outpatient substance abuse treatment services, attending appointments with low income housing 
programs, or complying with outpatient psychiatric treatment.  Treatment services received, alcohol and drug use, psychosocial 
functioning, and Human Immunodeficiency Virus (HIV) risk behaviors will be measured pre-treatment and at months 1, 3, and 6 
(post-treatment), and at follow-ups scheduled for 9, 12, and 18 months after intake. 
Compared to standard case management treatment, we expect that those assigned to the CM condition will decrease alcohol 
consumption and present for fewer inpatient detoxifications, while showing greater engagement and retention in outpatient 
treatment.  We also anticipate improvements in psychosocial functioning and decreases in HIV risk behaviors in the CM group.  
Patient characteristics that may be associated with a positive response to treatment will be assessed.  We will also evaluate the 
cost-effectiveness of this CM intervention in relation to standard case management services.
SUBPROJECT PROGRESS:
Total Enrollment: 104
Past Year Enrollment: 2 
• No changes in recruitment plans are needed (enrollment is complete).
• No unexpected safety concerns have occurred.
• Interim data and outcomes are not available.
• Changes to protocol: 1) Added to the protocol a new recruitment site, Connecticut Renaissance West in Waterbury, CT. 2) 
Clarified the timing of the follow-up interviews in the Informed Consent Form and protocol by stating that the interviews will 
occur "about 1, 3, 6, 9, 12 and 18 months" from intake. 3) Added new recruitment poster.
• Results not yet published as study is ongoing.
Do you wish to continue to receive General Clinical Research Center (GCRC) resources for the period April 1, 2008 through March 
31, 2009?  No, study enrollment is completed
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0549 549PROTOCOL:SPID: RESEARCHTYPE:  
GABRA2SHORT TITLE:
LONG TITLE: Haplotype Association Study of the GABRA2 Gene and Alcohol Dependence in Project MATCH Subjects
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TOTALS A B D
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PsychiatryCOVAULT, JONATHAN MD, PHD
PSYCHIATRY YALE UNIVERSITY, CT USAGELERNTER, JOEL MD
PsychiatryHESSELBROCK, VICTOR PHD
PsychiatryKRANZLER, HENRY MD
SUBPROJECT DESCRIPTION:
Alcohol dependence is a highly prevalent disorder that is associated with serious morbidity and mortality.  Alcohol dependence 
has a significant heritable component estimated to account for 50-60% of risk.  We have recently used a Connecticut sample of 
258 Caucasian alcohol dependent and 335 screened controls to confirm an association of alcohol dependence with the GABRA2 
gene reported in an abstract at the Research Society on Alcoholism in 2003.  We found a 7% excess frequency (44% vs. 37%) 
of a seven-marker haplotype extending 98,000 bp over the 3'-half of the GABRA2 gene for subjects with alcohol dependence.   
We are now proposing to extend our case control association investigations of the GABRA2 gene and alcoholism by examining 
a more diverse multi-center sample of 1100 alcoholic subjects collected in project MATCH (a multi-center alcoholism 
treatment trial) with a collection of 1100 control subjects.   We will use this sample to extend our observations in several ways: 
i) to test for the association in a larger and more geographically diverse sample, ii) to use additional markers to better define the 
3'-endpoint of association,  iii) potentially focus the area of association by use of a larger and more genetically diverse sample 
iii) to examine for association with subtypes of alcohol dependent phenotype and co-morbid conditions.  We will use the Duffy 
antigen as an initial screen for differences in Caucasian versus Black chromosome admixture in the MATCH versus control 
sample from the NYC Cancer Project.  If significant differences are detected we will plan to collaborate with Dr. Joel Gelernter 
at Yale whose laboratory has developed techniques using a panel of racially informative markers to allow statistical correction 
case-control genetic associations.
A second aim will be to examine human GABRA2 Carrier Deoxyribonucleic Acid (cDNA) clones for splice or coding sequence 
changes in linkage with a known exon 4 synonomous Single nucleotide polymorphism (SNP) present at higher frequency in 
alcoholics in our initial sample.
SUBPROJECT PROGRESS:
1) Number of subjects enrolled during the report period:  N/A   since initiation of study:  N/A   (this study uses blood samples 
collected from subjects enrolled in a multicenter National Institute of Health (NIH) alcohol treatment study 'Project Matching 
Alcoholism Treatments to Client Heterogeneity (MATCH)' several years ago as well as cases and controls collected at the 
University of Connecticut Health Center (UCHC) as part of other studies of alcohol dependence)
2) Planned changes in recruitment plans: n/a
3) Unexpected safety concerns and their resolution:  None occurred.
4) Interim data:  Single Nucleotide Polymorphisms (SNP) genotyping has been completed on 800 project MATCH together with 
600 control and 600 alcoholic cases from central Connecticut at 8 SNPs in the GABRA2 gene, 4 SNPs in the adjacent GABRG1 
gene and 3 SNPs in the intergenic region.   Results from indicate the markers in these two genes are both associated with diagnosis 
of alcohol dependence, but with greater effect size for markers in the Gamma-Aminobutyric Acid A Receptor, Gamma 1 
(GABRG1) gene.  The results are not explained linkage disequilibrium between markers in the two genes, although there is moderate 
linkage between the two haplotype blocks in the two genes.  In a more recently completed analysis, we found that that the risk 
allele for both GABRA2 and GABRG1 genes was associated with a poorer response to psychological treatment in project MATCH.  
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5) Proposed changes made or anticipated in the protocol:  None
6) We request the General Clinical Research Center (GCRC) protocol remain active with the potential request for additional 
genotyping of the study sample.
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0551 551PROTOCOL:SPID: RESEARCHTYPE:  
ILIADSHORT TITLE:
LONG TITLE: Idiosyncratic Liver Injury Associated With Drugs: A Retrospective Study
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/29/2004
 160Total # pts expected for entire study:
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NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
GASTEROENTEROLOGYPROTIVA, PETR MD
Medicine/GasteroenterologyBONKOVSKY, HERBERT MD
MedicineFRESTON, JAMES MD
MedicineROSSON, ROBERT MD
SUBPROJECT DESCRIPTION:
Background and Rationale:  Drug induced liver injury (DILI) is the single most common reason for regulatory actions 
concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing 
indications.  DILI is also a significant cause of morbidity and mortality in many patient populations.  To stimulate and facilitate 
research into DILI, the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) has recently established the 
Drug-Induced Liver Injury Network (DILIN).  One of the initial projects to be conducted by the network is to retrospectively 
establish a nationwide registry of patients who have suffered severe idiosyncratic liver injury associated with drugs (ILIAD), and 
to collect, immortalize and store serum, Deoxyribonucleic acid (DNA), and lymphocytes from these patients (hereafter referred 
to as the "ILIAD protocol").  This ILIAD protocol will serve as a resource for subsequent mechanistic investigations of the 
basis for susceptibility to severe idiosyncratic DILI.
Specific Aims and Objectives:  The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of 
individuals who have experienced severe DILI caused by four specific drugs, and the relevant clinical data concerning the episode 
of DILI; and, (b) to create a bank of biological specimens obtained from these individuals.  Corresponding information from 
control subjects will also be collected.  These biological specimens will be DNA, plasma, and immortalized lymphocytes.   
Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for 
phenotyping studies.  A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that 
they may be recontacted in the future.  It is expected that this will facilitate additional studies exploring the mechanisms of 
DILI. 
Targeted Drugs: The initial drugs to be targeted in the ILIAD protocol are isoniazid (INH), phenytoin, clavulanic acid / 
amoxicillin (Augmentin and valproic acid.  For INH, phenytoin, or clavulanic acid / amoxicillin, severe liver injury is defined as 
a documented serum total bilirubin > 2.5 mg/dl; for valproic acid, the criteria are compatible symptomatic clinical presentation 
that is severe enough to prompt hospitalization and evidence of liver dysfunction International normalized ratio (INR) > 1.5 or 
Alanine transaminase (ALT) > 3 X Upper Limit of Normal (ULN), and/or characteristic liver biopsy). The target drugs were 
chosen because they cause severe DILI at a high rate compared with other drugs, making our target enrollment for each drug (n 
= 50-100) attainable.  In addition, these drugs are frequently administered to reasonably healthy patients not concurrently 
receiving other drugs more likely to be hepatotoxic, facilitating causation assessment. 
Basic Study Design: The five DILIN clinical centers will identify and contact patients at their own and affiliated institutions who 
may have suffered a liver injury due to one of the targeted drugs.  They will also contact gastroenterologists, hepatologists, and 
other health care professionals most likely to have treated DILI cases.  In the latter case, an information packet will be sent by 
the treating physician to the potential subject, and interested subjects will be requested to contact one of the five clinical sites.  
In either case, the subject will be given a brief description of the study's purpose and procedures, and when further interest in the 
study is expressed, s/he will be mailed provided with an information packet including the informed consent document, The 
Health Insurance Portability and Accountability Act (HIPAA) authorization and release of medical record forms.  Once these 
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documents have been received reviewed by the subject, study staff will contact the potential subject by telephone a second time.  
This follow-up contact will either occur by telephone or in person at the subject's convenience.  Informed consent will be 
obtained, and if this occurs over the telephone, it will be witnessed by a third party on the line.  Then, requisite information will 
be collected using a telephone or personal interview format.  Prior to ending this phone call the end of the second contact, the 
subject will be asked to sign the consent, HIPAA authorization, and release of medical information forms and return provide 
them to the DILIN clinical site.  Arrangements for blood drawing will be made.  The blood sample will be shipped to the Rutgers 
University Cell and DNA Repository (RUCDR) where DNA will be extracted and lymphocytes will be immortalized.  DNA, 
plasma and immortalized lymphocytes will be frozen and stored for future studies.  Once the signed documents have been 
received, medical records and charts will also be retrieved from the appropriate health care provider(s).  Detailed clinical 
information concerning the DILI event will be abstracted from the charts and entered onto case report forms.  This 
information will then be reviewed by the DILIN Causality Committee, and it will make the final determination on whether the 
patient was a true DILI case.
SUBPROJECT PROGRESS:
There are a total of eight subjects enrolled into this study. There was no new enrollment during the current report period. There 
are no changes in recruitment plans at this time. In addition, there are no unexpected safety concerns to report. At this time, there 
only publication that has resulted from this study is: Etiology of New-Onset Jaundice: How Often Is It Caused By Idiosyncratic 
Drug-Induced Liver Injury In The United States? (pdf) American Journal of Gastroenterology, Oct. 2006, © 2006 by Am. Coll. of 
Gastroenterology, however the GCRC was not cited on this publication.
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0557 557PROTOCOL:SPID: RESEARCHTYPE:  
Effects of DHEA and Exercise on Bone, Muscle and BalanceSHORT TITLE:
LONG TITLE: Effects of Dehydroepiandosterone (DHEA) and Exercise on Bone, Muscle and Balance
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 8/3/2004
 150Total # pts expected for entire study:
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Center on AgingKENNY, ANNE MD
MedicinePRESTWOOD, KAREN MD
SUBPROJECT DESCRIPTION:
Bone and muscle loss in microgravity have been identified by National Aeronautics and Space Administration (NASA) as key 
barriers to successful long-term space flight.  Further, the potential importance of balance effects of flight were highlighted by 
the disequilibrium findings in John Glenn following his return from a space shuttle flight and the initiative of NASA to assess 
longitudinally balance in cooperation with the Baltimore Longitudinal Aging Study.  The bone and muscle loss in microgravity 
are not completely understood.  There are several changes that occur during space travel that may influence changes in bone 
and muscle including weightlessness, hormone changes, nutritional changes, stress response, and protein metabolism (1, 2, 3).  
Many changes that occur with space travel are also seen with aging and culminate in a syndrome described as frailty (4,5,6).  
Changes with aging include increases in cortisol and insulin levels, decreases in sex hormones, poor nutritional intake and 
anorexia contributing to bone, muscle and balance loss.  Study of interventions that may mitigate the effects of aging on frail, 
older individuals, may provide insights into countermeasures and strategies for minimizing bone, muscle and balance loss in 
space. 
Most geriatricians agree that frailty is a syndrome of decreased reserve and resistance to stressors, resulting in cumulative 
declines across multiple physiologic systems, resulting in increased vulnerability to adverse outcomes ( 4,5,6).  Physical markers 
of frailty include declines in lean body mass, strength, endurance, balance, walking performance, low activity and some include 
osteopenia (4,5,6,7).  Many of the components of frailty are interrelated and all are associated with declining reserve.  Since 
multiple of these components must be present clinically to constitute frailty, a physical continuum of robust to prefrail to frail 
can be envisioned.  Fried et al. has proposed a phenotype of frailty, highlighting 5 characteristics from the physical markers of 
frailty, and used the phenotype to assess the contribution of baseline frailty status to the incidence of health outcomes during 3 
and 7 years of follow-up (8).  For this phenotype, frailty is defined as having 3 of the 5 characteristics and prefrailty has having 
1 or 2 of the 5 characteristics. Frailty and prefrailty are associated with increased risk of death, hospitalization, falls, worsening 
Activities of Daily Living (ADL) disability and worsening mobility (8). 
Dehydroepiandosterone (DHEAS) and yoga may mitigate or reverse the effects of aging and frailty on bone, muscle and balance 
loss.  The mechanism of the effects may be direct - working through androgen or estrogen receptors in bone, muscle or brain.  
Or the effects may be indirect, countering effects of the stress response.  
Hypotheses: Muscle strength and balance will improve in women with frailty selected for dehydroepiandosterone sulfate 
(DHEAS) levels below 305 ng/dl treated with DHEAS supplementation and Hatha yoga.  The effects of both treatments will 
improve outcomes more than either treatment alone and may be additive. In addition, lean body mass, skeletal muscle mass, 
markers of bone turnover and physical performance will improve following treatment with DHEA and/or yoga.
SUBPROJECT PROGRESS:
The study is closed to recruitment and study visits were to complete classes and data collection by July 2006. There have been no 
safety concerns There are no interim data or publications to date but we are currently working with statisiticians to complete 
analysis and prepare manuscripts
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0558 558PROTOCOL:SPID: RESEARCHTYPE:  
Clinical Behavior of Lithium Disilicate, Single-Unit, CAD/CAM CrownsSHORT TITLE:
LONG TITLE: Clinical Behavior of Lithium Disilicate, Single-Unit, Computer-aided Design/Computer-aided Machining 
(CAD/CAM) Crowns
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 24  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 8/5/2004
 40Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
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Phase III
NON-HOST INSTITUTION: STATE, 
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Oral Rehab, BiomaterialsKELLY, JOHN R DDS, DSC
ProsthodonticsSQUIER, RACHEL DMD, DSC
SUBPROJECT DESCRIPTION:
This trial will examine the performance of 40 single unit crowns (25 posterior and 15 anterior) for a period of at least 2 years.  
Crowns will be fabricated from a lithium disilicate glass-ceramic using a computer-aided design/computer-aided machining 
(CAD/CAM) process.  Both the material and the processing equipment have FDA 510-K clearance for this clinical application.  
The principal investigator (PI) initiated this trial at UConn as an important complement to ongoing laboratory efforts to better 
understand clinical behavior and aid ongoing research into the development of validated laboratory tests of ceramic-ceramic 
compatibility and bulk fracture.
SUBPROJECT PROGRESS:
This study was closed to enrollment for the reporting period. All 2 year recalls were finished and a final report was submitted to the 
sponsor. 
There were two additional bulk crown failures this year, no unexpected safety concerns and no changes to protocol. Scanning 
electron microscopy and EDAX chemical analysis were used on four failed crowns to identify a likely failure mechanism. 
Nothing related to this research has yet been published.
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0560 560PROTOCOL:SPID: RESEARCHTYPE:  
Study of College Student Daily Life: Addendum - Interaction of GeneticSHORT TITLE:
LONG TITLE: Study of College Student Daily Life: Addendum - Interaction of Genetic Variation and Daily Life 
Experiences
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 8/19/2004
 574Total # pts expected for entire study:
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Community MedicineTENNEN, HOWARD PHD
Community MedicineAFFLECK, GLENN PHD
PACE UNIVERSITY, NY USAARMELI, STEPHEN PHD
PSYCHOLOGY UCONN, STORRS, CT USACILLESSEN, ANTONIUS PHD
PsychiatryCONNER, TAMLIN PHD
PsychiatryCOVAULT, JONATHAN MD, PHD
PSYCHOLOGY LOYOLA, IL USADEHART, TRACY PHD
ALLIED HEALTH SCIENCES UCONN, STORRS, CT USADUFFY, VALERIE PHD
PsychiatryFORD, JULIAN PHD
PSYCHOLOGY AMERICAN UNIVERSITY, DC USAGUNTHERT, KATHLEEN PHD
PsychiatryHERMAN, AREY BA
PsychiatryKRANZLER, HENRY MD
SUBPROJECT DESCRIPTION:
The proposed study is an addendum to an existing Alcohol Research Center longitudinal study of college students' daily alcohol 
consumption employing a daily report methodology to study the linkage of daily life events and students' health-related and 
school related behaviors.  The 574 students currently enrolled in this study will be offered the opportunity to enroll in this 
genetics addendum which will (a) examine the influence of a functional polymorphism, 5-HTTLPR, in the promoter region of 
the serotonin transporter gene, and an alcohol dependence associated halplotype of the GABRA2 gene encoding the 
benzodiazapine receptor subunit GABRA a-2, on the use of alcohol by college students (b) evaluate the interaction of 
5HTTLPR and GABRA2 genotypes with daily life stressors, positive experiences, social interactions/peer influences, and 
positive or negative mood states on the use of alcohol by college students. In an exploratory aim we will also examine the 
effects of variation in two other genes influencing serotonin signaling: i) TpH2 which encodes the brain specific form of 
trypthophan hydroxylase, the rate limiting enzyme in serotonin synthesis, and ii) MAOA encoding monoamine oxidase, a key 
enzyme involved in metabolic inactivation of synaptic serotonin (as well as norepinepherine and dopamine).
SUBPROJECT PROGRESS:
1) Number of subjects enrolled during the report period:  none   since initiation of study:  410   
2) Planned changes in recruitment plans: none
3) Unexpected safety concerns and their resolution:  None occurred.
4) Interim data:  Polymorphisms in several genes have been examined.  Results for two genes (SLC6A4 and HTR1B) have shown 
significant associations with clinically relevant behavioral phenotypes (stress related alcohol use, daily anxiety reactivity, and 
aggressive behaviors).  Results from this work have been published in the past year.  Results for two other genes (TPH1 and TPH2) 
did not show hypothesized association with alcohol use, the results of this analysis have been recently accepted for publication 
(Gacek et al).    
5) Proposed changes made or anticipated in the protocol:  None.
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6) Continued GCRC support requested - We request the GCRC protocol remain active with the potential request for additional 
genotyping of the study sample.
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0562 562PROTOCOL:SPID: RESEARCHTYPE:  
Drug- and CAM-Induced Liver InjurySHORT TITLE:
LONG TITLE: A Multi-Center, Longitudinal Study of Drug- and Complementary/Alternative Medicine (CAM)- Induced 
Liver Injury
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
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AIDS: N
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MedicineROSSON, ROBERT MD
SUBPROJECT DESCRIPTION:
Background and Rationale:  Liver injury due to prescription and non-prescription medication use is a medical, scientific, and 
public health problem of increasing frequency and importance in the United States.  Indeed, drug-induced liver injury (DILI) is 
the most common reason for nonapproval, withdrawal, limitation in use, and clinical monitoring by the Food and Drug 
Administration (FDA).  However, detection of signals for liver injury frequently relies upon the reporting of cases by 
practitioners to health authorities in post-marketing surveillance.  Under-reporting of cases, lack of mandatory reporting 
systems, and difficulties in establishing a diagnosis make the current system sub-optimal.  Moreover, with the growing use of 
complementary and alternative medications (CAM), there have also been increasing reports of liver toxicity due to various 
non-prescription herbal, dietary, and food additive supplements.  Because the manufacturing, dispensing, and testing of these 
products is not regulated, the hepatotoxic potential of these formulations is poorly characterized or completely unknown.  As a 
result, there is a great need to develop an improved means of detecting, defining, and studying DILI in the United States. 
The DILIN prospective study is a multi-center study designed to gather clinical information and biological specimens on cases 
of suspected liver injury due to drugs and CAM.  The goals of this study include the earlier recognition of DILI, especially due to 
newer drugs, development of standardized instruments and terminology to help identify cases of DILI, investigating clinical and 
genetic risk factors that predict DILI, and performing a careful longitudinal follow-up of DILI subjects.  The biological samples 
collected will be used in future studies of the mechanisms and genetics of DILI.
Specific Aims and Objectives:  The primary objective of this study is to prospectively identify bona fide cases of liver injury due 
to drugs and complementary and alternative medications within 6 months of presentation.  Secondary objectives include 
collecting clinical data and biological specimens including blood, DNA, urine, and liver tissue from affected patients and matched 
controls for future mechanistic and genetic studies.  We will also investigate the clinical, immunological, and environmental risk 
factors of drug-mediated hepatotoxicity by comparing DILI cases to matched controls with a similar drug exposure history but 
no evidence of clinically significant liver injury.  The natural history of drug- and CAM-induced DILI will be tracked for at least 
6 months following enrollment, with longer follow-up for those in whom there is evidence of chronic liver injury at 6 months.  
We will also develop and test causality assessment instruments for drug and CAM-induced liver injury that are sensitive, specific, 
and reproducible.
Basic Study Design: The DILIN Prospective Study is a multi-center, prospective, epidemiological study.  Patients who are 
referred to one of the DILIN clinical sites and who, in the opinion of a gastroenterologist / hepatologist, experienced a 
drug-induced liver injury will be enrolled.  Detailed clinical data and biological specimens will be collected.  Clinical data will be 
reviewed by the DILIN Causality Committee, and it will make the final determination of whether the subject qualifies as a bona 
fide DILI case.  Up to three matched controls will be individually matched to each index case.  They will be matched by age, 
duration of exposure to the implicated medication, and from the same clinical site.  DILI cases (only) will be followed for at 
least 6 months to derive the longitudinal profile of drug- and CAM-induced liver injury.  Detailed clinical data and biological 
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specimens will be collected at this time point.  Patients who satisfy the definition of chronic DILI will be evaluated at 12 
months and yearly thereafter.
SUBPROJECT PROGRESS:
A total of 62 subjects have consented to this study, 58 of whom were deemed eligible after the baseline visit. During the current 
reporting period, 11 eligible subjects have been enrolled. In our New England-Northeastern Consortium, we are establishing satellite 
sites to help identify and enroll suitable subjects throughout the northeastern quadrant of the USA. Out of four previously approved 
sites: SUNY, Syracuse (PI: R. Levine); University of Rochester - Strong Memorial Hospital (PI: B. Maliakkal); Hartford Hospital 
(PI: R. Rosson); and Hebrew Health Care Inc. of Hartford, two sites: Hartford Hospital and Hebrew Health Care Inc. of Hartford, 
were closed. SUNY has screened 15 and enrolled 12 subjects. University of Rochester has screened 7 and enrolled 4 subjects. 
Hartford Hospital has screened 4, enrolled one subject and referred 11 subjects 7 of which have been enrolled at the University of 
Connecticut Health Center (UCHC). Hebrew Health Care has screened 1 subject. Dartmouth-Hitchcock Medical Center (PI: D. van 
Leeuwen) has been a good source of subject referrals, 6 of whom have enrolled at UCHC. 
There are no safety concerns to report. Because this is an observational study, primarily to develop a registry of subjects, there is 
minimal risk for subjects to take part, and we do not expect any significant adverse events. During the past year, the only 
modifications submitted to the IRB were administrative modifications; Dr. Bonkovsky's role in the study changed from principal 
investigator to co- investigator, now Dr. Petr Protiva serves as principal investigator, Dr Michael Grupka, Dr Paul Appleton, 
Kathleen Curley, and Thomas Kiely were added to the study stuff, Laura Glynn was removed from the study.  Due to a difficulty in 
the recruitment and enrollment of the study subject Hartford Hospital and Hebrew Health Care Inc. of Hartford, were closed as 
study satellite sites.
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0563 563PROTOCOL:SPID: RESEARCHTYPE:  
Substance Abuse BehaviorSHORT TITLE:
LONG TITLE: Individual Differences and Long-Term Follow-Up of Substance Use Behaviors
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 105  0  0
 0  0  0
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Offsite Visits  0  0  0
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DEPT OF PSYCHIATRY UNIVERSITY OF CHICAGO, IL USAKING, ANDREA PHD
SUBPROJECT DESCRIPTION:
The goal of this investigation is to compare unique behavioral and physiological responses to alcohol and their associations in 
light and heavy social alcohol drinkers.  We plan to specify their objective, performance, and subjective alcohol response in a 
preclinical laboratory study.  Measures will be obtained during both rising and declining blood alcohol concentrations in order to 
better understand potential factors involved in the earlier stages of heavy alcohol use.  We also plan to follow-up on study 
participants for several years after the preclinical phase of the study to examine whether acute alcohol response factors are 
significantly associated with future drinking patterns and alcohol consequences.
SUBPROJECT PROGRESS:
For recruitment purposes, this protocol is commonly referred to as The Chicago Social Drinking Project (CSDP). 
Number of Enrolled Subjects: Enrollment for the CSDP ceased in July 2006.  Our final total for the study was 198 enrolled subjects. 
Of these 198 subjects, 190 completed all three required experimental sessions.  At this time, two subjects have withdrawn from the 
study (1 subject for unstated reasons in 2/06 and another who passed away following her 2-Year Follow-Up interview) leaving 188 
subjects currently engaged in the longitudinal follow-up portion of the study. 
Changes in Recruitment Plan: The CSDP is no longer recruiting new subjects; thus, no changes in the recruitment plan are 
warranted. 
Unexpected Safety Concerns and Their Resolution: No unexpected safety concerns occurred during this reporting period. 
Interim Data and Outcome: During this period, the CSDP utilized the interactive voice recording (IVR) phone system provided by 
the University of Connecticut to complete quarterly follow-up data collection (at 3, 6, 9, 15, 18, and 21 months following the 
final in-lab experimental session). Data obtained from these follow-up interviews provide information regarding changes in the 
subject's alcohol consumption and cigarette smoking behavior as well as moods and significant life events. From 4/1/07 to 3/31/08, 
the CSDP successfully completed 171 of 171 of these interviews.  In addition, at 12 and 24 months, subjects completed a more 
extensive annual follow-up, consisting of demographic and substance use updates and psychosocial measures completed via online 
survey as well as a brief diagnostic interview completed during a brief phone conversation. During this period, the CSDP completed 
97 of 97 of these interviews.   Overall, the CSDP reports a 100% follow-up rate during this reporting period and an impressive 
99.05% follow-up rate for the duration of the entire study.
Proposed Changes to Protocol: No changes are proposed for this protocol
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0568 568PROTOCOL:SPID: RESEARCHTYPE:  
Chemotherapy Induced ThrombophiliaSHORT TITLE:
LONG TITLE: Chemotherapy Induced Thrombophilia
Inpatient
Scatter Bed
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Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
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 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/19/2004
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Medicine/Hem-OncBONA, ROBERT MD
Medicine/Hem-OncSMARADOTTIR, AGNES MD
SUBPROJECT DESCRIPTION:
The hypothesis for this study is that chemotherapy itself induces thrombophilic state in cancer patients by causing endothelial 
damage and therefore is able to activate the coagulation system. It is our aim to show that markers of endothelial damage and 
activation of the coagulation cascade is induced when patients receive chemotherapy. Each patient will serve as his/her own 
control.
SUBPROJECT PROGRESS:
This study closed in the General Clinical Research Center (GCRC) as of April 30, 2007.
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0569 569PROTOCOL:SPID: RESEARCHTYPE:  
Breaking the Cycle of Behavioral Health ProblemsSHORT TITLE:
LONG TITLE: Breaking the Cycle of Behavioral Health Problems
Inpatient
Scatter Bed
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Scatter RN Hours
TOTALS A B D
 0  0  0
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 0  0  0
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Offsite Visits  0  0  0
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NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryFORD, JULIAN PHD
PsychiatryABU-HASABALLAH, KHAMIS PHD
PsychiatryALBERT, DAVID PHD
PsychiatryMOFFITT, KATHIE H PHD
PsychiatrySTEINBERG, KAREN PHD
PsychiatryTANEV, KALOYAN MD
Community MedicineTENNEN, HOWARD PHD
SUBPROJECT DESCRIPTION:
The study is a randomized clinical trial comparing two psychotherapy interventions with an active comparison condition to 
determine their efficacy in addressing behavioral, cognitive, affective, and interpersonal substrates of a core problem in complex 
Post Tramatic Stress Disorder (PTSD) that often occurs for persons living in adverse socioeconomic circumstances and in 
violent families and communities.  One goal of the study is to reduce the severity of or produce remission from PTSD and 
associated anxiety, mood, and addictive disorders, in order to reduce impulsivity, aggression, dissociation, and isolation by 
high-risk or previously incarcerated women. The long-term goal, which will be assessed in subsequent studies over time is to 
reduce the likelihood of their or their children becoming involved in, or victimized by other persons' involvement in, illegal 
activities. Children will not be involved in the present study, only women who are the mothers of young children.
Aim #1:  To test the efficacy of Target Affect Regulation Guide for Education and Therapy (TARGET) and Present Centered 
Therapy (PCT). TARGET (Frisman, Ford, & Lin, 2004) and PCT (McDonagh-Coyle, Friedman, McHugo, Ford et al., in press) 
have demonstrated efficacy in randomized trial studies, but have not been tested specifically with mothers of young children. 
The study will assess outcomes that are of potential importance not only for the well being of the participating women but for 
their ability to develop secure attachments with their child which are protective against exposure to violence, crime, and 
victimization and associated with positive psychosocial development by children.  Outcome measures reflect self-regulatory 
capacities compromised by trauma which are essential for effective caregiving by adults.
Aim #2:  To compare the efficacy of TARGET and PCT on theory-based differential outcomes. TARGET and PCT use similar 
but different therapeutic strategies. Each teaches skills for managing negative emotions and critical symptoms (e.g., inhibiting 
impulsivity). TARGET teaches a skill sequence for affect regulation and social/interoceptive information processing, while PCT 
teaches a skill sequence for recognizing and solving problems in relationships.  We expect that TARGET and PCT will reduce 
stress-related avoidance and depression and enhance active coping with current stressors. TARGET should be superior to PCT in 
enhancing  the ability to cope with trauma memories, stress reactivity, and anxiety, and therefore, physical well-being and 
ability to remain free from illegal activities or future or further involvement with criminal justice systems.  PCT should be 
superior to TARGET in enhancing the participant's overall social adjustment.
SUBPROJECT PROGRESS:
The study has been closed for recruitment during this reporting time. A total of 174 participants have been enrolled. All 
participants have completed study procedures including the daily phone calls to the interactive voice response system (IVR) 
operated by the General Clinical Research Center (GCRC). There have been no unexpected safety concerns and no modifications 
were submitted. Data analyses are currently being prepared. No publications have been completed at this time.
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0572 572PROTOCOL:SPID: RESEARCHTYPE:  
Oral Infection and Inflammation in Transplant PatientsSHORT TITLE:
LONG TITLE: Oral Infection and Inflammation in Transplant Patients
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 9/30/2004
 108Total # pts expected for entire study:
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PeriodontologyDONGARI-BAGTZOGLOU, ANNA DDS, 
PHD
Behavioral SciencesBURLESON, JOSEPH PHD
SURGERY HARTFORD HOSPITAL, CT USAHULL, DAVID MD
PeriodontologyIOANNIDOU, EFFIE DDS
SUBPROJECT DESCRIPTION:
Chronic periodontitis and oral candidiasis are the most frequent opportunistic oral infections associated with 
immunosuppression caused by disease or treatment. These oral infections are frequently asymptomatic and therefore can remain 
undiagnosed and untreated. Solid organ transplant recipients represent a growing population of chronically immunosuppressed 
patients whose oral health status has been largely uncharacterized. Because recent studies have shown that chronic oral infection 
can trigger low grade systemic inflammation which may contribute to vascular disease and because chronic graft vasculitis can 
lead to transplant rejection, studies characterizing the oral and systemic inflammatory status in this patient population are 
urgently needed. Serum interleukin-6 (IL-6) and C-reactive protein (CRP) are well established, sensitive markers of systemic 
inflammation which have been shown to be elevated in chronic periodontitis patients and are also good diagnostic indicators for 
transplant rejection. In this proposal we hypothesize that in transplant patients with Candida stomatitis or chronic 
periodontitis, chronic elevation of serum IL-6 may directly or indirectly (via induction of CRP) be associated with chronic graft 
allograft failure. 
To begin to explore a potential relationship between chronic oral opportunistic infection and chronic transplant rejection we 
propose to a) study the prevalence of oral candidiasis  and chronic periodontitis in their patients population; b) collect 
preliminary data on a possible association between the presence of these oral opportunistic infections and a history of chronic 
rejection; and c) determine the levels of IL-6 and CRP in the serum of transplant patients and study their relationship with i) 
the presence of oral infection; and ii) the levels of oral mucosal IL-6 expression in situ. The pilot work proposed herein will 
provide the framework for the design of a larger scale prospective clinical study which will conclusively address the role of oral 
opportunistic infections in systemic inflammation and chronic transplant rejection in this special needs patient population.
SUBPROJECT PROGRESS:
We have enrolled more than 115 transplant patients at Hartford Hospital and more than 70 healthy subjects at the University of 
Connecticut Health Center (UCHC) since initiation of the study, none during the last report period. This study continues to be 
closed to recruitment. There were no unexpected concerns or changes in plans/protocol. The following abstracts were accepted for 
presentation: Ioannidou E*, Hull D, Burleson J, Dongari-Bagtzoglou AI. Relationship between chronic periodontitis and chronic 
organ transplant rejection".  2007 IADR meeting (Continental European and Israeli Divisions). Ioannidou E*, Hull D, Burleson J, 
Dongari-Bagtzoglou AI. "Periodontitis is an independent predictor for elevated serum CRP levels in solid organ transplant 
recipient". 2007 AAP meeting.
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0574 574PROTOCOL:SPID: RESEARCHTYPE:  
CO2 Production and Ventilation in COPDSHORT TITLE:
LONG TITLE: CO2 Production and Ventilation in Chronic Obstructive Pulmonary Disease (COPD)
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/19/2005
 50Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
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NON-HOST INSTITUTION: STATE, 
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Medicine/Pulmonary MedicinBURKI, NAUSHERWAN K MD
PulmonaryMARTIN, ISHMAEL MD
Medicine/PulmonarySALERMO, EDWARD MD
SUBPROJECT DESCRIPTION:
1. Resting minute ventilation (Ve) is increased in normocapnic patients with COPD.
2.  The ratio of CO2 production (VCO2) to resting Ve, is decreased in COPD
3.  Whilst the relationship VCO2/arterial PCO2 in COPD is similar to normals, the relationship  Ve/arterial PCO2 is decreased. 
4.  VCO2 is similar in normocapnic and hypercapnic COPD, but Ve/VCO2 is decreased in 
hypercapnic vs normocapnic COPD. 
5.  In contrast to normal subjects, both normocapnic and hypercapnic COPD patients respond to an added respiratory resistive 
load with a decrease in Ve and increase in end-tidal PCO2. 
       
SPECIFIC AIMS
1. In patients with normocapnic COPD, and in healthy normal subjects, measure resting Ve, VCO2, end-tidal CO2 and anatomic 
deadspace (Vdan) and alveolar deadspace (Vdalv) and examine the relationship amongst these parameters and in relationship to 
arterial PCO2 (PaCO2).
2. In patients with hypercapnic COPD, measure resting Ve, VCO2, end-tidal CO2, PaCO2, Vdan and Vdalv and examine the 
relationship amongst these parameters, and compare the results to normocapnic COPD patients.
3. In normocapnic and hypercapnic COPD patients, and in healthy normal subjects, examine the effects of an added resistive 
load on Ve, VCO2, and end-tidal CO2 to approximate the effects of acute exacerbations of COPD on these parameters.
Ventilatory failure is associated with an increased arterial PCO2 (PaCO2). Arterial PaCO2 is determined by the balance between 
CO2 production and excretion from the body (VCO2). CO2 production is known to be increased in obesity (1), during exercise 
(2), fever, and with high carbohydrate diets (3, 4).  
   
The critical importance of CO2 has been recognized for a very long time: Were it not for the peculiar properties of carbon 
dioxide - a very weak acid and a gas - our bodies would be unable to survive in their present state" (5).  A great deal is known 
about the production of CO2 (VCO2) by the human body as a natural physiologic process: CO2 is produced in muscle as a 
product of metabolism, diffuses rapidly into blood where it is transported to the lungs and excreted.  
The production of CO2 is dependent on three factors: metabolism, blood carriage mechanisms (acid/base, buffering 
mechanisms), and pulmonary excretion.
Dietary factors which alter CO2 production are due to the differences between carbohydrates and fat: in glycolysis, 1 mol of 
CO2 is produced in regenerating 6 mol of ATP, whereas in non-esterified fatty acid metabolism 1 mol of CO2 is produced for 8 
mol of ATP. Thus CO2 production is dependent on the balance between fat and glycogen oxidation, and can be influenced by 
dietary changes (3, 4).
CO2 is carried in the blood as dissolved CO2 and [HCO3-] and is affected by the acid -base state.  The excretion of CO2 by the 
lungs is considered primarily a function of ventilation, and complete equilibration is assumed between the PCO2 of capillary 
blood and the alveoli (2). However, under stress, such as during exercise, a disequilibrium occurs, related to the breathing cycle 
and blood flow. In healthy normal subjects there is a direct, curvilinear relationship between alveolar ventilation (VA) and 
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arterial PCO2.
SUBPROJECT PROGRESS:
We are currently continuing to study both normal (>60 years age) and COPD patients. We have completed studies in an additional 
5 normal subjects, and 3 COPD patients. The data have not been analysed yet.
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0575 575PROTOCOL:SPID: RESEARCHTYPE:  
NSABP B39SHORT TITLE:
LONG TITLE: NSABP B39/RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) 
Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/28/2005
 10Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
Breast conserving therapy (BCT) has become an accepted option in the treatment of most patients with Stage 1 and 2 breast 
cancer.  The major advantages of BCT are superior cosmetic results and reduced psychological and emotional trauma compared 
to mastectomy.  However, BCT also has disadvantages.  The technique is more complex and prolonged treatment regimen 
requiring approximately 5-7 weeks to complete.  For patients who are elderly or whom live a distance from treatment centers, 
logistical problems can prove to be prohibitive.  In addition, with the more frequent use of adjuvant chemotherapy in patients 
with both node negative and node positive breast cancer, delays can occur prior to the initiation of radiation therapy or 
hormonal therapy.  Despite the advantages of BCT, only 10-40% of patients who are candidates for BCT actually receive it.  
Most of the logistical problems associated with BCT relate to the protracted course of external beam radiation to the whole 
breast.  Standard therapy generally includes 5 weeks of radiation to the whole breast followed by a boost to the tumor bed with 
either additional 8-10 fractions of external beam radiation or 2-3 day interstitial implant.  Studies have shown that it appears 
radiation therapy after tumor excision exerts its maximal effect upon reducing breast cancer recurrence at or near the tumor 
site. 
The primary aim of the study is to determine whether partial breast irradiation (PBI) limited to the region of the tumor bed 
following lumpectomy provides equivalent local tumor control in the breast compared to conventional whole breast irradiation 
(WBI) in the local management of early stage breast cancer.  The secondary aims are 1) to compared overall survival, 
recurrence-free survival, and distance disease-free survival between women receiving PBI vs. WBI;  2) to determine whether PBI 
delivered on 5 treatment days over a period of 5-10 days can provide a comparable cosmetic result to WBI; 3) to determine if 
PBI produces less fatigue and treatment-related symptoms compared to WBI; 4) to determine if perceived convenience of care 
is greater for women receiving PBI compared to women receiving WBI; and 5) to compare acute and late toxicities between the 
radiation therapy regimens.
SUBPROJECT PROGRESS:
There have been 0 patients accrued to this study. This study was closed here at UCHC as of 05-14-2008. There have been no 
safety concerns, no publications.
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0576 576PROTOCOL:SPID: RESEARCHTYPE:  
NSABP R04SHORT TITLE:
LONG TITLE: NSABP R04: Treatment with Two Chemotherapy Drugs Combined with Radiation Therapy for Patients 
with Rectal Cancer
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/28/2005
 10Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
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NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
Rectal cancer remains a significant oncologic problem, with approximately 34,700 new cases diagnosed each year with an 
expected overall 5-year survival of 50%.  Surgical resection is the primary therapy, which unfortunately often requires creation 
of permanent colostomy.  Due to high recurrence rate with surgery alone, adjuvant chemoradiation has become standard 
practice for the treatment of advanced rectal cancer.  However, the optimal treatment schedule remains unknown.  This 
protocol will examine if preoperative radiotherapy plus capecitabine is similar to preoperative radiotherapy (XRT) plus 
continuous intravenous infusion (CVI) of 5-FU in achieving durable local-regional disease control.  Because studies using 
postoperative chemotherapy and radiotherapy did not improve disease free survival or overall survival, more recent trials have 
been looking at preoperative radiotherapy.  A trial conduced in Sweden, using preoperative radiotherapy reports a significant 
increase in survival and similar trials conducted by the Dutch has shown a decrease in local recurrence.  The clinical usefulness of 
capecitabine has been demonstrated in 2 large phase 3 studies comparing 5-FU to capecitabine in untreated colorectal patients.  
The studies have shown that oral administration of capecitabine results in higher response rate that 5-FU.  Also, capecitabine 
has certain characteristics that make it a potentially useful radiosensitizer.  The primary aim is to compare the rate of 
local-regional relapse in patients receiving preoperative oral capecitabine with XRT to CVI 5-RU and XRT.  The secondary 
aims are to downstage the primary tumor, increase the number of patients undergoing sphincter-saving surgery, correlate genetic 
patterns and the presence of absence of specific tissue biomarkers with response and prognosis, compare capecitabine and CVI 
5-FU in the setting of preoperative XRT for rectal cancer, examine the differences in toxicity and burden of care for the 2 
chemotherapy treatment regimens, and to describe the impact of the type of surgical management of rectal cancer on QOL at 1 
year after surgical treatment.  
Study Design
Patients must have histological diagnosed adenocarcinoma of the rectum, be amenable to surgical resection and tumor must be 
located < 12cm from the anal verge.  Patients will then be stratified by gender, tumor stage, and intent for surgery.  Following 
stratification they are randomized to receive either CVI 5-FU and XRT or capecitabine and XRT.  The chemotherapy ends with 
the last XRT dose.  This is followed by surgery.
SUBPROJECT PROGRESS:
2 enrolled at The Hospital of Central Connecticut (THOCC) for which the University of Connecticut Health Center (UCHC) is the 
operating Institutional Review Board (IRB). There are no unexpected safety concerns and no anticipated changes to the protocol. 
The General Clinical Research Center (GCRC) is not cited in any publications.
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0577 577PROTOCOL:SPID: RESEARCHTYPE:  
NSABP B-38SHORT TITLE:
LONG TITLE: NSABP B38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with 
Node-Positive Breast Cancer
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/28/2005
 10Total # pts expected for entire study:
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Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
Recently, oncologists have begun treating breast cancer patients with dose dense (DD) regimens. This means that the patients 
receive the chemotherapy drugs over a much shorter period of time. Surprisingly, the overall toxicities
experienced by the patients is no worse and the efficacy equal if not superior. Studies have shown that women with breast cancer 
treated with Docetaexel/Doxorubicin/Cyclophosphamide (TAC) (Arm I) or ddose-dense.   Doxorubicin/Cyclophosphamide 
followed by DD Paclitaxel (DD AC-P) (Arm II) have improved treatment outcome compared to previously used chemotherapy 
regimens. Unfortunately some women still develop local, regional, and systemic disease recurrence. This reality provides a 
compelling reason to continue efforts to further improve therapy for node-positive breast cancer. To date there has not been a 
study to directly compare TAC to DD AC-P and this trial will
provide that comparison. Another potential advantage of DD AC-P is that it's reported toxicity profile provides opportunity 
for incorporating a fourth chemotherapy agent into the program. The anti-metabolite gemcitabine has shown promise in 
combination with paclitaxel for treatment of mestastatic breast cancer arguing for its potential use in the adjuvant setting. A 
phase 2 study of gemcitabine in combination with paclitaxel as a third-line therapy showed a response rate of 55% with a 
manageable toxicity profile. On the basis of the activity of the gemcitabine/paclitaxel combination
demonstrated in these trials, coupled with the favorable toxicity profile of the dose-dense schedule, they propose to determine 
whether sequential dose-dense AC followed by DD AC-PG (Arm III) can further improve the outcome provided by both TAC 
and DD AC-P. 
The primary aims of this study are to determine whether the DD AC-PG regimen is superior to the TAC and the DD AC-P 
regimens in improving DFS and to compare the relative DFS of TAC and DD AC-P. Secondary
aims are to determine whether DD AC-PG is superior to TAC and DD AC-P in improving overall survival, compare survival of 
the TAC and DD AC-P regimens Alone, and to compare the toxicities of the 3 regimens.
Study Design: The study will be conducted in women with operable, invasive carcinoma of the breast with histologically positive 
axillary nodes. Patients will be stratified by number of positive nodes, hormone receptor status, and type of surgery and planned 
radiotherapy. Following stratification, patients wi11 be randomized to 1 of the 3 chemotherapy regimens. Women with ER 
positive and/or PR positive tumors should receive hormonal therapy for a minimum of 5 years following completion of 
chemotherapy. All women who have had a lumpectomy wi11 have whole breast irradiation. Chest wall and regional nodal
irradiation will be prospectively determined at the discretion of the investigator and will be used as a stratification factor. The 
study will enroll 4800 patients.
SUBPROJECT PROGRESS:
University of Connecticut Health Center (UCHC): 6 patients were enrolled: all 6 patients completed their therapy without 
complications and are currently in the follow-up phase.  All of the patients are doing well and have no evidence of disease.
The Hospital of Central Connecticut (THOCC): 4 patients were enrolled: 1 deceased beginning of March 2007; 3 finished 
treatment and are in follow-up phase.  Patients are doing well otherwise.
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0578 578PROTOCOL:SPID: RESEARCHTYPE:  
NSABP B36SHORT TITLE:
LONG TITLE: NSABP B36: A Clinical Trial of Adjuvant Therapy Comparing 6 Cycles of 5-FU, Epirubicin and 
Cyclophosphamide (FEC) to 4 Cycles of Adriamycin and Cyclophosphamide (AC), With or Without 
Celecoxib, in Patients with Node Negative Breast Cancer
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/28/2005
 50Total # pts expected for entire study:
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Phase III
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
SurgeryKURTZMAN, SCOTT MD
SUBPROJECT DESCRIPTION:
The primary aim of this phase III trial are to determine whether a regimen of 6 cycles of 5-fluorouracil (5-FU), epirubicin and 
cyclophosphamide (FEC-100) is superior to 4 cycles of Adriamycin and cyclophosphamide (AC) in prolonging disease-free 
survival (DFS) in patients with node-negative breast cancer.  Chemotherapy (AC or FEC-100) plus celecoxib is superior to 
chemotherapy along in prolonging DFS in women with node-negative breast cancer.
SUBPROJECT PROGRESS:
There have been 0 patients accrued to this study. This study was closed here at the University of Connecticut Health Center 
(UCHC) as of 05-14-2008. There have been no safety concerns, no publications.
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0581 581PROTOCOL:SPID: RESEARCHTYPE:  
Changing ART Adherence BehaviorSHORT TITLE:
LONG TITLE: Changing Antiretroviral (ART) Adherence Behavior for HIV-related Morbidity and Mortality
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 257  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: Y
START DATE: 4/28/2005
 360Total # pts expected for entire study:
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PSYCHOLOGY UCONN - STORRS, CT USAFISHER, JEFFREY D PHD
Medicine/Infectious DiseasDIECKHAUS, KEVIN MD
SUBPROJECT DESCRIPTION:
Antiretroviral therapy (ART) has enormous promise for reducing Human Immunodeficiency Virus (HIV)-related morbidity and 
mortality, but ART regimens are often complex, prone to side effects, and expensive, and ART adherence is often extremely 
poor. The individual and public health consequences of suboptimal ART adherence are significant and include treatment failure, 
viral load increase, immune compromise, development of multidrug resistant (MDR) HIV, and potential transmission of drug 
resistant HIV to uninfected others. Although the consequences of suboptimal ART adherence are well-recognized, ART 
adherence promotion efforts in clinical settings are typically intermittent and ad hoc. When adherence promotion 
interventions are systematically implemented in clinical care settings, they almost always involve exceedingly time-, cost-, and 
labor-intensive one-on-one counseling procedures that cannot be widely deployed to assist substantial numbers of HIV+ patients 
to adhere to ART over time. Moreover, to date, relatively few theoryART adherence promotion interventions have been 
conducted, rigorously evaluated, and found to be effective in increasing ART adherence. The present research employs a 
well-validated conceptualization of health behavior change, the Information-Motivation-Behavioral Skills (IMB) model (J. 
Fisher & Fisher, 1992, 2000, 2002; W. Fisher & Fisher, 1993, 1999; W. Fisher et al., in press), as a basis for the design and 
implementation of a cost-, time- and labor-efficient, completely individualized and engaging, computer-assisted ART adherence 
promotion intervention. The intervention we propose will be employed on an ongoing basis in the context of routine clinical 
care, to teach adherence enhancement strategies to HIV+ patients about to begin ART, and to increase adherence and 
maintenance of adherence among HIV+ patients currently on ART. 
The proposed research has four specific aims:
1.  We will conduct elicitation research with HIV+ patients in clinical care and with HIV care clinicians, to explore the dynamics 
of ART nonadherence in the HIV+ clinical population, and to identify the optimal structure and content of a theory-based, 
computer-assisted ART adherence intervention linked to clinical care visits. Elicitation research findings will be systematically 
integrated to guide the development of the intervention and to increase its ecological validity by adapting it to the dynamics of 
ART nonadherence among clinic patients, and to the realities of real-life clinical settings.
2.  Based on elicitation research findings, guided by the IMB model, and employing motivational interviewing (MI) techniques as 
an intervention delivery system, we will design, pilot test, refine, and fully implement a theory-based, computer-assisted ART 
adherence intervention that is linked to naturally occurring HIV clinical care. 
3.  We will conduct rigorous intervention outcome research comparing the effects of the ART adherence intervention with an 
appropriate standard-of-care control group with respect to multiple measures of adherence collected over 18 months. Rates of 
adherence, estimated by three types of indicators (self-reports of adherence to medication, pharmacy refill records, and viral 
load assessments) will be collected over an 18 month period and will serve as the major outcomes of interest. We hypothesize 
that participants in the intervention condition will demonstrate better adherence, as defined by greater gains in absolute values 
of the adherence indicators noted above and by a larger proportion of participants who experience success in achieving and 
sustaining clinically optimal levels of adherence (e.g., ¡Ý 95%), compared to those in the control condition. Additionally, we 
predict that individuals who use the intervention¡ training arm component before beginning ART will demonstrate better initial 
degrees of adherence, compared to controls. Finally, we predict that changes in adherence as a result of the intervention will be 
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mediated by intervention effects on ART adherence information, motivation, and behavioral skills.
4.  We will use the standard-of-care control group from the intervention outcome research as a no-cost cohort for a longitudinal 
natural history study of ART adherence in HIV+ patients. We will test putative proximal determinants of adherence to therapy, 
including levels of adherence-related information, motivation, and behavioral skills. We will also test the influence on adherence 
of subjective and objective health status, substance use, depressed mental health functioning, changing ART regimens, 
development of new drugs, and other historical events that may occur over the course of the study. We hypothesize that ART 
adherence will be predicted longitudinally by ART adherence related information, motivation, and behavioral skills. We also 
hypothesize that longitudinal trends in adherence will be influenced by factors such as substance use, mental health functioning, 
and historical events.
SUBPROJECT PROGRESS:
At this time, the study is no longer recruiting participants nor is the study running LifeWindows sessions in clinic.  The study is in 
the data analysis stage.
A total of 138 participants were recruited for the LifeWindows Study at the University of Connecticut Heath Center (CHIP). Two 
Participants transferred within study clinics, and 11 participants were screened-out leaving 125 participants at UCHC to completed 
baseline.
Baseline Information
Study wide, 594 [125] active participants completed baseline measures. Condition assignment was 290 treatment arm [59] and 304 
control arm [66].  
Of these, 61% (361) [60%, 75] were male, 39% (229) [40%,50] female, and .7% (4) [0%, 0] were transgendered or intersexed. 
26% (156) [26%, 32] were Latino, and in response to self-report items, 44% (262) [32%, 40] reported being Black, 24% (141) 
[34%, 42] White, 7% (40) [9%, 11] reported other or multiple races, and 25% (151) [26%, 32] reported solely Latino. 
Routes of HIV infection varied, with the most common being heterosexual sex (39%, 232 [37%, 46]), followed by IDU (21%, 126 
[14%, 18]) and MSM (14%, 85 [22%, 28]), while estimated date of diagnosis with HIV ranged from 1981 to 2006 within and 
across all clinics. 
Participants, according to self-report, were predominantly heterosexual (73%, 431 [66%, 82]), with fewer reporting gay (19%, 
112 [27%, 34]) or bisexual (7%, 39 [4%, 5]). 
Over a quarter of the participants were employed at baseline (39%, 233 [42%,53]), with a small number finding medications hard 
or very hard to afford (7%, 42 [5%, 6]). Housing was fairly stable within this population, with 91% (538 [96%, 120]) reporting a 
relatively stable place to live. A small number were on a self-prescribed break from all or some of their medications at baseline 
(7%, 43 [3%, 4]), and almost half reported consistent use of a pillbox as a strategy to take medications (46%, 270 [40%, 50]). 
Finally, active injection drug use (in the past month) was reported by 6% of participants (38 [3%, 4]) at baseline. In terms of 
overall functioning, the sample was generally comparable to other HIV-positive sample in functioning slightly below the national 
average in physical and mental health measures (SF8 = ~46 (sd=10) and ~43 (sd=12), respectively [45.8(sd=10.59) and 
43.4(sd=12.54)]. 
Average adherence (across all individual HIV medications prescribed) at baseline was generally high, with 89% (sd= .25) of 
prescribed HIV medication pills taken per day averaged over the previous 3-days (90%, sd=23%), 86% (sd= .27) of prescribed HIV 
medications taken within the prescribed time-frame over the last 3-days (88%, sd=26%), and across participants the average for 
Visual Analog Scale reports of adherence at baseline was 88% (sd= 21% [92%, sd=17% ]).  It is important to note that all 
continuous adherence measures at baseline were kurtotic and non-normally distributed. Determining the most representative metric 
and appropriate analyses for these outcomes is the focus of our first phase of data analyses. 
In terms of barriers to adherence, across all sessions, an average of 12 (sd=6 [11, sd=5.49]) IMB-model based adherence-deficit 
areas were triggered by participant responses. For those in the treatment arm, the software program then would offer an 
opportunity to work on any of these individually triggered potential problem areas, and the average amount of time spent 
specifically within intervention activities within the selected area for improvement was 11 minutes at baseline session (sd=6 [9.30, 
sd=5.54 ]). 
The total time commitment for completing a baseline LifeWindows session ranged between 24 minutes (sd=10.10 [7.20, sd=2.92 ]) 
for those in the control arm to 39 (sd= 14.58 [31, sd=9.16 ]) minutes for those in the treatment arm.  Time commitments 
decreased from baseline to average 13 [21] minutes for control sessions (sd= 4.46 [sd=6.99 ]) and 25 [20] minutes for treatment 
arm sessions (sd= 8.39 [sd=4.85 ]), with about 9 [12] minutes (sd= 3.79 [sd=2.6 ]) spent specifically engaging in intervention 
activities.
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The only change made to our study protocol during this Progress Report timeframe was the addition of adherence study nurses for 
the purpose of collecting Resistance data.  No other changes were made during this time period.
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Brain Changes and Risk FactorsSHORT TITLE:
LONG TITLE: Brain Changes and Risk Factors
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SUBPROJECT DESCRIPTION:
Mobility is a critical component of independence and the quality of life of older persons.  A significant number of older persons 
with mobility impairment demonstrate ischemic lesions in brain white matter (WM).  
We hypothesize that: Students with a high level of vascular disease risk factors, will have a larger initial volume and higher 
accrual rate of white matter signal abnormality (WMSA); impaired mobility is caused by site-specific WMSA damaging 
fronto-parietal periventricular WM and WMSA accrual rate is stable allowing predication of Ss at risk" for large WMSA 
increases.  The link between ischemic WM lesions, which appear on MRI as WM signal abnormality (WMSA), and vascular 
disease risk factors (VDRF), as a cause, requires better definition.  We propose to link VDRF to mobility impairment associated 
with WMSA and then determine if the risk factors predict incident cases.  This will allow us to assess the magnitude of the 
VDRF as a cause of mobility impairment in order to plan new treatment strategies. 
We will use quantitative Magnetic Resonance Imaging (MRI) and quantitative measures of mobility to link WMSA to mobility 
disorders.  In preliminary studies, we separated older persons into groups with normal and impaired mobility.  Automated 
quantitative segmentation of the MR images showed an accrual of WMSA is related to a disease process.  Site-specific 
periventricular WMSA involving frontal and parieto-occipital regions were present in Students with impaired mobility.  
Follow-up MRIs on 14 Students, 20 months after the initial scan, showed WMSA accrual was related to WMSA volume at 
baseline suggesting a continuous process and that the volume of WMSA increased at a five-fold greater rate in mobility impaired 
compared to normal Students.  We have recently determined that the quantitative measures of mobility are reliable.  To move 
beyond correlation, we are proposing a 5-year project with 2 components:  a cross-sectional analysis of 99 Students 70 years 
and older stratified by mobility, followed by a 4 year longitudinal follow-up.  
The cross-sectional component will determine the relationship of VDRF, WMSA volume, WMSA location, use diffusion tensor 
imaging to identify/quantify damage to WM pathways and quantitative measures of mobility.  Using the same measures, the 
longitudinal component will: 1) establish the link between VDRF and mobility impairment; 2) establish clinical predictive value 
of imaging; 3) evaluate the causal relationship of WMSA to mobility; 4) refine our understanding of the anatomic substrate of 
mobility impairment; and 5) define the progression of this disorder.
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SUBPROJECT PROGRESS:
   Data collected for the cohort in our sub-study have included standardized clinical blood pressures (BP), 24-hour ambulatory BPs, 
and the following vascular plasma biomarkers: C-reactive protein, lipoproteins, fibrinogen, plasminogen-activator inhibitor-1, 
glucose/insulin concentrations. We have been evaluating the relations among the various BP components and white matter lesion 
(WML) volume and ultrasound-derived carotid intimal-medial thicknesses.
   Initial cross-sectional analyses have demonstrated that approximately 15% of the total sample had elevated WML volumes; no 
significant correlations between the clinic nor 24-hour BP values and WML volumes have been observed. However, there are 
moderate and statistically significant positive relations among both 24-hour mean and sleep systolic BP and carotid intimal-medial 
thickness.  Follow-up ambulatory BP and vascular biomarkers have been obtained in approximately half of the original cohort at 2 
years. Analyses of the relations among these parameters and the brain and vascular target organ involvement are pending 
completion of the cohort at this time period.
   Mobility baseline data analysis is complete and 24 month data analysis has been progressing as data is collected.  A manuscript is 
in preparation detailing the sensitivity and specificity of the baseline data based upon the measurement variables selected.  A frailty 
measure has been developed and will be applied to all data analyses.  Analyses of the relationships between mobility variables and 
MRI, Cognitive, Cardiovascular and other measures await completion of the respective preliminary data analyses in those areas.  
   We found significant inverse correlations between lesion burden in these WM regions and outcome measures of mobility.  
Logistic regression analysis indicated lesion burden in the SCC as the most significant regional predictor of low mobility 
performance. Another significant predictor was the body mass index. Voxel-based group analysis showed that independently of 
mobility status the most frequent WM damage occurred in periventricular areas within the anterior and posterior aspects of the 
corona radiata. 
   White matter hyperintensities (WMHs) on T2 weighted and FLAIR sequences are ubiquitous in older persons and although 
initially a nuisance, population-based studies have linked them with vascular disease risk factors, most notably hypertension.  
Limited pathologic data indicate that WMHs correspond to areas of poor white matter integrity with spongiosis, demyelation and 
glial proliferation.  This description suggests non-specific tissue damage consistent with ischemia/infarction.  Logic leads one to 
infer microvascular disease as the causative agent with ischemia/infarction of small areas of white matter resulting in the WMHs. 
The anatomy of the blood supply to deep hemispheric white matter supports this as it is derived from end arterioles, distal in the 
vascular tree and thus vulnerable to disruption.  What makes this important is the increasing link of WMHs to the major geriatric 
syndromes including cognitive and mobility impairment and well as urinary dysfunction.  Our analysis of lesion burden and mobility 
indicate that damage to motor pathways plays an important role in mobility impairment of elderly individuals.  We believe that 
this indicates that for a significant fraction of older persons these lesions are playing a role in limiting their mobility.  Furthermore 
we have comparable data for urinary function which is compromised by lesion burden in frontal white matter tracts.  We are 
currently analyzing the effects of regional lesion burden on cognition but have already demonstrated that total white matter lesion 
burden is associated with diminished speed of executive function.  Thus we have demonstrated that WMHs play a role in impaired 
mobility, urinary dysfunction and diminished cognitive power by limiting brain connectivity.  Our approach differs from others in 
that we are utilizing the regional specificity of the lesions to characterize their effects on the functional capacity of older persons.  
We have also shown that vascular disease risk factors are related to carotid artery intima-media thickness but not to brain WMH 
burden.
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SUBPROJECT DESCRIPTION:
Malaria, a disease caused by protozaon parasites of the genus Plasmodium, is one of the most dangerous infectious disease 
affecting human populations. The purpose of this research is to determine the conditions that help the multiplication of the 
parasite in human red blood cells. The scientific information received from this study may help understand the disease and 
identify new drugs or a vaccine against malaria. Research in the Lab will focus on how the Human Malaria Parasite develops 
within human red blood cells. Our goal is to characterize, at the molecular level, the pathways essential for the parasites survival 
with an eye toward future drug development
SUBPROJECT PROGRESS:
1. Number of Subjects enrolled during the reported period: 0  
2.  Number of Subjects enrolled since initiation of the study: 18 subjects (26 blood draws)  
3. Any changes in recruitment plans that might be needed: No  
4. Unexpected safety concerns and their resolution: None  
5.Interim data and outcomes if appropriate: None  
6.Any proposed changes made or anticipated in the protocol. 
Study was closed on 1/23/2008
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SUBPROJECT DESCRIPTION:
Malaria, a disease caused by protozaon parasites of the genus Plasmodium, is one of the most dangerous infectious disease 
affecting human populations. The purpose of this research is to determine the conditions that help the multiplication of the 
parasite in human red blood cells. The scientific information received from this study may help understand the disease and 
identify new drugs or a vaccine against malaria.  Research in the Lab will focus on how the Human Malaria Parasite develops 
within human red blood cells. Our goal is to characterize, at the molecular level, the pathways essential for the parasite survival 
with an eye toward future drug development.
SUBPROJECT PROGRESS:
1. Number of Subjects enrolled during the reported period: 6 subjects (7 blood draws)
2.  Number of Subjects enrolled since intiation of the study: 20 subjects (40 blood draws)
3. Any changes in recruitment plans that might be needed: No
4. Unexpected safety concerns and their resolution: None
5.Interim data and outcomes if appropriate: None
6.Any proposed changes made or anticipated in the protocol. Enrollment was increased from 10 to 35 and was approved on 
4/19/07.
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SUBPROJECT DESCRIPTION:
Little research has been done to assess the level of osteoporosis evaluation or diagnosis, bone mass measurement or contributors 
to bone loss and fall risk in residents of assisted living communities.    Hypotheses and Specific Aims 1)Individuals residing in 
assisted living will have a low rate of osteoporosis evaluation or diagnosis relative to community dwelling elders. We will survey 
individual for history and evaluation of osteoporosis in assisted living and compare to a group of age and gender matched 
community dwelling adults 2)Individuals residing in assisted living will have low bone mass, measured by heel ultrasound, 
compared to community dwelling elders.  Quantitative ultrasound will be used to assess bone mass. 3)The stiffness index T score 
will correlate with calciotropic hormones (directly with 25OHD and inversely with parathyroid hormone (PTH)) and directly to 
physical performance measures (hand grip, walking speed and physical activity).  Study Design: Cross-sectional analysis of 79 
residents of assisted living with a comparison to 79 age and gender-matched community dwelling adults.  Research volunteers 
will undergo bone assessment using heel ultrasound, questionnaires to assess fracture history and previous osteoporosis 
evaluation, falls in previous 6 months, dietary intake of calcium, vitamin D and protein, and will have physical performance 
measures including hand grip strength and walking speed.   In a previous study of 55 community dwelling older men (mean age 
73 + 8 y), correlations were found between stiffness index T score and physical activity score (r=.30,p=.043), walking speed (r=
-.37, p=.006) and a trend with handgrip (r=.24, p=.07). Based on this previous work, we calculate that we will need to assess 158 
subjects. The proportion of underserved individuals in the assisted-living, elderly population will be contrasted with that in the 
healthy, non-assisted-living, older population using contingency table methods.  The frequency of osteoporosis detected by heel 
ultrasound will be calculated and compared to established, national, age-adjusted, prevalence estimates.  Correlation analysis will 
be used to evaluate associations between heel ultrasound, bone mineral density, vitamin-D levels, parathyroid hormone levels, 
and frailty measures.  For the contrast of proportions, samples of 79 assisted-living subjects and 79 non-assisted-living subjects 
will provide 80% power to detect odds ratios of 3.0 or more when testing at the 5% level of significance.  When combined, 
those samples will also provide 80% power to detect correlation coefficients greater than +0.22 or smaller than -0.22. pard
SUBPROJECT PROGRESS:
We have begun data analysis and submitted one paper for publication thus far.  The paper is under review and the General Clinical 
Research Center (GCRC) has been cited.  We plan further analysis and will continue to require biostatistical support.
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SUBPROJECT DESCRIPTION:
Despite the popularity of Cognitive-Behavioral Treatment (CBT) in substance use disorders, recent findings have indicated that 
CBT may be no more effective than other, less theoretically driven, treatments, and that CBT treatments often fail to result in 
coping skills acquisition. In order to explore the possibility that current manual-driven modes of CBT delivery  may not be 
adequate to successfully teach coping skills, we are proposing a pilot project for the development of an individualized assessment 
and cognitive-behavioral treatment program (IATP) for alcohol-dependent persons, in which experience sampling conducted 
via random calls to cell-phones is used to provide data to create individualized treatment plans.  Data collected during 
experience sampling will include momentary assessments of patients cognitions, affects, and coping behaviors with respect to 
drinking. 
Participants will be 112 men and women meeting criteria for alcohol dependence or alcohol abuse, who will be randomly 
assigned to either a standard packaged manual-driven cognitive-behavioral treatment program (PCBT) like that used in Project 
MATCH, or to IATP. Patients in both treatments will be asked to engage in experience sampling for two weeks prior to 
treatment, and for another two weeks after treatment has ended, in order to compare in-vivo measures of coping skills 
utilization, pre- and post-treatment, between the two groups. Therapy will be conducted over 12 sessions in both treatments. 
In IATP, the information gathered from experience sampling will form the basis of a functional analysis of patients' drinking 
and drinking urges during the monitoring period. Cognitive appraisals, moods and coping responses will be evaluated as 
antecedents and consequences of  drinking behavior. Therapists will use the information to address specific cognitions, affects, 
and behaviors that are adaptive and maladaptive, and will work with the patient to substitute adaptive coping tactics instead. 
In PCBT the experience sampling data will not be specifically used in therapy, but will still provide in-vivo measures of drinking 
and coping skills. It is hypothesized that IATP will yield significantly better coping skills acquisition than will PCBT, and that 
change in coping skills will predict better post treatment outcomes for IATP. These results would have implications for our 
delivery of treatment, and for the validity of coping skills training for alcohol addiction. 
Specific Aims are as follows:
1. To determine whether an Individualized Assessment and Treatment Program (IATP) results in greater acquisition of coping 
skills than does a standard Packaged Cognitive-Behavioral Treatment (PCBT).
H1: It is hypothesized that IATP will result in significantly greater increases in reported use of coping skills from pre- to 
post-treatment relative to PCBT.
2. To determine if coping skills acquisition in IATP accounts for treatment outcome over and above the contribution made by 
pretreatment individual differences (i.e., motivation and self-efficacy). 
H2: It is hypothesized that pre- to post-treatment increases in coping skills in the IATP condition will account for more 
variance in drinking outcomes  at post-treatment than will pretreatment individual difference variables.
3. To determine whether IATP, based on functional analysis of in-vivo patient monitoring, will yield better outcomes at 
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post-treatment than will PCBT
H3: It is hypothesized that IATP will yield better drinking outcomes at post-treatment than will the standard packaged CB 
approach. Drinking outcomes will include proportion days abstinent, and proportion heavy drinking days during the treatment 
period.
SUBPROJECT PROGRESS:
110 patients enrolled in the study thus far, 16 in this study period. Enrollment is complete. Follow-up rate is 87%.No changes in 
recruitment plans needed. No safety concerns. No interim data available as yet. No changes in protocol made or anticipated. No 
publications available at this time.
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SUBPROJECT DESCRIPTION:
Evidence suggests that some groups of pregnant workers may be at risk for premature delivery or small-for-gestational-age 
(SGA) births as a consequence of workplace psychosocial stressors.  Clear associations between occupational stressors and 
adverse pregnancy outcomes have been difficult to draw. Factors including study design, retrospective assessment of exposure, 
and choice of exposure measurement may be partially obscuring any association between work-related stress and pregnancy 
outcomes.  
The overall goals of this proposed developmental and planning grant are to obtain preliminary data assessing two models of 
occupational stress during pregnancy, in particular measuring repeatedly and longitudinally across the course of pregnancy to 
evaluate the possibility that these may change across pregnancy.  This proposal aims also to evaluate the use of the 
effort-reward imbalance (ERI) model, which has not been tested in pregnant workers or used in studies of pregnancy outcomes.  
Using a sample of 200 pregnant working women, this study proposes repeated, longitudinal measures of occupational stress at 
four different times across the course of pregnancy. 
Principal aims of the study are: 
1) To explore the use of newer instruments measuring occupational psychosocial stressors in pregnant women; specifically using 
the Effort-Reward Imbalance (ERI) model, with comparison to, and possible combination of features with, the Demand-Control 
(DC) model. 
2) To evaluate the psychometric properties of the ERI in pregnancy, including reliability, and content validity.  
3) To evaluate the construct validity of the stress scales, to enable their use in measuring occupational psychosocial strain in 
pregnancy. 
4)  To evaluate the possibility that occupational psychosocial stressor levels in working women change across the unique time 
period represented by pregnancy, assessing the direction and magnitude of this change.  Statistical methods for 
repeated-measures and hierarchical data will be used to examine trajectories of occupational stressors as well as their possible 
modification by other individual-level factors.  Outcomes will be measured by subjects' measures of their stress, health, and 
fatigue, as well as blood pressure measurements and salivary cortisol levels.  The work proposed here represents a necessary first 
step in the ability to test these hypothesized effects, and will assist in determining whether newer models of the psychosocial 
parameters of stress in the workplace might be useful in measuring an association with adverse pregnancy outcomes.  
As well, this work will represent an initial assessment of whether changes in measured parameters of stress, or distinct 
trajectories over time, occur during the course of pregnancy.  Once these aims are accomplished, the resultant exposure 
measurements can be used in ongoing studies to recognize and target particular types of work that may be associated with 
adverse birth outcomes.  The exploratory work proposed here may enhance understanding of special populations at risk from 
work stressors.
SUBPROJECT PROGRESS:
This study which effectively started in early 2006 began recruiting in the spring of 2006. 40 subjects were recruited in the first year 
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and an additional 30 recruited and completed at least one interview in the current reporting period. Data are collected on scannable 
questionnaire forms; initial data on the first 30 subjects has just been scanned and received. Analysis of data from the first 30 
participants completing all four survey waves and for which data was scanned and entered into our database shows findings that are 
consistent with the hypotheses of the study and already of statistical significance, which was unexpected at this stage, but positive 
for the study.  
Larger-than-expected changes in within-individual work effort (mean difference 2.2 units,  p<0.01), work overcommitment (2.6 
units, p<0.001) and a marginal difference in work rewards (1.6 units, P=0.18) from early pregnancy through to term or 
near-delivery are already seen in our preliminary analyses, with >25% of subjects still to complete the full set of questionnaires.  
Moreover, there are major significant differences by race/ethnicity in findings which are consistent with other work by the PI; 
these show very strong differences in self-rated job control, which is lower in blacks than whites despite equivalent or better 
educational attainment in blacks (from the initial questionnaires, for blacks, 8/8 in low control work vs 18/32 for whites; p = 0.012 
by chi-sq.  Very limited data is yet available for birthweight, since  <50% of subjects have reported back, but based on few data 
points this shows a high correlation with job control in blacks (r2 =  0.83) vs whites (0.06) which is also consistent with our data 
from other studies.  Cortisol measurements will be run en masse by the GCRC lab and are not yet available for analyses.  Overall, 
based on limited preliminary data we are seeing stronger evidence of changes in job characteristics across pregnancy than we had 
anticipated, and substantial racial/ethnic differences.  
There have been no unexpected safety concerns or problems during the performance of this study to date. No changes have been 
made or are anticipated in the protocol. As the study remains in data collection and analysis stages, no publications have yet been 
completed.
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SUBPROJECT DESCRIPTION:
Major depressive disorder is a well-established risk factor for incident coronary heart disease and women have higher rates of 
major depressive disorder than their male counterparts.  Endothelial functioning is impaired during current depressive episode.  
However, it is unknown whether this impairment continues once the depressive episode resolves. The overarching question this 
study asks is whether previous (but specifically not current) major depressive disorder is associated with endothelial dysfunction 
in post-menopausal women. 
This retrospective, controlled study will investigate the relationship between previous major depressive disorder and current 
coronary heart disease risk in postmenopausal women who are matched for age and Bone Mass Index (BMI). The independent 
variable is previous major depressive disorder. A reliable, valid, and widely used method for assessing previous behaviors, the 
timeline follow back method, has been adapted for use with the gold standard diagnostic interview (SCID) to assess previous 
major depressive disorder. The dependent variable is brachial artery flow mediated dilation. Specific aims are to:
1. Determine whether currently nondepressed women who have experienced previous major depressive disorder have impaired 
flow mediated dilation relative to their never depressed counterparts. We hypothesize that currently non-depressed women who 
have experienced previous major depressive disorder will have impaired flow mediated dilation relative to their never depressed 
counterparts.
2. Determine whether there is a 'dose-response' relationship between number of depressive episodes over the lifespan and flow 
mediated dilation. We hypothesize that more depressive episodes over the lifespan will be related to decreased flow mediated 
dilation.  
3. Determine whether treatment for depression attenuates any deleterious effects that depression exerts on flow mediated 
dilation.  We hypothesize that previously depressed women whose depression was treated pharmacologically will have less 
impaired flow mediated dilation than their counterparts whose depression was untreated.
SUBPROJECT PROGRESS:
From 4/1/2007 until 3/31/2008, 19 participants enrolled.  Since initiation of the study, 39 women have enrolled, and 38 have been 
fully eligible to participate. One woman was excluded from the study after ICF was obtained and during first visit data collection.  
This was because it was discovered during first visit that they did not meet set criteria to complete the study. Modifications to the 
project approved by IRB this year include: 1) Approval of a new recruitment add targeting women with a history of depression.  At 
this time, we have nearly completed enrollment of women without a history of depression, but still need approximately 40 women 
with a history of depression. 2) Approval of a new HIPAA form in accord with IRB"s revision to language.  3) Removal of Dr. 
Mallareddy from the study.  She has completed her fellowship and is no longer affiliated with the University of Connecticut Health 
Center (UCHC).  Dr. White has assumed her responsibilities.  4) Approval of a Dr. Gina Abbott as Principal Investigator Back up. 
5) Approval of new Informed Consent Form (ICF) incorporating changes in language regarding storage of samples (we will no 
longer be storing samples beyond close of study), method of payment (The General Clinical Research Center (GCRC) requests 
checks be made out to "cash", and the addition of the GCRC Research Subject Advocate's (RSA's) phone number. There are no 
unexpected safety concerns.
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LONG TITLE: Prevention of Recurrent Aphthous Stomatitis Using Vitamins
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Oral DiagnosisLALLA, RAJESH BDS, PHD
SUBPROJECT DESCRIPTION:
Recurrent aphthous stomatitis (RAS), also known as canker sores, is the most common soft tissue disease of the mouth in 
humans in all geographic regions, including Connecticut. In a large study of over 10,000 young adults, 38.7% of men and 49.7% 
of women reported two or more previous occurrences of RAS. These ulcerations are painful and affect the patient's ability to 
eat and drink. 
Further, they may also impact on oral hygiene practices and speech. Thus, RAS has a significant effect on the patient's quality 
of life. There is currently no known method to prevent RAS. Topical and/or systemic steroids are sometimes used for the 
treatment of this condition. However, because these drugs have significant side-effects, they are used only for the treatment of 
the most severe cases. The vast majority of patients with RAS do not have any scientifically validated options for prevention 
or treatment.  Several studies have demonstrated that patients with RAS are more likely to have lower blood levels of vitamins, 
such as B12 and folic acid, compared to healthy controls. More importantly, multiple studies have demonstrated that specific 
replacement therapy to correct such deficiencies is effective in inducing improvement or remission of this disease. 
A workshop convened by the National Institutes of Health (NIH) recommended complete hematologic screening of all patients 
with RAS. However, testing for vitamin deficiencies is invasive and expensive. It is not feasible to take blood samples on every 
patient with RAS and test for such deficiencies. Therefore, this is rarely done in practice and patients continue to suffer from 
these lesions. 
This study proposes an alternative approach: To prevent RAS using a multivitamin supplement that would correct any 
deficiencies of factors known to commonly contribute to RAS. If successful, this would result in a simple, cost-effective 
approach to reducing the morbidity of this prevalent disease. 
We propose a double-blind, placebo-controlled clinical study in 120 subjects who suffer from RAS. Subjects will be randomly 
assigned to either a multivitamin supplement or an inactive placebo, in a 1:1 ratio (60 in each group). The study medication will 
be taken once a day for one year. We will document, in all subjects, the number of RAS episodes in one year and the duration of 
episodes. These will be compared between the two groups to find out if the multivitamin supplement was effective in reducing 
the number or duration of RAS episodes. We will also collect data on pain and normalcy of diet during RAS episodes to 
determine if the multivitamin supplement had any effect on these variables. 
To enhance subject compliance and retention, we will use Interactive Voice Response (IVR) technology that uses the telephone 
to administer survey questions.  A blood sample will be collected from all consenting subjects at baseline. This blood sample will 
be used to measure the baseline levels of vitamins B12 and B9 (folic acid). These are the principal vitamins whose deficiency has 
been associated with RAS. All subjects will be asked to complete a Diet History Questionnaire at the beginning and at the end of 
the study. The purpose of this questionnaire is to estimate dietary intake of the vitamins being supplemented, at baseline and 
over the one-year period of the study.
SUBPROJECT PROGRESS:
Number of subjects enrolling during the report period: 52, and since initiation of the study: 147.  No changes in recruitment plans 
are needed.  There were no unexpected safety concerns.  Interim data and outcomes: None.   Proposed changes made or anticipated 
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in the protocol: None.
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Chlorhexidine and Localized Taste StimulationSHORT TITLE:
LONG TITLE: Effect of Chlorhexidine on Taste in Specific Regions of the Tongue in Humans
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Oral DiagnosisFRANK, MARION DMD
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GENERAL MEDICINE PIERCE FOUNDATION LABORATORY, CT 
USA
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SUBPROJECT DESCRIPTION:
The effect of chlorhexidine on taste perception with whole-mouth stimulation is well established. The intensities of both salty 
and bitter compounds are reduced after treatment with chlorhexidine, the active ingredient in mouth rinses used to control 
periodontitis. This study addresses whether effects on salty and bitter are localized to distinct regions of the human tongue. The 
hypothesis is that salty will be affected more on the front of the tongue, bitter on the back of the tongue. The hypothesis is 
based on differential localization of specific taste qualities to distinct areas. For example, salt receptors are differentially located 
to the front of the tongue; whereas, bitter receptors are located more to the back of the tongue. Subjects, who will be tested for 
taster status with 6-n-propylthiouracil, will be 24 paid volunteers. Treatment rinses include 1.34 mM chlorhexidine gluconate, 
the concentration in PeridexÒ, and a water control. Test stimuli are: 1.0 M NaCl, 32 mM citric acid, 1.0 M sucrose and 1.0 mM 
quinine. Subjects will participate in 2 sessions, with one rinse condition per session (1.34 mM chlorhexidine or water) and at 
least 2 days between sessions. Rinse condition for sessions will be randomly assigned. Following a 5-min waiting period after the 
treatment rinse, stimuli will be applied with a cotton swab to 8 points on the tongue: The tip, lateral edge, dorsal rear and palate, 
bilaterally; exactly as presented in the Taste and Smell Clinic Spatial Taste Test. Bilateral test stimuli will be presented at a pace 
of 1 per min. The effect of chlorhexidine on different tongue regions will be analyzed using repeated measures Analysis of 
Variance (ANOVA). Within subjects factors include time (before and after treatment rinse), chlorhexidine concentration (0, 
1.34 mM), and stimulus compound (NaCl, citric acid, sucrose, quinine). Our predicted outcome is that chlorhexidine effects on 
bitter taste will be more substantial on the tongue's lateral edge and dorsal rear sites than on the tongue tip and palate. The 
chlorhexidine effects on the salty taste will be the opposite: more substantial on tongue tip and palate than on lateral edge and 
dorsal rear tongue sites. An alternate outcome is that effects on salty and bitter tastes will be similar in all regions
SUBPROJECT PROGRESS:
This year we published one paper. The abstract follows.  
Regional specificity of chlorhexidine effects on taste perception.
Grover R, Frank ME.
Chlorhexidine (CHX) gluconate, a bitter bis-biguanide antiseptic, reduces the intensity of the salty taste of NaCl and bitter taste of 
quinine in humans. 
This study addresses regional specificity of CHX's effects on taste. Perceptual intensity and quality were measured for separate taste 
bud containing oral loci innervated either by afferent fibers of cranial nerve (CN) VII or CN IX. Measurements were obtained 
following three 1-min oral rinses with either 1.34 mM CHX or water, the control rinse. CHX rinse reduced the intensity of NaCl 
more at the tongue tip and palate than at posterior oral sites. Thus, fungiform and palatal salt-taste receptors may differ from 
salt-taste receptors of the foliate and circumvallate taste papillae. The intensity of quinine.HCl was reduced equally by CHX at all 
sites tested but was frequently tasteless on the less sensitive anterior sites, suggesting quinine receptor diversity. In rodents, a 
portion of NaCl-taste receptors in the receptive field of CN VII is sensitive to the epithelial Na+ channel blocker amiloride and a 
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portion is amiloride insensitive; all CN IX receptors are amiloride insensitive. The current results are the first to suggest that there 
may also be distinct, regionally specific populations of NaCl-taste receptors in humans.
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MedicineONCKEN, CHERYL MD
SUBPROJECT DESCRIPTION:
Cigarette smoking is responsible for the greatest number of preventable poor outcomes among pregnant women.  How tobacco 
smoke harms developing fetuses is largely unknown.  We propose to explore mechanisms that may explain how maternal 
tobacco use leads to low birth weight among infants.  This translational tobacco research project focuses on identifying new 
biomarkers of prenatal tobacco exposure, which is important to understanding the effects of maternal smoking on infants and 
children. Project 1 hypothesizes that  tobacco smoke changes the chemical structure of genes in the placenta (i.e., DNA 
methylation) and in the baby critical to fetal growth by altering Deoxyribonucleic acid (DNA) methylation. The ultimate effect 
of these changes may be low birth weight. Cord and placental tissue will be obtained at the time of delivery from 15 smokers and 
from 15 nonsmokers. Many of these samples will be obtained from subjects who are already participating in R01 "Nicotine 
Replacement Treatment for Pregnant Smokers" that is being conducted at Hartford Hospital. 
Maternal DNA will be extracted using our standard techniques. The DNA will be subjected to sodium bisulfite treatment that 
converts unmethylated but not methylated cytidine to uracil. Sodium bisulfite treatment will be performed using standard 
protocols.  Ribonucleic acid (RNA) from umbilical cord, placenta, and maternal blood will be extracted utilizing Trizol protocol.  
Measurement of Insulin-like growth factor 2 (IGF2) Messenger Ribonucleic Acid (mRNA) levels will be performed by standard 
quantitative real-time polymerase chain reaction (RT-PCR) techniques.
SUBPROJECT PROGRESS:
We have enrolled 15 smokers and non-smokers to examine methylation of IGF2 gene in cord tissue. Of these subjects, IGF2 
analyses has been analyzed by Dr. Lalandes, lab, but their were questions regarding validity of the data. The General Clinical 
Research Center (GCRC) lab is now confirming this analyses. And finally, Hur data analyses is also underway. We hope to have this 
completed by august of 2008. Thus, All subjects have been enrolled. We are currently analyzing the samples and hope to report the 
data in a manuscript in the coming year.
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SUBPROJECT DESCRIPTION:
The general goal of the proposed work is to test a theory that links the Catechol-O-methyl transferase (COMT) and 
gamma-aminobutyric acid A receptor, alpha 2 (GABRA2) genes to intermediate phenotypes, and, in turn, to the important 
clinical problem of relapse to substance abuse.  It will test whether genes that have been empirically linked to substance 
dependence, and to measures of frontal brain function (viz., fast b power in the spontaneous electroencephalogram and frontal 
P300a amplitude), also confer an increased risk for relapse to these disorders.  The specific goals of the project are: (1) to 
examine whether the genotypes of 100 cocaine-, heroin, or polydrug-dependent patients who return to substance use within 4 
months after study enrollment are different from those of 100 patients who successfully maintain abstinence and 50 
non-substance-dependent controls; (2) to replicate our previous findings of enhanced electroencephalographic (EEG) fast b 
activity and reduced frontal P300a amplitude in patients who return to substance use in comparison to patients who maintain 
abstinence and to healthy non-substance-dependent controls; (3) to determine if polymorphisms in GABRA2 and COMT genes 
are respectively associated with phenotypic variation in EEG fast b power and frontal P300a amplitude; (4) to determine if 
genetic markers improve the prediction of relapse beyond the predictive accuracy attained with EEG fast b power and frontal 
P300a amplitude, in combination with other known risk factors, including severity/chronicity of dependence, age, type of 
substance dependence, and Antisocial Personality Disorder.
SUBPROJECT PROGRESS:
This report describes progress during Year 3 of NIDA grant # R01 DA017666-01A2, "Genetic versus phenotypic markers of 
relapse risk".  As described in our progress report for Years 1 and 2, the recruitment and screening of study participants began on or 
about February  1, 2006.  As of March 13, 2008, we have successfully recruited and tested 96 patients.  The current number of 
recruits is slightly behind our projected goal.  We are now (March 2008) in the 32nd month (i.e., approximate mid-point) of a 60 
month project and are only 29 subjects shy of recruiting 50% of the sample.  We are not concerned about this minor shortfall 
because we are now beginning to recruit 50 subjects to fill a healthy group of non-drug-dependent subjects who will be 
demographically matched to the patients.  The subjects forming this group can be acquired and completed easily because they are 
required to participate in one laboratory session only and are not followed over time (unlike the drug dependent groups).  Thus, in a 
relatively short period of time, our recruitment total can jump from 96 to 146.  We anticipate no difficulties in attaining our final 
recruitment goal.
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SUBPROJECT DESCRIPTION:
Tobacco smoke contains over 4000 chemicals and 60 carcinogens, thus the mechanisms by which maternal smoking causes fetal 
and infant harm are likely to be multi-factorial. Studies suggest that infants born to smokers have altered auditory processing, 
which has been correlated with deficits in reading and spelling in school-aged children. Nicotine exerts its effects mostly via 
specific receptors in both neuronal and non-neuronal tissue which may, in turn modulate expression of cytokines, which act as 
mediators. However the roles played by nicotinic receptors and cytokines in fetal development have not been well studied. 
Objective:1.To determine if maternal smoking during pregnancy is associated with infant abnormalities in the auditory 
component of the Brazelton Neonatal Behavioral Assessment Scale (BNBAS),a scale devised to test auditory function.2. To 
determine if maternal smoking increases/alters nicotinic receptor (nAChR) expression in umbilical cord blood and cord tissue,a 
non-neuronal tissue that is more readily available .3.To determine if maternal smoking causes an increased level of the 
inflammatory cytokine interleukin-8(IL-8) in fetal circulation, which in turn may be related to neuronal injury and auditory 
dysfunction in infants and in turn will serve as a potential biomarker to predict which babies are at risk.4. Differences in nAChR 
expression and IL-8 production will be correlated with auditory functioning in newborn infants of smokers and non-smokers.
SUBPROJECT PROGRESS:
Study: 78 mothers were recruited, of which 44% were smokers (S) and 56% were non-smokers (NS).There was no difference in 
groups with regards to ethnicity, race and sex of the baby but a difference was noted with respect to maternal age (less in 
smokers-P= 0.02).The birth weight (BW) of babies in the S group(2.48 kg 0.40) was< the NS group (3.31 kg 0.40); p <0.0001.IL8 
protein in cord blood/tissue was higher in S (125.03) vs NS (43.12)(F statistic = 0.0006) which correlated with poor scores on the 
NBAS exam p<0.05.On logistic regression using NBAS scores and smoking status, controlling for birth weight, babies in the S group 
had poor scores with regards to habituation items, with a worse performance in inanimate and animate auditory and visual 
(social-interactive) items. Quality of alertness was poor in babies of S group, p = 0.01. Microarray analyses of cord tissue were done 
to study differential regulation of growth related genes. Conclusions: The birth weight of babies born to smokers was < that of 
non-smokers. The babies of mothers who smoked were found to have poor scores on the auditory and visual components of the 
NBAS exam which when combined with high IL8 levels may help in identifying babies with neurodevelopmental problems in the 
newborn period. (Abstract presented at the Society for Pediatric Research Meeting in Toronto Canada, May 6, 2007). The results 
of microarray studies were presented at the Eastern Society of Pediatric Research meeting in Philadelphia (March 2008) A 
manuscript based on the microarray findings in umbilical cord samples, was submitted to 'Pediatric Research' for publication. The 
journal has accepted it for publication and we expect to see it in their August 2008 issue. 
Another manuscript based on the Brazelton findings is in preparation. 
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Placental cotinie levels have been analyzed and the data are being evaluated. 
Further work is planned on studying the placental samples for genes of interest and collaborations with other researchers are being 
sought.
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SUBPROJECT DESCRIPTION:
Fatigue is the most common and the most debilitating symptom of cancer and cancer treatments. In at least 50% of cancer 
patients, the etiology of fatigue remains unidentified even after a comprehensive work-up. This idiopathic' cancer fatigue (iCF) 
is highly prevalent in patients with breast cancer and prostate cancer.  Despite its high prevalence and its devastating effect on 
quality of life, very little evidence exists on pharmacological interventions for treatment of this incapacitating problem 
affecting the lives of millions of cancer patients. Until we identify the precise mechanisms underlying the pathophysiology of 
cancer fatigue, it is crucial that we evaluate and develop novel pharmacological interventions targeting the general hypoarousal 
mechanisms. The analeptic properties of thyrotropin-releasing hormone (TRH) are well established in multiple animal models. 
Intravenous TRH studies conducted in patients as a cognitive enhancer and an antidepressant, confirmed these analeptic actions 
of TRH. Patients in these trials showed significant and persistent improvement in energy, motivation, cognition and 
psychomotor retardation. This novel pilot study proposes a 4-week randomized double blind placebo-controlled cross-over trial 
to evaluate the efficacy and safety of synthetic thyrotropin-releasing hormone (TRH) to treat cancer-related fatigue in breast 
cancer and prostate cancer patients. In addition to assessing the impact of TRH administration on fatigue, we will also 
investigate its impact on patients' depressive and anxiety symptoms, overall psychological status, overall quality of life and 
global clinical status. We will also investigate the impact of TRH administration on immune and endocrine dysfunction 
associated with the cancer-related fatigue. This pilot study is a proof-of-principle study and is a vital first step towards the future 
development of TRH-based therapeutics including oral TRH analogs to treat cancer-related fatigue.
SUBPROJECT PROGRESS:
Number of subjects enrolled during the report period:  3
Number of subjects enrolled in the study altogether:  4
Any changes in recruitment plans that might be needed:  As per the Progress Report from last year, we contacted Dr. Andrew 
Salner, Director of the Radiation Oncology Program at Hartford Hospital, to obtain the assistance of his group in recruiting 
subjects for this study, and we received Institutional Review Board (IRB) approval for adding this site.  We are now communicating 
with Dr. Kenneth Miller from the Cancer Center at Yale University School of Medicine to determine whether he and his radiation 
oncology colleagues would be willing and able to assist us in subject recruitment. If we find that Dr. Miller and his colleagues are 
willing to help with subject recruitment, we will seek and obtain the appropriate IRB approvals from Yale and the Uconn Health 
Center IRB's.
  
Unexpected safety concerns and their resolution: None to report.
Interim data and outcomes if appropriate:  No data to report at this time as we continue to remain blinded to study treatment 
assignment.
Any proposed changes made or anticipated in the protocol.  None
Publications:  none
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SUBPROJECT DESCRIPTION:
Receptor agonists are the most important group of drugs used in the treatment of asthma.  A number of studies have established 
that genetic variations of the ß2-adrenergic receptor have important effects in modulating responses to therapy for asthma.  
We propose to investigate the influence of a patient's ß2-adrenergic receptor genotype on the clinical response to b2-AR 
agonist therapy during acute severe asthma exacerbation in children.
The overall objective is to assess the influence of a patient's ß2-adrenergic receptor (b2-AR) genotype on the clinical response 
to ß2-AR agonist therapy.  Our hypothesis is that children admitted with status asthmaticus who are homozygous for the Gly16 
allele of the ß2-AR gene have a longer Intensive Care Unit (ICU) length of stays than children who are heterozygous at this 
locus or homozygous for the Arg16 allele when treated with high-dose continuous ß2-AR agonists (both inhaled and 
intravenous).  Secondary aims are (1) to assess the rate of improvement in MPIS based on genotype and (2) to attempt to 
correlate asthma phenotype with genotype by comparing demographic data and hospital course.
SUBPROJECT PROGRESS:
There are two arms to this trial, a prospective arm and a retrospective arm. The retrospective arm to this trial was added by 
Institutional Review Board (IRB) addendum on February 28, 2006 and was approved by the General Clinical Research Center 
(GCRC) Advisory Committee (GAC) on March 30th, 2006.  Currently 74 children have enrolled in the prospective arm and 37 
children have enrolled in the retrospective arm.  The retrospective arm of this trial is completed and now closed.  In the 
prospective arm, we plan to enroll 90 children over a 3 year period.  Enrollment in the prospective arm began on December 28th, 
2005 and should complete enrollment in the Fall of 2008.  The core laboratory at the General Clinical Research Center (GCRC) 
has successfully able to obtain genotype results on all patients enrolled in the study. 
There have been no safety concerns with this study.  Nor are there any proposed changes or anticipated changes in the protocol or 
in the recruitment plans.
In the retrospective arm, since the previous report, we have enrolled an additional 5 patients into this study (now n=37).  The 
addition of these subjects did not change the results of this study.  Children with the Gly/Gly genotype had significantly shorter ICU 
length of stay, duration of continuous albuterol therapy, and were significantly less likely to require IV ß2-AR therapy than 
children with other ß2-AR genotypes.  We concluded that a child's ß2-AR genotype significantly affected that child's response to 
acute ß2-AR agonist therapy.  An abstract summarizing these findings was presented at the American College of Chest Physicians 
International Meeting in October 2007.  Support and funding from the GCRC was been sited in this abstract.  There have been no 
safety concerns or adverse events associated with this study. There are no proposed changes to this study.  Other than the abstract 
submitted above, there have been no associated publications.
In the prospective arm, since the previous report, we have enrolled an additional 27 patients into this study (now n=74).  This 
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enrollment was slower than expected due to a milder than expected asthma season with less children requiring ICU admission.  
However, we continue to plan on completing enrollment this Fall, following the Spring 2008 and Fall 2008 asthma seasons.  At 
interim analysis, genotyping data is available for 67 of these 74 children.  Thus far, at amino acid position 16, fifteen (22%) 
children had the Gly/Gly genotype, six (61%) children had the Arg/Arg genotype, and forty-one (61%) children were heterozygous 
(Arg/Gly).  There were also similar admission severity of illness between in these two groups of children as quantified by admission 
MPIS.  However, those children with the Gly/Gly genotype had significantly shorter ICU length of stay and duration of 
supplemental oxygen therapy when compared to those with Arg/Gly or Arg/Arg genotypes.  This supports the findings in the 
retrospective arm of this trial.
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SUBPROJECT DESCRIPTION:
The study of adults with serious mental illness will evaluate two promising manualized therapeutic interventions for complex 
post-traumatic stress disorder (PTSD):  1) Trauma Adaptive Recovery Group Education and Therapy (TARGET) and 
Present-Centered Therapy (PCT), as proposed in the Principal Investigator's (PI's) National Institute of Mental Health 
(NIMH) Career Development study grant.  Both interventions will provide 16 one-to-one educational and therapeutic sessions 
that teach coping skills and stress reduction techniques.  The aims of the study are: Aim 1)  To test how participation in 
TARGET and PCT relates to clinically and statistically significant improvements will occur in PTSD symptoms, psychosocial 
functioning, and emotion/impulse regulation; Aim 2)  To compare the differential affects of TARGET and PCT on affect 
regulation, social support, stress-related information processing and cognitive coping, and the reduction of serious mental illness 
(SMI) symptoms;  Aim 3)  To identify changes in daily self-regulation after TARGET and PCT. A diverse sample (N=60) of 
adults will be recruited in the UConn Department of Psychiatry Partial Hospital Program (PHP) and offered the opportunity to 
receive 16 sessions of individualized counseling when they are discharged from PHP. After screening for eligibility and obtaining 
valid signed consent forms, participants will be randomly assigned to one of the two experimental conditions.  Psychometric 
self-report and daily monitoring measures will be obtained at baseline, post-treatment, and 4-month follow-up assessments and 
multivariate statistical techniques will be used for analysis of treatment effects. The study builds on findings by the PI and Co-I 
Albert who have demonstrated that adults with SMI commonly have untreated PTSD.
SUBPROJECT PROGRESS:
One participant has been enrolled in this study since 4/1/07. A total of 20 participants have been enrolled since the start of the 
study, and is currently closed to enrollment. All of the participants have completed treatment and follow-up interviews. The 
interactive voice response system (IVR) component operated by the GCRC has also been completed by all study participants. The 
UCHC IRB has approved the study until 11/10/08. At the next continuation, a request will be made for expedited review for data 
analyses only. 
There have been no unexpected safety concerns in the past year, however, there was one serious adverse event reported to the 
UCHC IRB due to a study participant being hospitalized for psychiatric reasons. This was an expected event due to the population 
that was included for enrollment. 
There was an addendum included with the last continuation for approval of the John Dempsey release of information form to be 
stamped by the IRB to allow for communication with staff from the partial hospital program (PHP). This allowed for 
communication with the PHP staff regarding referring individuals for the study and to be able to communicate necessary 
information without breaking confidentiality.
The data are currently being prepared for analyses. No outcomes are ready to be reported at this time. There have been no 
publications, but hopefully this data will provide significant results that will facilitate future grants and enable us to further include 
those that have mental illness and substance use issues and are also coping with past traumatic experiences to research and provide 
treatment.
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SUBPROJECT DESCRIPTION:
Obesity has been linked to hyperinsulinemia due to insulin resistance. Insulin resistance is defined as the inability of insulin to 
act at the level of its target tissues. It contributes to arterial endothelial dysfunction, which in turn is a marker for impending 
cardiovascular disease. As the incidence of childhood obesity approaches epidemic proportions, there is a strong need to 
decrease their cardiovascular risk in the long term. Metformin, an oral hypoglycemic agent, decreases insulin levels while 
improving endothelial dysfunction and decreasing serum markers for heart disease, in obese adults.
Our hypothesis is that metformin will decrease cardiovascular risk factors in obese adolescents with hyperinsulinemia. Our 
specific aims are: 1) to examine the effect of metformin on the following surrogate markers of cardiovascular disease: a) 
Endothelial function via ultrasound to assess dilation of the brachial artery. b) Serum markers namely C-reactive protein, von 
Willebrands factor, fibrinogen, homocysteine and a fasting lipid profile. 2) to study the correlation of these cardiovascular 
markers on indices of insulin sensitivity, namely Homeostasis Model Assessment (HOMA-index) and Quantitative insulin 
sensitivity check (QUICKI). Our plan is to conduct a double blinded, placebo controlled trial and measure the above at baseline 
and at the end of sixteen weeks. We will enroll 15 adolescents in each group - metformin 850 mg twice a day and placebo. The 
goal is an increase in dilation of the brachial artery of 5% in the metformin group and 1% in the placebo group; using a within 
subject variability of 3-4%, two-tailed significance level of 0.05 and power of 80%.
SUBPROJECT PROGRESS:
No subjects were enrolled during the report period. 44 subjects were enrolled since the initiation of the study.  There are no 
unexpected safety concerns. Data analysis has ben completed. 
We had baseline data on 44 subjects. 54% of subjects had an elevated Cardiac CRP, 77% of subjects had an elevated fibrinogen, 52% 
of subjects had elevated brachial flow mediated dilation (FMD). Waist circumference correlated with area under the curve of glucose 
(r=0.428). BMI correlated with systolic blood pressure (r=0.448) and with TSH (r=0.441). Triglycerides correlated with markers of 
insulin {AUC-I (r=0.650), AUC-G (r=0.493), HOMA-R (r=0.487), QuickI (r=-0.482) and ISI (r=-0.602)}. 
29 subjects completed the 16 week study. Metformin did not produce any changes when compared to placebo. Change in absolute 
levels of 25 hydroxyvitamin D correlated positively with fibrinogen (r=0.705), positively with triglycerides (r=0.701), negatively 
with peak FMD (r=-0.738) and negatively with HOMA-R (r=-0.576). The percentage change in AST from baseline correlated 
negatively with the percentage change in CIR 30 (r=-0.544). (p<0.01 for all correlations).
Conclusions: Cardiometabolic abnormalities are common in obese hyperinsulinemic adolescents. We found correlations between 
markers of obesity, insulin resistance, cardiovascular disease and non-alcoholic fatty liver disease. TSH correlated with BMI 
suggesting that there may be some subclinical hypothyroidism in this group. An increase in Vitamin D levels was associated with a 
decrease in insulin resistance but an increase in cardiovascular disease markers.  
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There are no publications to date. The study is closed.
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SUBPROJECT DESCRIPTION:
This is a pilot study designed to examine the potential efficacy and tolerability of zonisamide for the treatment of alcoholism, 
and to compare this to topiramate, a similar medicine with demonstrated efficacy in a randomized clinical trial. Zonisamide is 
potentially better tolerated and easier to titrate in the outpatient setting than topiramate.
SUBPROJECT PROGRESS:
A total of 15 subjects were enrolled during the report period (a total of 24 since initiation of the study). As of 3/31/08, a total of 
20 subjects had been randomized to receive treatment with either zonisamide or placebo. 
We have not changed the recruitment plans, and are not planning any changes, although we did modify the advertisements in order 
to clarify that counseling is offered as part of study participation. There have been no unexpected safety concerns associated with 
this study. 
Interim outcomes data are not available at this time. There have been no publications associated with this study since data 
collection is ongoing. 
Changes made in the protocol during the report period were: 1) addition of Dr. Carolyn Drazinic as a co-investigator (change made 
to the Informed Consent Form (ICF) as well), 2) a revised Health Insurance Portability and Accountability Act (HIPAA) form was 
added, 3) The protocol and ICF were modified to add the rare/uncommon (but expected) possible adverse effects of paresthesia and 
taste perversion, 4) a new subject handout was added that illustrates standard drinking and educates the patients on non-hazardous 
drinking. All of these modifications have been approved by the IRB.
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SUBPROJECT DESCRIPTION:
1. To obtain pilot data on 4-week continuous quit rates associated with either 12 weeks of treatment with topiramate alone or 
topiramate in combination with 10 weeks of nicotine patch for smoking cessation.
2. To obtain pilot data on the effects of 12 weeks of topiramate alone or topiramate combined with 10 weeks of nicotine 
patch, on nicotine withdrawal symptoms, smoking satisfaction, and adverse effects during smoking cessation.
3. To obtain pilot data on weight gain over 12 weeks with either topiramate alone or topiramate in combination with the 
nicotine patch.
SUBPROJECT PROGRESS:
71 subjects screened and 53 subjects have been randomized to treatment.  Our goal is 60 subjects randomized to treatment. We 
have not analyzed any data.
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SUBPROJECT DESCRIPTION:
Alcohol abuse and dependence are important public health problems. Inherited (i.e., genetic) risk factors are thought to be 
important in the development of alcohol use disorders. Recent family-based and case-control studies of genetic factors in 
alcohol dependence indicate that variation in the GABA-A gene, GABRA2, is associated with alcohol dependence. Our 
preliminary results from alcohol challenge studies in humans suggest that variation in GABRA2 also influences the subjective 
effects of alcohol, suggesting a potential mechanism by which the gene may influence risk of alcohol dependence. Based on 
these preliminary data, the aims of this study are to: 1) examine the effect of alcohol on multiple domains of the response to 
acute alcohol administration in 30 social drinkers and to 2) examine the moderating effect of GABRA2 genotype on these 
subjective measures in response to acute alcohol administration. We hypothesize that, during the ascending limb of the BrAC, 
the stimulating and rewarding effects of alcohol will be moderated by GABRA2 genotype, such that individuals who are 
homozygous for the A-allele at SNP rs279858 (an intronic marker in GABRA2) will show a greater response to the effects of 
alcohol than will carriers of the alcohol-dependence-associated G-allele. In contrast, other effects of alcohol, such as sedation, 
motor incoordination, and decreased cognitive performance (the latter two measured by static ataxia and working memory, 
respectively), will not be influenced by GABRA2 genotype, as these effects are more likely to involve modulation of receptors 
containing the GABA-A á-1 subunit. The identification of specific genetic determinants for variation in the quality or 
magnitude of responses to alcohol may help in our understanding of why some individuals are vulnerable to, or protected from, 
alcohol dependence.
SUBPROJECT PROGRESS:
1) Number of subjects enrolled during the report period: 90 Since initiation of study: 156.   
2) Planned changes in recruitment plans: Study enrollment expected to be complete by end May 2008.
3) Unexpected safety concerns and their resolution:  There have been no unexpected safety concerns associated with this study and 
no serious adverse events.  Approval was requested and received from the IRB for subject 612-086's to repeat 2nd lab session due to 
an alcohol dosing error by the pharmacy (problem reported to the Institutional Review Board (IRB)).  
4) Interim data:  none to date, awaiting completion of study.   
5) Proposed changes made past year or anticipated in the protocol: Cheryl Oncken and Grace Chen were added as co-investigators.  
IRB approved Principal Investigators (PIs) request to increase in enrollment to 200 subjects on 8/13/07. Approval was requested to 
conduct a brief pre-screening visit for initial medical eligibility and to obtain saliva for genetic inclusion testing.  This could occur 
off site (especially those at UCONN Storrs campus).  IRB approved on 9/10/07. Approval was requested to add an additional 
specific aim #3, investigation of genetic variation in other candidate genes beyond GABRA2 and between subject differences in 
alcohol response.  Several other genes are emerging from literature reports as being related to alcohol effects or alcohol 
dependence.  Protocol and ICF were modified to address this change.  Protocol was also modified to correct the current IRB 
approved enrollment number.  IRB approved on 11/5/07.  Request made to IRB and approved for increase in potential number of 
study completers to 80 (from 60) in the event a larger than anticipated number of subjects complete all 3 monthly lab sessions. 
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IRB approved January 2008 - A recruitment web site URL - www.uchcalcoholstudy.com (refer to study #1) - was added to all 
recruitment materials for this study.  The PI purchased a short easy to remember URL www.uchcalcoholstudy.com for a site that 
we may use to link interested potential participants to our study brochure, ICF and contact information contained in a separate web 
page.
6) Continued General Clinical Research Center (GCRC) support requested - We request the GCRC protocol remain active, resource 
needs - GCRC clinic exam room for alcohol lab session, GCRC nursing/research assistant support for alcohol lab sessions, core lab 
for DNA isolation and genotyping.
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SUBPROJECT DESCRIPTION:
About 40-60% of methadone maintenance patients are also cocaine dependent. Cocaine dependence is associated with 
significant morbidity and mortality, but few traditional therapies are efficacious in treating cocaine dependence in this difficult 
patient population. Contingency management (CM) strategies that provide positive incentives upon direct evidence of cocaine 
abstinence are promising interventions. Typically, vouchers, exchangeable for retail goods and services, are used as reinforcers. 
When voucher amounts range from $1000 to $3000 over a 12-week treatment period, CM can reduce cocaine use in 
methadone patients. We have data from cocaine-dependent patients treated in drug-free settings that suggest a novel 
reinforcement system that provides the chance to win prizes, rather than vouchers, may also be efficacious in decreasing 
cocaine use, at potentially lower costs. The purpose of the study is to evaluate the efficacy of voucher and prize CM in 
cocaine-dependent methadone patients.
Cocaine-dependent methadone patients (n=240) will be randomly assigned to one of four conditions: standard treatment, 
standard treatment plus usual magnitude prize CM ($300), standard treatment plus higher magnitude prize CM ($900), or 
standard treatment plus voucher CM ($900). Urine samples will be screened 2-3 times weekly for 14 weeks, and follow-up data 
will be collected throughout a 12-month period. We expect that CM will decrease cocaine use relative to standard treatment, the 
efficacy of prize CM will be magnitude dependent, and $900 prize CM will be more efficacious than $900 voucher CM. 
We will also examine patient characteristics and their association with treatment response.  Further, we will obtain a detailed 
analysis of relapse following CM treatment and evaluate the cost-effectiveness of CM. In sum, this study will provide a stringent 
test of the relative efficacy and cost-effectiveness of voucher and prize CM, and it will address moderators of response to CM in 
the treatment of cocaine-dependent methadone patients.
SUBPROJECT PROGRESS:
Total Enrollment: 131
Past Year Enrollment: 65
No changes in recruitment plans are needed.
• No unexpected safety concerns have occurred.
• Interim data and outcomes are not available.
• Changes to protocol: 1) Removed Tressa Hanson as study coordinator and contact. Danielle Barry and Ellen Ciesielski were 
added as study coordinator and study contact, respectively. Sean Sierra and Shanelle Carmichael were added as consenters and Todd 
Olmstead was added as co-investigator. 2) Clarified description of when the Service Utilization questionnaire (SU) is administered 
(at baseline and at each follow-up interview). 3) Expanded the description of the payment for urine samples submitted to include 
other small items up to $3 in value (e.g., toiletries, snacks, bus tokens, etc.) in addition to gift certificates in the protocol and 
Informed Consent Form (ICF). 4) Revised the description of standard treatment in the protocol because we have observed that 
clinics vary on whether group therapy is mandated. 5) Clarified the form of payment for interviews by adding the words "in gift 
certificates" for the baseline assessment and "check" for the follow-up assessments in the protocol. 6) Removed two outdated 
references to the Substance Dependence Severity Scale (SDSS) in the protocol. 7) Clarified that FileMaker is used in conjunction 
with Excel and SPSS for data in the protocol. 8) Added a Methadone Treatment History Questionnaire. 9) Three questions added to 
the Addiction Severity Index regarding Medical Status and Drug/Alcohol Use. 10) A comments Box added to the bottom of page 2 
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of the Brief Symptom Inventory to document any discussion regarding suicidal or homicidal ideation if needed for potential adverse 
events records. 11) Additional codes and spaces were added to the Service Utilization in order to improve the accuracy of data 
collection and questions regarding visits with parole officers were also added. 12) Removed outdated phone number from one 
recruitment flyer.
• Results not yet published as study is ongoing.
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through March 31, 2009?  Yes
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SUBPROJECT DESCRIPTION:
Our main goal is to improve the skeletal health of children with cerebral palsy (CP), a population with a high lifetime risk of 
fractures. In this study we seek pilot funding to examine the prevalence of vitamin D (vit D)
insufficiency and deficiency in children with CP in the greater Hartford area. This is a necessary step before a planned 
intervention trial of vit D in children with CP. Vit D sufficiency is a requirement for normal bone
mineralization, and plays roles in muscle strength, regulation of cell differentiation and immune function. Consequently, it is 
desireable to prevent vit D insufficiency/deficiency in children in general. Children with CP
may be at higher risk for vit D deficiency because of limited exposure to unfiltered sunlight, impaired nutrition because of 
swallowing dysfunction and use of anticonvulsants that increase vit D breakdown. In addition, vit
D deficiency is more prevalent in Northern latitudes, even among healthy children. In consequence, children with CP in the 
greater Hartford area may be at particular risk for vit D insufficiency/deficiency. However, there are no prevalence data 
concerning the sufficiency of vit D stores in children with CP in our geographical area. Our anecdotal clinical experience 
indicates that children with CP frequently have reduced serum 25 (OH) vit D, an indicator of vit D reserves. Therefore, we 
hypothesize that children with CP in the Hartford area have a higher prevalence of vit D deficiency than healthy children. To 
test this hypothesis, we aim to measure serum 25 (OH) vit D in children with CP and their unaffected, healthy siblings living in 
the same household. Seasonal differences will be examined, since vit D stores tend to decrease in colder, dimmer months. We 
will invite children with CP who are followed at the Special Kids Support Center (SKSC) at the Connecticut Children's Medical 
Center (CCMC) to participate. These children are well characterized clinically, including use of
anticonvulsants. Multiple clinical specialists will assess these children. Children with CP will have motor function assessment 
during the study visit at SKSC and a clinical nutritionist will obtain data on calcium and vit D intake. The PI will exclude 
primary and secondary bone diseases. Children with vit D deficiency will be treated with oral vit D. This screening study will 
provide pilot data for a subsequent intervention trial that aims to find the optimal dose of enteral vit D to restore normal vit D 
status in children wit CP. Timely identification and treatment of vit D deficiency will improve bone health in these fragile 
individuals.
SUBPROJECT PROGRESS:
Total of 62 subjects were enrolled in the study since the initiation. There are no changes in the recruitment plan. There are no 
unexpected safety concerns. There are no anticipated changes in the protocol. There are no publications based upon the current 
study yet.
We analyzed the data of 62 subjects and submitted the findings as an abstract to the Annual Meeting of American Society for Bone 
and Mineral research. The abstract including the available data is as follows:
Is Vitamin D deficiency more common in children with cerebral palsy than in healthy children? 
S.Yigit , B. McKinney, J.Pedersen, B.Draheim, F.Sylvester
Children with cerebral palsy (CP) may be at higher risk for vitamin D(vit D) deficiency because of limited exposure to unfiltered 
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sunlight, impaired nutrition because of swallowing dysfunction and use of anticonvulsants that increase vit D breakdown.  In 
addition, vit D deficiency is more prevalent in Northern latitudes, even among healthy children. Therefore, we hypothesized that 
children with CP have a higher prevalence of vit D deficiency than their unaffected siblings.  To test this hypothesis, we measured 
serum 25 (OH) vit D (RIA, Immunodiagnostic Systems Ltd, Fountain Hills, AZ) levels in children with CP and their unaffected, 
healthy siblings living in the same household.  Seasonal differences were examined. Vit D deficiency was defined as serum level <15 
ng/ml and vit D insufficiency as serum level < 20 ng/mL based on previously published pediatric studies. 31 children with CP and 31 
healthy siblings as controls between ages of 6 -18 years were enrolled. 12.9 % of children with CP were vit D deficient while 29 % 
of the siblings were deficient. Vit D insufficiency was found in 29 % of children with CP and 38.7 % of healthy siblings. Only 20 % 
of the children with CP and 13 % of healthy siblings had 25 (OH) vit D level of more than 30 ng/ml, a level considered as optimal. 
While the mean 25 (OH) vit D levels were low on both groups, healthy siblings had a significantly lower 25 (OH) vit D levels 
compared to the children with CP (mean 25 (OH) vit D level for children with CP 24.5 ± 12.9, healthy siblings 19.6± 8.4, 
p=0.04). Low vit D levels were more prevalent in healthy siblings during winter season (mean 25 (OH) vit D level for children with 
CP 33.2 ± 16.5, healthy siblings 19.8± 8.8, p=0.01). 80 % of the healthy siblings were consuming < 1 serving of milk per day. 58.8 
% of the children with CP who had sufficient vit D levels were on supplemental tube feedings. Only one CP patient with vit D 
deficiency was on tube feedings but was on a ketogenic diet. None of the healthy siblings were taking vit D supplements while only 
2 children with CP were on multivitamin supplements. Vit D deficiency/ insufficiency appear to be a prevalent public health care 
problem in both children with CP and healthy children. Although children with CP have higher risk factors, healthy siblings seem 
to have a higher prevalence of vit D deficiency/ insufficiency. Children with CP who are on tube feedings are less likely do develop 
vit D deficiency/ insufficiency. Healthy children may need counseling for prevention.
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SUBPROJECT DESCRIPTION:
Metabolic syndrome is a major risk factor for cardiovascular disease (CVD). It involves the clustering of three or more of the 
following conditions -obesity, hypercholesterolemia, hyperglyceridemia, hypertension, and hyperglycemia. Available 
prevalence estimates suggest that 20-to-25 percent of the U.S. adult population currently have this syndrome. Numerous studies 
demonstrate that weight loss via changes in diet and exercise can reduce the severity, and even the existence, of these 
conditions. However, at the present time, no published investigation has reported on the frequency, circumstances, or success of 
weight reduction activities among persons with metabolic syndrome. The broad objective of the research outlined in this 
proposal is to address this gap in our understanding of metabolic syndrome and, thereby, to provide a basis for the formulation 
of public health initiatives that might reduce its severity, prevalence, and evolution into CVD. Using data from the National 
Health and Nutrition Examination Survey (NHANES) we will conduct statistical analyses to address the following questions:
1. Do individuals with metabolic syndrome perceive obesity and being overweight as a problem that needs to be addressed?
2. What nutritional and lifestyle changes are persons with metabolic syndrome undertaking in order to manage the condition 
and its effect on levels of CVD risk?
3. What factors enhance and/or inhibit the initiation of weight loss activities among persons with metabolic syndrome?
4. Which types of weight loss activities hold the most potential for achieving weight loss in those with metabolic syndrome?  
The project will utilize staff and expertise of the Biostatistics Core of the University of Connecticut General Clinical Research 
Center (GCRC) and faculty clinicians. The proposed project will contribute to our understanding of the scope and, perhaps, 
growth of the epidemic of metabolic syndrome in the U.S. population. It will also shed light on the simplest and most 
economical factors through which that epidemic might be controlled.
SUBPROJECT PROGRESS:
This project utilizes the GCRC Biostatistics Core to analyze data from the 1999-2000, 2001-2002, and 2003-2004 waves of the 
National Health and Nutrition Examination Survey (NHANES). Since the survey has already been administered by the National 
Center for Health Statistics, the project does not involve enrollment of new subjects at the University of Connecticut Health 
Center (UCHC) or within the GCRC. Because the project involves only the analysis of existing, publicly available data, the UCHC 
Institutional Review Board has determined that it does not constitute human subjects research. Therefore, there are no issues 
related to subject recruitment and no issues related patient safety. 
By the end of Year 14 of GCRC funding, statistical analyses for this project were essentially complete (except for minor 
refinements) and a manuscript was in preparation. Study findings include the following: 1. demonstration that increases in the 
national prevalence of metabolic syndrome among adults in the United States continue to occur, having reached a level of 
approximately 34% during the 1999-2004 period; 2. discovery that metabolic syndrome develops through two distinct patterns of 
risk factors that appear to be determined substantially by age -one pattern that occurs primarily before age 40 and another that 
occurs primarily after age 50; 3. determination that, on an annual basis, approximately 50% of persons with metabolic syndrome 
who are overweight engage in some type of "weight loss" activity and that approximately 50% do not; 4. determination that, on 
an annual basis, less than 20% of persons with metabolic syndrome who are overweight succeed in intentionally losing 10 pounds or 
more; 5. demonstration that physician advice regarding overweight status, the presence of other metabolic syndrome components 
(high blood pressure, high cholesterol, and diabetes), and the need for weight loss constitutes one of the strongest predictors both of 
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the attempt to lose weight and of successful weight loss; 6. recognition that more than 40% of individuals with metabolic syndrome 
who are overweight report that they have never been told by their doctors that they are overweight. Use of GCRC resources will 
continue into Year 15 of GCRC funding, but the resources required (primarily, time from Biostatistics Core staff) will be minimal.
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0618 618PROTOCOL:SPID: RESEARCHTYPE:  
Girls in RecoverySHORT TITLE:
LONG TITLE: Girls in Recovery from Life Stress (GIRLS)
Inpatient
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AIDS: N
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SUBPROJECT DESCRIPTION:
The purpose of the GIRLS study is to provide counseling to adolescent girls in the juvenile justice system who are experiencing 
Post Traumatic Stress Disorder (PTSD) to help them regulate their emotions, planning, decision-making, and actions/ 
interactions in ways that will reduce PTSD and enhance their safety, responsible civic involvement, learning, peer, family, and 
adult relationships, and physical and psychological well-being. 
The study will be the first randomized clinical trial of two promising manualized therapeutic interventions for complex 
post-traumatic stress disorder (PTSD):  1) Trauma Adaptive Recovery Group Education and Therapy (TARGET; Frisman, Ford, 
& Lin, 2004) and Life Skills/Life Story (LS/LS; Cloitre et al., 2002).  Both interventions will provide 16 one-to-one educational 
and therapeutic sessions that teach coping skills and stress reduction techniques.  
The aims of the study are: 
1) To test how participation in TARGET and LS/LS relates to clinically and statistically significant improvements will occur in 
PTSD symptoms, psychosocial functioning, and emotion/impulse regulation; 
2) To compare the differential affects of TARGET and LS/LS on affect regulation, social support, stress-related information 
processing and cognitive coping, and the reduction of impulsive or aggressive thinking/behavior; 
3) To identify changes in daily self-regulation after TARGET and LS/LS; and  4)  To identify alterations in brain activity that 
change after TARGET and LS/LS.  An ethnically diverse sample (N=52) of juvenile justice-involved girls between 13 and 17 
years of age will be recruited in clinic, community, detention, and residential programs. After screening for eligibility and 
obtaining valid signed consent forms, participants will be randomly assigned to one of the two experimental conditions.  Within 
each condition, trained clinicians will administer 16 sessions of individualized counseling using manual for the specified 
intervention. Psychometric self-report and daily monitoring measures will be obtained at baseline, post-treatment, and 4-month 
follow-up assessments and multivariate statistical techniques will be used for analysis of treatment effects.    
The research conducted highlights the need to address trauma among justice-involved youths. Most have experiences past 
traumas and many exhibit risk behaviors (substance use and suicidal ideation) that jeopardize their wellbeing and reduce their 
ability to engage in prosocial lifestyles.  Contact with court-related services presents a critical window of opportunity.  Juvenile 
justice agencies have the chance to identify at-risk youths through early screening and assessment and referral to 
age-appropriate and gender-sensitive treatment services.
SUBPROJECT PROGRESS:
Thirty three participants have been enrolled in the GIRLS study since 4/1/07. A total of 70 have been enrolled since the beginning 
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of the study. Nine did not meet eligibility requirements at the time of the baseline interview. A total of 61 participants will be 
included in the data analysis. The GIRLS study closed for recruitment at the end of February, 2008. Funding for the study is 
provided by the Office of Juvenile Justice and Delinquency Prevention (OJJDP) through the end of August, 2008. This will provide 
the study staff with completing follow-up interviews. Thirteen girls are currently receiving the counseling component of the study. 
We expect a total of 15 girls to begin making their final round of phone calls to the interactive voice response (IVR) system 
operated by the GCRC within the next 3 months. 
Modifications that were approved in the past year included changes in study personnel, re-assenting of girls that would allow for the 
GIRLS study staff to communicate with staff where the girls were recruited in order to help with scheduling appointments, the study 
safety procedures were modified as requested by the Department of Children and Families (DCF) to allow for a streamlined protocol 
in the event that a girl presents with suicidal ideation, the protocol for screening a participant was modified to include asking the 
parent/guardian permission before screening was done, some of the study forms were updated and modified, one measure (traumatic 
events screening inventory TESI) was modified to include specific ages of trauma occurrence, recruitment material was modified to 
reflect new changes as was the consent form and protocol, the consent form was modified to reflect the reduction of follow-up 
interviews from 3 to 2 if time point of the end date of the study did not allow for the final interview to be done, the treatment 
completion window was extended to allow for clinician/participant vacations, illnesses, or other activities that may come up, a 
reduction in the time period for the final follow-up interview was modified from 6 months to 4 to allow for all girls that were 
consented to complete the 3 study interviews, and recently we submitted a modification to be able to complete the post-treatment 
and follow-up interview in the participant's home. This will allow for increased number of interviews to be completed.
 
There have been no unexpected safety concerns in the past year, but there have been 10 adverse events concerning suicidal 
ideation, one participant was arrested at her residential facility for assaulting a staff member, two girls were sent to detention from 
their residential facility for aggressive behavior, and two girls went AWOL from their residential facility. A report to DCF was 
made because a GIRLS study participant reported to a study clinician that her friend (also a GIRLS study participant) told her that 
her stepfather was sexually abusing her. Five serious adverse events occurred regarding hospitalization for suicidal behavior. All of 
these events were reported to the UCHC and DCF IRB, as well as to the review board for the Court Support Services Division 
(CSSD). 
The data are currently being prepared for analyses. No publications have been completed at this time.
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SUBPROJECT DESCRIPTION:
Alcohol has multiple pharmacological effects, though which of these effects relate to the risk of alcohol dependence is not 
clear.  Family-based and case-control genetic studies of alcohol dependence indicate that genetic variations of the GABAA gene, 
GABRA2, influence the risk of developing alcohol dependence.  Preliminary results from our alcohol laboratory studies in 
humans suggest that variation in GABRA2 influences the subjective effects of alcohol.  Animal studies indicate that the 
neuroactive steroid allopregnanolone is an alcohol-modulated endogenous agonist at GABAA receptors and that genetic 
variation in steroid 5ƒÑ-reductase type I gene which generates neuroactive steroids, may moderate alcohol effects.  Studies in 
humans have identified a functional ƒÝ-opioid receptor polymorphism (Asn40Asp) that moderates the feedback regulation of 
the HPA axis and may be associated with variation in the neurosteroid response to acute alcohol.  To better define the role of 
GABRA2 gene variation, neuroactive steroids and genetic variants of 5ƒÑ-reductase and ƒÝ-opioid receptor genes on the acute 
effects of alcohol in humans, we propose to conduct a laboratory study of non-alcohol dependent drinkers using a 4-session 
design in which alcohol/placebo beverage is paired with dutasteride/placebo pretreatment.  Dutasteride, an inhibitor of both type 
I and type II 5ƒÑ-reductase enzymes, blocks the production of 5ƒÑ-reduced neuroactive steroids.  This study will extend our 
preliminary findings with finasteride by including a) a placebo control for alcohol, b) a more specific inhibitor of both 
5ƒÑ-reductase isoenzymes, c) a larger group of subjects (including both light and heavy drinkers), d) quantitative tests of static 
ataxia and response inhibition, e) plasma concentrations of neuroactive steroids and their adrenal steroid hormone precursors at 
several time points following alcohol administration, and f) the effects of polymorphisms in steroid 5ƒÑ-reductase enzymes and 
ƒÝ-opioid receptor genes on acute alcohol effects (including changes in levels of neuroactive steroids).
SUBPROJECT PROGRESS:
1) Number of subjects enrolled during the report period:  26   Since initiation of study:  26
2) Planned changes in recruitment plans: We will explore during the next year the feasibility of conducting the alcohol lab sessions 
at the Storrs campus for the Spring 2009 semester.
3) Unexpected safety concerns and their resolution:  There have been no unexpected safety concerns associated with this study and 
no serious adverse events. Due to a pharmacy error in providing a lower dose of alcohol, one subject was asked and agreed to repeat 
one of the lab sessions. 
4) Interim data:  Limited examination of data from first 15 completers currently underway. Dutasteride found to have expected 
reduction in subjective responses to alcohol, but with greatest effect in 5 subjects who were classified as heavy drinkers.
5) Protocol changes made past year or anticipated:
 
IRB Approved on 4/12/2007: Question 13a was added to the phone screener to help determine subject's eligibility based upon 
availability for completion of the study visits.  Questions 27c and 27d were added to carefully screen for alcohol dependence, and 
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questions 30a and 30b were added to carefully screen for drug abuse.  Protocol was modified to add alcohol expectancies 
questionnaire to baseline data collection.  the Informed Consent Form (ICF) was modified to include the following description of 
lab sessions: "In such an event, you would receive payment for that session but may or may not be invited back for any additional 
drinking sessions based on decision of study investigator."  ICF was modified to include the following description of time of 
sessions: "This study requires a total of nine visits over a period of approximately 14-16 weeks: 1 screening visit, 4 lab sessions 
(scheduled about 1 month apart), and 4 "pre-lab sessions" (which take place 2-4 days before the lab sessions)." Dr. Cheryl Oncken 
was added as co-investigator.  Certificate of Confidentiality (COC) was added to the study.  Recruitment materials were modified to 
further clarify study details concerning visits and consumption of alcohol and medication.
IRB Approved on 5/30/2007:  The header for all recruitment materials was modified from "Recruiting Healthy Research 
Volunteers" to a more specific header "Healthy Adult Men Needed for Alcohol Study".  The study protocol was modified to include 
an additional brief cognitive test - GMLT. This test adds 4-5 minutes to each assessment battery.  We shortened the GoStop task 
by 2 minutes making a net change of 2-3 minutes.  The ICF was modified to include the name of Peter Snyder, PhD who developed 
the GMLT as co-investigator of the study.
IRB Approved on 7/16/2007: Approval granted to offer subjects the opportunity to repeat the medication (or placebo) 
administration followed by the alcohol lab session in the event they missed a particular lab session after they have completed the 
entire set of 4 planned medication (placebo) administrations in order to make full use of the data from fully completed paired 
medication and alcohol lab sessions for that subject.  In other words, an additional pre-lab visit and matching lab session will be 
offered to individuals who have completed 4 pre-lab visits and 3 matching lab visits (however, miss the 4th lab visit). The 
additional pre-lab visit and matching lab session will be identical to the visits that the subject missed due to unforeseen events (ie 
drug or placebo and alcohol or placebo drink). These visits will take place approximately one month after the subject finishes their 
scheduled series of study visits. The subject will be asked to sign an additional consent form explaining these procedures & any 
risks. The study phone script was modified to clarify and further explain certain details concerning the subject's involvement in the 
study.  A statement concerning duration of study visits and method of blood draws, at each lab session, through an IV catheter in 
the arm, has been added to the phone script.  The study quick reference criteria list for staff use was modified to add information 
concerning the amount of blood that will be drawn at each of the visits, and it's method through an IV catheter.  Questions #15a, 
30, and 39-43 were added to the study phone screener and questions #20, 21, 21a, 21b, 26b, 30b, and 34 were modified to assist 
with the careful screening of subjects for study eligibility.
IRB Approved on 10/18/2007: Approval granted to offer pre-screening brief visits, particularly for interested UConn Storrs 
campus students or staff which would occur at the Storrs campus (Psychology Department interview room) to avoid participants 
who screen out based on Body Mass Index (BMI), medical history or genetic inclusion criteria from needing to travel to UCHC.  
We also offer this brief pre-screening visit at the UCHC clinical site for subjects who live nearby and would not be inconvenienced 
to attend both a pre-screening visit and a baseline study screening visit should they meet study inclusion criteria at the 
pre-screening visit.  Approval granted for an additional ICF, ICF Form C, and Medical History form for the pre-screening visit.   
Details of the pre-screening visit were added to the study phone script and study criteria list.  Approval granted to include the 
following forms as part of a nursing history packet (in addition to the previously IRB approved nursing history): Physician's Order 
Sheet, Nursing Medical Administration Record, Medical and Alcohol Administration Sheet, EZ Screen, Physician's Sober exam, 
Progress Notes, Physical Exam report, Medical Review of Systems, and Psychiatric Review of Systems.  Approval granted to have 
subject #619-006 repeat this lab session after his fourth lab session.  In the contingency response letter of this review, a 
typographical error was addressed to the approval of a repeat lab session for subject #619-006.  The correct subject for the 
repeated lab session was subject #619-004.  Please note that the IRB approval letter was not modified to reflect the correction 
made of subject #619-006 to subject #619-004.
IRB Approved on 11/9/07:  Dr. Carolyn Drazinic was IRB approved as a co-investigator for this study to provide additional MD 
cross-coverage if needed.  ICF and protocol version dates were revised.
IRB approved at time of annual renewal January 2008:
We requested the removal of Amira Pierucci-Lagha, PhD as co-investigator for she is no longer employed at the UCHC nor 
affiliated with this study.  Please note that removal of Dr. Pierucci-Lagha was submitted on the 3/7/2007 IRB approved 
continuation.  However, her name still appears on all IRB approval cover letters & notices.  We have modified the HIPAA 
Authorization form, used for the pre-screening visit and screening visit, with the updated version/language now required by the IRB.  
A recruitment web site URL - www.uchcalcoholstudy.com (refer to study #2) - was added to all recruitment materials for this study.  
The PI purchased a short easy to remember URL www.uchcalcoholstudy.com for a site that we may use to link interested potential 
participants to our study brochure, ICF and contact information contained in a separate web page.  Currently, subjects are providing 
timeline follow-back data on their alcohol and drug consumption.  IRB approval given to contact subjects one month after 
completion of their last visit (4th lab visit, or IRB approved repeat visit) to gather alcohol consumption data for the 30 days that 
follow the last visit.  On the day of the fourth laboratory visit, subjects will be given a pre-paid stamped envelope and a timeline 
follow-back calendar, for the 30 days that follow the last visit.  Subjects will be asked to complete the timeline follow-back calendar 
with the number of alcohol beverages consumed within the past 30 days, and mail it back to the study staff at UCHC.  Subjects will 
be given a reminder call when the 30 days are soon to be due.  If a subject fail to mail the timeline follow-back data after the 30 
days, study staff will contact the subject to potentially collect the data over the phone.  This information has been added to the 
study protocol and ICF.  This final 30-day reporting of alcohol use will provide additional information to monitor whether study 
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participation including the pre-lab medication influences alcohol use outside of the study visit and to allow comparison of the 4 lab 
study conditions on such alcohol use. Addressed IRB guidelines for deoyxribonucleic acid (DNA) testing in protocol:  The study 
protocol and ICF were modified to address the DNA/genetic testing aspects of this research study as recently requested by the IRB.  
The following elements have been fully addressed in the protocol: An explanation of the purpose of the DNA testing aspects of 
this research study and a description of the DNA test to be run on the collected samples.A description of any foreseeable risks and 
discomforts to the subjects regarding DNA testing. A description of any benefits to the subject or others that may reasonably be 
expected from the Deoxyribonucleic Acid (DNA) testing.  A statement describing the extent, if any, to which the confidentiality 
of these records/samples identifying the subject will be maintained. To responds to new IRB guidelines regarding DNA sample 
storage:  The protocol and ICF have also been modified to explain that all DNA samples and data sets will be completely 
de-identified at the conclusion of subject enrollment and completion of the primary outcomes analysis.  A notification will be sent 
to the IRB once all DNA samples and phenotypic data are completely de-identified. The protocol was updated to provide 
information concerning the use of a Certificate of Confidentiality (CC) from the Food and Drug Administration (FDA) under the 
Section 301(d) of the Public Health Service Act (42 U.S.C. 241 (d)) to protect the researchers from being forced, even by court 
order or subpoena, to identify research subjects. (Please note that the CC was IRB approved on 4/12/2007). All ICF's were 
modified to include "DAlc" as an abbreviation to the studies name.  This will help study staff distinguish and identify the informed 
consents for this study.
6) Continued GCRC support requested - We request the GCRC protocol remain active, resource needs - GCRC clinic exam room for 
alcohol lab sessions, GCRC nursing/research assistant support for alcohol lab sessions, ancillaries, core lab for hormone assays, DNA 
isolation and genotyping.
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SUBPROJECT DESCRIPTION:
To monitor the inhibition of 5a-reductase (5AR) enzyme activity at 1, 3, 7, 14, 21 and 28 days following administration of a 
single dose of dutasteride (2, 3, or 4 mg) by measuring the change in blood levels of 3a-androstanediol glucuronide (3a-diolG) and 
the ratio of dihydrotestosterone (DHT) to testosterone.  To accomplish this aim, an open-label, between-subjects dose 
comparison study design will be employed with subjects receiving a 2, 3, or 4 mg dosage.  Subjects (up to n=40 enrolled to allow 
a minimum of 24 completers) will be randomly assigned to one of the 3 dose levels.  Results of this study will inform the dose 
selection for a subsequent placebo-controlled, within-subject, crossover study of dutasteride on the effects of alcohol. A 
secondary aim of this study is to examine the correlation of a genetic variation in the type I 5AR gene and baseline DHT/T 
ratio and effect of dutasteride at day 3.  A variation in this gene, whose product is one of the targets of dutasteride, has been 
reported to be associated with higher baseline levels of DHT.
SUBPROJECT PROGRESS:
1) Number of subjects enrolled during the report period:  none   since initiation of study:  26  
2) Planned changes in recruitment plans: The study is currently closed to enrollment.  The last subject completed participation of 
this study on 01/02/07.  
3) Unexpected safety concerns and their resolution:  There were no unexpected safety concerns associated with this study.  No 
subjects experienced serious adverse events. No subjects dropped out of the study due to adverse experiences related to the study 
medication.
  
4) Interim data:  With regard to the primary aim, as expected dutasteride reduced the concentration of 5-alpha reductase hormone 
metabolites, this was evident in examination of either dihyrotestosterone or 3a-androstanediol glucuronide.  The later metabolite 
showed less variation between subjects and a more consistent pattern of change overtime.  These results validate the future use of 
3a-androstanediol glucuronide as a marker of dutatsteride in our GCRC protocol #619 study.  Our results indicate that the 4 mg dose 
provides more consistent inhibition (80%) of enzyme activity in the 3-7 day window during which we plan to study the effect of 
dutasteride pre-treatment on alcohol responses in GCRC protocol 619.  The inhibition was progressively reduced in the 2-4 week 
interval and was reversed at all doses by 6 weeks. Study medication was well tolerated at the 2mg, 3mg, and 4mg dose.   
During the past year we examined hormone data for association with 2 Single Nucleotide Polymorphisms (SNPs) in each of the two 
isoforms of 5-alpha reductase.  During the next year we will explore other candidates for pharmacogenetic effects as we observed 
large between subject differences in hormone changes due to dutasteride.
5) Proposed changes made or anticipated in the protocol:  The PI plans to conduct GC/MS analysis of the collected plasma samples 
to more finely describe the nature of changes in 5a-reduced steroids following a single dose of dutasteride to better inform the 
primary R01 funded GCRC protocol #619.
6) Continued GCRC support requested - We request the GCRC protocol remain active with the potential request for additional 
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genotyping of the study sample for pharmacogenetic purposes.
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SUBPROJECT DESCRIPTION:
As evidenced by a number of current initiatives such as National Institute of Drug Abuse (NIDAs) initiative on stress and drug 
abuse, Healthy People 2010, and the National Institute of Health (NIH) Agenda for Research on Women's Health for the 21st 
Century, the relationship between substance abuse and violence has become a national priority.  Moreover, although research 
demonstrates associations between intimate partner violence (IPV) victimization and the development of substance use 
disorders among women, this phenomenon has not been adequately examined (NIDA, 2003b; Wekerle & Wall, 2002). This is of 
particular concern because women, by virtue of substantially higher risks of victimization  (Dansky, Byrne, & Brady, 1999), 
may be at increased risk to use substances to cope with their tension and stress.  A gap exists in the literature in its ability to 
explain this complex temporal relationship within a single episode and, across multiple episodes over time.  This gap was the 
catalyst for the current study which will gather information regarding the temporal relationships of IPV events to substance use 
among a community sample of 180 abused women.  Specific aims are; a) to gather pilot data on the temporal relationship of 
substance use and IPV events, and b) to examine the effectiveness of three methods of data collection 1) paper diaries; 2) 
monthly, retrospective, semi-structured interviews; and 3) telephone data collection methods.  For each data collection 
condition, feasibility will be assessed by a) compliance with the instructions, b) perceived safety in completing assessments, c) 
reported honesty, d) reported ease, e) preference for methodology assigned, or alternate methodology, f) percent attrition by 
methodology, and g) degree and pattern of missing data.  *** The only participants to have contact with the GCRC would be 
those participating in the telephone data collection condition (i.e., approximately 60 participants).
SUBPROJECT PROGRESS:
During this reporting period the study protocol was developed and programmed into the Interactive Voice Response (IVR) system. 
Three participants pilot tested the protocol. Full implementation of the study began in December. Sixteen participants have been 
enrolled in the study and 1 participant completed the study. The response rate for the IVR group (one of the three groups in the 
study and the only group that has a connection to the GCRC) was 52.00%.  No publications have been written about this study.
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SUBPROJECT DESCRIPTION:
Contingency management (CM) interventions are highly efficacious in improving substance abuse treatment outcomes. These 
interventions have been provided primarily in an individual format, but most therapy for substance abusers is delivered in the 
context of groups. We have preliminary data suggesting that our prize-based CM, which is substantially less costly than 
traditional voucher-based CM, can be administered in a group setting. This study will evaluate the efficacy of prize-based CM 
when administered exclusively in groups. Substance dependent patients beginning intensive outpatient day treatment (N=360) at 
one of three community-based programs will be randomly assigned to one of two conditions: (a) standard, non-CM treatment or 
(b) standard treatment plus prize CM delivered in groups. In the CM condition, patients will earn the opportunity to win prizes 
ranging from $1 to $100 in value for attending groups and submitting drug-free biological specimens. Substance use and 
psychosocial problems will be measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up 
evaluations. 
We will also assess patient characteristics that may be associated with improved outcomes within and across conditions. We will 
evaluate the cost-effectiveness of group-based CM by assessing receipt of psychosocial and medical services and criminal justice 
system involvement throughout the treatment and follow-up periods.
SUBPROJECT PROGRESS:
Total Enrollment: 271
Past Year Enrollment: 79 
No changes in recruitment plans are needed.
• No unexpected safety concerns have occurred.
• Interim data and outcomes are not available.
• Changes to protocol:  1) Added Justyna Tymoszczuk and Shanelle Carmichael as consenters, Jeremiah Weinstock as study 
coordinator and Ellen Ciesielski as study contact. 2) Revised study screening form to include a space for the research assistant to 
initial this form. 3) Partial Consent Waiver to complete screening approved. 4) Added the Methadone Treatment History 
Questionnaire. 5) Changed the timeframe in which study enrollment occurs from 48 hours to 1 week after treatment start for those 
being recruited from outpatient programs in order to facilitate recruitment. 6) Deleted a phrase in the Inclusion Criteria section of 
the protocol that refers to a recruitment site was approved to be removed from the protocol on 9/18/06. 7) Revised screener form 
to facilitate study recruitment. The additional questions help to better determine preliminary eligibility based on basic 
inclusion/exclusion criteria. 8) Added Dr. Jeremiah Weinstock as member of the DSM Committee for this study. 9) Three questions 
added to the Addiction Severity Index regarding Medical Status and Drug/Alcohol Use. 10) A comments Box is added to the bottom 
of page 2 of the Brief Symptom Inventory to document any discussion regarding suicidal or homicidal ideation if needed for 
potential adverse events records. 11) Additional codes and spaces were added to the Service Utilization in order to improve the 
accuracy of data collection and questions regarding visits with parole officers were also added. 12) Clarified that a modified version 
of the SCID is used to measure antisocial personality disorder. 13) Removed Marcia DeSousa and added Trisha Feery as a consenter. 
14) Added questions to the Addiction Severity Index (ASI) regarding HIV status and previous and current treatment. 15) Revised 
Cigarette Smoking History questionnaire.
• Results not yet published as study is ongoing.
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Do you wish to continue to receive GCRC resources for the period April 1, 2008 through 
March 31, 2009?  Yes
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0624 624PROTOCOL:SPID: RESEARCHTYPE:  
Omega-3SHORT TITLE:
LONG TITLE: Effects of Omega-3 Fatty Acids on Bone and Fragility
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 302  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 4/20/2006
 150Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Center on AgingKENNY, ANNE MD
NUTRITION UCONN, STORRS, CT USALAMMI, KEEFE PHD
MedicinePILBEAM, CAROL MD, PHD
ImmunologySECOR, ERIC MD
Medicine/PulmonaryTHRALL, ROGER PHD
Ctr for BiostatisticsWALSH, STEPHEN J SCD
SUBPROJECT DESCRIPTION:
Osteoporosis is a bone thinning disease that results in fractures that occur with minimal trauma. The direct health care costs 
related to osteoporosis are estimated to be 14 billion dollars per year, comparable to costs in heart failure and asthma.  Frailty 
or poor physiologic reserve to deal with stressors, in the general population over age 65 is estimated to be 7%; frailty is 
associated with an increase risk of falls and fracture.  Both osteoporosis and frailty are thought to have inflammation as a 
contributing factor.  Omega-3 fatty acids found in fish oil [eicopentaenoic acid (EPA, 20:5n-3) and docohexaenoic acid (DHA, 
22:6n-3)] have been shown to decrease markers of inflammation (cytokines) and decrease death due to heart disease.  A number 
of studies in animals suggest that fish oil (or EPA and DHA supplementation) inhibits bone break down, increases calcium 
absorped from the diet and and enhances calcium in bone.  Studies done in humans are few.  The studies have used a mix of 
essential fatty acids including n-6 and n-3 fatty acids.  N-6 fatty acids are thought to increase inflammation while n-3 fatty acids 
are thought to decrease inflammation.  The effects of the fatty acids appear to depend on the level of n-6 to n-3.  In one study, 
investigators demonstrated that n-6/n-3 fatty acid mixture supplementation increased bone mineral density or bone thickness of 
the spine and hip over 18 months in a group of older, nursing home residents with osteoporosis or low bone mass.  As far as we 
know, no study as evaluated the role of n-3 fatty acids in the frailty syndrome, characterized by sarcopenia or muscle loss, 
inflammation, low estrogen, growth hormone and testosterone levels,  poor nutrition and disability.
SUBPROJECT PROGRESS:
This study is actively underway. We have recruited 125 subjects, shy of the 150 we had hoped to recruit due to slow recruitment in 
the beginning.  We modified the inclusion criteria and resulted in markedly improved recruitment.  We have had very few drop outs 
(only 7) and all have been for minor complaints.  No unexpected safety concerns have been noted.  There are no interim outcomes 
available at this time.  No publications have occurred.  The last subject will complete the study in the end of July and data analysis 
will begin at  that time.
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0625 625PROTOCOL:SPID: RESEARCHTYPE:  
Androgen ReceptorSHORT TITLE:
LONG TITLE: Androgen Receptor Polymorphisms in East Asian Men
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 1  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/18/2006
 0Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PathologyRAJAN, THIRUCHANDURAI V MD, 
PHD
SUBPROJECT DESCRIPTION:
The specific aim is to examine androgen receptor polymorphisms that have been associated with increased risk of osteoporosis 
and bone fracture. The hypothesis driving this proposal is that the androgen receptor genes of ethnic East Asian Indians will 
encode a protein with larger numbers of glutamine residues than other groups.
SUBPROJECT PROGRESS:
During the reporting period in question we were provided the following services from the GCRC: Sample collection, 
Deoxyribonucleic Acid (DNA) extraction, and genotyping on androgen receptor polymorphisms.
This study closed to enrollment in July of 2007 and is currently in data analysis.  We hope to have publications based on this data 
published within the next year.
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0626 626PROTOCOL:SPID: RESEARCHTYPE:  
AsthmaSHORT TITLE:
LONG TITLE: Genes, Home Allergens and Asthma in Puerto Rican Children
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 158  0  0
 0  0  0
 0  0  0
Offsite Visits  239  0  0
AIDS: N
START DATE: 5/18/2006
 100Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PediatricsCLOUTIER, MICHELLE MD
SUBPROJECT DESCRIPTION:
Asthma affects over 14 million people in the United States.1 The prevalence of asthma in the U.S. increased by 74.9% from 
1980 to 1996; 1 ethnic minority populations such as Puerto Ricans are disproportionately represented in this trend of 
increasing asthma morbidity. 2, 3 Puerto Ricans had the highest age-adjusted asthma mortality from 1990 to 1995 among U.S. 
Hispanics in general and among Hispanics in the U.S. Northeast in particular.  Although asthma is a major public health problem 
among Puerto Ricans, little is known about the contribution of genetic and environmental factors to asthma in this population. 
5 To date, results of genome-wide analyses for linkage to asthma phenotypes have been published by 11 groups in 13 distinct 
populations. 6-17 None of these genome scans included Puerto Ricans. Because of the high prevalence of single-parent 
households among Puerto Ricans in the U.S. mainland,18 family-based studies of genetic association would be difficult to 
perform in this population. A population-based case-control study of genetic association for asthma and asthma-related 
phenotypes among Puerto Ricans in the U.S mainland is feasible and would offer a unique opportunity to examine genetic and 
environmental risk factors in a minority population with high asthma morbidity. We have recruited children with asthma in 
Hartford (Connecticut) as part of a program to improve asthma management by physicians in this community.19 In these 
children, we have shown that Puerto Rican ethnicity is associated with sensitization to specific allergens and increased asthma 
severity.20, 21 Among school children in Hartford, we have collected data in a group of Puerto Rican children with asthma 
(cases) and a group of Puerto Rican children without asthma (controls). We propose to conduct a case-control study of 
association between selected genetic and environmental factors and asthma in Puerto Ricans. Between 75% and 94% of Puerto 
Rican children with asthma are atopic (see C.4.c).22 In atopic children, production of cytokines (IL-4, IL-5, IL-9, and IL-13) 
by T-helper (Th)2 cells promotes increased production of immunoglobulin E (IgE), eosinophilia, mast cell differentiation, and 
long-term expression of allergen-specific immunity.23,24 Atopy and atopic asthma may result from lack of upregulation of 
Th1 immune responses and/or inadequate downregulation of Th2 immune responses.25, 26 We hypothesize that single 
nucleotide polymorphisms (SNPs) in genes that control the development and regulation of Th1 cells, Th2 cells, and regulatory 
T cells (Tregs) are associated with asthma and/or intermediate phenotypes of asthma (asthma phenotypes") in Puerto Rican 
children. We further hypothesize that parental report of exposure to pets in early life (during pregnancy and/or the first year of 
life) is associated with reduced risks of asthma and atopy, and that current exposure to high levels of indoor allergens is 
associated with a) increased asthma severity and abnormal lung function phenotypes (reduced FEV1 and FEV1/FVC, increased 
airway responsiveness, and reduced bronchodilator responsiveness) in Puerto Rican children with asthma and b) atopy 
phenotypes (e.g., increased serum total IgE) in Puerto Rican children with and without asthma. In addition, we hypothesize that 
variants in genes that control the development and regulation of Th1 cells, Th2 cells, and Tregs interact with indoor allergen 
exposures in influencing asthma and asthma severity in Puerto Rican children. 
To test these hypotheses, we will pursue the following specific aims:  1. To recruit 500 Puerto Rican children with asthma 
(cases) and 500 Puerto Rican children without asthma (control subjects).  2. To test for association between Single Nucleotide 
Polymorphisms (SNPs) in 20 positional candidate genes and i) asthma (in all subjects),  ii) lung function phenotypes (airway 
responsiveness, FEV1, FEV1/FVC, and bronchodilator response)and atopy phenotypes (skin test reactivity to allergens, serum 
total and allergen-specific IgE, and eosinophil count) separately in cases and in control subjects, and iii) asthma severity in 
cases. 3a. To examine whether i) parental report of exposure to pets (dogs and/or cats) in early life is associated with reduced 
risks of asthma (in all subjects) and atopy (separately in cases and in control subjects), and b) current exposure to indoor 
allergens (dust mite, cockroach, dog, cat, mouse, and rat) is associated with increased asthma severity and abnormal lung 
function phenotypes in cases, and with atopy phenotypes separately in cases and in control subjects. 3b. To examine 
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interactions between exposure to the indoor allergens outlined in Specific Aim 3a  and SNPs in the candidate genes selected in 
Specific Aim 2.
SUBPROJECT PROGRESS:
During the time period from 4/01/07-3/31/08 we enrolled a total of 227 children into our genetic study. In total, to date, we have 
enrolled 421 children. We continue to make good progress on this project.  On average, our no show rate for the home visits is ~ 
43% while the no show rate for the hospital visits is ~38%. While these rates are significant, they are anticipated. In an effort to 
address attendance to the home and hospital visits, we continue to place reminder calls to the families the day before the scheduled 
visit as well as on the day of the visit. In addition, we also mail reminder letters that include magnets with the family's appointment 
information and our office phone number.
Recruitment efforts continue to focus within Hartford public schools during the academic year (flyer distribution, attendance at 
Open House, parent/teacher conferences, PTO meetings, and after school programs). When weather permits, we also conduct live 
recruitment after school when parents typically go to the school to pick their child up. In addition, throughout the school year, we 
make efforts to attend various health fairs in Hartford. As summer vacation approaches, we will be focusing our recruitment efforts 
at the Boys and Girls Clubs in Hartford as well as other community agencies (i.e. Mi Casa, Hispanic Health Council, summer camps, 
etc.). 
To date, we have not experienced any unexpected safety issues while conducting recruitment or study visits and we do not 
anticipate any safety concerns. However, study equipment was stolen from our office in January 2008 (one laptop and one KoKo 
spirometer). Appropriate individuals were notified and replacement equipment was secured via Connecticut Children's Medical 
Center (CCMC). Various CCMC IRB approved safety precautions have been identified and implemented; these were outlined and 
approved by the CCMC IRB.
We continue to collaborate with our colleagues in Boston. No publications have resulted from this work to date, as it is too early. 
Based on recent scientific evidence that vitamin D may influence the pathogenesis of asthma and asthma morbidity, our Boston 
colleagues propose that we measure vitamin D levels in blood samples. Due to the impracticality of re-consenting existing 
participants (addresses and phone numbers frequently change), we wish to do this by using the blood samples that we have already 
collected on existing participants. We submitted a request to the CCMC IRB on 4/18/08, the IRB of record, requesting permission 
to modify our consent form to indicate that blood collection will be used to measure vitamin D levels in addition to gene testing 
(DNA) and allergy testing. We are awaiting approval.
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0628 628PROTOCOL:SPID: RESEARCHTYPE:  
Discrimination StressSHORT TITLE:
LONG TITLE: Daily process pilot study of discrimination stress and diabetes outcomes in African American Women
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 14  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/30/2006
 10Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Behavioral Sci & Comm HlthWAGNER, JULIE PHD
Community MedicineTENNEN, HOWARD PHD
Medicine/HypertensionWHITE, WILLIAM MD
SUBPROJECT DESCRIPTION:
Our group is investigating the influence of racial discrimination on diabetes outcomes among African American (AA)women. 
Our next step is an National Institute of Health (R01) for a daily process study that will test the hypotheses that glycemia, 
blood pressure, and health behaviors will be more affected by daily stress in women with high lifetime discrimination than their 
low discrimination counterparts. The pilot project proposed here will collect data to support that R01 application regarding the 
feasibility of the data collection , the acceptability of the protocol to participants, and the effect sizes among relationships. 
Ten diabetic AA women will wear continuous glucose sensor and ambulatory blood pressure monitoring equipment for 3 
consecutive days, and report health behaviors for 7 consecutive days. Twice daily, participants will provide data on daily 
stressors using an interactive voice response telephone system. Information regarding recruitment, retainment, participant 
burden, effect sizes, technical challenges with data collection, and modification of questionnaires for daily assessment will 
increase the likelihood of a successful R01 application.
SUBPROJECT PROGRESS:
From 4/1/2007 until 3/31/2008, 6 women enrolled.  Since the initiation of this pilot study, 9 woman enrolled and all have 
completed the study.  Modifications to the project approved by the Institutional Review Board (IRB) this year include: 1) 
Approval of the Informed Consent Form (ICF) and Protocol revisions to reflect new IRB rules and language regarding storing of 
samples.  Samples will no longer be stored beyond completion of the study.  2) Approval the removal of Dr. Madhavi Mallareddy 
as a co-investigator.   Dr. Mallareddy has completed her fellowship and is not longer affiliated with UCHC.  Dr. White has assumed 
her responsibilities. 3) Approval of revised HIPAA; language changed to comply with new IRB guidelines dated 9/2007. 4) A 
Principal Investigator (PI) back up form was approved naming study coordinator Dr. Gina Abbott as PI Back up. 
There are no unexpected safety concerns. 
Preliminary data shows support for the hypotheses, and feasibility of conducting this multi-faceted study.  PI is submitting a larger 
grant (RO1) based on this pilot data. 
There are no publications at this time.
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0629 629PROTOCOL:SPID: RESEARCHTYPE:  
ATOMSHORT TITLE:
LONG TITLE: Contingency Management Reinforcement for Adolescent Cannabis Abuse
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 87  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 6/15/2006
 72Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
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NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryKAMINER, YIFRAH PHD
Behavioral SciencesBURLESON, JOSEPH PHD
SUBPROJECT DESCRIPTION:
The specific hypotheses to be tested are 1) Implementation of Voucher Based Reinforcement Therapy (VBRT) for youth with 
Cannabis Use Disorder is feasible and acceptable for both youths and therapists; 2) VBRT for youth produces a reduction of 
cannabis use during and at the completion of treatment; and 3) VBRT reinforcement for youth enhances a superior reduction of 
cannabis use relative to the non-reinforcement control condition. The proposed trial follows the guidelines for a preliminary 
Stage I study developed by the National Institute of Drug Abuse (NIDA) (Rounsaville et al., 2001).  The goals of a Stage I 
project are 1) to determine whether or not a Stage II project is indicated for the therapy examined in a Stage I project, and 2) if 
so, provide the necessary procedures, manuals, measures, and data needed to support a Stage II application (e.g., effect size 
estimates). Decision on appropriateness of Stage II project implies that the data generated supports the feasibility and clinical 
utility of the therapy examined for that condition, and/or behavior that it is designed to treat.
SUBPROJECT PROGRESS:
Number of subjects enrolled during the report period is 22 and since initiation of the study is 59.  The study is now closed to 
enrollment; therefore no changes in recruitment plans are needed.  No safety concerns.  No interim data and outcomes are 
available at this juncture.  No proposed changes made or anticipated in the protocol.  No publications completed yet.
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0630 630PROTOCOL:SPID: RESEARCHTYPE:  
Student Daily Life ExperiencesSHORT TITLE:
LONG TITLE: Howard University Study of College Student Daily Life Experiences and the Interaction of Genetic 
Variation
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 6/15/2006
 330Total # pts expected for entire study:
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PsychiatryCOVAULT, JONATHAN MD, PHD
PsychiatryHERMAN, AREY BA
PsychiatryKRANZLER, HENRY MD
GENETICS HOWARD UNIVERSITY, DC USASCOTT, DENISE BS
PHARMACOLOGY HOWARD UNIVERSITY, DC USATAYLOR, ROBERT MD
Community MedicineTENNEN, HOWARD PHD
MEDICINE HOWARD UNIVERSITY, DC USAWILLIAMS, CARLA PHD
SUBPROJECT DESCRIPTION:
This study is designed to evaluate the day-to-day associations among alcohol use, school-related behaviors, stressful events and 
mood states over the course of a one month period. Specifically, this study uses a web-based daily report tool to focus on how 
individuals cope with stressful daily events and negative mood states and, in turn, how coping efforts and mood affect alcohol 
use.  Additionally, this project will examine (a) the influence of a functional polymorphism, 5-HTTLPR, in the promoter 
region of the serotonin transporter gene (as well as two other variations in this gene), and alcohol dependence associated 
haplotypes of the GABRA2 and GABRG1 genes encoding the and ƒ×-1 subunits of the GABAA receptor on the use of alcohol 
by college students, and (b) evaluate the interactive effects of genotypes with daily life stressors, positive experiences, social 
interactions/peer influences, and positive or negative mood states on the use of alcohol by college students. In an exploratory 
aim we will also examine the effects of variation in other neurotransmitter related genes including: i) Monoamine oxidases 
(MAOA) which encodes monoamine oxidase, a key enzyme involved in metabolic inactivation of synaptic serotonin (as well as 
norepinepherine and dopamine), ii) TpH2 which encodes the brain specific form of trypthophan hydroxylase, the rate limiting 
enzyme in serotonin synthesis, iii) a functional promoter variant of the serotonin 5-HT1A presynaptic autoreceptor gene 
HTR1A and iv) CB-1 which encodes the brain form of the cannabinoid receptor and is thought to be involved in the regulation 
of appetitive and substance use behaviors.
This study will follow a protocol used in a parallel ongoing multi-year longitudinal study of college student daily life experiences 
at the University of Connecticut (UConn), Storrs, CT.  By comparing results from these two campuses we hope to compare and 
contrast the influence of mood states, life events and genetic variation on alcohol use behaviors to identify shared and unique 
characteristics for the two college student samples.  This cross sectional study at Howard University will provide important 
information about the feasibility of using methodologies developed at UCHC / Storrs sites at other college campuses to examine 
the generalizability of findings from our current  Alcohol Research Center / GCRC study at the Storrs campus.
SUBPROJECT PROGRESS:
1) Number of subjects enrolled during the report period:  none;  since initiation of study:  149   
2)  Planned changes in recruitment plans: Preliminary results from this and from GCRC#560 were used in support of a new grant 
application which was recently funded to continue this project by enrolling a larger sample of Howard University college students 
(approximately 150 students each semester for 6 semesters). 
3)  Unexpected safety concerns and their resolution:  None occurred.
4)  Interim data:  Salivary Deoxyribonucleic Acid (DNA) has been prepared from the 149 participants to data and used to generate 
genotype data at the 5HTTLPR locus and the HTR1B 3'UTR polymorphism. The sample is too at this time for genetic 
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association studies of behavioral phenotypes. 
5)  Proposed changes made or anticipated in the protocol:  The new R21 grant supporting subject recruitment at Howard 
University includes specific aims to examine awakening salivary cortisol as a potential biological marker of recent stress or stress 
reactivity.  GCRC core lab assay of salivary cortisol from 4 samples collected on 4 occasions from each participant has been added 
to the GCRC protocol.  Interactive Voice Response (IVR) will be used to track subject compliance with collection parameters for 
awakening salivary cortisol.
6)  Continued GCRC support requested - core lab for salivary DNA, genotyping and salivary cortisol.  Informatics support for IVR.
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0632 632PROTOCOL:SPID: RESEARCHTYPE:  
Racism in Minority ChildrenSHORT TITLE:
LONG TITLE: Perceptions of Racism in Minority Children
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  21  0  0
AIDS: N
START DATE: 6/20/2006
 600Total # pts expected for entire study:
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NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PEDIATRICS INSTITUTE OF LIVING, CT USAPACHTER, LEE MD
SUBPROJECT DESCRIPTION:
The objective of this project is 1)to gain an understanding of the ways children of different ethnic minority backgrounds 
perceive, interpret, conceptualize, and process racism (racial discrimination and prejudice).  2)to utilize this information to 
create valid and reliable instruments for measuring perceptions of racism in minority children which will be based on 
developmental theory and which have saliency for children of different ethnicities, and 3)to use these instruments in studies 
aimed at understanding the effects of perceived racism on a]the developmental competencies and behavioral health of minority 
children, as well as b]disparities in health and health care outcomes seen in minority populations.  Institutional Review Board 
(IRB) approval is being sought for Objective 2:  the creation and testing of instruments (questionnaires) aimed at measuring 
perceptions of racism in minority children.  A proto-questionnaire has been developed based on data gathered from 
semi-structured interviews with minority youths.  This questionnaire includes items that pertain to 1) whether a child has 
experienced situations in which he/she perceived as being discriminated against based on ethnicity, skin color, accent, or culture.  
2)the child's emotional response to the incident, and 3)the child's coping response.  
The present study proposal is to administer this proto-questionnaire to a sample of minority youth between the ages of 8 and 
18, and psychometrically analyze the response to determine validity and reliability of the instrument.  In addition to the 
Perceptions of Racism questionnaire, the Revised Children's Manifest Anxiety Scale and the Child Depression Inventory will be 
administered (as measures to be used in the determination of construct validity).  These analyses will likely result in refinement 
of the proto-questionnaire, which can then be used in future studies to determine the effects of racism (as a psychosocial 
stressor) on minority child behavioral health and development, as a contributory stressor in acute and chronic illness etiology, 
as well as it's effects on health care and health services issues.  Initial piloting of the proto-questionnaire will be conducted at the 
Boys and Girls Club of Asylum Hill.  Additional testing will be conducted in the Hartford Public School System (upon approval 
from the Superintendent's Office of the Hartford Public School System).  At the Boys and Girls Club, a convenience sample of 
minority (i.e., African American, Puerto Rican, and West Indian/Caribbean) children attending summer camp will be recruited.  
In the public school system, samples based on classroom assignment in middle and high schools will be procured.  In both 
settings, informed consent of the parent, as well as child assent will be obtained.  Although general descriptive demographic 
information such as age and ethnicity will be obtained, anonymity and confidentiality will be maintained; no personal identifiers 
will be recorded.  Data analyses will include factor analysis for subscale identification, item analyses, item-scale correlations, 
determination of the internal consistency reliability (coefficient alpha), and construct validity determination through 
correlation analyses.
SUBPROJECT PROGRESS:
During the present reporting period we have finished enrollment and enrolled 35 new participants into the study. This raises our 
final total subject number to 277. We have begun data analysis during this report period as well.  We are in the process of using the 
data to develop and refine an instrument to measure perception of racism in children and youth, using traditional psychometric 
analyses as well as structural equation modeling. We have also begun descriptive analyses of the occurrence of perceptions of 
racism in this sample, vis-à-vis race/ethnicity, age, and gender.  We are in the process of writing manuscripts for publication.
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0634 634PROTOCOL:SPID: RESEARCHTYPE:  
Serotonin 1ASHORT TITLE:
LONG TITLE: Serotonin 1A Receptor and Mood in Daily Life
Inpatient
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Outpatient
Scatter RN Hours
TOTALS A B D
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 0  0  0
Offsite Visits  0  0  0
AIDS: N
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PsychiatryCONNER, TAMLIN PHD
PsychiatryCOVAULT, JONATHAN MD, PHD
PsychiatryKRANZLER, HENRY MD
Community MedicineTENNEN, HOWARD PHD
SUBPROJECT DESCRIPTION:
Recent evidence identifies variation in the gene encoding the serotonin 1A (5-HT1A) receptor (genetic locus HTR1A)as a 
potential factor in the development of mood and anxiety disorders, with carriers of the G allele of the C(-1019)G single 
nucleotide polymorphism (SNP) of HTR1A being more vulnerable to such disorders than non-carriers.  We request funding to 
examine this allelic variation and its relation to mood-related outcomes in two existing data sets--416 Deoxyribonucleic acid 
(DNA) samples from college students taking part in an ongoing study of student life (IRB#03-128) and 1,510 DNA samples 
from a large case-control sample collected by Dr. Kranzler as part of an ongoing study of the genetics of alcohol dependence 
and co-morbid disorders (IRB# 96-156).  The first primary aim will be to test whether variation in teh HTR1A SNP predicts 
mood-related outcomes in the college student sample [measured by daily self-reported anxiety and other moods obtained across 
multiple years of study participation] and the case-control sample [measured by participants' lifetime history of Diagnostic and 
Statistical Manual (DSM) diagnosed major depression].  The second primary aim will be to test whether variation in HTR1A 
interacts with variation in the 5-HTTLPR polymorphism of the serotonin transporter gene (obtained previously in all of 
samples 1 and half of sample 2) to predict mood-related outcomes and lifetime history of depression.  Results from primary 
analyses will provide pilot and feasibility data for a National Institutes of Health (NIH) R03 grant application by the Principal 
Investigator (PI) to examine the role of serotonin-related genetic predictors of mood-related experience.  A secondary aim will 
capitalize on existing data to determine whether variation in HTR1A and is possible interaction with 5-HTTLPR predicts 
differences in alcohol use for the student sample and differences in alcohol dependency in the case-control sample.  Results from 
the secondary aim will provide pilot data for the Alcohol Research Center renewal grant to be submitted in December, 2006.
SUBPROJECT PROGRESS:
This archival study involved genotyping on archived saliva samples of 416 college students and examining single gene associations 
with daily emotional outcomes. No additional subjects have enrolled since the start of this project on April 1, 2006 or since the 
previous GCRC progress report. No changes in recruitment plans were needed and no unexpected safety concerns have arisen. All 
genotyping and costs associated with the project was completed in 2007.
The primary hypotheses relating to the HTR1A polymorphism to daily mood states
were unsupported (reported in 2007 Progress Report); therefore, remaining funds were used to genotype snps in the tryptophan 
hydroxylase-2 (TPH2) gene [G(-703)T snp (rs4570625) and the T(-473)A snp (rs11178997)], CRHR1 (rs1876831), and DRD4 
(VNTR polymorphism in exon III). Furthermore, analyses were expanded to examine associations between these snps and daily 
alcohol use.
FINAL OUTCOMES
1. Analyses of associations between TPH2 SNPs and alcohol use have resulted in
publication (Gacek, Conner, Tennen, Kranzler, & Covault, in press). Fingings
replicated prior research showing no association between the TPH2 rs4570625
snp and quantity and frequency of alcohol use in this non-clinical population. The GCRC is cited in the acknowledgement section 
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of the paper. A final copy of the paper will be sent to the GCRC when it is published.
Gacek, P.*, Conner, T. S., Tennen, H., Kranzler, H. & Covault, J., (in press).
Tryptophan Hydroxylase 2 Gene and the alcohol use among college students.
Addiction Biology
*UCHC Master's in Public Health student Paul Gacek
2. Analyses of associations between TPH2 snps and daily mood states showed
significant results. Carriers of the riskier T allele of the G(-703)T snp reported more intense negative mood states in their daily 
life, compared to those homozygous for the less risky G allele. This pattern occurred in women only. Genotype carrier status 
accounted for 5% of the variance in negative mood levels for women in year 1, and 3% of the variance in negative mood levels for 
women in year 2. These patterns were three times as strong as associations found with traditional retrospective survey measures. 
Results will be written up for publication.
3. Statistical analyses of the CRHR1 and DRD4 snp data will be conducted over the 2008-2009 academic year. Results will be used 
for publications and to inform decisions whether similar genotyping should be done in a larger genetic data set currently being 
collected at UCHC (P.I., Howard Tennen).
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0635 635PROTOCOL:SPID: RESEARCHTYPE:  
Hip Fracture PilotSHORT TITLE:
LONG TITLE: Feasibility of Multi-Component Training in Patients 2 Months Post Hip Fracture
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 6  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/30/2006
 8Total # pts expected for entire study:
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Center on AgingKENNY, ANNE MD
Center on AgingFORTINSKY, RICHARD BA
SUBPROJECT DESCRIPTION:
Over 325,000 hip fractures occur in the US each year, with the cost to patients, families and the health care system estimated 
at between 14 and 20 billion dollars annually. (1-2) Despite improvements in medical management, significant residual disability 
remains in older persons post hip fracture.(3) The current practice goal for discharge from medical management at 2-3 months 
post surgery is independent, safe household ambulation.(4) Hip fracture-acquired dependency in functional activities of daily 
living persists well beyond that point: 20% of patients need help putting on pants, 50% need assistance to walk, and 90% need 
assistance to climb stairs 12 months after hip fracture.(5-6) These figures indicate that the current standard 
Medicare-reimbursed rehabilitation therapy fails to return a large proportion of patients to pre-fracture levels of function. Thus, 
while hip fractures are common and lead to extended disability under usual care management strategies, there is a paucity of 
evidence to justify extending medical management beyond the current standard in persons post-fracture.
This pilot will evaluate a 16-week, supervised multi-component intervention that is introduced as soon as the patient completes 
usual care (typically within two months of the fracture). The intervention has been designed to address four relevant precursors 
to community ambulation using stress overload and specificity of training principles. The effect of the intervention on 
impairments, functional limitations, and disability also will be examined.
SUBPROJECT PROGRESS:
The study has received Institutional Review Board (IRB) approval. We are working with orthopedic surgeons and local home care 
agencies to identify potential participants. We have recruited 3 subjects into the study and have 2 more in the screening process.  
We continue to work with orthopedic surgeons to identify subjects.  We have had no safety concerns but one subject did fall and 
sustain a broken pelvis (during usual activities, not during the intervention).  No manuscripts have been prepared from the data yet.
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0636 636PROTOCOL:SPID: RESEARCHTYPE:  
Marital InteractionSHORT TITLE:
LONG TITLE: Marital Interaction in Alcoholic Couples Over Time
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SUBSTANCE ABUSE RESEARCH UNIVERSITY OF MICHIGAN, MI USACRANFORD, JAMES PHD
SUBPROJECT DESCRIPTION:
We are trying to determine if alcoholism leads husbands and wives to engage in more negative behaviors in marriage, and if 
these behaviors in turn lead to higher levels of drinking, depressed mood, marital aggression, and divorce.  This project is 
designed to improve our understanding of several public health problems, including alcoholism, depression, marital aggression, 
and divorce.
SUBPROJECT PROGRESS:
UCHC GCRC Progress Report Summary for Project 5R21 AA015105-02.  The targeted enrollment for this project was n=50 
alcoholic couples.  In our previous progress report, we indicated that n=5 couples had completed the Time 1 (T1) interview and 
marital interaction task.  We also indicated that we had submitted a request for a second set of modifications to the research 
protocol to the UCHC IRB on 04.13.07.  These modifications, which included expansion of recruitment efforts, revisions to the 
informed consent, and changes to the recruitment brochure, were approved by the University of Michigan (U of M) Medical 
School IRB on 03.22.07 (Amendment eResearch ID: Ame00003772) and by the UCHC IRB on 05.21.07 (UCHC IRB Number: 
07-035-3).  Unfortunately, this expansion of recruitment efforts was not sufficient for us to meet our recruitment goals, and we 
therefore submitted a request for a third set of modifications to the research protocol. These modifications involved further 
expansion of recruitment efforts to include 1) unmarried heterosexual couples (18 or older) who have been living together in a 
committed relationship for at least 6 months; 2) posting the study on the University of Michigan Clinical Outcomes and Research 
Engine (M-Strides) and on public websites (e.g. Craig's list, Arborlist, etc.); and 3) distributing recruitment brochures to local bars 
and churches in the Ann Arbor area.  This third request was approved by the U of M IRB on 09.05.07 (Amendment eResearch ID: 
Ame00005000), and by the UCHC IRB on 10.11.07 (UCHC IRB Number: 07-035-3). In addition, the first Scheduled Continuing 
Review (SCR) of this project was approved by the U of M Medical School IRB on 04.28.07 (SCR eResearch ID: CR00003882) and 
by the UCHC IRB on 09.10.07.  The second SCR of this project was approved by the U of M Medical School IRB on 03.07.08 
(SCR eResearch ID: CR00006849 <https://eresearch.umich.edu/eresearch?PageID=CR00006849>).
Expansion of recruitment efforts allowed us to exceed our targeted enrollment, and we were able to recruit n=54 alcoholic couples 
into this study. Recruitment was closed on 01.15.08, and the final couple completed their T1 interview on 02.09.08. This final 
couple completed their final call to the UCHC Interactive Voice Response (IVR) system on 03.11.08.  Given that our final sample 
size was N=54 couples, with each spouse asked to complete 14 daily reports on their drinking, marital interactions, and moods 
every night for 14 consecutive nights using the UCHC IVR system, our IVR data set had a maximum of 54 × 2 × 14 = 1,512 
observations or diary days. Participants in our study completed a total of 1,418 IVR reports.  Thus, our total compliance rate was 
1,418 / 1,512 = 93.8%.
Couples are also asked to complete telephone interviews at T2 (6 months after T1) and T3 (12 months after T1).  As of today 
(05.11.08), n=23 couples have completed the T2 interview and n=5 couples have complete the T3 interview.  Due to recruitment 
challenges, data collection will continue beyond the originally scheduled end date of May 31st, 2008.  Accordingly, we submitted a 
request for a 12-month No-Cost Extension (NCE) to NIH on 03.13.08.  This request was approved by NIH on 03.31.08, and the 
new end date for this project is now 05.31.09.  No unexpected safety concerns have arisen and no further changes to the protocol 
are anticipated.  Because the final IVR data were collected only 2 months ago, we have not yet published any results from this 
project.  However, an abstract based on this project was recently accepted by the Research Society on Alcoholism.  As indicated 
below, this abstract cites the U of M and UCHC GCRCs.
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0637 637PROTOCOL:SPID: RESEARCHTYPE:  
The DMAC StudySHORT TITLE:
LONG TITLE: A Pilot study to assess the DNA Methylation patterns in Alcoholics and Controls-The DMAC Study
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 17  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
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PsychiatryHESSELBROCK, VICTOR PHD
Genetics and DevelopmentalGRAVELEY, BRENTON PHD
Genetics & Develop BiologyLALANDE, MARC MD
Pharmacology & ToxicologyLAMBRECHT, RICHARD PHD
Internal MedicineTHAPAR, MANISH MD
Ctr for BiostatisticsWALSH, STEPHEN J SCD
SUBPROJECT DESCRIPTION:
Deoxyribonucleic acid (DNA) methylation, which is thought to play an important role in carcinogenesis, is an emerging area of 
epigenetic research.  A recent Request For Applications (RFA) (AA-06-005) from the National Institutes of Health (NIH), to 
which a multidisciplinary investigative group from UCHC responded (Drs. Bonkovsky, Hesselbrock, Lalande, and Lambrecht) 
targeted epigenetic effects of alcohol and its metabolism as an important area of research.  Alcohol has long been associated 
with cancer and has recently been associated with increased DNA methylation levels. In this pilot study, we propose to 
determine whether and how DNA methylation patterns in chronic alcoholics are different from suitable controls. This will be 
the first step in finding out if DNA methylation patterns are altered in subjects with chronic alcohol dependence and provide 
important pilot data for later, larger proposals to the NIH and other external funding agencies focused on mechanisms whereby 
alcohol and its metabolites influence cancer risk and other epigenetic effects.
SUBPROJECT PROGRESS:
DNA methylation, which is thought to play an important role in carcinogenesis, is an emerging area of epigenetic research. 
Consistent with NIH Roadmap initiatives, a multidisciplinary investigative group from UCHC responded (Drs. Bonkovsky, 
Hesselbrock, Lalande, and Lambrecht) is examining the epigenetic effects of alcohol and its metabolism as an important area of 
research. Alcohol has long been associated with cancer and has recently been associated with increased DNA methylation levels. In 
this pilot study, we propose to determine whether and how DNA methylation patterns in chronic alcoholics are different from 
suitable controls. This will be the first step in determining if DNA methylation patterns are altered in subjects with chronic alcohol 
dependence and provide important pilot data for later, larger proposals to the NIH and other external funding agencies focused on 
mechanisms whereby alcohol and its metabolites influence cancer risk and other epigenetic effects. 
Specific Aims: This pilot study is designed to obtain preliminary data on the methylation patterns of DNA for genes known or 
suspected of playing a role in cancer development. Aim 1: To assess global DNA methylation status in well-characterized chronic 
alcoholics and to compare it to suitably matched non-alcoholic family members as controls. Hypothesis 1: There are clinically and 
statistically significant differences in global DNA methylation and in patterns of DNA methylation in chronic alcoholics, 
compared to matched non-alcoholic controls. Aim 2: To explore whether there are observable, meaningful differences in 
methylation patterns between the two groups at different gene loci and whether there are relationships between life time alcohol 
use and the degree or pattern of DNA methylation. Hypothesis 2: There are differences in methylation patterns between alcoholics 
and controls, which correlate directly with dose and duration of alcohol use. To achieve these aims we proposed a pilot study to 
examine the methylation pattern in DNA samples from 48 chronic alcoholics and 48 matched controls. 
The field of epigenetics is the study of heritable differences related to changes in DNA expression, which are not due to differences 
in the DNA sequences themselves. Although still in its infancy, epigenetics is expanding rapidly. DNA methylation is one of the 
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three main types of epigenetic inheritance. It is involved in many physiological and pathophysiological conditions, including 
regulation of gene expression and silencing of repeat elements in the genome. DNA methylation plays a role in many diseases, such 
as multiple sclerosis, diabetes mellitus, schizophrenia, alcohol dependence, and cancer. It has been shown that global methylation 
status in peripheral blood monocytes (PBM) is associated with plasma homocysteine levels in healthy individuals. Chronic 
alcoholics commonly have elevated homocysteine levels. The importance of homocysteine to DNA methylation status stems 
from the fact that homocysteine is a precursor of S-adenosyl methionine (SAM), which is the methyl donor when cytosine residues 
in the dinucleotide sequence CpG are methylated by DNA methyltransferases (DNMT). Bonsch, et al., showed associations among 
alcohol-associated elevated plasma homocysteine levels, the global methylation status, and the subsequent expression of DNMT 
mRNAs in alcoholic patients compared to controls. These findings support the hypothesis that ethanol exposure increases DNA 
methylation, and suggest that changes in DNA methylation status can be responsible for changes in expression of some of the 
genes involved in this methylation process. 
Further research will be needed to confirm this possible chain of alcohol-induced events. In all likelihood, many more genes (whose 
levels of expression are partially controlled by the methylation status of the DNA in their promoters) are yet to be discovered. 
Changes in DNA methylation are recognized as one of the most common forms of molecular alteration in human neoplasia. 
Hypermethylation of CpG islands located in the promoter regions of tumor suppressor genes has been firmly established as a 
frequent mechanism for gene inactivation in cancers.In contrast, global hypomethylation of genomic DNA17 and loss of IGF2 
imprinting were observed in tumor cells and a correlation between hypomethylation and increased gene expression was reported for 
many oncogenes.In addition, monitoring global changes in DNA methylation has been used for molecular classification of cancers. 
Most recently, gene hypermethylation was associated with clinical risk groups for neuroblastoma,1 as well as with hormone 
receptor status and response to tamoxifen in breast cancer. Therefore, it may be feasible to use methylation markers to classify 
and predict cancer risk, different kinds or stages of cancer, cancer therapeutic outcomes, and patient survival. 
Alcoholism and cancer risk: Chronic excessive alcohol consumption is the strongest risk factor for upper aerodigestive tract 
(UADT) cancer (oral cavity, pharynx, hypopharynx, larynx, and esophagus). Chronic alcohol use also increases the risk for cancer 
of the liver, colorectum and breast. Many epidemiological studies have demonstrated a correlation between alcohol ingestion and 
the occurrence of cancer in these organs. Because the ingestion of all types of alcoholic beverages is associated with an increased 
cancer risk, more likely than not, ethanol itself is the crucial compound that increases cancer risk. The exact mechanisms of 
ethanol-associated carcinogenesis have remained obscure. Multiple mechanisms are believed to be involved in alcohol-associated 
cancer development of the UADT, including the effect of acetaldehyde (AA), the first metabolite of ethanol oxidation, induction 
of cytochrome P-4502E1 (CYP2E1) leading to the generation of reactive oxygen species (ROS), and enhanced procarcinogen 
activation, modulation of cellular regeneration, and nutritional deficiencies. Folate deficiency, primarily the consequence of low 
dietary intake and destruction by AA, is common in alcoholics and contributes to the inhibition of transmethylation, which is an 
important factor in the regulation of genes involved in carcinogenesis. Acetaldehyde decreases DNA repair mechanisms and the 
methylation of cytosine in DNA. However it has been shown recently that chronic alcoholics have significantly increased levels of 
genomic DNA methylation. About 3.6% of all cases of cancer and a similar proportion of cancer deaths are attributable to 
consumption of alcohol. These figures are higher in selected regions of the world, in particular in Central and Eastern Europe. 
Among women, 60% of cancers attributable to alcohol occur in the breast. DNA Methylation: Methods for measurement of DNA 
methylation include methylation-specific enzyme digestion, bisulfite DNA sequencing, methylation-specific PCR (MSP) and 
MethyLight, methylation-sensitive single nucleotide primer extension (MS-SnuPE), MALDI mass spectrometry and differential 
methylation hybridization (DMH). However, none of these methods combines access to specific sequences in the genome with high 
throughput and low cost, which is needed for analyzing methylation profiles at high resolution in large sample sets. In addition, 
many of these methods are insensitive to low levels of methylation changes in diseased tissues, for example, 10% or 20% 
hypermethylation. 
We propose using the recently validated adaptation of a high-throughput single nucleotide polymorphism (SNP) genotyping 
system for DNA methylation detection, based on genotyping of bisulfite-converted genomic DNA. This technology combines a 
miniaturized bead-based array platform, a high level of assay multiplexing, and scalable automation for sample handling and data 
processing. We intend to use the technology developed by Illumina labs, including their methylation chip and bead array system. 
The bead array system is presently available at UConn. Illumina expects to have a fully functional assay system in the second half 
of this year. With use of this system, we will analyze methylation profiles of 1536 CpG sites from 371 genes. These genes were 
selected based upon their relevance to carcinogenesis. This assay can resolve a 22% methylation difference between samples with 
99% confidence and a 10% methylation difference with 95% confidence. 
Resources available through the NIAAA-funded Alcohol Research Center were used to identify suitable alcohol-dependent subjects 
and appropriate sibling controls. This information is available as part of the database of the long-standing Collaborative Study on 
the Genetics of Alcoholism, (COGA). Alcohol dependent adult subjects along with their nonalcohol dependent siblings were drawn 
from the COGA study sample. After being consented, 15 mL of peripheral blood was obtained and peripheral blood monocytes 
(PBM) was separated for DNA extraction using the Progene DNA purification kit and the standard protocol currently in use at the 
GCRC Core Lab. The plasma is being stored frozen (-80oC) in 1 mL aliquots for possible future use. The DNA samples, stored at 
-80oC were processed by the Molecular Core Lab under the supervision of Dr. B. Graveley. The DNA methylation pattern has been 
studied using the methylation chip from Illumina labs. We are continuing to analyze the results for differences in the methylation 
patterns in the sibling pairs. GCRC resources have been used for recruitment and enrollment of subjects (Clinical core), for the 
study visits (Nursing core and exam rooms, etc), for the processing of the blood samples, including the preparation of PBM and 
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subsequent extraction of DNA (Core laboratory). 
Subject recruitment was considerably slower than expected. To date only 29 sibling pairs, from a total of n=55 subjects, were 
recruited and  have also provided blood samples for DNA extraction. Following completion of this last subject pair, DNA 
extraction was be completed on all samples and the DNA sent to Dr Gravely's lab to examine the DNA methylation pattern using 
the recently available methylation chip obtained from Illumina labs. 
An initial analysis of these pilot data revealed no clear methylation pattern attributable to chronic alcohol use, but more careful 
analysis using other alcohol-related phenotypes -apart from a formal diagnosis - is underway.  There have been no unexpected 
safety concerns from this study; no publications or presentations have resulted from this work to date.
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Osteoporosis and Bone AugmentationSHORT TITLE:
LONG TITLE: Osteoporosis and Bone Augmentation/Implant Outcomes: An Observational Study
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ProsthodonticsFREILICH, MARTIN A DDS
Behavioral Sci & Comm HlthPENDRYS, DAVID DDS, PHD
SUBPROJECT DESCRIPTION:
Bone augmentation is frequently a necessary component of dental implant reconstruction. While in the future, tissue 
engineering methods including cell transplantation and the release of cell signaling agents will be available for clinical use, the 
current gold standard to increase bone volume is through autogenous grafting. Grafting tends to be successful in young healthy 
patients, but there is evidence that success rates of grafting procedures markedly decrease with age and certain systemic 
conditions, such as osteoporosis. In the US, there are roughly 10 million women over the age of 50 with osteoporosis and an 
additional 34 million with low bone mass or osteopenia." It is estimated that 40-50% of women over the age of 50 will sustain 
an osteoporotic fracture in their remaining lifetime. Given that a statistically significant correlation has been shown between 
hip and mandible BMD, this large population may be at increased risk for complications and low success rates for bone 
augmentation procedures compared to women with healthy bone. The relationship between this systemic health problem and 
implant success is not well documented and additional research in this area is needed. Despite the suggestion of the negative 
effect of low bone density/osteoporosis to bone graft success, no studies have been reported which carefully demonstrate this 
relationship.
SUBPROJECT PROGRESS:
Forty-two patients have signed consent at a screening visit and of those, 11 cases screen failed, 7 cases need to be reviewed to 
determine eligibility for the second of screening visits/Treatment planning visit, 24 have passed onto the second 
screening/Treatment plan visit.  Of those 24 cases, 2 withdrew, 4 have failed out, 4 cases need to be reviewed, 4 are pending surgery 
and 10 have been baselined (i.e. received implants). 
 
Changes in recruitment plans during the above-mentioned time period have included adding posters, brochures, and opening the 
recruitment to the general public.   No major scientific changes have been made to the protocol since the studies inception. 
However addendums included the addition of a surgical consult appointment prior to bone augmentation/implant surgery 
appointment in which the provider reviews the treatment plan with the patient and obtain standard consent for surgery.  The 
following changes were made to the inclusion and exclusion criteria are being made. Inclusion of those requiring a sinus elevation 
procedure less than or equal to 2mm in combination with their dental implant placement was also added to the protocol.  
No interim data or outcomes are available at this time.  No publications have been produced as a result of this study as of yet.
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Pulmonary epithelial effects of hypoxiaSHORT TITLE:
LONG TITLE: Pilot Study of Circulating Markers of Pulmonary Epithelial Effects of Hypoxic Exposure
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Medicine/Pulmonary MedicinBURKI, NAUSHERWAN K MD
SUBPROJECT DESCRIPTION:
Increasing evidence from in vitro animal studies suggests that hypoxia has direct cellular effects on the alveolar epithelium and 
the alveolocapillary membrane (1).  Indirect evidence indicates that this is also likely to be true in man, but there are few studies 
examining this. The alveolar epithelium and pulmonary vascular endothelium perform crucial functions critical to the overall 
integrity of the lung, including transfer of fluid and proteins between the alveolar lumen and the interstitial and intravascular 
spaces, mechanical stability of the lungs, and immune and anti-inflammatory functions. In man, hypoxia-induced damage to 
some or all of these pulmonary functions can be inferred from some clinical syndromes, such as high altitude pulmonary edema 
(HAPE), but the mechanism(s) of these actions of hypoxia are unclear (2). It is well established that removal of the hypoxic 
stimulus relieves acute mountain sickness (3), and recent data indicate an additive effect of supplemental inhaled CO2 with the 
oxygenation (4).   The majority of studies on hypoxia in man have focused on ventilatory neural regulatory mechanisms 
(5,6,7,8,9) and autonomic nervous control of the pulmonary circulation (2); studies of possible mechanisms of hypoxia-induced 
lung damage in man have, of necessity been invasive, such as analysis of bronchoalveolar lavage fluid, which itself may alter the 
milieu being studied (10) and invasive vascular studies (11). There have been no studies specifically evaluating the effects of 
hypoxia on the pulmonary epithelium in man, partly because until recently there were no available, generally accepted 
circulating biomarkers of pulmonary epithelial function. Clara cell protein (CC16) is expressed in pulmonary Clara cells and has 
been shown in animal (12) and human studies (13) to be a sensitive marker of pulmonary epithelial function. Circulating levels 
of CC16 are altered on exposure to ozone or other noxious stimuli (14, 15).  In order to investigate the effects of hypoxia, we 
performed studies on circulating markers of pulmonary epithelial and endothelial function in normal subjects exposed to 
hypoxia at sea level and identified changes in circulating levels of these markers. Our hypothesis is that exposure to hypoxia in 
normal human subjects directly affects pulmonary epithelial and endothelial cell function; in its severe form this may be 
manifested as pulmonary edema. This effect of hypoxia may be modified by mucosal acidification as would occur with an 
increase in alveolar CO2.
SUBPROJECT PROGRESS:
This study was approved by the General Clinical Research Center (GCRC) for 6 subjects which were enrolled. A manuscript is in 
preparation.
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Tonsillar CancerSHORT TITLE:
LONG TITLE: Prevalence of Human Papillomavirus in Tonsillar Cancer and Age Matched Diseases Free Controls
Inpatient
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SurgerySPIRO, JEFFREY MD
SUBPROJECT DESCRIPTION:
We hypothesize that 33% of the tonsillar squamous cell carcinoma tissue analyzed will have evidence of a virulent strain of 
Human Papilloma Virus (HPV) (16, 18, 31, 33).  Within this subgroup of subjects the response to therapy measured in 5 year 
survival data will be greater then the remaining 2/3rd.  We also expect that the tonsillar specimens of healthy non-cancerous 
patients will be free of virulent strains of HPV.  This would allow for a stronger argument of causation rather than association.  
To look for an increase in HPV for those patients who have no other risk factors.
SUBPROJECT PROGRESS:
Adam Lubinguhl graduated from Uconn School of Medicine in May 2007 and is now an Otolaryngology resident in Philadelphia. 
There has been no additional subject enrollment since the prior progress report. Follow-up was updated late in 2007 during 
preparation of an abstract for submission to the upcoming (July 2008) International Conference on Head an Neck Cancer. The 
study was accepted for a podium (oral) presentation at this upcoming meeting, and we plan on submitting a manuscript for 
publication as well. The GCRC will be cited in both cases.
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0641 641PROTOCOL:SPID: RESEARCHTYPE:  
StressorsSHORT TITLE:
LONG TITLE: Mental and Physical Stressors in the Diagnosis of Breast Cancer. A multidisciplinary analysis of distress and 
systemic biomarkers in patients referred for biopsy of a suspected breast cancer lesion
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 41  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 12/21/2006
 100Total # pts expected for entire study:
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Medicine/Hem-OncTANNENBAUM, SUSAN MD
SUBPROJECT DESCRIPTION:
Women begin to face their greatest fear when they have been told that their routine mammogram or breast exam is abnormal. 
Women experience an array of symptoms throughout the course of their diagnosis, treatment and recovery from breast cancer.  
Symptoms are perceived indicators of change in normal functioning as experienced by patients. Symptoms disrupt daily 
functioning, most notably social function and communication. Symptom outcomes impact functional and emotional status, 
health care service utilization, mortality/morbidity, financial status, and self-care/management. Research has demonstrated the 
presence of significant associations between symptoms experienced by breast cancer survivors, suggesting a complex web of 
symptom experience. The nature of the complex interactions between symptoms remains unclear. Patients with one symptom 
are likely to have others, as well.  Cancer-related fatigue, depressive-anxiety symptoms and sleep disturbances are the most 
frequent symptoms experienced by women diagnosed with breast cancer. These symptoms can have a devastating impact on 
their quality of life. Recent studies imply a correlation of these symptoms with selected markers of inflammation including 
levels of proinflammatory cytokines. 
Systemic Biomarkers:  Biomarkers like carcinoembryonic antigen, CA-125 and prostate-specific antigen (PSA) are helpful in 
monitoring and in some cases diagnosing cancer (41). Three new serum biomarkers derived from membrane proteins found on 
breast cancer cells, Aminopeptidase N (CD13), membrane type 1-matrix metalloproteinase (MT1-MMP), and stromal derived 
receptor-1 (SDR-1), are hopeful novel biomarkers that may prove useful in the diagnosis of breast cancer.  Aminopeptidase N, 
also known as CD13, is a membrane-bound, zinc-dependent peptidase that cleaves neutral amino acids from the N terminus of 
oligopeptides. In addition to being expressed by a number of tissues, CD13 is aberrantly upregulated on both the tumor cells and 
developing blood vessels of cancerous tissue.  Accumulating evidence points to CD13 as a key regulator in this tissue of both 
angiogenesis, or new blood vessel formation (42, 43), and the migration and invasion of tumor cells (44, 45).  Interestingly, 
although CD13 was first defined as a membrane bound protein, a soluble form was later detected in a variety of bodily fluids 
including blood. Moreover, a number of studies have shown CD13 to be elevated in the serum of cancer patients, and to 
correlate with larger tumor size (46, 47). To date, however, no studies have investigated CD13 serum activity as a prognostic 
marker.  Membrane type 1-matrix metalloproteinase (MT1-MMP) also shares similar characteristics as CD13. It is expressed as 
an inactive cell surface proteinase which is induced under breast cancer progression and angiogenic responses (48-50). 
Interestingly, the functional activation of MT1-MMP results in increased cell migration and invasion and has been shown to be 
actively translocated to the cell surface in hypoxia, both in vitro and in human breast cancer (51). It has also been shown to be 
shed from tumors as an active fragment which can be detected by MT1-MMP-specific   fluorescent peptide substrates (52, 53).  
The third biomarker is a novel cell surface protein which is over-expressed in human breast cancer and is selective for a highly 
invasive ductal carcinoma; high expression predicts distant metastasis (54). This cell surface protein also depicts cleaved protein 
isoforms in human breast tumor lysates indicating it may be shed in blood. This novel tumor antigen was identified from a breast 
cancer patients sentinel lymph node and an antibody directed against it was synthesized. This unique antibody will be used in a 
fluorescent-based assay on blood samples to determine whether it is a potential diagnostic marker.
SUBPROJECT PROGRESS:
Number of subjects enrolling (Correction to last year's stats)
 
Time Frame Enrolled Screened  
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4/1/06-3/31/07 7 16  
 
4/1/07-3/31/08 30 53  
 
4/1/08-6/09/08 4 7  
30 patients have been enrolled and 53 screened for the progress report period.  There are no changes to recruitment plans.  We 
plan to continue until we meet the recruitment goal of 100 patients.  There are no unexpected safety concerns.  Interim data was 
presented October 2007 to the Board of Directors of the CT Breast Health Initiative, Inc. (Please see attached slide).  Jayesh 
Kamath is presenting an abstract at the IPOS 10th World Congress of Psycho-Oncology in Madrid, Spain (Please see attached 
PDF).  There have been no changes made to the protocol within the reporting period.  The slide presentation does include 
reference to the GCRC.
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0642 642PROTOCOL:SPID: RESEARCHTYPE:  
PACTG 1047SHORT TITLE:
LONG TITLE: Pediatric Aids Clinical Trials Group (PACTG) 1047: Version 1-Phase II Safety and Immunogenicity Study 
of Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] L1 Virus-Like Particle [VLP] Vaccine 
(Gardasil®) in HIV-Infected Children > 7 to < 12 Yea
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
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Offsite Visits  0  0  0
AIDS: Y
START DATE: 11/16/2006
 1Total # pts expected for entire study:
YN MULTICENTER STUDYRESEARCH BIONUTRITION
YY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
Phase II
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PediatricsSALAZAR, JUAN MD
SUBPROJECT DESCRIPTION:
Pediatric Aids Clinical Trials Group (PACTG) 1047 is a phase II, double blind, placebo controlled study of the safety and 
immunogenicity of Quadrivalant Human Papilloma virus (QHPV) vaccine in a population of Human Immunodeficiency Virus 
(HIV)-1 infected boys and girls aged 7 years to under 12 years. The vaccine, also known as Gardasilwas developed by Merck Labs 
with the target viral types being 6, 11, 16, and 18.  The most common oncogenic Human Papillomavirus (HPV) types that 
cause cervical dysplasia and cancer, in both HIV-infected and uninfected women, are HPV 16 and 18.  The most common types 
of HPV, causing genital warts, are types 6 and 11.  On May 18, 2006, an advisory committee for the Federal Drug 
Administration (FDA) reviewed Merck's application for licensure of Gardasil®.  It is expected that the vaccine will receive 
approval in early June, 2006.  However, no HIV-infected children, or children with other immune compromising conditions, 
have been enrolled or received monovalent or quadrivalent HPV vaccine in any clinical trials.
The incidence of cervical cancer in HIV-infected women increases as immune competence decreases with progression of HIV 
disease.  Cervical cancer is more extensive and more difficult to cure in HIV-infected women than in HIV-uninfected women and 
the recurrence rate after standard clinical care is higher.  In addition, HIV-infected individuals are at increased risk for penile and 
anal cancer, including individuals who do not report prior anal intercourse. Because HPV is a sexually transmitted infection, 
prevention in women will be enhanced by prevention in their partners as well.  Thus, evaluation of a prophylactic vaccine, 
which might protect HIV-infected girls and boys from infection with the most common HPV types that cause anogenital 
dysplasia and external genital lesions, is an important scientific goal.
The study population will consist of 120 HIV-1 infected children recruited from multiple PACTG sites in the U.S. This protocol 
will be undertaken in children > 7 to < 12 years of age because it is likely that this preventative vaccine will be used before 
children become sexually active.  It is expected that, in terms of safety, QHPV Vaccine will be generally well-tolerated in 
HIV-infected children in this age group.   The subjects will be randomly selected to receive the study vaccine or placebo, with 
75% receiving the active vaccine and 25% receiving placebo during Stage I of the study.  Since it is expected that children with 
weaker immune status would respond differently from children with stronger immune systems, the population will be stratified 
into three groups based on their CD4% history and current CD4%.  
Stage I:  After satisfying eligibility criteria including real-time pregnancy testing for menstruating females, the vaccine/placebo 
is given intramuscularly 3 times (at entry, week 8 and week 24).  Subsequent safety assessment consists of at least 30 minutes in 
the clinic directly after immunization, a day 3 phone evaluation, study visits on week 4, 8, 12, 24, and 28.  Subjects will also be 
asked to keep a record of oral temperature and symptoms following the injections.  (See attached Appendix IV, the Vaccination 
Report Card)  Subjects will be strongly encouraged to phone the study nurse or Dr. Salazar should any unusual or alarming 
symptoms occur.  
Stage II:   At week 96, the groups will be unblinded.  If the vaccine has been deemed safe and well tolerated, a fourth dose will be 
given to those children who had received active QHPV.  The placebo group would now begin the regimen of active QHPV and 
follow up visits.  For the group who receives the fourth dose of active QHPV, safety follow up will occur at weeks 97, 100 and 
108.  Those who begin active QHPV at 96 weeks will be followed in a likewise fashion until study week 124. (Please see attached 
Appendix 1I A and IB.) Throughout the course of the study, immunogenicity will be evaluated via blood and saliva samples using 
ELISPOT (anti-HPV CMI), HPV antibody cLIA (Competitive Luminex Immunoassay) and IgG and IgA anti-HPV testing.
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SUBPROJECT PROGRESS:
Pediatric Aids Clinical Trials Group (PACTG) 1047 (Version 1.0) has had one subject participating at the Connecticut Children's 
Medical Center site since the opening of the study. Due to non-refunding of our site, this subject was discontinued from study 
participation as of Nov 2007.
This study has been closed to accrual.  
There have been no unexpected safety concerns reported by The PACTG 1047 team.
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0643 643PROTOCOL:SPID: RESEARCHTYPE:  
HITECSHORT TITLE:
LONG TITLE: Health Improvement Through Training and Employee Control (HITEC)
Inpatient
Scatter Bed
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TOTALS A B D
 0  0  0
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 0  0  0
Offsite Visits  0  0  0
AIDS: N
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Occupational/EnvironmentalCHERNIACK, MARTIN MD
SUBPROJECT DESCRIPTION:
This study compares two different approaches to combining workplace safety and health with personal health improvement.  
The primary focus is on improvement of musculoskeletal health (mobility and fitness, preventing and controlling joint disease, 
and workplace risk reduction), and the secondary focus is on depression and mental health.  One approach relies on traditional 
health promotion, where a management sponsored program offers an educational package and professional review of work 
organization and ergonomics.  The second approach involves developing groups within the workforce (Employee Sponsored 
Groups or ESPs) that will determine and construct workplace health and safety and personal health programs.  The study 
involves a comparison of costs, measures of health status, and evaluation of the effectiveness of the workforce planning groups.  
The direct involvement of the workers compensation insurance carrier in the study team is intended to produce realistic and 
respected agreements about health program conduct and content between the workforce and management.  There is a significant 
economic and econometric component, which is designed to link health and process outcomes to rate structure.
SUBPROJECT PROGRESS:
Subjects:  There are no subjects currently enrolled in this project.
Personnel:  There were no changes in key personnel over the year.  Professor Vicki Magley in the Department of Psychology at 
UCONN-Storrs has formally joined the project as an investigator.  Her background is in workplace violence.  Her involvement and 
the incorporation of HITEC and CPH-NEW fieldwork with the NIOSH-funded industrial psychology program at UCONN, has 
brought 3 new graduate trainees into HITEC.  Currently, 7 graduate students from UCONN Health Center and UCONN-Storrs are 
engaged in the project as their field practicum or as part of their thesis work.  
AIMS: HITEC has selected 2 matched sites, facilities with the State of Connecticut Department of Corrections.  These currently 
active study sites represent a departure from the original plan to use only Travelers clients, but reflected the strong interest on the 
part of the State of Connecticut in the challenged health of corrections officers.  Selection of the second pair of sites has not been 
concluded, and is discussed under Site Selection.  The original Aims are presented below. 1. Creation of semi-independent employee 
sponsored participant (ESP) groups that will devise a program combining individual health promotion with a corresponding 
worksite health and safety intervention. 2. Development of evaluation processes sufficient to compare outcomes from ESP 
programs to a more traditional wellness and ergonomic programs: the standard of care (SOC).  3. Development of economic and 
econometric models for assessing effectiveness, costs, and benefits of interventions, and providing a program evaluation model 
that is understandable, reproducible, and acceptable to all participating parties, and in particular to insurers and financial 
representatives. 4. Direct participation of the insurance carrier in quantifying costs and benefits, in developing a rate-based 
incentive structure, in "institutionalizing" the employer's involvement, and in disseminating results.  We have renamed the ESP 
sites participatory sites and refer to the SOC sites as professional sites.  AIM #1 remains in process.  Practically, we have prepared 
a series of operative scenarios based on participatory ergonomics to optimize the process.  The evaluation process for site 
comparison (AIM #2) is in place and has not changed in principle since last year.  Because of security considerations at DOC, 
environmental exposure evaluation has been modified.  While the development of models (AIM #3) is an ongoing process, there 
has been considerable progress in compiling practical data bases.  AIM #4 requires an adjustment.  Because the State of Connecticut 
is self-insured, the model developed with Traveler's underwriters for pard assigning a cost threshold no longer applies.  We have 
adjusted by working with the Comptrollers Office (group health) and the Department of Administrative Services (DAS) both to 
assure capital funding and to apply our cost-plus model to the public sector.
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Site Selection:
The DOC site selection process is described below.  As noted in the Year I progress report, a sophisticated selection strategy 
involving 1200 Traveler's clients was unsuccessful.  We have followed up on reasons for company caution with a survey to key 
personnel and to the responsible Traveler's account managers.  Results have been presented (APA-NIOSH Work, Stress, and Health 
Conference, 3/7/08), and publication is in progress.  The reasons for refusal are being studied with Traveler's to look for 
generalizable patterns.
We have continued to recruit through Travelers by holding Employer's Schools and have made solicitations outside of the 
Traveler's network.  The following 13 companies and sites were screened and directly solicited with site visits, PowerPoint 
presentations and summaries of worker's compensation costs.  The numbers conceal relatively different levels of recruitment 
effort.  Sites 5 and 6 extended over 4 months each with preliminary agreements and site materials prepared.  In both cases, the 
deteriorating economic climate and increased pressures from state regulators lead senior management to withdraw.  
 
ID Description Traveler's Client Location No(*) Yes Pending Status  
 
1. Accounting and finance Yes New York State No Poor financial climate  
 
2. Consumer warehousing Yes Mid-west No* Travel Costs  
 
3. Global manufacturing No CT and MA No* Restrictive policies  
 
4. Parts  manufacturer Yes Northern mid-west No* Travel Costs  
 
5. Utility No CT No Poor financial climate  
 
6. Utility No CT and MA No Legal and financial client  
 
7. Precision manufacturer Yes CT Pending In review  
 
8. Drivers/DOT No CT Pending In review  
 
9. Insurer Yes CT and NY Pending In review  
 
10. Food manufacturer Yes CT and NY No Insurer conflict  
 
11. Warehouse work No MA and CT No Union contract issue  
 
12. Precision manufacturer No CT and NY Pending In review  
 
13. Aerospace manufacturer No CT Pending In review  
 
14. Electronics manufacturer No CT and MA Pending In review  
(*)  HITEC rejected
The situation is far from negative.  The Connecticut DOT (Site 8) and Travelers itself (Site 9) are very interested in participation 
but we have reserved them as defaults, because of an intent to diversify beyond two State agencies in the first case, and because of 
conflict of interest and low injury rates in the case of Travelers office workers.  If the pending manufacturing sites decline over the 
next 2 months, we will engage either DOT or Travelers.  
Department of Corrections
The program at the Connecticut DOC is underway at two sites.  There was an extensive selection process which involved 
clearances with all of the unions and the DOC administration.  The MOU includes subsidization of time for participation in the 
study and an a priori commitment from the State for ergonomic related changes.  The selection process involved four elements.
1. A review of worker's compensation, demographic, and facilities based records from all State facilities
2. Repeated site visits to 9 facilities, including meetings with key personnel
3. A management readiness survey was sent to 598 supervisors at 21 facilities, in order to identify most culturally similar 
organizations.  
4. A DOC-wide steering committee was set-up involving central administration, wardens, union representatives and health 
personnel to advise on final selection, implementation and system-wide dissemination. 
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A summary of the two selected sites follows.
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0644 644PROTOCOL:SPID: RESEARCHTYPE:  
AnastrozoleSHORT TITLE:
LONG TITLE: Effect of Anastrozole on Bone Turnover Markers and Bone Mineral Density in Postmenopausal Women 
with Primary Breast Cancer: A Pilot Study
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 20  0  0
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 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/16/2006
 25Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineTAXEL, PAMELA MD
Medicine/Hem-OncTANNENBAUM, SUSAN MD
SUBPROJECT DESCRIPTION:
Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line 
therapy in the treatment of hormone-sensitive breast cancer.  However, because these medications produce a marked reduction 
in serum estrogen levels, this is likely to result in an increased rate of bone loss and risk of developing osteoporosis and fractures 
in postmenopausal women treated with these agents.  Indeed, substantial bone loss has been reported in several large clinical 
trials of AIs.  Osteoporosis drugs are available that could prevent this loss, but they have frequent side effects and are expensive.  
Thus, treating all women receiving AIs might not be the most appropriate and cost-effective approach.  A better approach 
might be to select women at highest risk of bone loss and only treat them with antiresorptive agents. We hypothesize that 
women who demonstrate high bone turnover, as reflected by markers which can be measured in blood and urine samples in the 
first 3 to 6-months on treatment, will have greater bone loss.  
The proposed pilot study will evaluate women who receive anastrozole therapy, are receiving adequate amounts of calcium and 
vitamin D and have baseline normal or moderately low bone mass in order to determine if early changes in bone turnover 
markers correlate with bone loss at one year.  If data from this pilot protocol support our hypothesis, then we would propose a 
larger trial to confirm it.  The ultimate aim is to predict which women are at higher risk of bone loss and therefore treat them 
earlier with bone-sparing agents, while those with lower risk could be monitored on conservative therapy.
SUBPROJECT PROGRESS:
The study has been actively screening women over the past year and we currently have enrolled 10 women during the above time 
frame. There is also 1 woman who is scheduled to start on 6/16/2008.
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SPOONSHORT TITLE:
LONG TITLE: Impact of a Protein Supplement on Bone Mass in Older Women
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Center on AgingKENNY, ANNE MD
INTERNAL MEDICINE YALE UNIVERSITY, CT USAISOGNA, KARL MD
NUTRITION UCONN - STORRS, CT USAKERSTETTER, JANE PHD
RADIOLOGY WOMEN'S IMAGING, CT USAWEIGERT, JEAN MD
SUBPROJECT DESCRIPTION:
Because increasing dietary protein increases urine calcium and metabolic acid load and because systemic acidosis favors bone loss, 
it is thought that higher protein diets increase bone resorption and decrease Bone Mineral Density (BMD).  However, most 
cross-sectional, population-based studies with bone density, or rates of bone loss as the principal outcome, indicate that higher 
dietary protein intakes are associated with higher (not lower) BMD and slower (not faster) rates of bone loss.  Further, 
increasing dietary protein in subjects consuming low-normal protein diets increases circulating levels of IGF-1 which is known to 
be important for bone anabolism. Three recent diet-controlled isotopic calcium studies showed no net loss of calcium from bone 
during high protein diets in humans (1-3).  In 1 of these 3 studies, we (1) showed that a high protein diet increased urinary 
calcium by increasing intestinal calcium absorption.  Importantly, during the high protein diet, there was a significant reduction 
in the fraction of urinary calcium of bone origin and a trend toward a reduction in the rate of bone turnover.  None of the 3 
isotopic studies found evidence for increased bone loss with increasing dietary protein.  In fact, they all suggest the opposite; 
higher protein diets actually improved calcium retention. These isotopic data lay the groundwork for a long-term protein 
intervention trial with BMD as the principal outcome variable.
SUBPROJECT PROGRESS:
The study is underway and recruitment is beginning.  Approximately 47 women have been recruited into the study and 6 women 
have discontinued due to medical illness or not tolerating the inconvenience of taking the protein supplement.  No unexpected 
safety concerns have arisen.  We are considering changes to the inclusion criteria to improve recruitment efforts.  There have been 
no publications from the study.
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Gene BankSHORT TITLE:
LONG TITLE: Behavioral Gene Bank
Inpatient
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PsychiatryDRAZINIC, CAROLYN MD
PsychiatryCOVAULT, JONATHAN MD, PHD
PsychiatryHESSELBROCK, VICTOR PHD
PsychiatryKRANZLER, HENRY MD
Genetics & Develop BiologyLALANDE, MARC MD
SUBPROJECT DESCRIPTION:
The purpose of this registry/repository is collect diagnostic data (psychiatric and medical diagnoses) and tissue specimens from 
subjects and/or family members in order to build a Behavioral Gene Bank (BGB).   The registry/repository aims to study: subjects 
with known or suspected genetic or medical syndromes; families with high concentrations of psychiatric illnesses; and subjects 
with dysmorphic features or other clinical characteristics suggestive of a genetic or chromosomal disorder. Relatives of 
individuals with these features and healthy controls will also participate.  Subjects will be invited to participate in further 
behavioral studies in the future.
SUBPROJECT PROGRESS:
The purpose of this protocol is to establish a Behavioral Gene Bank, in which blood samples from patients with mental illness such 
as bipolar disorder and schizophrenia are collected for genetics research.  This protocol was initially approved by the IRB on 
February 28, 2007 and was then IRB approved for annual continuation on 01/24/2008 (valid through 01/25/2009).  A total of 32 
subjects have been enrolled since July, 2007.  An IRB approved recruitment brochure is posted on the GCRC website for the general 
public in the "current research" section.  There have been no unexpected safety concerns.  There are no publications as of yet.  
Proposed changes made to the protocol have been administrative only with no risk to participants.
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Taste and Colon CancerSHORT TITLE:
LONG TITLE: The Taste and Colon Cancer Collaboration Project
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ALLIED HEALTH SCIENCES UCONN, STORRS, CT USADUFFY, VALERIE PHD
CANCER CENTERCONWAY, JUDITH ARNP
MedicineLEVINE, JOEL MD
ALLIED HEALTH SCIENCES UCONN - STORRS, CT USASULLIVAN, BRIDGET MD
SUBPROJECT DESCRIPTION:
New colon cancer cases in the US have increased 38% from 1950 to 2001, reaching over 106,370 in 2004 (1) and resulting in 
substantial morbidity and mortality.  Colon cancer is an end result of a multiphase process. Aberrant Crypt Foci (ACF) appear 
to be the earliest identifiable neoplastic lesions in the colon (2) through use of magnifying chromoendoscopy.  ACF may be 
detected in humans years before the appearance of neoplasms (2).  Those that are dysplastic are most likely to progress to an 
adenoma (3), which is a pedunculate polypoid structure that grows into the lumen of the colon.  Number of adenomatous polyps 
is considered the precursor of most large-bowel cancers.  The genetics of colon cancer are very heterogeneous (4).  Adenomas 
can occur sporadically or in readily defined high-risk groups, including those with family history of colon cancer or 
premalignant polyps.  Although chemoprevention is being actively investigated (5-7), there is little at the present time to offer 
high-risk patients other than an increased watchfulness for malignant transformation. Strong epidemiologic and experimental 
data suggest that dietary factors play an important role in reducing the risk of colon cancer for genetically predisposed 
individuals (8), with as many as 7 in 10 cancers being preventable through diet and lifestyle changes (9).  Diets that promote 
excess energy intakes, not the source of energy per se (8), and adiposity increase colon cancer risk (10), especially in men (11).  
Risk of colon cancer varies genetically, which may explain why individuals who have the same dietary behaviors, vary in 
colon cancer risk.  Polymorphisms in folate-metabolizing enzymes affect risk of colorectal neoplasia (22) with some genotypes 
deriving more benefit from diets rich in vegetable-related nutrients (23).  Associations between colorectal cancer risk and meat 
consumption patterns and prepartion varies with genetic differences in metabolism of heterocyclic amines, particulary to 
genetic variants in cytochrome p-450 and glutathione S-trasferase activity (24).  Higher intakes of vegetables also appears to 
decrease risk of spontaneous colon tumors, particularly in individuals who have mutations of the adenomatous polyposis colic 
gene (25).
Preliminary data suggests that another genetic variation in colon cancer risk involves genetic variation in taste.  In a sample of 
251 men, those who tasted PROP as more bitter had a higher number of polyps, but only among those who were years of age 
(26).  Those who had polyps were most likely to be overweight/obese and, according to a subset of study sample, those who 
tasted PROP as most bitter reported lowest intake of vegetables.
SUBPROJECT PROGRESS:
There were no subjects enrolled during the report period and since initiation of the study because of staffing changes in the Colon 
Cancer Prevention Center.  We are working to start data collection over the summer and to continue from that point.
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SUBPROJECT DESCRIPTION:
Postmenopausal women are at significantly higher risk for developing osteoporosis and cardiovascular disease. Hormone 
replacement therapy was suggested as a risk lowering, health promoting strategy for these chronic diseases among this high-risk 
female population. However, growing health concerns surrounding the use of hormone replacement therapy have resulted in the 
increased consumption of soy foods as an alternative natural" therapy. Soy contains an abundant mixture of isoflavones, a class 
of flavonoids, which have phyto-estrogenic activities. The growing knowledge in this area has prompted a 15-fold escalation in 
soy food sales to $4 billion dollars annually in comparison to the early 1990's. Despite the continued marketing of soy foods 
and their perceived health promoting benefits for postmenopausal women, there remains a lack of credible evidence that the 
consumption of these products will protect against the development of osteoporosis and/or cardiovascular disease. Moreover, 
the current paradigm regarding soy has shifted such that the intestinal metabolism of soy isoflavones to bioactive metabolites 
may dictate its benefits. Thus, in the absence of more thoroughly understanding the benefits of soy consumption and its 
metabolism in humans, useful dietary recommendations will not be possible. The long-term goal of our research program is to 
develop and evaluate dietary strategies that will
be effective in preventing and/or ameliorating oxidative stress-mediated processes implicated in the pathogenesis of chronic 
disease. The objective of this Donaghue Medical Research Foundation application is to define the mechanisms by which dietary 
soy consumption, as a complementary and alternative medical therapy, can favorably improve inflammatory and metabolic
processes involved in bone and cardiovascular health in postmenopausal women. Our central hypothesis is that the metabolism 
profile of soy isoflavones will dictate an individual's response to specific biomarkers of bone and cardiovascular health. Our 
hypothesis is supported by our preliminary data indicating that 12-mo of daily soy consumption in postmenopausal women
resulted in highly variable within-group responses with respect to bone mineral density and plasma lipoproteins. The lack of a 
uniform metabolic response suggests that other physiological factors, such as the variable metabolism of isoflavones by 
intestinal microflora, could potentially explain why select postmenopausal women had favorable biological responses whereas 
other did not. Our multi-disciplinary team is ideally positioned to undertake this important human health problem. Dr. R. Bruno 
(Principal Investigator) has been actively involved in studying the mechanisms by which phytonutrients contribute to human 
health and has experience in the analytical measurements of flavonoids and antioxidants from biological samples. In addition, 
Drs. J. Kerstetter (Consultant), K Prestwood and A Kenny are authorities in bone health and have already successfully conducted 
the 12-mo soy intervention trial in postmenopausal women from which our hypothesis has been formulated.
SUBPROJECT PROGRESS:
The underlying objectives of this project were to enable our critical understanding of the bioavailability of soy isoflavones on bone 
health and cardiovascular disease and to assess the potential protective effects of equol, a soy isoflavone metabolite, on these 
parameters. Indeed, a considerable body of epidemiological literature suggests a protective effect of soy consumption in 
post-menopausal women which has lead to the hypothesis that soy isoflavones, the purported bioactive constituents of soy, exhibit 
estrogenic effects that protect against bone and cardiovascular disorders. Thus, the scope of this project was to evaluate serum soy 
isoflavones (daidzein and genistein) and a primary isoflavone metabolite (equol) in serum samples archived from a 12-mo 
prospective clinical trial where post-menopausal women (n = 97).  The participants were randomized to daily dietary 
supplementation with A) control protein (20 g/d) + placebo, B) control protein (20 g/d) + 100 mg/d isoflavones, C) soy protein 
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(20 g/d) + placebo, or D) soy protein (20 g/d) + 100 mg/d isoflavones. 
During this reporting period, we did not enroll any additional participants and we did not use the services of the UCHC GCRC.  
Thus, in the absence of any additional participant enrollment, there were no adverse events to report. Also, no procedural changes 
were made to this project from the original submission of this application.  
We successfully developed a high sensitivity HPLC binary gradient separation method coupled with Coularray electrochemical 
detection (Figure 1) to obtain the necessary lower limits (~50 nmol/L) of detection required to assess serum isoflavones (daidzein, 
genistein, and equol) from free living individuals. In brief, serum isoflavone conjugates were hydrolyzed with â-glucuronidase and 
sulfatase, followed by sample protein precipitation with acetonitrile, delipidation with hexane.  Subsequently, isoflavones were 
extracted with with methyl-t-butyl-ether (MTBE), dried under nitrogen gas and then reconstituted in HPLC mobile phase prior to 
HPLC injection.  The procedure has a linear operating range of 0.5-500 pmol injected (R2 > 0.99) for each analyte and the within 
day and between day CV of the assay was <8%.
This method was then utilized to examine serum concentrations of soy isoflavones from our study participants.  Indeed, the use of 
this method enabled our ability to 1) assess compliance of the participants to their respective treatment or placebo, 2) determine 
serum isoflavone plasma responses, and 3) characterize the proportion of the study population who were equol (isoflavone 
metabolite) producers.  
Data analysis for this project is actively underway.  However, we are pleased to report that >95% of participants were compliant to 
the supplementation intervention regimen.  We also established that ~40% of those assigned to the isoflavone supplements were 
equol producers.  This is of particular importance because experimental evidence suggests that equol exhibits greater estrogen 
receptor binding activity than native soy isoflavones.  Thus, we hypothesize that the equol producers in this study will have more 
favorable changes on health outcomes.  Our currently statistical approaches are exploring the relationship of serum isoflavone 
concentrations and equol production with well established biomarkers of bone health, cardiovascular disease, and inflammation.  We 
expect that these analyses will be completed during the next 3-mo and that up to three manuscripts will be submitted for 
publication in peer reviewed scientific journals during fall 2008.
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SUBPROJECT DESCRIPTION:
To examine aspects of the systemic adaptive cellular response to infection with Treponema pallidum in secondary syphilis 
patients.
Specific Objectives:  To determine by intracellular cytokine staining the T. pallidum antigen specificity of circulating T cells in 
secondary syphilis patients.  To determine if circulating T cells in secondary syphilis patients are undergoing apoptosis.  To 
determine if T regulatory cells are increased in the blood of secondary syphilis patients. Adaptive Immunity in Secondary 
Syphilis.  Secondary Objective: To compare the relative yield of T. pallidum genomic DNA (flaATAQMAN) by Real Time 
Quantitative Polymer Chain Reaction (PCR) assay between whole blood, plasma, serum and PBMC samples obtained from 
secondary syphilis patients.
SUBPROJECT PROGRESS:
(A) Specific Aims:  
Specific Aim 1.  To examine aspects of the local and systemic inflammatory response to infection with Treponema pallidum of 
particular relevance to HIV transmission and dissemination. This Aim was divided in two components:  (a) to study the expression 
of HIV co-receptors in dermal inflammatory cells within syphilitic lesions and peripheral blood of patients with secondary syphilis 
and (b) to study the ex vivo effect(s) of T. pallidum on surface expression of HIV co-receptors by T-cells, macrophages and 
dendritic cells and how these changes influence HIV susceptibility and infectiousness.  
Specific Aim 2.  To establish the effect of early syphilis on viral load in patients with HIV co-infection.  As previously agreed upon 
and reported in the previous year's progress report, the second Aim was eliminated. Instead we have significantly expanded Aim 1.
(B) Studies and Results:  
Specific Aim 1.  Part (a):  This component has been completed and the results published in the Journal of Infectious Diseases 
(March 15, 2007).  We demonstrated that dermal lesions from secondary syphilis patients contained a mixture of mononuclear 
cells, including T cells, monocytes/macrophages, and DCs, but no B cells.  Lesional monocytes were larger and more granular and 
expressed high levels of CD14, indicating that these cells had differentiated into macrophages.  Both CD11c+ monocytoid DCs 
(mDCs) and CD11c- plasmacytoid DCs (pDCs) were present in dermal infiltrates and expressed the HIV chemokine co-receptor 
CCR5, which is also associated with leukocyte trafficking into inflamed skin.  Both subsets expressed DC-SIGN, a member of the 
C-type lectin family which is linked with DC-T-Cell interactions and is a key HIV co-receptor.  HLA-DR expression increases in 
mDCs but not pDCs, point to the primary role of this subset has in T. pallidum internalization and antigen presentation.  Dermal 
infiltrates also had substantial numbers of memory and memory effector CD4+ and CD8+ T cells.  Together these findings in skin 
confirmed that innate and adaptive immune responses co-evolve in tissues during active syphilitic infection setting the stage for 
local stimulation of T. pallidum-reactive lymphocytes.  Our study also revealed the extent of immunophenotypic alterations of 
immune cells obtained from peripheral blood.  Firstly, secondary syphilis patients displayed marked immunophenotypic 
modifications in circulating CD4+ T cell subsets, supporting the notion that neosensitized T cells differentiate into memory, 
memory/effector, and effector subsets.  These cells are probably trafficking from lymph nodes to sites of infection (i.e. skin) to 
interact with their cognate treponemal antigens.  Secondly, we showed that over a third of circulating mDCs and pDCs expressed 
the HIV co-receptors, CCR5 and DC-SIGN.  Circulating monocytes, similar to those in the dermis, also had increased CD14 MFI 
levels.  It is our contention that these immunophenotypic changes in circulating monocytes and DCs occur as a result of their 
direct interaction with circulating spirochetes.  Part (b):  For this aim we have first examined the effects of spirochetes on 
monocytes and dendritic cells on PBMCs and isolated monocytes using an ex vivo model.  We have already shown that spirochetes 
up regulate monocyte cell surface expression of the activation markers CD40 and CD83 and secretion of the proinflammatory 
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cytokines, TNFá, IL-6, and IL-1â.  We have also demonstrated that for these events to occur the spirochetes need to be 
internalized and that in the case of T. pallidum internalization is critically dependent on the presence of human syphilitic sera.  
Results from these studies were published in collaboration with Meagan Moore, a talented MD/PhD student in Dr. Radolf's 
laboratory (see Infection and Immunity April, 2007).  These have separate GCRC approval and the report has already been 
submitted by Dr. Radolf.
(C) Significance:  Our published findings provide strong evidence that in the course of secondary syphilis, T. pallidum induces a 
potent innate and adaptive cellular immune response in both skin and peripheral blood.  In accord with our underlying hypothesis, 
while this inflammatory response promotes clearance of the spirochete and may ultimately lead to some degree of resistance; it 
also provides an environment optimal for bidirectional transmission of HIV.  The degree of innate and adaptive immune cell 
activation in peripheral blood also serves as a potential explanation for why individuals co-infected with HIV have demonstrable 
increases in HIV viral load.  Finally, this research has also propelled the city of Cali's public health department to set up a campaign 
to improve diagnosis, treatment and follow-up of venereal syphilis.  In addition, the collaboration has already improved gestational 
syphilis case ascertainment and a subsequent decrease in congenital syphilis cases.
There have been no safety concerns that would warrant changes in the protocol.
All clinical activities and enrollments take place at the study site in Cali, Colombia. However, the database for this study is still in 
development at the GCRC in collaboration with the investigator.
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SUBPROJECT DESCRIPTION:
Periodontal diseases are chronic gram-negative oral infections initiated in the gingiva and leading to alveolar bone destruction 
and gradual loss of tooth supporting connective tissues. Cumulatively, these infections affect more than 70% of the general 
population. Recent evidence indicates that chronic severe periodontal disease is associated with systemically elevated 
inflammatory mediators. Chronic kidney disease (CKD) patients are also characterized by a chronic inflammatory state which 
contributes to an extremely high rate of atherosclerotic complications. Recently, both serum interleukin-6 (IL-6) and 
C-reactive protein (CRP) levels have been found to predict cardiovascular mortality in CKD patients on HD. We hypothesize 
that periodontal infections are highly prevalent in the CKD population and that both periodontal infections and depressive 
symptoms affect the systemic inflammatory status of HD and pre-dialysis CKD patients.
SUBPROJECT PROGRESS:
The overall aim of the study was to compare the periodontal status between the HD and control subjects and explore the 
relationship between hemodialysis, periodontal variables and systemic inflammation. The aim of these studies was also to collect 
preliminary data to support the K23 application and conduct appropriate power analyses. Participants received a complete clinical 
periodontal examination that included clinical attachment loss (CAL), probing depth (PD), plaque score (PS), bleeding on probing 
(BOP) and number of missing teeth. Venous blood was collected prior to clinical evaluation for quantification of serum IL-6 and 
CRP levels. Within 2 hours of blood collection, sera were separated after clotting for 30 minutes at 4oC followed by centrifugation 
at 3000xg for 15 minutes. Sera were analyzed in duplicate by enzyme-linked immunosorbent assay without knowledge of the 
periodontal disease or dialysis status of the participants. The assay analytical sensitivity was 2.0 pg/ml and the variation in IL-6 
protein values within runs was less than 1%. The medical records of the HD patients were reviewed and all relevant information 
was collected using a standardized data extraction form.
So far we recruited 38 subjects. Overall, in the hemodialysis population, the mean age was 55.7 years, 46.2% were females, 33.3% 
were diabetic. When comparing the mean PD values between the two groups, HD subjects had higher, with a trend to significance, 
values than control subjects. Also, patients in the HD group
 showed more sites with BOP (p=0.50) and higher PS (p=0.10), although these were not statistically significant. When comparing 
the serum CRP levels between subjects with periodontitis vs. subjects without periodontitis, we found that the serum CRP levels 
were elevated with a trend to significance (p=0.1) in the subjects with periodontitis. Moreover, the serum IL-6 levels in subjects 
with periodontitis were more elevated compared to the subjects without periodontitis although they didn't reach statistical 
significance (p=0.4).
Although supportive of the hypothesis to be further tested in the proposed work, accurate interpretation of these preliminary data 
is prohibited by the small sample size, which does not permit examination of confounding factors such as diabetes, concurrent 
NSAID use, dialysis vintage or other systemic factors that may influence CRP and IL-6 levels in this population. Therefore, we are 
proposing to conduct a larger scale study to examine the periodontal status of HD and pre-dialysis CKD patients and take into 
account all relevant comorbidities, so that we can accurately assess the influence of periodontal infections in their systemic 
inflammatory status.
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SUBPROJECT DESCRIPTION:
The mechanism of increased bone resorption with estrogen is not fully understood, but there is good evidence for effects on 
osteoclastic precursors of the hematopoietic lineage, and on the osteoblastic cells of mesenchymal lineage that interact with 
hematopoietic cells to produce osteoclasts. Circulating osteoclast precursors have been clearly demonstrated in peripheral blood, 
and there is some evidence for circulating osteoblast precursors as well 2. We have shown that short term estrogen treatment 
can alter the expression of receptor activator of NFligand (RANKL) indicating an effect on the osteoblastic lineage, and the 
response to macrophage colony stimulating factor (MCSF) and RANKL, indicating an effect on hematopoietic lineage. Initial 
aim of this study will be to analyze osteoclastogenesis in peripheral blood before and after estrogen treatment, when MCSF, 
RANKL and other direct stimulators of osteoclastogenesis are added, thus testing the effects on hematopoietic lineage. RANKL 
expression will also be measured, and if changes are observed, then additional studies to isolate and analyze effects of estrogen 
on cells of osteoblastic lineage can be carried out.
SUBPROJECT PROGRESS:
Peripheral blood osteoclastogenesis in being studied in postmenopausal and premenopausal women. We started out with 
postmenopausal women and tested changes in multiple aspects of our protocol (including plating density, Ficoll preparation, type 
of centrifugation, type of culture plate, duration of culture) until we were successful in making large numbers of osteoclasts in vitro. 
A considerable variability was noted in the postmenopausal and in the premenopausal women for reproducibility of these assays, 
although premenopausal women had more robust osteoclastogenesis. 
Currently we are using various methods including flow cytometry and antibody labeled beads to better identify and isolate the CD14 
monocytes that serve as precursors of the osteoclasts to minimize variability in these assays. We think that reproducible 
differences between pre- and postmenopausal women would be useful preliminary data for applying for other grants.
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SUBPROJECT DESCRIPTION:
Otoacoustic emissions (OAEs) are sounds generated by the inner ear and their properties have been used to assess inner ear 
function.  There are a number of ways of eliciting and measuring OAEs, e.g., click-evoked OAEs or distortion product OAEs.   
Both of these techniques are currently in use clinically, however, it is recognized that both have shortcomings (i.e., poor 
frequency specificity in the case of click-evoked and as yet indeterminant site of DPOAE generation thus unclear correlation 
with site of cochlear pathology in the case of DPOAEs). Stimulus frequency otoacoustic emissions (SFOAEs) offer the most 
frequency specific method of assessing function along the cochlear partition.  Up to now measurement of SFOAEs has been too 
time consuming to allow use in clinical applications.  We have developed a rapid method for recording stimulus frequency 
otoacoustic emissions (SFOAEs).  Here we propose to develop this technique into a useful clinical tool with potential to replace 
CEOAES and DPOAEs, and obtain normative data and preliminary results from hearing impaired listeners.
SUBPROJECT PROGRESS:
We tested 8 subjects this year.  All subjects underwent audiometric evaluation and fulfilled inclusion criteria.  Additionally, all were 
tested using the novel stimulus frequency otoacoustic emissions.  No safety concerns were encountered.  The preliminary results 
demonstrating our technical capability was presented at the annual meeting of the Association for Research in Otolaryngology in 
February 2008.  Since February 2008 we have not collected any further data because of increased clinical demand on the Principal 
Investigator (PI).  Currently, data collection and analysis are on hold pending IRB continuation.  If our data analysis suggests we 
have gathered sufficient results from normal hearing ears to establish a baseline for our measures, we may propose to test some 
hearing impaired subjects to assess sensitivity and specificity of our novel method as a diagnostic tool.  We will, of course, apply 
for IRB modification and GCRC approval prior to proceeding.  We are not likely to take these steps until late July 2008 when the 
clinical load on the PI is expected to decrease.
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SUBPROJECT DESCRIPTION:
Excess body fat (i.e., adiposity) has been implicated as a primary risk factor for colorectal cancer (CRC), but the precise 
physiological mechanisms underlying this relationship remain largely unknown. Adiposity frequently triggers the insulin 
resistance syndrome, a hallmark of which is a dysregulated Insulin-like Growth Factor (IGF) system. IGFs are potent mitogens 
that play a pivotal role in cellular renewal and apoptosis. A growing body of pre-clinical and epidemiologic evidence links 
various IGF abnormalities with CRC risk. A few epidemiologic studies have examined the association between circulating IGF 
abnormalities and colonic polyps, yet this relationship has not been fully explored. The specific aims of the proposed study 
aims are to examine features of polyps (number, size, histology) in relation to: 1) Circulating markers of insulin resistance (i.e., 
fasting levels of: IGF-1, IGF-2, IGF binding protein 3, insulin and glucose; and, 2) Circulating proinflammatory cytokines (CRP, 
tumor necrosis factor-alpha.) We will examine these relationships in a sample of 80 non-diabetic patients receiving 
colonoscopy at UCHC. Should the impact of biochemical abnormalities related to insulin resistance be observed in early colonic 
lesions, it would offer new insights into CRC etiology and strengthen the evidence base about CRC prevention related to excess 
body fat.
SUBPROJECT PROGRESS:
A project initiation was held, and an Institutional Review Board (IRB) application was submitted but the study was closed out in 
early 2008 due to delays in starting patient recruitment as a result of a medical leave by the study gastroenterologist as well as 
other staffing gaps.  Subsequently, the project was subsumed into GCRC # 674 (Swede, PI) due to common research aims.
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SUBPROJECT DESCRIPTION:
Our group has been investigating associations between history of depression and mental stress on the one hand, and endothelial 
function on the other hand, in postmenopausal women. To date we have found that relative to their never depressed 
counterparts, women with a history of depression show impaired resting endothelial function. The association between history 
of depression and resting endothelial dysfunction is especially strong in women with type 2 diabetes. Preliminary data from our 
group also suggest that women with a history of depression may show more endothelial dysfunction in response to an acute 
stressor than their never depressed counterparts.  Our group is now interested in testing interventions to improve resting 
endothelial function, and endothelial stress reactivity, in women at risk for endothelial dysfunction. Expressive writing 
interventions have shown benefits for a variety of health and mental health outcomes in healthy, medical, and psychiatric 
samples. This pilot and feasibility study will explore the effects of an expressive writing intervention on endothelial function in 
women with diabetes. Twenty women will participate, who will be recruited as part of GCRC study #453. History of depression 
and current depressive symptoms will be assessed at baseline. Resting endothelial function and endothelial stress reactivity will be 
assessed at baseline using brachial artery flow-mediated dilation (FMD). Participants will then be randomized to either an 
expressive writing condition, or a control writing condition. Women in the expressive writing condition will write about the 
facts and emotions related to a personal trauma or upsetting event. Women in the control writing condition will write about 
assigned topics devoid of emotional content (e.g., fashion, daily tasks, shopping lists). All participants will complete 
twice-weekly writing sessions for 4 weeks. Participants writing exercises will be mailed to the investigator so that the postmark 
can verify compliance with the writing schedule. One month after the last writing exercise, participants will return for follow-up 
resting FMD and FMD stress reactivity assessments. We hypothesize that relative to the women in the control writing 
condition, women in the expressive writing condition will show improvement in resting FMD and FMD stress reactivity. We 
further hypothesize that depression history will modify the effect of the intervention such that women with a history of 
depression will benefit more from the intervention than their never depressed counterparts. We recognize that we will be 
underpowered to detect significance; the goal of this pilot is to detect trends in the hypothesized directions. The specific aims 
are to: 1) estimate an effect size to be used in a power analysis for a subsequent external grant proposal; 2) address the 
acceptability of the protocol for this population; 3) gather participant feedback to be used to modify the intervention for future 
proposals.
SUBPROJECT PROGRESS:
From 4/1/2007 until 3/31/2008 (and since initiation of the study), 3 women enrolled. One withdrew from the study citing time 
commitments, one is currently participating, and one has completed.  No modifications were made to this pilot study.  There were 
no expected safety concerns for this study.  The study began enrolling in February of 2008, and there are no publications at this 
time.
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Offsite Visits  0  0  0
AIDS: N
START DATE: 4/19/2007
 12Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineMUKHERJI, BIJAY MD
ImmunologyCLARK, ROBERT MD
Infectious DiseaseDORSKY, DAVID MD
SUBPROJECT DESCRIPTION:
This project is designed to examine the molecular mechanism underlying suicidal death in tumor antigen specific cytolytic T 
lumphocytes (CTL) when they re-encounter antigen and to examine how such deaths in the CTL can be prevented so as to 
orchestrate a robust and long-lived CTL response during cancer immunotherapy.  The studies will be done in ex-vivo laboratory 
experiments and in animals bearing grafts of human melanoma cells.
SUBPROJECT PROGRESS:
Number of subjects entered - 15 
There has been no change in the recruitment plan
There has been no unexpected safety concern
Experiments and Data analysis are continuing
No change in the protocol
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0659 659PROTOCOL:SPID: RESEARCHTYPE:  
HIV on Hepatitis CSHORT TITLE:
LONG TITLE: Impact of HIV on Hepatitis C Infection in Hemophilia
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 1  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: Y
START DATE: 4/19/2007
 9Total # pts expected for entire study:
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NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Medicine/Hem-OncBONA, ROBERT MD
SUBPROJECT DESCRIPTION:
This study is being done at hemophilia centers throughout the United States. The purpose of this study is to collect medical 
information, blood samples and liver tissue samples from study subjects with hemophilia and hepatitis C (HCV). The major aim 
of the study is to find how frequently individuals with hemophilia develop cirrhosis (liver scarring) from chronic hepatitis C 
infection, and whether co-infection with human immunodeficiency virus (HIV) may worsen liver disease outcome due to their 
hepatitis C.
SUBPROJECT PROGRESS:
One subject was enrolled into this study during the reporting period and since initiation of the study. There are no recruitment 
plans as the study has been closed. The IRB closed this study effective as of 11/26/07. Our study subject did not experience any 
adverse events during the time of his study participation. The study site has not given us any interim data or outcomes for this 
study.
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0660 660PROTOCOL:SPID: RESEARCHTYPE:  
Effects of TabaccoSHORT TITLE:
LONG TITLE: The Effects of Tobacco on Brain Structure and Function are Amplified by Genotype
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 19  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/17/2007
 100Total # pts expected for entire study:
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NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryBAUER, LANCE PHD
PsychiatryCOVAULT, JONATHAN MD, PHD
PSYCHIATRY INSTITUTE OF LIVING, CT USAPEARLSON, GODFREY MD
SUBPROJECT DESCRIPTION:
Red peppers (Capsicum frutescens) have been used for several thousand years as food additives and for a broad variety of medical 
applications in Indian, Native American, African and Chinese medical traditions. CP is the pungent component of red peppers. 
Chemically, it is a derivative of vanillyl amide, 8-methyl-N-vanillyl-6-noneamide and has a molecular weight of 305.42. The 
receptor for CP is vanilloid receptor 1 (VR1). VR1 has been shown to be highly expressed in nociceptive neurons of dorsal root 
and trigeminal ganglia. CP binds to VR1 on sensory neurons to convey the sensation of pain. Apart from its neurological 
functions CP has also been shown 
to be active immunologically, in generating more antibody-producing cells compared to untreated controls. Dietary CP in 
BALB/c mice has been shown to enhance lymphocyte proliferation and serum immunoglobulin levels. Inhalation of CP
has been shown to interfere with neural responses involved in inflammation in the lungs of Lewis rats and such interference 
modulates immunity to inhaled antigens. We and others have observed that mouse and human dendritic cells (DCs), a key cell 
type in immune responses, have the receptor for CP, and engagement of this receptor has powerful immune consequences. Our 
recent data suggest that intra-lesional administration of CP into a preexisting murine tumor results in retarded progression of 
the injected tumor regardless of whether the tumor is at its early or late stage. Further, it leads to significant inhibition of 
growth of other, un-injected tumors in the same animal. We have shown that only tumor cells but not normal cells undergo 
apoptosis in response to CP but CP elicited anti-tumor immunity is T cell mediated and tumor-specific.
CP has been used previously in clinical studies. Intradermal and topical application of CP has been used to study mechanisms of 
allodynia and hyperalgesia and the efficacy of drugs in relieving the symptoms. The dose of CP varied
from 20 to 250ƒn£gg. Pain intensity and vital signs were monitored after CP administration. We have used intra lesional CP in 
mouse tumor model with MTD at a dose of 200 £gg. The common toxicity noticed was scar at the injection site. Based upon 
our observations in the laboratory, we have hypothesized intra lesional use of CP in patients with melanoma may have 
immunological relevance in this disease.
SUBPROJECT PROGRESS:
The general goal of the activity is to provide data regarding structural and functional brain abnormalities in middle-aged adults at 
increased genetic and environmental risk for cerebrovascular disease.  The activity is a clinical research project to be completed 
within a one year period.  The list of objectives includes the recruitment of 100 adults varying in risk as defined by the presence 
versus absence of a history of heavy tobacco use.  Each of these groups will be further stratified by ApoE-e4, Factor XIII 
Val34Leu, and Paraoxonase-1 Gln192Arg genotypes in separate analyses.  High resolution structural magnetic resonance images 
will be collected of the whole brain.  In addition, evoked electroencephalographic responses and cognitive test performance will be 
recorded to determine whether the MRI abnormalities are physiologically significant.  The primary analyses will examine the 
independent and interactive effects of smoking and genotype."
As of this date (with 4 quarters of funding remaining), we have enrolled and tested 24 study participants.   With the initial delays 
associated with hiring study personnel and receiving approvals from 3 separate IRB/human subjects committees (at Universtiy of 
Connecticut Health Center (UCHC), Institute of Living/Hartford Hospital (IOL/HH), and the Connecticut Department of Public 
Health (CT DPH)) now passed, we foresee no barriers in meeting future enrollment targets.  We are recruiting participants from 
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multiple sources.  Of course, at this early stage of data collection, we have no findings to report.
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0661 661PROTOCOL:SPID: RESEARCHTYPE:  
FMSclerostinSHORT TITLE:
LONG TITLE: Comparison of Serum Levels of Sclerostin in Premenopausal and Postmenopausal Women
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 30  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 5/17/2007
 40Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
YN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineMIRZA, FARYAL MD
SUBPROJECT DESCRIPTION:
Osteocytes inhibit bone formation by secreting sclerostin, a peptide which is a product of the SOST gene and a negative 
regulator of osteoblasts (1, 2). Once secreted, sclerostin is transported to the osteoblasts on the bone surface, where it regulates 
their function. Sclerostin has been shown to inhibit osteoblast development in vitro by inhibiting proliferation, as well as early 
and late stages of osteoblast differentiation, in both mouse and human osteogenic cells. Sclerostin also stimulates osteoblast 
apoptosis (3). In sclerosteosis, the inhibitory effect of sclerostin is absent due to mutations in the SOST gene, which results in 
an increase in bone mass as a result of increased bone formation.
SUBPROJECT PROGRESS:
Number of premenopausal women enrolled during report period is 9.
Number of premenopausal women enrolled since beginning of study is 12, of those 3 are presently active. There are 2 more 
scheduled to start in May of 08. 
Number of postmenopausal women enrolled since beginning of the study is 25. Of those 3 were found to be not eligible, 2 were lost 
to follow-up. 20 completed the study.
We are doing well with recruitment. 25 postmenopausal women have been recruited for the study, of which 20 completed the 
study. 12 premenopausal women have been enrolled in the study so far and we anticipate that we may complete enrollment by the 
end of June, 2008.
No safety concerns have been reported to date. There are no publications as yet.
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0662 662PROTOCOL:SPID: RESEARCHTYPE:  
Pharmacogenetics of WarfarinSHORT TITLE:
LONG TITLE: Pharmacogenetic Testing for Warfarin Therapy
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 143  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 6/21/2007
 150Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
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NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Genetics & Dev. BiologyFANG, MIN MD, PHD
Medicine/Hem-OncBONA, ROBERT MD
SUBPROJECT DESCRIPTION:
Pharmacogenetics is a new and rapidly evolving discipline.  The goal is to enhance efficacy and safety by applying genetic 
information to clinical administration of medications. Warfarin, an anticoagulant, is one of the most common prescription 
medications worldwide.  As much as it is a life-saver, warfarin can also pose high risk of morbidity and mortality.  Major 
bleeding episodes happen in ~7% of patients.  Current dosing algorithms do not account for genetic factors.  Recent studies have 
shown strong evidence that individuals with certain genetic variants require lower doses.  The Federal Drug Administration 
(FDA) has proposed drug label changes for warfarin.  And the National Academy of Clinical Biochemistry (NACB) has drafted 
guidelines and recommendations for pharmacogenetic testing in general.  Currently, the Department of Health & Human 
Services (HHS) posted a draft report of the Secretarys Advisory Committee on Genetics, Health, and Society for public 
comments until June 1, 2007.  This report recommended that the FDA work with professionals to develop dosing guidelines, 
encourage clinical trials exploring the relationships between diagnostics and drug response, and to translate the findings from 
prospective studies into treatment guidelines. We have successfully employed the Invader technology to develop a genotyping 
assay for patients under warfarin treatment.  To determine the clinical performance characteristics of this test, we propose this 
protocol to retrospectively genotype patients under warfarin therapy.  New algorithms of warfarin dosing determination will be 
evaluated. This study will pave the way for clinical implementation of randomized prospective clinical research on warfarin 
dosing accuracy, cost effectiveness, and patient burden reduction.
SUBPROJECT PROGRESS:
   - Number of subjects enrolling during the report period and since initiation of the study: 150
   - Any changes in recruitment plans that might be needed : No
   - Unexpected safety concerns and their resolution :  No
   - Interim data and outcomes if appropriate:  We found that pharmacogenetics information is helpful for warfarin dose prediction.  
However, the published algorithm from the UK group needs minor adjustment when applied to our population, especially regarding 
the parameter of height.  Data analysis is underway.
   - Any proposed changes made or anticipated in the protocol:  No.
   - Publications: manuscript in preparation.  Will cite GCRC funding number
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0663 663PROTOCOL:SPID: RESEARCHTYPE:  
Bone HealthSHORT TITLE:
LONG TITLE: Bone Health in Women with Breast Cancer on Aromatase Inhibitors
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 6/21/2007
 55Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NY CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
MedicineTAXEL, PAMELA MD
MedicineMIRZA, FARYAL MD
SUBPROJECT DESCRIPTION:
Aromatase Inhibitors (AIs) are a class of compounds that inhibit the synthesis of estrogens from androgens by blocking the 
Cytochrome P-450 Enzyme Aromatase which catalyzes the conversion of androgens to estrogens in the peripheral tissue 
(adipose tissue, bone, vascular endothelium, brain and breast tumors). They will effectively reduce the amount of circulating 
estrogens and therefore play a powerful role in treatment of estrogen and progesterone- receptor sensitive breast cancer 
patients. Because they cause a marked reduction in serum estrogen level, women treated with such agents are at an increased risk 
of developing osteoporosis and bone fractures, as many clinical trials have reported. In the Bone Health Service of the Cancer 
Center at University of Connecticut Health Center, we have been evaluating women who will receive AI's for breast cancer. In 
preparation for a randomized controlled trial, we propose to evaluate parameters of bone health in this population.
SUBPROJECT PROGRESS:
This project is currently completing data entry and analysis with the assistance of the General Clinical Research Center (GCRC) 
statistician.
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0664 664PROTOCOL:SPID: RESEARCHTYPE:  
3RSSHORT TITLE:
LONG TITLE: Behavioral and Physiological Responses to Race-Related Stress in Diabetic Women
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 13  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 9/20/2007
 80Total # pts expected for entire study:
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NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
Behavioral Sci & Comm HlthWAGNER, JULIE PHD
SUBPROJECT DESCRIPTION:
The broad goal of this project is to establish evidence that race-related stress is associated with physiological and behavioral 
processes that may contribute to the disproportionate rates of diabetes complications among African American women.  We 
propose studying the effects of racial stress on blood pressure, glycemia, insulin sensitivity, and diabetes self-care  important 
factors which underlie most, if not all, complications.  We propose investigating experimentally induced racial stress and 
day-to-day, self-reported racial stress.
SUBPROJECT PROGRESS:
During this period, equipment was ordered and staff was trained to administer the components of this study.  Enrollment for the 
study began in February, 2008.  From initiation to 3/31/2008, 5 women enrolled and completed the study.  An additional 30 
participants have been screened and scheduled for enrollment after 4/1/2008.  Several modifications to the project approved by 
IRB this year include:
There are no unexpected safety concerns. There are no publications at this time.
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0665 665PROTOCOL:SPID: RESEARCHTYPE:  
Topiramate TreatmentSHORT TITLE:
LONG TITLE: Topiramate Treatment of Problem Drinkers
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 10/23/2007
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PsychiatryKRANZLER, HENRY MD
PACE UNIVERSITY, NY USAARMELI, STEPHEN PHD
MedicineONCKEN, CHERYL MD
Community MedicineTENNEN, HOWARD PHD
SUBPROJECT DESCRIPTION:
The proposed study is a 12-week trial comparing topiramate (TOP), at a dosage of 200 mg/day, with an inactive placebo.  We 
will randomly assign 160 problem drinkers (i.e., heavy drinkers without evidence of physical dependence on alcohol) who want 
to reduce their drinking.  It is estimated that 30% of the general population are problem drinkers (NIAAA 2007).  Despite its 
high prevalence, problem drinkers are understudied, particularly with respect to medications that may help them to reduce their 
drinking to safe levels.  The study will extend to this patient population findings from a trial of TOP, which showed the drug to 
be well tolerated and efficacious in moderately-severe alcohol-dependent patients (Johnson et al. 2003).  The aims of the 
present study are to examine: 1) TOPs safety and efficacy in reducing drinking and heavy drinking, 2) the relations among 
medication, daily mood, expectancies, and drinking behavior, and 3) the durability of TOP's effects during a six-month 
post-treatment follow-up period.  A fourth, exploratory aim, is to estimate the effect size of variation in genes encoding GABA 
and glutamate receptors as moderators of both the therapeutic and adverse effects of TOP.  A fifth aim is to to examine allelic 
and haplotypic association to alcohol use disorders and related behavioral and psychiatric phenotypes by examining variants in 
genes that have been implicated in the pathophysiology or risk of these behaviors or disorders.  The study will use interactive 
voice response technology to collect daily measures of drinking, mood, and medication usage.  Biological measures of alcohol 
consumption (i.e., GGTP and CDT) will be used to validate self-reports.  Hierarchical linear modeling will be used to examine 
effects at the between-person and within-person levels of analysis.  Careful evaluation of the study's hypotheses will provide 
important information on the efficacy and mechanism of effects of TOP as a treatment for problem drinkers.
SUBPROJECT PROGRESS:
Subject enrollment began in March 2008.  A total of 3 subjects were enrolled during the report period (a total of 3 since initiation 
of the study).  No changes in recruitment plans are needed at this time.  There have been no unexpected safety concerns associated 
with this study.  Interim data are not available since data collection is ongoing.  This study uses interactive voice response 
technology (IVR) for daily data collection, with support from the General Clinical Research Center (GCRC). Since this study was 
originally approved we made the following changes in the protocol (all changes IRB-approved): 1) the Medical Management 
counseling session manual was finalized and underwent IRB review (including a new subject handout used during the counseling 
sessions: Quick Reference Medication Grid); 2) the Research and Development (RAND) 36-Item Health Survey replaced the Short 
Form (SF)-36 in the battery of study questionnaires; 3) the up-titration medication schedule was modified to state (where 
applicable) that instead of two 25 mg capsules, one 50mg capsule will be used.  This will help reduce medication costs, and use of a 
50 mg dosage in this manner has been well tolerated in other clinical trials of topiramate; 4) we updated the description of the 
counseling session monitoring and feedback plan; 5) we added information to the protocol regarding topiramate's potential effects 
on hormonal birth control (i.e., that topiramate may make some types of hormonal contraceptive methods less effective; and, 
that women should report any changes in their bleeding patterns to the study clinician); 6) we added a statement to the consent 
form asking participants to allow us to audiotape the counseling sessions and we added information regarding topiramate's potential 
effects on hormonal birth control; 7) As per UConn Health Center (UCHC) Institutional Review Board (IRB) guidance, the HIPAA 
Authorization was revised with the new UCHC template; 8) the IVR Script and Wallet Card were modified to update language 
describing the collection of drinking, smoking, and medication data.; 8) addition of a co-investigator (Carolyn Drazinic); 9) edits to 
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IVR script (during preliminary testing of the IVR telephone script, we found some areas of the script needing small edits in order to 
improve the flow of questioning.  The content of the information being collected has not changed and no new questions were added 
to what was previously IRB-approved.  Due to the edits we made to the script, the following subject handouts and forms were 
modified so that they are consistent with the IVR script to be used during the conduct of the study: IVR Follow-Along Sheet IVR 
Wallet Card, and IVR Information Form); 10) We updated some study questionnaires to add the visit number to the heading (in 
order to facilitate data entry) and study documents used with the Pharmacy to add the study abbreviation ("Top/Alc"), which will 
help identify the study for Pharmacy staff; 11)  we modified the parameters to be used to randomize subjects into groups for 
assignment to placebo vs. topiramate: we removed the variable "drinking days" and added the variables "drinks per drinking day" 
and "number of DSM-IV alcohol dependence symptoms".  The variable "heavy drinking days" was changed to "percent heavy 
drinking days".  All data were already being collected under IRB-approved protocol, so no changes are necessary to the information 
being collected from subjects.  We updated the protocol and URN form to reflect these changes.
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0666 666PROTOCOL:SPID: RESEARCHTYPE:  
Radiation-induced MucositisSHORT TITLE:
LONG TITLE: Anti-Inflammatory Intervention in Radiation-induced Oral Mucositis
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/15/2007
 9Total # pts expected for entire study:
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COUNTRYDEPARTMENTINVESTIGATOR
Oral DiagnosisLALLA, RAJESH BDS, PHD
Oral DiagnosticsPETERSON, DOUGLAS DMD, PHD
SUBPROJECT DESCRIPTION:
Head and neck cancer accounts for 5 to 40% of all malignancies, depending on geographical location in the world. Most head 
and neck cancer patients are treated with radiation therapy (RT) in combination with surgery and/or chemotherapy. Almost 
100% of patients treated for head and neck cancer, with radiation therapy to fields involving the oral cavity, develop 
erythematous, erosive and ulcerative lesions of the oral mucosa referred to as oral mucositis. These lesions are extremely 
painful, compromise nutrition and quality of life and may necessitate interruptions in RT, thus adversely affecting cancer 
therapy outcomes 1, 2. Thus, the literature defines oral mucositis as the major dose-limiting toxicity of RT to the head and 
neck region. Significant evidence implicates inflammatory responses to RT in the pathogenesis of oral mucositis 3. Evidence 
available to date supports the investigation of anti-inflammatory agents in this condition. More specifically, evidence supports 
the testing of a corticosteroid mouthrinse to reduce the severity of radiation-induced oral mucositis. However, with the 
exception of one small uncontrolled study 4 which indicated impressive efficacy, topical corticosteroids have not been formally 
evaluated for this condition. This constitutes an important gap in knowledge because oral mucositis is the single most 
debilitating complication of radiation therapy for head and neck cancer. Our long-term goal is to identify effective therapeutic 
interventions to reduce mucosal injury and pain in radiation-induced oral mucositis. The objective of this application is to 
conduct a Phase I study that will provide information necessary to design an extramurally-funded, randomized, 
placebo-controlled trial testing the effects of a topical corticosteroid mouthrinse on radiation-induced oral mucositis.
SUBPROJECT PROGRESS:
This study received initial IRB approval on 01/22/2008.  There were no subjects enrolled on this study for the period 4/1/07- 
3/31/08.  There are no changes in recruitment plans for this study.  
There have been no unexpected safety concerns identified since the initiation of this study. There has been no data collected 
through 3/31/08.
There are no planned modifications to the protocol at this time.
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0667 667PROTOCOL:SPID: RESEARCHTYPE:  
AlbuterolSHORT TITLE:
LONG TITLE: Genetic Influences of Albuterol Responsiveness in Children with Bronchiolitis
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 11/21/2007
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PEDIATRICS CONNECTICUT CHILDREN'S MEDICAL, 
CT USA
CARROLL, CHRISTOPHER MD
SUBPROJECT DESCRIPTION:
Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 
hospitalizations per year in the U.S.  Of these hospitalized children, 8% will require ICU admission and 67% of these children 
will require mechanical ventilation.  Mortality in previously healthy children is generally low, however, in children with 
high-risk medical conditions such as prematurity or congenital heart disease, mortality can be as high as 3%.  In addition, 
bronchiolitis infections are associated with long term respiratory problems including development of recurrent wheezing, airway 
hyper-reactivity, and asthma.  Despite four decades of clinical trials, there are no therapies demonstrated to be effective in 
shortening either hospitalization or length of intensive care stay in children with bronchiolitis.  Treatment for this disease is 
largely supportive.  Current controversies involve the utility of bronchodilators, steroids, antiviral therapies, and 
immunoprophylaxis.  Other attempted therapies include nebulized hypertonic saline, atrovent, nebulized deoxyribonuclease I 
(pulmozyme), and inhaled nitric oxide.  Although a mixture of these therapies are used in children with bronchiolitis based on 
individual provider preference, none have been definitively shown to improve outcomes in children with bronchiolitis.  
Recently, investigators have shown that genetic factors have important influences on a patientresponsiveness to ¥â2-adrenergic 
receptor (¥â2-AR) agonists (such as albuterol).  A single nucleotide polymorphism (SNP) at amino acid position 16 of the 
©¬2-AR gene is the most common polymorphism and has been shown to be the most functionally relevant.  A change at base 
46 from adenine to guanine results in the amino acid sequence of the ©¬2-AR containing a glycine (Gly), rather than an 
arginine (Arg), at amino acid position 16.  Patients homozygous for Gly at this position (Gly/Gly) have been shown to have 
improved responsivness to ©¬2-AR agonist therapy when compared to children homozygous for Arginine (Arg/Arg) or 
heterozygous (Arg/Gly).  Previous work has shown that bronchodilator responses in bronchiolitis range from marked 
improvement to actual deterioration of lung function.  One reason for the inconsistency of these findings is the lack of 
sufficiently sensitive methods for evaluation of lung function in infants.  In addition, grouped mean responses can fail to show 
individual variation in responsiveness.  For example, a recent study demonstrated that post-albuterol bronchodilator 
measurements did not differ significantly from baseline measurements in an entire group of infants aged 2-18 months with 
bronchiolitis; however, 11 of the 41 patients (27%) showed significant increases in lung function following inhalation of 200 
mcg albuterol via metered dose inhaler.  We believe that genetic factors influence responsiveness to albuterol therapy in 
children with bronchiolitis.  Specifically, we believe that ¥â2-AR polymorphisms at amino acid position 16 affect 
responsiveness to acute ¥â2-AR agonist therapy in children with bronchiolitis.  In support of this concept, Moore et al recently 
demonstrated that RSV infection did not influence isoproterenol-induced cAMP formation in tracheal smooth muscle cells 
obtained from 2 donors homozygous for the Gly16 haplotype, but it significantly decreased isoproterenol-induced cAMP 
formation in cells from 2 individuals homozygous for the Arg16 haplotype.  Thus, our hypothesis is that: children with 
bronchiolitis who are homozygous for glycine at amino acid position 16 (Gly/Gly) will have improved responses to albuterol 
therapy.  We propose to investigate this research question in a prospective observational trial.  Children admitted to the ICU 
with bronchiolitis, who are intubated and mechanically ventilated with a cuffed endotracheal tube and who are receiving albuterol 
will be included.  Measurement of pulmonary function will be recorded before and after the albuterol from values routinely 
determined by the Servo-I ventilator in use in the Pediatric ICU at CCMC.  Genotyping of the ©¬2-AR gene will be performed 
at the General Clinical Research Center at the University of Connecticut Health Center.  Genotyping will be performed from 
whole blood that is added onto routine blood sampling.  Children will be stratified based on their genotype and outcomes 
compared.  Providers will be blinded to genotype at the time of treatment.
6/27/2008   9:32:04AM 208
REPORT PD:  04/01/2007-03/31/20085M01RR006192-14 Final
SUBPROJECT PROGRESS:
Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 
hospitalizations per year in the U.S.  Recently, genetic variations of the â2-adrenergic receptor (â2-AR) have been shown to 
influence responsiveness to â2-AR agonist therapy in children with asthma.  We suspect that genetic variations of the â2-AR also 
affect response to â2-AR agonist therapy in children with bronchiolitis.  Our hypothesis is that mechanically ventilated children 
with bronchiolitis who are homozygous for glycine at amino acid position 16 (Gly/Gly) will have improved pulmonary resistance 
following â2-AR agonist therapy than children who are homozygous for arginine or heterozygous at amino acid position 16.  
This project was approved on December 3, 2007 and began enrollement in December 15, 2007.  Since that time, we have enrolled 
15 of a planned 50 children in this trial.  Genotyping of the ß2-AR gene was performed by the core laboratory of the GCRC.  The 
core laboratory was able to genotype all samples provided.  However, due to the small numbers of patients enrolled, interim 
data/statistical analysis has not been performed at this time.
There have been no safety concerns with this study.  Nor are there any proposed changes or anticipated changes in the protocol or 
in the recruitment plans.  There have been no publications or abstracts submitted for this study.
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Smoking in Substance AbusersSHORT TITLE:
LONG TITLE: Contingency Management in Substance Abusers
Inpatient
Scatter Bed
Outpatient
Scatter RN Hours
TOTALS A B D
 0  0  0
 0  0  0
 0  0  0
 0  0  0
Offsite Visits  0  0  0
AIDS: N
START DATE: 12/20/2007
 120Total # pts expected for entire study:
NN MULTICENTER STUDYRESEARCH BIONUTRITION
NY CLINICAL TRIALINFORMATICS CORE
NN CORE LABBIOSTATISTICIAN
NANCILLARIES ONLY
NON-HOST INSTITUTION: STATE, 
COUNTRYDEPARTMENTINVESTIGATOR
PsychiatryALESSI, SHEILA PHD
SUBPROJECT DESCRIPTION:
Cigarette smoking, the most common source of preventable morbidity and mortality in the United States, is more prevalent and 
has more serious adverse health consequences in substance abusers compared to the general population. Contingency 
management (CM), in which tangible incentives are provided contingent on a target behavior like abstinence, is highly 
efficacious in improving substance abuse treatment outcomes and may be a useful smoking cessation tool in this difficult 
population. We have preliminary data suggesting the efficacy of CM for smoking abstinence. In this application, we propose a 
larger study to more rigorously evaluate a prize-based CM procedure for initiating smoking abstinence in residential substance 
abuse treatment patients who want to quit smoking. Patients (N=102) who meet diagnostic criteria for alcohol, cocaine, 
marijuana, or opiate abuse or dependence will meet with research staff on two days for quit preparation sessions (2 per day). 
These sessions include testing a breath sample for evidence of smoking twice each day (separated by at least 5 hours), counseling 
based on Public Health Service (PHS) guidelines for quitting smoking during the second session each day, and setting a quit date. 
After these sessions, participants will be randomly assigned to: (a) standard care or (b) standard care plus prize CM for smoking 
abstinence with the opportunity to win prizes ($1-$100 in value) for submitting samples that meet smoking abstinence criteria 
(e.g., CO ¡Ü 6ppm; cotinine ¡Ü 30ng/mL). Nicotine withdrawal, urges to smoke, depressive symptoms, and other (non-nicotine) 
substance use will be assessed weekly. In addition, self-efficacy, motivation to change, substance use, psychosocial problems, and 
depressive symptoms will be assessed at intake and 1, 2, 3 and 6 months following the quit date. Primary outcomes will be 
smoking abstinence based on CO and cotinine test results. Mediation effects of self-efficacy and motivation to change on 
outcomes will be tested. Participant characteristics that may be associated with improved outcomes within and across conditions 
will also be assessed. It is hypothesized that smoking abstinence rates will be higher in the CM condition compared to the 
standard care condition.
SUBPROJECT PROGRESS:
Total Enrollment: 0
Past Year Enrollment: 0 
No changes in recruitment plans are needed.
No unexpected safety concerns have occurred.
Interim data and outcomes are not available.
Changes to protocol: 1) Added the following sentence to the Informed Consent Form (ICF), "You will receive a $1 gift certificate 
each time samples are submitted at Quit Preparations sessions and study sessions during weeks 1-4 for a total of up to $44" as 
stated in the Compensation section (page 5) in order to introduce the concept earlier in the document. 2) Revised the order of the 
sentence on page 3, first paragraph of the ICF under Treatment B to enhance comprehension. 3) Deleted the mention of 
McDonald's gift certificates in the ICF as McDonald's $1 gift certificates may not be available for our purchase in the near future. 
4) Clarified on page 9 of the protocol that the Mini-Mental State Exam is administered at intake as deemed necessary by the 
research assistant. 5) Revised the Patient Information Form, by removing questions related to cigarette smoking. The Patient 
Information Form will continue to be administered at baseline only. The cigarette smoking questions have been incorporated into a 
more extensive questionnaire called the Cigarette Smoking History Questionnaire that we administer at baseline and each follow-up 
interview. 6) Revised the Addiction Severity Index (ASI) adding questions regarding HIV status and previous/current treatment 
history questions. 7) Clarified in the protocol that questions related to gender, ethnicity and other demographic information is 
incorporated into the ASI. 8) Replaced the Beck Depression Inventory-II (BDI-II) with the Center for Epidemiological Studies- 
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Depressed Mood scale. 9) Added the Ways of Coping Checklist-Revised
Results not yet published as study is ongoing. 
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through March 31, 2009?  Yes
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SUBPROJECT DESCRIPTION:
Thirty percent of female smokers are postmenopausal, and this proportion is expected to grow as the population ages. Based on 
the elevated risk of osteoporosis in postmenopausal smokers, together with the high prevalence of depression history and 
considerable weight gain we observed in previous studies, we have chosen to examine the potential utility of exercise as an 
adjunct treatment for smoking cessation in postmenopausal women. The specific research aims of this study are to: 1)to 
evaluate wheter adding an established moderate resistance/aerobic exercise program for postmenopausal women 50 years of age 
and older to a standard smoking cessation treatment program improves short and long term smoking outcomes; 2)to examine 
the main and interactive effects of history of depression and exercise on smoking cessation treatment; 3)to use interactive 
voice recording (IVR) technology to examine the mechanisms by which exercise may improve smoking treatment outcomes in 
postmenopausal women; 4)to examine whether adding a moderate exercise program to a standard smoking cessation treatment 
program for postmenopausal women improves health outcomes such as, weight gain, bone mineral density, and quality of life 
measurements. Study sites will include The University of Connecticut Health Center and the Unviersity of Minnesota. Subjects 
(N=364) must be postmenopausal, at least 50 years of age, and smoke at least 10 cigarettes per day. All subjects will receive 
smoking treatment (behavioral counseling and varenicline) and will be randomly assigned to either 1)a supervised exercise 
program or 2)a supervised relaxation control condition. We hypothesize that 1)postmenopausal women randomized to the 
exercise condition will have greater end of treatment abstinence rates and end of year abstinence rates than will those women 
assigned to an attention control condition. 2a)women with a history of depression will have reduced short and long-term 
smoking abstinence rates. b)ameliorative effects of exercise on smoking cessation and depression will exist such that women 
with a history of depression will abstain from smoking at a rate equivalent to those with no such history; 3)exercise may 
improve smoking cessation by reducing nicotine withdrawal symptoms and negative affect, and by increasing self-efficacy for 
smoking cessation; 4)women randomized to the exercise condition will have increased bone mineral dinsity at the hip, and 
improved quality of life compared to women in the control condition. An effective exercise program added to smoking 
cessation for postmenopausal women has the potential to address many health problems in this at-risk population, and 
markedly improve quality of life.
SUBPROJECT PROGRESS:
 7 subject s were enrolled (signed consent), 6 randomized to RX.
 1 subject dropped out after screening. Time limitations too much
 1 subject dropped out after 1 class due to a number of reasons (didn't like group setting, interfered with work, unable to tolerate 
any meds for smoking cessation)
1 subject dropped out after 2nd session declining to participate further
1 subject moved
3 subjects remain in treatment (10 out of 12 weeks).  All have remained abstinent.  
Our revised proposal is only a 12 week study.  We are planning on submitting for approval for longer term follow-up on pilot 
subjects.  
We are applying for funding, will only enroll a limited number of subjects to obtain feasibility data. We are considering one more 
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group session to enroll a few more participants.
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SUBPROJECT DESCRIPTION:
Contingency management (CM) interventions are highly efficacious in improving substance abuse treatment outcomes, but few 
studies have implemented this approach with alcohol use disorder patients. Further, no known studies have experimentally 
evaluated how duration of CM affects outcomes. This issue appears to be of central importance for impacting long-term 
behavior change, given the well-established association between length of treatment engagement and outcomes. In this 
application, we propose to evaluate the efficacy of prize-based CM when administered according to a usual duration of 12 weeks 
versus an extended duration of 24 weeks. We will also investigate how probabilities of reinforcement may impact the 
relationships between CM duration and outcomes. Alcohol abusing or dependent patients (N=310) beginning intensive 
outpatient day treatment at community based clinics will be randomly assigned to one of four conditions: (a) standard treatment 
as usual (ST) at the clinic without CM; (b) ST with CM for 12 weeks with a 0.5 probability of winning prizes for each negative 
sample submitted and an expected average maximum earnings of $300 in prizes; (c) ST with CM for 24 weeks with a 0.34 
probability of winning prizes for each negative sample submitted and an expected average maximum earnings of $300 in prizes; 
or (d) ST with CM for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted and an expected 
average maximum earnings of $500 in prizes. During weeks 1-12, two breath samples per week will be collected from all 
patients, and those in the CM conditions will have the opportunity to win prizes for submission of negative samples. Those 
assigned to the longer duration CM conditions will continue to receive reinforcement for negative samples provided weekly 
during weeks 13-24. In group d, probabilities of reinforcement will be identical to those used in group b, but they will remain 
available for an additional 12 weeks. In group c, the probabilities of winning prizes will be lower so that the magnitude of overall 
reinforcement is consistent with group b. Alcohol use, other drug use, psychosocial problems, and HIV risk behaviors will be 
measured at baseline, during and post treatment, and throughout an 18-month follow-up period. We expect that CM will 
decrease alcohol use to a greater extent than non-CM treatment, and that availability of CM for 24 weeks may result in longer 
term benefits than 12 week exposure to CM. This study will be the first to evaluate the effects of probability of winning prizes 
on response to CM. We will also assess patient characteristics that may be associated with improved outcomes within and across 
treatments
SUBPROJECT PROGRESS:
Total Enrollment: 2
Past Year Enrollment: 2 
No changes in recruitment plans are needed.
• No unexpected safety concerns have occurred.
• Interim data and outcomes are not available.
• Changes to protocol:  1) Added Danielle Barry as Study Coordinator and removed Sheila Alessi as Study Coordinator. 2) 
Clarified that the Demos referred to in the Assessment table in protocol are included in the ASI questionnaire. 3) Replaced the 
University of Rhode Island Change Assessment (URICA) with the Readiness to Change Questionnaire (RTCQ). 4) Added two new 
questionnaires: Alcohol Abstinence Self-Efficacy (AASE) scale to assess self-efficacy and the Coping Strategies Scale (CSS) to 
evaluate coping skills. 5) Clarified that the urine tests for stimulants, opiates, and marijuana will be performed using cups rather 
than sticks. 6) Expanded the description of the payment for urine samples submitted to include other small items up to $2 in value 
(e.g., toiletries, snacks, bus tokens, etc.) in addition to gift certificates. 7) Specified in both the ICF and protocol that the random 
breath testing may be administered as needed one or more times during the 24-week treatment phase. 8) Corrected several 
typographical errors discovered in the protocol and ICF. 9) Removed two items from our 10-item Consent Quiz in order to match 
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the description of the 8-item Quiz in the protocol. 10) Updated HIPAA form to the IRB template. 11) Added questions to the 
Addiction Severity Index (ASI) regarding HIV status and previous and current treatment. 12) Clarified in the protocol that the 
DSM Checklist for stimulants includes cocaine, amphetamine and methamphetamine. 13) Clarified in the protocol amphetamine 
and methamphetamine, in addition to cocaine, will be recorded in the Timeline Follow-back (TLFB). 14) Revised version of the 
Cigarette Smoking History questionnaire and to clarify that it will be administered at intake and at each follow-up. 15) Added the 
following sentence to the ICF, "The breath sample will test for alcohol" in order to introduce the concept of testing breath samples 
for alcohol earlier in the document. 16) Added the name of one of the co-investigators, Danielle Barry to the audiotaping portion 
of the consent on page 6 of the ICF. 17) Revised Consent Quiz for enhanced comprehension.
• Results not yet published as study is ongoing. 
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through 
March 31, 2009?  Yes
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Pilot 
(CReFF)
Research Core Inf. Total
Number of Subprojects  0  151  0  151
Number of Investigators  0  199  0  199
Number of Published  0  56  0  56
Number of In Press  0  6  0  6
RESOURCE SUMMARY:  SUBPROJECTS
The following only includes information associated with subprojects.
ASubprojects Using B D
Offsite Research Visits
Scatter RN Hours
Outpatient Visits
Scatter Bed Days
 0  0
 5,992  284
 0
 0
Inpatient Days
 0  0  0
 0  0  0
 4,410  0  0
Total SPID CountSubprojects Using
 9
 26
 40
 0
 62
 0
 151
Core Lab
Clinical Trial
Multicenter
Ancillaries Only 
Biostatistician
Informatics Core
Research Bionutrition
 82Patient Days/Visits
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RESOURCE SUMMARY:  ADMINISTRATIVE
GCRC Personnel Function
 0.410Program Direction
 1.600Administration
 0.000Nutrition and dietary support
 1.400Bioinformatics, computer systems managers
 0.530Biostatistician
 7.600Nursing
 1.200Research Subproject Advocacy
 3.850Core lab staff
 0.900Other
 17.490Total FTEs:
INVESTIGATORS On Subprojects Not On Subprojects
 199  11Clinical Investigators
Subproject Investigators by Country  1
CANADA  1
USA Subproject Investigators by State  53
CT  39
DC  4
IL  2
MA  4
MI  1
NC  1
NY  2
GEOGRAPHICAL USAGE BY INVESTIGATORS AT NON-HOST INSTITUTIONS
 1
 8
 0
 111
 11
 0
 1
NO DEGREE
NON-Doctoral ONLY
Other Doctoral Only
Educator Only
Dental Only
MD and Other Doctoral
MD Only
PHD and Other Doctoral
PHD and Dental
PHD and MD
PHD Only
 18
 0
 0
 68
CLINICAL INVESTIGATORS BY DEGREE
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RESOURCE SUMMARY:  PUBLICATION/SUPPORT
PUBLICATIONS Published
Cited Total Cited Total
In Press
 49  68  6 1Journals
INVESTIGATOR SUPPORT
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$46,994INDUSTRY
$2,813,449OTHER
$67,646PVAS
$538,605SCC
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PHS
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$179,450CDC
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CENSUS DATA (for A, B, C, and D Patients)
ADMISSIONS INPATIENT DAYS
A AB BD DAge Group
Age Census Inpatient
a. less than 1 year  0 0 0 0 0 0
b. 1 thru 12 years  0 0 0 0 0 0
c. 13 thru 21 years  0 0 0 0 0 0
d. 22 thru 65 years  0 0 0 0 0 0
e. 66 and over  0 0 0 0 0 0
Total  0 0 0 0  0  0
ADMISSIONS INPATIENT DAYS
A AB BD DAge Group
Age Census Scatter Bed
a. less than 1 year  0 0 0 0 0 0
b. 1 thru 12 years  0 0 0 0 0 0
c. 13 thru 21 years  0 0 0 0 0 0
d. 22 thru 65 years  0 0 0 0 0 0
e. 66 and over  0 0 0 0 0 0
Total  0 0 0 0  0  0
OUTPATIENT VISITS
A B DAge Group
Age Census Outpatient
a. less than 1 year  0 1 22
b. 1 thru 12 years  0 7 166
c. 13 thru 21 years  0 0 472
d. 22 thru 65 years  0 227 3,719
e. 66 and over  0 49 1,613
Total  0 284 5,992
OFFSITE RESEARCH VISITS
A BAge Group
Age Census Offsite
a. less than 1 year  1  0
b. 1 thru 12 years  210  0
c. 13 thru 21 years  217  0
d. 22 thru 65 years  3,969  0
e. 66 and over  13  0
Total  4,410  0
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M
on
th
D
ay
s O
pe
n
TO
T
TO
T
A A AB B BC D D DCT
O
T
Month Census
A B T
O
T
OFFSITE 
RESEARCH VISITS
 0 0 0 0 0 0 0
A
PR
-0
7
 4
82  1
3  0  0 0
 4
95 3
0  0
 5
32  0
 5
32
 0 0 0 0 0 0 0
M
A
Y
-0
7
 3
94  1
9  0  0 0
 4
13 3
1  0
 4
85  0
 4
85
 0 0 0 0 0 0 0
JU
N
-0
7
 5
38  6
5  0  0 0
 6
03 3
0  0
 3
51  0
 3
51
 0 0 0 0 0 0 0
JU
L-
07
 4
82  7
5  0  0 0
 5
57 3
1  0
 3
09  0
 3
09
 0 0 0 0 0 0 0
A
U
G
-0
7
 4
62  2
9  0  0 0
 4
91 3
1  0
 3
43  0
 3
43
 0 0 0 0 0 0 0
SE
P-
07
 3
76  1
3  0  0 0
 3
89 3
0  0
 3
81  0
 3
81
 0 0 0 0 0 0 0
O
C
T-
07
 7
41  9  0  0 0
 7
50 3
1  0  4
8  0  4
8
 0 0 0 0 0 0 0
N
O
V
-0
7
 5
64  5  0  0 0
 5
69 3
0  0
 4
95  0
 4
95
 0 0 0 0 0 0 0
D
EC
-0
7
 4
37  6  0  0 0
 4
43 3
1  0
 4
32  0
 4
32
 0 0 0 0 0 0 0
JA
N
-0
8
 5
82  1
5  0  0 0
 5
97 3
1  0
 4
27  0
 4
27
 0 0 0 0 0 0 0
FE
B
-0
8
 4
58  1
5  0  0 0
 4
73 2
9  0
 2
94  0
 2
94
 0 0 0 0 0 0 0
M
A
R
-0
8
 4
76  2
0  0  0 0
 4
96 3
1  0
 3
13  0
 3
13
 3
66  0  0 2
84
 5
,9
92 0 0 0 0 0 0 0
 6
,2
76 0 0
To
ta
l
 4
,4
10  0
 4
,4
10
6/27/2008   9:32:04AM 227
REPORT PD:  04/01/2007-03/31/20085M01RR006192-14 Final
AwardedUsed UsedUsed AwardedAwardedFunding Category
SCATTER BED OUTPATIENTINPATIENT
Utilization Table
A
B
C
D
 0  0
 0  0
 0  0
 0  0
 0  0
 0  0
 0  0
 0  0
 0  5,992
 0  284
 0  0
 0  0
OUTPATIENT VISITS
Outpatient
A B C DLength of Stay (hrs)
OFFSITE VISITS
A B
 0 0 276 5,221a.  < 1 hour  4,410  0
 0 0 3 542b.  >= 1 and <= 3  0  0
 0 0 5 98c.  >  3 and <= 6  0  0
 0 0 0 65d.  >  6 and <= 10  0  0
 0 0 0 66e.  > 10 hours  0  0
Total  0 0 284 5,992  4,410  0
NumberGCRC Capacity
Outpatient Rooms
Inpatient Beds Used for Outpatients
Total Inpatient Beds
 8 
 0 
 0 
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PATIENT CARE COMPUTATION:     (Figures to be rounded to nearest dollar)
INPATIENT
If proposed rate is used, show date filed with HHS:1.
If rate has been published by HHS, show date of agreement: 8/3/20062.
3. 6/30/2007through4/1/2007Period applicable rate:
RATE 1
4.A. Routine Cost (or Space Cost for Per Diem Method):
4.B. Per Diem Method: Category A days x $
 0
 0  790.04  0=
4.C. Scatter Beds: Category A days x $
Total (4A and4B and 4C)
 0  790.04 =
$0
 0
Service Patient Credit (routine method):5.
Category B days x $
Category C days x $
Category D days x $
Total Service Patient Credits5.A.
5.B. All Other Inpatient Credits (specify:  grants, contracts, other 
sources)
Total Credits (5A and 5B)
 0  0.00
 0  0.00
 0  0.00
 0
 0
 0
=
=
=
 0
$0 
 0
Inpatient Ancilliaries Required Solely for Research Purposes, Adjusted to Cost (Schedule 1)6.
Category A days x $
Category B days x $
 0  0.00
 0  0.00
=
= 0.00
 0.00
Scatter Bed B days x $
Other Costs (Specify:  Drugs, raw food, special diets, outside laboratories, etc.  provide Justification)7.
Scatter Bed A days x $ 0  0.00
 0  0.00
8. Total Inpatient Charges (Lines 4, 6 and 7, less 5)
=
=
$0Total Inpatient Ancillaries
$0
$0
 0.00
 0.00
OUTPATIENT
Space Charge9. $0
10. Outpatient Ancill
Category B Visits x $
Category A Visits x $ 1,414
 97
 4,575.95
 0.00
=
=
Total Outpatient Ancillaries $4,576
 3.24
 0.00
11. Other Costs (Specify:  drugs, raw food, special diets, outside laboratories, facility fees, etc.  Provide 
justification)
Outpatient Credits:12.
Category B Visits x $
Category C Visits x $
Category D Visits x $
 97
 0
 0
 1.00
 0.00
 0.00
Total Outpatient Credits12.A.
12.B. All Other Outpatient Credits (specify:  grants, contracts, other sources)
Total Credits (12A and 12B)
 97
 0
 0
=
=
=
$97
($97)
$29,373
$0
Total Outpatient Charges (Lines 9, 10, and 11, less line 12)13. $33,852
Total Ancillary Costs Connected with Ancillary-Only Projects14. $0
Total Ancillary Costs Connected with Offsite Research Visits15. $0
$33,852TOTAL PATIENT CARE CHARGES (Lines 8 + 13 + 14)
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INPATIENT
If proposed rate is used, show date filed with HHS:1.
If rate has been published by HHS, show date of agreement: 3/6/20072.
3. 3/31/2008through7/1/2007Period applicable rate:
RATE 2
4.A. Routine Cost (or Space Cost for Per Diem Method):
4.B. Per Diem Method: Category A days x $
 0
 0  924.99  0=
4.C. Scatter Beds: Category A days x $
Total (4A and4B and 4C)
 0  924.99 =
$0
 0
Service Patient Credit (routine method):5.
Category B days x $
Category C days x $
Category D days x $
Total Service Patient Credits5.A.
5.B. All Other Inpatient Credits (specify:  grants, contracts, other 
sources)
Total Credits (5A and 5B)
 0  0.00
 0  0.00
 0  0.00
 0
 0
 0
=
=
=
 0
$0 
 0
Inpatient Ancilliaries Required Solely for Research Purposes, Adjusted to Cost (Schedule 1)6.
Category A days x $
Category B days x $
 0  0.00
 0  0.00
=
= 0.00
 0.00
Scatter Bed B days x $
Other Costs (Specify:  Drugs, raw food, special diets, outside laboratories, etc.  provide Justification)7.
Scatter Bed A days x $ 0  0.00
 0  0.00
8. Total Inpatient Charges (Lines 4, 6 and 7, less 5)
=
=
$0Total Inpatient Ancillaries
$0
$0
 0.00
 0.00
OUTPATIENT
Space Charge9. $0
10. Outpatient Ancill
Category B Visits x $
Category A Visits x $ 4,578
 187
 47,888.30
 0.00
=
=
Total Outpatient Ancillaries $47,888
 10.46
 0.00
11. Other Costs (Specify:  drugs, raw food, special diets, outside laboratories, facility fees, etc.  Provide 
justification)
Outpatient Credits:12.
Category B Visits x $
Category C Visits x $
Category D Visits x $
 187
 0
 0
 1.00
 0.00
 0.00
Total Outpatient Credits12.A.
12.B. All Other Outpatient Credits (specify:  grants, contracts, other sources)
Total Credits (12A and 12B)
 187
 0
 0
=
=
=
$187
($187)
$80,228
$0
Total Outpatient Charges (Lines 9, 10, and 11, less line 12)13. $127,930
Total Ancillary Costs Connected with Ancillary-Only Projects14. $0
Total Ancillary Costs Connected with Offsite Research Visits15. $0
$127,930TOTAL PATIENT CARE CHARGES (Lines 8 + 13 + 14)
4/1/2007 6/30/2007
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INPATIENT OUTPATIENT
OTHER COSTS DURING YEAR
Itemized costs.  These totals appear on line 7 (Inpatient Other Costs) and on line 11 (Outpatient Other Costs) of the Patient 
Care Computation sheet.
DRUGS, RAW FOOD, SPECIAL DIETS, LABS, ETC.
Medica/Dental Supplies  0.00  9,057.95
Outside Labs  0.00  16,099.83
Patient Nutrition  0.00  408.01
Research Pharmacy  0.00  3,807.45
Grand Total:  0.00  29,373.24
7/1/2007 3/31/2008
INPATIENT OUTPATIENT
OTHER COSTS DURING YEAR
Itemized costs.  These totals appear on line 7 (Inpatient Other Costs) and on line 11 (Outpatient Other Costs) of the Patient 
Care Computation sheet.
DRUGS, RAW FOOD, SPECIAL DIETS, LABS, ETC.
Medical/Dental Supplies  0.00  24,740.37
Outside Labs  0.00  43,974.17
Patient Nutrition  0.00  1,114.43
Research Pharmacy  0.00  10,399.46
Grand Total:  0.00  80,228.43
INPATIENT
If proposed rate is used, show date filed with HHS:1.
If rate has been published by HHS, show date of agreement:2.
3. Period applicable rate: through
8/3/2006
04/01/2007 06/30/2007
4.A. Routine Cost (or Space Cost for Per Diem Method):
4.B. Per Diem Method:  0
 0
 0 Category A days
4.C. Scatter Beds:
Total (4A and4B and 4C) $0 
 0 0 Category A days
5. Service Patient Credit (routine method):
 0
$0 
 0
Total Credits (5A and 5B)
All Other Inpatient Credits (specify:  grants, contracts, 
other sources)
5.B.
5.A. Total Service Patient Credits
Inpatient Ancilliaries Required Solely for Research Purposes, Adjusted to Cost (Schedule 6.
Category A days 
Category B days 
 0
 0
 0
 0
Scatter Bed B days
Other Costs (Specify:  Drugs, raw food, special diets, outside laboratories, etc.  provide 
Justification)
7.
Scatter Bed A days
8. Total Inpatient Charges (Lines 4, 6 and 7, less 5
$0 Total Inpatient Ancillaries
$0 
 0
 0  0
 0
$0 
OUTPATIENT
Space Charge9.
10. Outpatient Ancillaries Required Solely for Research Purposes, Adjusted to Cost (Schedule 2)
Category B Visits
Category A Visits
Total Outpatient Ancillaries $52,464 
 5,992
 284
 52,464
 0
$0 
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Other Costs (Specify:  drugs, raw food, special diets, outside laboratories, facility fees, etc.  Provide 
justification)
11.
Outpatient Credits:12.
Category B Visits 
Category C Visits
Category D Visits
Total Outpatient Credits12.A.
12.B. All Other Outpatient Credits (specify:  grants, contracts, other sources)
Total Credits (12A and 12B)
$284 
$(284)
 0
 0
 284 284
 0
 0
$0 
$109,602 
 0 
 0 
$161,782 Total Outpatient Charges (Lines 9, 10, and 11, less line 12)13.
Total Ancillary Costs Connected with Ancillary-Only Projects
15. Total Ancillary Costs Connected with Outpatient Research Visits
14.
$161,782 TOTAL PATIENT CARE CHARGES (Lines 8 + 13 + 14)
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ANCILLARY CHARGES REQUIRED FOR RESEARCH PURPOSES
Department/ Cost Center INPATIENT
Gross Charges Net ChargesAdjustment 
Factor  (%)
BAA B
TOTAL
Department/ Cost Center OUTPATIENT
Gross Charges Net ChargesAdjustment 
Factor  (%)Rate Period:  4/1/2007-6/30/2007 BAA B
Clinical Lab  0.00 4,369.34 12,851.00  0.00  34.00%
Nuclear Medicine  0.00 206.61 296.00  0.00  69.80%
 13,147.00  0.00TOTAL  0.00 4,575.95
Rate Period:  7/1/2007-3/31/2008 BAA B
Clinical Lab  0.00 24,794.30 64,568.49  0.00  38.40%
DXA  0.00 11,092.00 11,092.00  0.00  100.00%
Pathology  0.00 9,000.00 9,000.00  0.00  100.00%
Professional Fees  0.00 452.00 565.00  0.00  80.00%
Radiation Therapy  0.00 2,550.00 2,550.00  0.00  100.00%
 87,775.49  0.00TOTAL  0.00 47,888.30
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CORE LABORATORY
SPIDS# of  TestsTest Name
# of  
SPIDS
25-OH Vitamin D  261  3 0609, 0624, 0614
Bone Specific Alkaline Phosphatase  135  1 0624
Cortisol  149  2 0590, 0497
Creatinine  78  1 0413
DNA Extraction  3,371  28 0602, 0637, 0665, 0646, 0628, 
0630, 0582, 0657, 0660, 0611, 
0612, 0619, 0599, 0340, 0357, 
0471, 0478, 0495, 0492, 0494, 
0413, 0518, 0461, 0231, 0453, 
0531, 0466, 0468
Endothelin 1-21  108  1 0591
E-Selectin  27  1 0568
Estradiol  175  2 0624, 0542
Estrone  40  1 0542
Estrone Sulfate  40  1 0542
FACS Analysis  228  1 0624
Genotyping  33,397  9 0602, 0630, 0560, 0612, 0619, 
0549, 0495, 0492, 0466
hsCRP  89  3 0641, 0653, 0591
IL-1 beta  102  2 0568, 0497
IL-10  75  1 0497
IL-2  75  1 0497
IL-4  75  1 0497
IL-6  137  3 0641, 0653, 0497
intact PTH  199  2 0624, 0614
Lyme Screening  260  1 0496
Nitric Oxide  108  1 0591
N-telopeptide Collagen Crosslinks  213  2 0624, 0413
Osteocalcin  135  1 0624
PBMC Isolation  296  2 0646, 0624
Processing  12,056  35 0637, 0601, 0638, 0641, 0644, 
0645, 0624, 0661, 0628, 0664, 
0562, 0653, 0582, 0591, 0659, 
0660, 0611, 0619, 0599, 0365, 
0487, 0496, 0497, 0413, 0426, 
0461, 0051, 0442, 0528, 0268, 
0529, 0453, 0535, 0466, 0542
RNA Extraction  73  3 0637, 0646, 0461
RT-PCR  513  2 0600, 0530
Sequencing  248  6 0637, 0625, 0612, 0549, 0492, 
0530
SHBG  175  2 0624, 0542
Testosterone  79  1 0542
Thrombin/Anti-thrombin III complex  27  1 0568
Tissue Factor  27  1 0568
TNF alpha  108  3 0568, 0581, 0497
VEGF  27  1 0568
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6/27/2008   9:32:04AM 235
REPORT PD:  04/01/2007-03/31/20085M01RR006192-14 Final
MEDICAL STUDENTS
The University of Connecticut School of Medicine has a Medical Student Summer Fellowship Program through the Office 
of Medical Student Affairs. The students formally apply to that program. Applications are reviewed by the Program 
Director and the Associate Dean for Medical or Dental Affairs and selection is based on available faculty sponsorship. All 
applicants with clinical projects meet with the GCRC Program Director. The Program Director presents all potential 
applicants' projects to the Scientific Advisory Committee. The SAC selects the applicants with the most relevant GCRC 
projects and ensures that a clinical investigator is available as a mentor. All applicants are required to attend an present at 
a weekly seminar series with the GCRC Associate Program Director for Education and Planning. All applicants are 
required to present their work at a Medical Student Research Day at the end of the summer.
Students and their Mentors.
Degree Sought
DOUGLAS, KARA R
BS, BS
KRANZLER, HENRYMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title Effects of Aripiprazole on Subjective Responses to Alcohol
SPIDS 0536, 0536
I assisted data cleaning and analysis for the following study and co-authored a manuscript, 
which is nearing readiness to be submitted for publication:  Aripiprazole is of interest as a 
potential pharmacologic intervention for the treatment of alcoholism. This study included 
18 healthy subjects who were assigned to receive a high, low, or no-med dosage of 
aripiprazole in a randomized, double-blind, within-subjects design. The subjects then 
completed an alcohol challenge lab during which vital signs were monitored and self-report 
surveys were used to measure subjective alcohol effects. It was found that the high dosage of 
aripiprazole significantly reduced the pleasurable and euphoric effects of alcohol 
consumption, while increasing feelings of sedation.
Project Summary
Degree Sought
GRILLE, MICHAEL
MD, BS
PROTIVA, PETRMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title The Effect of Acute Aerobic Exercise on the Colorectal Mucosa
SPIDS
An investigation of the possible mechanisms responsible for the observed risk reduction in 
colon cancer associated with aerobic exercise.  The study focuses on several pathways with 
effects on apoptosis and cell cycle progression including IGF receptor-mediated signaling, 
PGE, and changes in gene expression.
Project Summary
Degree Sought
KAPTUCH, JUSTIN
MD, BS
ONYIUKE, HILARYMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title A retrospective review of cervical corpectomy in instrumented and 
non-instrumented fusions: indications, radiological features, 
complications, and outcomes
SPIDS
This study examines the indications and outcomes of a surgery, cervical corpectomy, 
commonly performed to alleviate cervical spinal cord compression or cervical myelopathy.
Project Summary
Degree Sought
KOZLAK, SCOTT
DMD, BS
LALLA, RAJESHMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title Vitamin Levels in Patients with RAS
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SPIDS 0592, 0592
Vitamin levels in patients with recurrent aphthous stomatitis (RAS) are measured using a diet 
history questionnaire and accompanying Diet-Calc software from the National Cancer 
Institute.  These levels are compared to the levels found in a normal population to look for 
differences between the RAS cohort and the normal population.
Project Summary
Degree Sought
MADEJ, OLGA
BA, MD
MENZOIAN, JAMESMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title Incidence and Risk Factors for Transient Hypotension Following 
Carotid Endarterectomy and Carotid Angioplasty with Stenting.
SPIDS
I worked on a retrospective review of 500+ charts from 3 hospitals: John Demspey, St. 
Francis, and Hartford. I collected demographic and pertinent medical history data from 
patients that underwent carotid surgery for the treatment of carotid artery occlusive disease. 
The purpose was to determine the incidence of transient hypotension after the procedures 
(at the 3 hospitals), and what, if any, risk factors exist.
Project Summary
Degree Sought
ROPER, NITIN
MD, BS
FANG, MINMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title Pharmacogenetics of Warfarin Therapy
SPIDS 0662, 0662
Coumadin (warfarin) is a blood thinner to help prevent serious and even fatal blood clots.  
However, it is not easy to determine the correct dose.  If a patient does not take enough 
Coumadin, blood clots can form and if the dose given is too high, a person can have 
bleeding, which can be fatal.  Some of the differences in individual dose needed to achieve 
therapeutic effect may be caused by the enzymes in an individual that break down the drug.  
Current dosing schedules, however, do not account for these genetic factors.  Recent studies 
have shown strong evidence that individuals with certain genetic makeup require lower doses 
of Coumadin.  
The purpose of this research study is to identify patient genetic factors that may allow for a 
lower dose of Coumadin to be used and to find a better way to determine the correct dose for 
every patient.
Project Summary
Degree Sought
WALSH, KEVIN
BA, MD
MAYER, BRUCEMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title Determining the Role of Nck in Cellular Protrusion and Motility 
Stimulated by PDGF
SPIDS
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Membrane protrusion plays an important role in cell motility.  Altered membrane 
protrusion and cell motility have been linked with many diseases including atherosclerosis, 
diabetic retinopathy, and cancer.  The Nck1 and Nck2 adaptor proteins link tyrosine 
phosphorylation with cytoskeletal dynamics, however, the role Nck plays in controlling 
membrane protrusion downstream of the activated PDGFR has not been elucidated.  In this 
study the cellular levels of the Nck1 or Nck2 adapter proteins in NIH3T3 cells were down 
regulated using siRNA, and the cells were imaged using DIC microscopy.  The cells were 
imaged for 10 minutes under starvation conditions, and imaged for another 10 minutes 
following PDGF stimulation.  The protrusion patterns were then examined using kymograph 
analysis.  The average protrusion velocity was similar for control and Nck1 knockdown cells 
under starvation (0.0387 um/s).  PDGF stimulation resulted in increased protrusion velocity 
by 56% in control cells, and 7% in Nck1 knockdown cells. The average protrusion distance 
was also similar for control and Nck1 knockdown cells under starvation (1.36 um).  PDGF 
stimulation resulted in increased protrusion distance by 83% in control cells, and 26% in 
Nck1 knockdown cells.  These results suggest Nck plays an important role in mediating 
cellular protrusion downstream of the activated PDGFR.
Project Summary
Degree Sought
ZAKKO, LIAM
MD, BA
SMILOWITZ, HENRYMentor Name
Period 06/01/2007 - 08/31/2007
Funds Received  3,200 *
Project Title Cellular Basis for the Efficacy of Uric Acid-Enhanced 
Immunotherapy for F-98 Rat Glioma
SPIDS
Experimental results have shown that the lifespan of Fischer 344 rats with intracranial 
implantation of F-98 malignant glioma was improved when followed by T regulatory cell 
depletion and weekly injections of Granulocyte Macrophage Stimulating Factor (GM-CSF) 
transfected and then irradiated F-98 cells (GVax).  The improvement was even more marked 
when the weekly GVax injections were accompanied with a dose of uric acid.  An attempt 
was therefore made to determine the cellular mechanism for the difference in outcomes 
between these treatment methods by looking for the differences in immune cell responses to 
F-98 tumor cells in vitro.  Flow cytometry data indicated that lymphocytes from the rats 
with uric acid injections produced 3 fold more Interferon gamma (IFN- g) than untreated rats 
and about 40% more IFN- g than rats treated with GVax without uric acid.  Interestingly, 
however, about 30% of the IFN- g produced did not come from T-cells, but from other 
lymphocytes.
The research this summer attempted to discover what other cells were producing IFN- g.  It 
was hypothesized that perhaps Natural Killer (NK) cells or Natural Killer like T (NKT) cells 
were responsible.  To test this theory a number of Fischer 344 Rats were treated with Gvax 
and uric acid.  Five days after treatment the rats' spleens were collected and lymphocytes 
were isolated.  Fluorescent labeling of the lymphocytes after this extraction, followed by 
flow cytometry, revealed a number of cell populations: some cells were áâTCR+ indicating 
they were T-cells; other cells were CD161+ indicating they were NK cells; still other cells 
were áâTCR+ and CD 161+ indicating they were NKT cells.  Performing the same 
experiment except incubating the lymphocytes overnight in cell growth medium revealed 
the same populations.  Repeating the experiment, however, with the lymphocytes incubated 
overnight in the presence of F-98 cells appeared to cause the loss of CD 161+ cell 
populations.  Experiments showed that the loss of these populations occurred over the 
course of a couple hours, suggesting that the markers for the cells were being down-regulated, 
or blocked, rather than the cells being degraded.  Also a further experiment in which 
lymphocytes were incubated in a 50/50 mix of normal medium and medium that was 
conditioned over F-98 cells showed the same loss of CD 161+ population.  From this result 
it was concluded that a secretion from the F-98 cells was responsible for the CD 161+ 
population loss.  Attempts were made to determine the nature of this secretion and its 
affect, but this remains an area where further study is necessary.  These results also 
prevented a conclusion from being reached on the nature of the cells producing IFN- g.
Project Summary
No Reported Students.
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CLINICAL RESEARCH FEASIBILITY FUND (CReFF)
Specialty
Mentor Name
Funds Received
Period
Project Title
Attachment(s)
Project Summary
No CReFF Participants Reported.
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SCIENTIFIC HIGHLIGHTS
Addictions Research
PAST SPID(s):SPID(s): 0051, 0468, 0470, 0536, 0560, 0598 0220,0295,0605
KEYWORDS: ALCOHOL, DRUGABUSE, NICOTINESMOKING
Studies in addictive behaviors, including problem drinking, dependence on alcohol, drugs and tobacco, and 
compulsive gambling, are major areas of National Institutes of Health (NIH) funded research carried out by 
investigators at the University of Connecticut Health Center (UCHC).  Many of these studies are conducted in the 
General Clinical Research Center (GCRC) and/or utilize GCRC resources, including the biostatistics, informatics, 
clinical, and laboratory cores.
Dr. Henry Kranzler, Professor of Psychiatry, Program Director of the GCRC, and Associate Scientific Director of 
the UCHC Alcohol Research Center (ARC), which is funded by the National Institute on Alcohol Abuse and 
Alcoholism (NIAAA), and Dr. Jonathan Covault, Associate Professor of Psychiatry, Director of the GCRC Core 
Laboratory and Director of the Molecular Genetics Laboratory of the ARC, have continued to examine candidate 
genes in the GABA system in relation to alcohol dependence.  Together with Dr. Lance Bauer, they found that 
allelic variation in GABRA2, which maps to chromosome 4p, encodes the alpha-2 subunit of the GABA-A 
receptor, and has been shown in multiple studies to be associated to alcohol dependence, predicts the drinking 
behavior over time of individuals being treated with psychotherapy for alcohol dependence.  In that study, they 
also found preliminary evidence of an allele X treatment interaction, representing a potential opportunity for 
individualized psychosocial treatment of alcohol dependence.  Together with Drs. Howard Tennen and Tamlin 
Conner, Drs. Covault and Kranzler examined the effects of GXE on drinking and drug use in a sample of college 
students.  They found that the short promoter allele of the serotonin transporter gene (SLC6A4) was associated 
with more frequent drinking and drug use among individuals who had experienced stressful events during the year 
preceding study enrollment.  Together with Dr. Carlos Hernandez-Avila, Drs. Kranzler and Covault examined the 
pharmacogenetics of naloxone stimulation of plasma cortisol, which despite its inclusion of a putatively functional 
polymorphism in OPRM1, the gene encoding the mu-opioid receptor, differed as a function of European vs. Asian 
ancestry, suggesting the presence of a balancing polymorphism in Asians. Drs. Kranzler and Covault have also 
collaborated actively with Dr. Joel Gelernter of Yale University on studies of the genetics of alcohol and drug 
dependence.  
Dr. Victor Hesselbrock, Chair of the GCRC Advisory Committee (GAC) and Principal Investigator of the 
NIH-funded ARC at UCHC, is a major collaborator in the multi-center Collaborative Study on the Genetics of 
Alcoholism (COGA). Dr. Hesselbrock provides a vital connection between COGA, which continues to lead the field 
of alcohol research in relation to the elucidation of the alcohol dependence phenotype and the genetic basis of the 
disorder, and the UConn ARC and GCRC.  
Dr. Cheryl Oncken, Associate Professor of Medicine and Associate Program Director of the GCRC, completed a 
study of nicotine replacement in pregnant women, including a genetic substudy that was a major component of the 
last GCRC competitive renewal.  Together with Drs. Naveed Hussain and Winfried Krueger, she completed a study 
of the effects of smoking on RNA expression in the umbilical cords of children born to mothers participating in the 
clinical trial. 
Dr. Nancy Petry, Professor of Psychiatry, directs a highly productive program studying alcohol and drug 
dependence and compulsive gambling.  The GCRC supported a number of studies of Dr. Petry, all of which continue 
to recruit actively. All studies are conducted at community-based treatment programs throughout New England. Dr. 
Lance Bauer has continued analysis of an NIH-funded project in the examination of cognitive control among 
patients with HIV/AIDS.  In addition, he has developed an active program of research in relation to 
electrophysiologic and genetic predictors of the longitudinal course of alcohol and drug use among individuals with 
dependence on these substances.
Publications:
Chen ACH, Tang Y, Rangaswamy M, Wang J, Almasy L, Foroud T, Edenberg HJ, Hesselbrock V, Nurnberger Jr. JI, Kuperman S, 
O'Conner SJ, Schuckit MA, Bauer LO, Tischfield J, Rice JP, Bierut LJ, Goate A, Projesz B Association of Single Nucleotide 
Polymorphisms in a Glutamate Receptor Gene (GRM8) with Theta Power of Event-Related Oscillations and Alcohol Dependence 
Neuropsychiatric Genetics
Grucza RA, Wang JC, Stitzel JA, Hinrichs AL, Saccone SF, Saccone NL, Bucholz KK, Cloninger CR, Neuman RJ, Buddle JP, Fox L, 
Bertelsen S, Kramer J, Hesselbrock V, Tischfield J, Nurnberger Jr JI, Almasy L, Poresz B, Kuperman K, Schuckit MA, Edenberg HJ, 
Rice JP, Goate AM, Bierut LJ A Risk Allele for Nicotine Dependence in CHRNA5 is a Protective Allele for Cocaine Dependence 
Biological Psychiatry
Luo X, Kranzler HR, Zuo L, Lappalainen J, Yang BZ, Gelernter J ADH4 gene variation is associated with alcohol dependence and drug 
dependence in European Americans: results from HWD tests and case-control association studies. Neuropsychopharmacology 31 
1085-95 2006
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Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde J, Fox L, Goldstein E, Reyes O, Kuperman S, Nurnberger Jr JI, 
Schuckit MA, Tischfield J, Hesselbrock V, Porjesz B, Edenberg H, Bierut LJ, Goate AM Genetic Variation in the CHRN5 Gene Affects 
mRNA Levels and is Associated with Risk for Alcohol Dependence Molecular Psychiatry
Luo X, Kranzler HR, Zuo L, Wang S, Schork NJ, Gelernter J Diplotype trend regression analysis of the ADH gene cluster and the 
ALDH2 gene: multiple significant associations with alcohol dependence. Am J Hum Genet 78 973-87 2006
Covault J, Tennen H, Armeli S, Conner TS, Herman AI, Cillessen AH, Kranzler HR Interactive effects of the serotonin transporter 
5-HTTLPR polymorphism and stressful life events on college student drinking and drug use. Biol Psychiatry 61 609-16 2007
Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence.Biol Psychiatry. 
2007 Sep 15;62(6):616-26. Epub 2007 May 23.
Petry NM Concurrent and predictive validity of the Addiction Severity Index in pathological gamblers. Am J Addict 16 272-82 2007
Barta WD, Kiene SM, Tennen H, Abu-Hasaballah KS, Ferrer R The idiographic study of inconsistent condom use behavior of persons 
living with HIV. AIDS Care 19 1058-64 2007
Barta WD, Portnoy DB, Kiene SM, Tennen H, Abu-Hasaballah KS, Ferrer R A Daily Process Investigation of Alcohol-involved Sexual 
Risk Behavior Among Economically Disadvantaged Problem Drinkers Living with HIV/AIDS. AIDS Behav 2007
Bauer LO The effects of HIV on P300 are moderated by familial risk for substance dependence: implications for a theory of brain 
reserve. Drug Alcohol Depend 94 92-100 2008
Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR. Population-specific effects of the Asn40Asp 
polymorphism at the mu-opioidreceptor gene (OPRM1) on HPA-axis activation.Pharmacogenet Genomics. 2007 Dec;17(12):1031-8.
Ittiwut C, Listman J, Mutirangura A, Malison R, Covault J, Kranzler HR, Sughondhabirom A, Thavichachart N, Gelernter J 
Interpopulation linkage disequilibrium patterns of GABRA2 and GABRG1 genes at the GABA cluster locus on human chromosome 4. 
Genomics 91 61-9 2008
Ittiwut C, Listman J, Mutirangura A, Malison R, Covault J, Kranzler HR, Sughondhabirom A, Thavichachart N, Gelernter J 
Interpopulation linkage disequilibrium patterns of GABRA2 and GABRG1 genes at the GABA cluster locus on human chromosome 4. 
Genomics 91 61-9 2008
Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR. Variation in GABRA2 predicts drinking behavior in project 
MATCH subjects.Alcohol Clin Exp Res. 2007 Nov;31(11):1780-7.
Agrawal A, Hinrichs AL, Dunn G, Bertelsen S, Dick DM, Saccone SF, Saccone NL, Grucza RA, Wang JC, Cloninger CR, Edenberg HJ, 
Foroud T, Hesselbrock V, Kramer J, Bucholz KK, Kuperman S, Nurnberger JI, Porjesz B, Schuckit MA, Goate AM, Bierut LJ Linkage 
scan for quantitative traits identifies new regions of interest for substance dependence in the Collaborative Study on the Genetics of 
Alcoholism (COGA) sample. Drug Alcohol Depend 93 12-20 2008
Hirunsatit R, IlomÃ¤ki R, Malison R, RÃ¤sÃ¤nen P, IlomÃ¤ki E, Kranzler HR,Kosten T, Sughondhabirom A, Thavichachart N, 
Tangwongchai S, Listman J,Mutirangura A, Gelernter J, Lappalainen J. Sequence variation and linkage disequilibrium in the GABA 
transporter-1 gene(SLC6A1) in five populations: implications for pharmacogenetic research.BMC Genet. 2007 Oct 17;8:71.
Luo X, Kranzler HR, Zuo L, Zhang H, Wang S, Gelernter J. ADH7 variation modulates extraversion and conscientiousness 
insubstance-dependent subjects.Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):179-86.
Hussain N, Krueger W, Covault J, Walsh S, Kranzler HR, Oncken C Effects of Prenatal Tobacco Exposure on Gene Expression 
Profiling in Umbilical Cord Tissue. Pediatr Res 2008
Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde JP, Fox L, Goldstein E, Reyes O, Saccone N, Saccone S, Xuei X, 
Bucholz K, Kuperman S, Nurnberger J, Rice JP, Schuckit M, Tischfield J, Hesselbrock V, Porjesz B, Edenberg HJ, Bierut LJ, Goate AM 
Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry 2008
Dick DM, Aliev F, Wang JC, Grucza RA, Schuckit M, Kuperman S, Kramer J, Hinrichs A, Bertelsen S, Budde JP, Hesselbrock V, Porjesz 
B, Edenberg HJ, Bierut LJ, Goate A Using dimensional models of externalizing psychopathology to aid in gene identification. Arch Gen 
Psychiatry 65 310-8 2008
Schuckit MA, Smith TL, Hesselbrock V, Bucholz KK, Bierut L, Edenberg H, Kramer J, Longacre E, Fukukura T, Kalmijn J, Danko GP, 
Trim R Clinical implications of tolerance to alcohol in nondependent young drinkers. Am J Drug Alcohol Abuse 34 133-49 2008
Kranzler HR, Covault J, Pierucci-Lagha A, Chan G, Douglas K, Arias AJ,Oncken C. Effects of aripiprazole on subjective and 
physiological responses to alcohol.Alcohol Clin Exp Res. 2008 Apr;32(4):573-9. Epub 2008 Feb 8.
Bauer LO A family history of psychopathology modifies the decrement in cognitive control among patients with HIV/AIDS. Brain 
Cogn 67 103-14 2008
Luo X, Zuo L, Kranzler H, Zhang H, Wang S, Gelernter J Multiple OPR genes influence personality traits in substance dependent and 
healthy subjects in two American populations. Am J Med Genet B Neuropsychiatr Genet 2008
Dick DM, Aliev F, Wang JC, Saccone S, Hinrichs A, Bertelsen S, Budde J, Saccone N, Foroud T, Nurnberger J, Xuei X, Conneally PM, 
Schuckit M, Almasy L, Crowe R, Kuperman S, Kramer J, Tischfield JA, Hesselbrock V, Edenberg HJ, Porjesz B, Rice JP, Bierut L, 
Goate A A Systematic single nucleotide polymorphism screen to fine-map alcohol dependence genes on chromosome 7 identifies 
association with a novel susceptibility gene ACN9. Biol Psychiatry 63 1047-53 2008
Edenberg HJ, Xuei X, Wetherill LF, Bierut L, Bucholz K, Dick DM, Hesselbrock V, Kuperman S, Porjesz B, Schuckit MA, Tischfield 
JA, Almasy LA, Nurnberger JI, Foroud T Association of NFKB1, which encodes a subunit of the transcription factor NF-kappaB, with 
6/27/2008   9:32:04AM 241
REPORT PD:  04/01/2007-03/31/20085M01RR006192-14 Final
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Bone, Endocrine and Aging
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Drs. Pamela Taxel, Joseph Lorenzo, Carol Pilbeam and Lawrence Raisz have been working to expand studies of 
estrogen and osteoclastogenesis that they have successfully completed using bone marrow cells to a much larger 
study population through the use of peripheral blood cells, which are much easier to obtain than are bone marrow 
cells.  The laboratory techniques for culturing osteoclasts from peripheral blood mononuclear cells (PBMCs) have 
been developed and this group is working on studies in which they will correlate PBMC and bone marrow 
osteoclastogenesis with bone turnover rates in older postmenopausal women who are estrogen deficient.
In addition, several clinical trials are underway to assess the effects of hormones on bone density or bone turnover 
in aging adults.  Dr. Anne Kenny, Associate Professor of Medicine and Associate Program Director (APD) of the 
GCRC, is completing a 2-year randomized trial of testosterone replacement in older men with osteoporosis and 
frailty, assessing the impact on bone mineral density, bone turnover, and physical performance/fall risk.  She is also 
completing a 6-month, randomized, controlled trial of dehydroepiandosterone and/or exercise in older 
postmenopausal women with osteopenia and frailty, which is also using bone turnover, physical function, and 
balance as outcome measures.  The results from these studies will be analyzed later in 2008. She has two ongoing 
trials that include: a) omega-3 fatty acid supplementation in older, frail postmenopausal women that assesses bone, 
physical performance, and immune function and b) an 18-month intervention trial of protein supplement to assess 
bone and muscle effects (collaboration with Drs Karl Insogna (Yale) and Jane Kerstetter (University of 
Connecticut-Storrs). Dr. Taxel is conducting clinical trials assessing the impact of alendronate and/or estrogen on 
bone density and markers of bone turnover in men with prostate cancer undergoing suppressive therapy with 
leutinizing hormone releasing hormone and women with breast cancer receiving anti-estrogen therapy.  Dr. Faryal 
Mirza has completed a pilot study on the effect of estrogen deprivation with aromatase inhibitors on blood pressure 
in post-menopausal women which shows that 24 ambulatory blood pressure increases with estrogen deficiency, 
largely due to a rise in nocturnal systolic pressure. This study was presented at the annual Meeting of the Endocrine 
Society in June 2008.
Publications:
Taxel P, Kaneko H, Lee SK, Aguila HL, Raisz LG, Lorenzo JA Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in 
bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int 19 193-9 2008
DENTAL
PAST SPID(s):SPID(s): 0364, 0453, 0487, 0497, 0591, 0592, 0611, 0628, 0638 0554
KEYWORDS: DENTAL, BEHAVIOR, BONE
Investigators from the UConn School of Dental Medicine are also active in the GCRC and often collaborate with 
research groups in the School of Medicine. Dr. Mark Litt, Professor of Oral Health and Diagnostic Sciences, 
continues to collaborate with Drs. Oncken and Kranzler in a study of topiramate for smoking cessation, which uses 
daily interactive voice response (IVR) technology (supported by the GCRC) to obtain multiple within-day 
assessments of mood and other variables that may enhance our understanding of the mechanism of effects on risk 
of smoking. He also conducts research on contingency management for drinking and cannabis abuse, and on 
short-term interventions for temporomandibular disorder (TMD). Interventions with TMD patients involve 
focused instruction in changing self-efficacy and decreasing "catastrophizing" with measurement outcomes including 
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real time" assessments of pain ratings, mood and coping (using computerized IVR) and changes in pro- and 
anti-inflammatory cytokines.
Dr. Robert Aseltine, Associate Professor of Oral Health and Diagnostic Sciences, has been active in screening, brief 
intervention, and referral efforts to reduce drinking among patients admitted to emergency departments in urban 
settings.  He has been supported by the GCRC particularly through the use of interactive voice response (IVR) 
technology to obtain data longitudinally from individuals participating in these studies.
Dr. Julie Wagner, Assistant Professor of Oral Health and Diagnostic Sciences, demonstrated a clear dose-response 
relationship between depressive episodes and endothelial function measured by brachial artery flow-mediated 
dilation.  These analyses control for a number of potential confounds, including current sub-clinical depressive 
episodes, ethnicity, hormone replacement therapy, and metabolic syndrome.  She has also reported that among 
diabetic women, those with a history of fully remitted depression have higher HbA1c, more diabetes symptoms, and 
worse emotional functioning than their never depressed counterparts even after controlling for numerous 
confounds.
Dr. Anna Dongari-Bagtzoglou, Associate Professor of Oral Health and Diagnostic Sciences is investigating potential 
systemic effects of oral inflammatory processes, including oral candidiasis in kidney and heart transplant recipients 
and how periodontal infections and depressive symptoms affect the systemic inflammatory status of hemodialysis 
and pre-dialysis chronic kindney disease patients.  Recent findings indicate that periodontal attachment loss 
emerged as a significant predictor of glomerular filtration rate (renal function deterioration in allograft transplant 
patients) after adjusting for cofounders.  In addition, kidney and heart transplant recipients are infected with 
Candida in higher percentages, have higher titers and higher frequency of asymtomatic colonization than healthy 
controls.
Dr. Martin Freilich, Professor of Reconstructive Sciences, has begun a major observational study of bone health, 
especially osteoporosis, as a risk factor in bone augmentation and dental implant placement.  This R01-funded 
project is expected to generate numerous hypotheses for further investigation.
Dr. Rajesh V. Lalla, Assistant Professor of Oral Health and Diagnostic Sciences, received a Mentored 
Patient-Oriented Research Career Development Award (K23) from the National Institute of Dental and 
Craniofacial Research (NIDCR).  As part of his K23 training, he is currently conducting two clinical research studies 
with GCRC support: (1) "Prevention of Recurrent Aphthous Stomatitis Using Vitamins," which will help to 
determine the role of vitamin deficiencies in the pathogenesis of Recurrent Aphthous Stomatitis, which is the most 
common ulcerative oral mucosal disease affecting humans.  Conduct of this study is progressing well, with 100 
subjects been enrolled to date. (2) "COX-2 Inhibition in Radiation-induced Oral Mucositis" will help elucidate the 
pathogenesis of this debilitating condition and may identify a new therapeutic approach.  Oral Mucositis is very 
painful and negatively impacts nutritional intake and quality of life.
Publications:
Academic ED SBIRT Research Collaborative The impact of screening, brief intervention, and referral for treatment on emergency 
department patients' alcohol use. Ann Emerg Med 50 699-710, 710.e1-6 2007
Bernstein E, Bernstein J, Feldman J, Fernandez W, Hagan M, Mitchell P, Safi C, Woolard R, Mello M, Baird J, Lee C, Bazargan-Hejazi 
S, Broderick K, Laperrier KA, Kellermann A, Wald MM, Taylor RE, Walton K, Grant-Ervin M, Rollinson D, Edwards D, Chan T, 
Davis D, Buchanan Marshall J, Aseltine R, James A, Schilling E, Abu-Hasaballah K, Baumann BM, Boudreaux ED, Maio RF, 
Cunningham RM, Murrell T, Doezema D, Anglin D, Eliassen A, Martin M, Pines J, Buchanan L, Turner J, D'Onofrio G, Degutis LC, 
Owens P An evidence based alcohol screening, brief intervention and referral to treatment (SBIRT) curriculum for emergency 
department (ED) providers improves skills and utilization. Subst Abus 28 79-92 2007
Litt MD, Kadden RM, Kabela-Cormier E, Petry NM Coping skills training and contingency management treatments for marijuana 
dependence: exploring mechanisms of behavior change. Addiction 103 638-48 2008
Herbst S, Pietrzak RH, Wagner J, White WB, Petry NM. Lifetime major depression is associated with coronary heart disease in 
olderadults: results from the National Epidemiologic Survey on Alcohol and RelatedConditions.Psychosom Med. 2007 
Nov;69(8):729-34. Epub 2007 Oct 17.
Wagner J, Tennen H, Mansoor G, Abbott G Endothelial dysfunction and history of recurrent depression in postmenopausal women 
with Type 2 diabetes: a case-control study. J Diabetes Complications 2008
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The project by Drs. Peter Krause, Professor of Pediatrics, and Stephen Wikel, Professor of Immunology, entitled 
"Health Burden of Deer-Associated Zoonoses," is primarily focused on the immunologic response to deer tick bites 
in humans, with the long-term goal of developing a vaccine to prevent tick-borne infection in people. Current 
work includes a histopathologic study of dermatologic reactions to deer tick bite in mice and humans and a review 
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of the clinical manifestations and immunopathogenesis of local and systemic reactions to deer tick bite in people. 
Recent findings on the histopathologic response to tick bite in mice and humans have been submitted for 
publication. They suggest that human cutaneous hypersensitivity to tick bite may alter pathogen transmission. 
Studies also focus on determining the underlying mechanisms of heightened resistance to tick-borne pathogen 
transmission and identification of tick saliva molecules responsible for inducing and eliciting protective responses. 
A secondary objective of the project is to investigate the health burden of human babesiosis.
Drs. Krause, Wikel, and colleagues are actively investigating the epidemiology and immunology of babesiosis in a 
highly endemic area. These studies include genetic determinants of resistance to human babesiosis in relation to 
aging.
Publications:
Hsieh YF, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ Serum reactivity against Borrelia burgdorferi OspA in patients with 
rheumatoid arthritis. Clin Vaccine Immunol 14 1437-41 2007
Feder HM, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP, Ad Hoc International Lyme Disease Group, Agger WA, 
Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, Draper T, 
McSweegan E, Halperin JJ, Klempner MS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP, Sood S, Weinstein A, 
Wong SJ, Zemel L A critical appraisal of "chronic Lyme disease". N Engl J Med 357 1422-30 2007
Krause PJ, Daily J, Telford SR, Vannier E, Lantos P, Spielman A Shared features in the pathobiology of babesiosis and malaria. Trends 
Parasitol 23 605-10 2007
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, 
Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, 
Coleman M, Girotto JE, Spielman A Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 46 370-6 
2008
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ADMINISTRATION
The General Clinical Research Center (GCRC) significantly restructured contract arrangements 
with Connecticut Children's Medical Center (CCMC).  This was done to support pediatrics 
investigators better while making the most cost-effective use of funds.  It entailed meetings 
over several months with research finance and administration managers at both entities, and 
pediatric investigators and study coordinators.  Contract arrangements now include an 
umbrella memorandum of understanding between the GCRC and CCMC, and individual 
contracts for specific GCRC Advisory Committee (GAC) approved, GCRC-sponsored  projects.  
Where clinical laboratory services are approved by GAC, additional associated contracts are 
established with Clinical Lab Partners (CLP), a wholly owned subsidiary of Hartford Hospital.  
As CCMC is on the same physical campus as Hartford Hospital, this allows investigators to 
use local resources, rather than working through the logistics of transporting samples for 
testing at UCHC with possible compromise of the samples.
The success of our prior year's data entry services "proof of concept" pilot encouraged fuller 
roll-out.  This support service was expanded from double-data entry to include study-specific 
consultations on data management strategies, case report form design and SPSS database 
development, and data quality procedures and documentation.  Staffing continues to be from 
the Informatics Core supervising student assistants.  Funding for this activity continues to 
come from the School of Medicine.
This is the third year of administering a grant-making program funded by the Donaghue 
Foundation.  The $110,000 annual program is focused on bio-nutrition research of a practical 
benefit to Connecticut residents. It is open to investigators at the University of Connecticut 
(UConn) Storrs and Farmington campuses as well as local area hospitals and 
community-based organizations, who hold UConn academic appointments.  Based on the 
Request for Proposal and scientific review processes, 5 projects were approved and funded.  
Three projects were approved the Institutional Review Board (IRB) and initiated during this 
reporting period.
Several deferred internal administrative projects were undertaken to organize and archive 
GCRC administrative and financial records.  This included reviewing records retention 
requirements, working with investigators on inventorying, returning and purging research 
records and files, and relabeling research records to be consistent with study informed 
consent forms.  We also began converting paper transaction detail to electronic images, and 
consolidating and documenting off-site storage holdings.
In preparation for the eventual transition from a GCRC to a clinical and translational science 
institute (CTSI), work began on developing fee-for-service operational centers for Core 
Laboratory, Informatics, Biostatistics, and Clinical (medical and dental) research services  
("service centers").  The Service Centers were established as financial entities with published 
fee schedules.  Services have been advertised to investigators on a limited basis and will be 
more broadly communicated in the future.  Manual cost-tracking and billing functions have 
been developed but are being refined as UConn plans for CTSI governance and technical 
infrastructure.
ADMINISTRATIVE NARRATIVES
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BIOSTATISTICIAN
The Biostatistics Core worked with established and potential GCRC investigators in the 
development and design of new research projects.  It also performed analysis of data from 
GCRC protocols and guided GCRC investigators and staff members in conducting their own 
data analyses.  Core staff included the director (Dr. Stephen Walsh, 30% annual effort) and a 
master's-level statistician (Ms. Deborah Dauser-Forrest, 25% annual effort).  Dr. Walsh 
provided consultations to GCRC investigators and also served as a member of the Executive 
Committee and of the GAC.  His role on the GAC was to review the statistical integrity of every 
new protocol submitted to the GCRC.  He also presented a lecture on sample size and power in 
the Clinical Research Coordinator's Course sponsored by the Clinical Core and a session on 
study design in the program for summer research scholars.  Ms. Dauser-Forrest conducted 
data analysis for GCRC projects under the direction of Dr. Walsh and monitored subject 
recruitment to GCRC protocols to document each protocol's progress in achieving recruitment 
objectives.
CORE LAB
During the April 2007 - March 2008 year 14 grant period, the Core Laboratory reported 41,050 
assay results, an increase of 34% compared with year 13.  These included 2,924 hormone or 
protein analyte results, 33,397 genotype results, 248 DNA sequence analysis of PCR 
amplicons, isolation of DNA or RNA from 3,444 samples, and analysis of 228 blood samples by 
FACS.
During this past year we used institutional funds to replace a -80°C freezer and purchase a 
384-well PCR thermocycler to support higher volumes of genotyping assays.  Migration of our 
sample data base to the FreezerWorks software system purchased in year 13 has been 
completed.  All archived as well as new samples are now included in our FreezerWorks sample 
storage and tracking database.  This has significantly improved our ability to manage 
thousands of archived samples for more efficient staff time use.
The largest growth area for assay requests is in the area of genetics and gene expression.  
When possible, to avoid duplication of equipment, we continue to make use of resources in 
other UCHC labs to support this need.  The Core Lab has developed partnerships in the past 
year with the Translational Genomics Core at UCHC to provide microarray services for GCRC 
protocols including gene expression and DNA methylation arrays.  One such project used 
gene expression array coupled with qPCR in the Core Lab to identify smoking-related changes 
in umbilical cord gene expression.  These results were recently accepted for publication in 
Pediatric Research.  Due to the increased requests for examination of epigenetic DNA 
methylation levels by investigators, Core Lab staff have recently been trained in use of a 
shared instrument (Biotage Pyrosequence Work Station) for quantitative CpG methylation 
assays to respond to investigator needs.  The instrumentation would also allow the Core Lab 
to provide quantitative single nucleotide polymorphism (SNP) allele frequency from pooled 
case-control studies.  Finally, we have partnered with two other laboratories to maintain and 
use a robotic liquid handling work station to more efficiently prepare 384-well sample plates for 
genotyping.
The Core Laboratory continues to be licensed by the State of Connecticut Department of 
Public Health with a CLIA certification.  In our most recent 2-year inspection in August 2006, 
no deficiencies were identified.
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INFORMATICS CORE
The Informatics Core continues to manage and develop a variety of platforms and functions 
that are key to the research and administrative functions of the GCRC.
Interactive Voice Response (IVR). The IVR system, which was acquired in the Fall of 2002, 
continues to grow.  The system, used to host and administer phone-based interviews, has 
been expanded to include 90 telephone lines that are made available to administer 
questionnaires.  Since inception, the system has supported 21 studies with 15 studies being 
active in Year 14.  In addition to supporting investigators at UConn, IVRS has hosted studies 
for investigators from other institutions, including Yale University, the University of 
Michigan, the University of Chicago, and Arizona State University.  In the past year, the 
system administered over 15,000 calls to 576 study participants, lasting approximately 1,000 
hours.  This effort has thereby substantially reduced study staff time required to collect data 
from participants and has eliminated the time required for double entry of these data 
(increasing the accuracy of the data as well).  The IVR System represents one of the great 
successes of the Informatics Core, but as such has required substantial time and effort from 
Dr. Abu-Hasaballah, Informatics Core Director, and his staff.
Data Entry. The GCRC has expanded the data entry service it offers investigators.  We have a 
well-trained team of three undergraduate students who enter data for studies approved to use 
this service, using the SPSS Data Builder/Workstation modules. Once the data have been 
double entered and verified, they are made available for checking and analysis, and 
subsequent export to other applications and formats.  Currently the data entry team has 11 
approved studies being developed or in active entry.  Several more studies are pending IRB 
approval to be initiated.
Fileshare. The GCRC has provided investigators disk space on a high capacity, high 
availability file server to store study data and other protocol related files.  Access to the 
fileshare is based on a role-based access permission schema that allows investigators and 
their staff to access their protocol folder and data only.  In addition, the file server contains 
group and personal folders for GCRC staff. 
Research Portal. The Informatics Core is leading efforts at UConn to develop a web-based 
research portal.  The first phase of the portal is the creation of a recruitment registry, where 
interested members of the public visit the portal, learn about clinical research, search for 
clinical studies, and self-enter their information in the registry.  Investigators will be able to 
search the registry for potential volunteers.  We anticipate this registry would serve as an 
invaluable tool in recruitment efforts in clinical research at UConn. The initial design and 
development work was completed, with roll-out of the new recruitment registry expected in 
July 2008.  The second phase of the portal is the development of a registry of investigators 
and their area of research interest/expertise. We hope this investigatory registry will serve as a 
matchmaking vehicle to help promote interdisciplinary research.
Administrative Software.  The Informatics Core provides technical support to several internal 
applications.  Our Integrated Information System (IIS), a web-based application developed 
in-house for electronic submission and management of GCRC resource utilization, staff task 
reporting, and study participant visit tracking, is in its third year of production.  A number of 
reports and features continue to be added to the system to enhance data quality and increase 
the system's utility in the ongoing operation of the GCRC as well as supporting NIH reporting.  
Additionally, several commercial software packages are used: Freezerworks  (to track 
specimens in storage freezers), Grant Manager (to manage GCRC finances), and Personnel 
Manager (to project and track payroll expenses and time and effort).
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NURSING
The Clinical Core continues to use a combination of clinical research nurses and clinical 
research assistants (CRAs) to meet current and anticipated research study needs.  Currently, 
the Clinical Core consists of 5 nurses who are research facilitators (RFs) (4 full-time, 1 
part-time), 1 clinical research nurse (CRN), 3 clinical research assistants (CRAs), and 2 dental 
assistants (DA, 1 part time and 1 full time), each of whom coordinates 4-9 clinical research 
protocols.  Of 8 staff eligible for certification by the Society of Clinical Research Associates 
(SoCRA), 7 are currently certified.
 
Personnel Changes - In the last year, changes in the Clinical Core included the departure of an 
APRN, Michelle Kelly and the hiring of a CRA, Paul Appleton.  Paul was hired to replace 
veteran CRA, Laura Glynn, who graduated from nursing school in May 2007 and took a 
position in an acute care facility.  Paul Appleton, MD, comes to the GCRC with little research 
experience, but with greater than 10  years experience in anatomical and clinical pathology.  He 
is funded by the GCRC grant at 50% time, coordinating 2 trials, and he receives 50% salary 
support on an NIDDK grant to one of the GCRC investigators.  Dr. Appleton is in the process 
of applying for medical credentialing though the University's Medical Staffing Office.  This will 
enable him to assist investigators by conducting physical examinations and minor medical 
procedures.
Thomas Kiely, RNC, Nurse Manager, continues to review currently active GCRC clinical 
studies to identify the clinical staff expertise and time and effort needed.  Over the last year the 
clinical research teams, generally consisting of an RF and a CRA, have proved to be a valuable 
combination that can share the coordinating efforts for several protocols.  In these situations, 
the RF (a registered nurse) usually serves as the team leader.  This approach has three 
strengths: it provides for staff cross-coverage, it helps to ensure that all aspects of a study are 
adequately addressed, and it allows staff to complement one another in terms of their skills, so 
that each team has the clinical skills necessary to complete all phases of the clinical contact. 
For the sixth year, the Clinical Core sponsored a two-day Clinical Research Coordinators 
Course.  The course provides participants with 12 Connecticut Nurses' Association  
continuing education units (CEUs), which are approved by the American Nurses Credentialing 
Center's Commission on Accreditation.  The course serves to introduce to CRAs, technicians, 
nurses, and others interested in study coordination the principles of clinical research.  It 
consists of didactic presentations and the identification of relevant resources by experienced 
research personnel.  The course goal is to promote a conceptual awareness of what 
distinguishes clinical research from clinical practice.  There are12 hours of sessions led by 
staff from the GCRC, Clinical Trials Unit, Human Subjects Protection Office, and the 
Investigational Pharmacy Service.   The course covers the research process, with an emphasis 
on the many facets of study coordination that are necessary for safe and effective clinical 
research.  Specific topics covered include subject recruitment, compliance, IRB review, 
industry-sponsored studies, the drug development process, adverse event reporting, 
informatics, and fiscal compliance.  Participant evaluations indicate that the course, which 
draws students from throughout the Greater Hartford region, is very highly valued.
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OTHER
Other - Dental
NCRR approved both interim and final relocation plans for the Dental Clinical Research Center 
(DCRC).  Architect drawings are nearly complete for the renovation of a new facility being 
accomplished with $300,000 in UConn support and $50,000 of industry in-kind gifts.  This 
clinic will be a state-of-the-art, attractive facility containing three operatories, a patient waiting 
room, a business office, dirty and clean preparation rooms and a small dental laboratory.  
Dental faculty were engaged in 8 active studies (approximately $3,000,000 in direct costs 
during this fiscal year) most of which will continue into fiscal year '08- '09.  In the past year the 
DCRC accommodated one new R01 and a GCRC-funded pilot project.  Staffing remained stable 
during the year with our 1.6 FTE dental assistants functioning well together in study 
coordination and research patient contact functions.
Other - Education and Training 
This was an important year for our activities in education and training.  Under the leadership 
of Dr. Anne Kenny, a Master of Science in Clinical and Translational Research (MSCTR) was 
developed, approved by the University and the Connecticut Board of Higher Education and 
accredited.  The first class began in September 2007 with 5 students and was the major formal 
didactic offering in clinical research.  The program graduated its first student in May 2008.
The GCRC course "Principles of Clinical Research" was quite successful during the past few 
years under the leadership of Dr. Howard Tennen.  The course was suspended during the past 
year, to make it possible to initiate the MSCTR.  The course is being transitioned to an on-line 
offering with plans for 22 video lectures, related readings and monthly face-to-face meetings 
with course leaders.  The transition to the on-line course is nearly complete and the new 
course will be offered beginning in the fall 2008.  Plans are for the course to be offered three 
times annually in the fall, spring, and summer sessions.
This was another stellar year for GCRC-sponsored seminars.  From September 2007 through 
June 2008, a total of 19 seminars were held, with an average attendance of 35 people at each 
seminar. 
We had eight summer fellows sponsored by the GCRC in the summer of 2007, two college 
students, five medical school students and a dental school student.  The summer student 
seminars on clinical research, which ran for eight weeks, were open to all summer students at 
the Health Center and were attended by 11 students each week.
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PROGRAM DIRECTION
Bruce Koeppen, MD, PhD, Dean of Academic Affairs and Principal Investigator. for the GCRC, 
continues to meet monthly with the GCRC Executive Committee.  These meetings provide a 
forum to plan for the GCRC and to coordinate GCRC activities with other research activities at 
UCHC.
Henry Kranzler, M.D., Professor of Psychiatry, continues in the role of Program Director.  Dr. 
Kranzler is an NIH-funded clinical investigator with a research program that focuses on the 
pharmacological treatment of alcohol dependence (one of the top 10 priority goals of the NIH) 
and on the genetics and pharmacogenetics of alcohol and drug dependence.
 
The leadership of the GCRC continues to include three Associate Program Directors.  Anne 
Kenny, M.D., Associate Professor of Medicine, Cheryl Oncken, M.D, M.PH., Associate 
Professor of Medicine, and Lawrence Raisz, M.D., Professor of Medicine, share this role.  This 
arrangement has served the GCRC very well, and we expect to continue it for the foreseeable 
future.  Institutional support is provided to augment M01 support for these individuals, so 
that the total support for the Associate Program Directors from the GCRC grant is 0.30 FTE.  
Lesley Mancini, M.B.A. continues as the Administrative Director and Thomas Kiely, R.N.C. is 
the Nurse Manager and Director of the Clinical Services Core.  The directors of the other cores 
remain unchanged.  Jonathan Covault, M.D, PhD. continues as Director of the Core 
Laboratory; Khamis Abu-Hasaballah, Ph.D. continues as Director of the Informatics Core;  J. 
Robert Kelly, D.D.S., Ph.D. continues as Director of the Dental Clinical Research Core; and 
Stephen Walsh, Sc.D. continues as Director of the Biostatistics Core.  Kathleen Salomone, 
A.P.R.N., M.S.W., continues in the role of Research Subject Advocate (RSA), a 70% position.  
Ms. Salomone's position also includes 30% time with the UCHC Human Subjects Protection 
Office (which oversees the functions of the UCHC Institutional Review Boards), supported by 
institutional funds.  Ms. Rene Bumbera has replaced Ms. Theresa George in assisting Ms. 
Salomone in discharging the duties of the RSA.
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RES SUBJECT ADVOCACY
Kathleen Salomone, MSW, APRN continued in her role as Research Subject Advocate (RSA) 
for the GCRC, reporting to Dr. Bruce Koeppen and working closely with Dr. Henry Kranzler 
(GCRC Program Director), Dr. Victor Hesselbrock (Chair of the GAC), GCRC staff and 
investigators and the Human Subjects Protection Office (HSPO) of UConn Health Center.
Ms. Salomone reviewed all protocols submitted to SAC requesting GCRC resources at the time 
of initial application and annual continuation . She ensured that every protocol reviewed by 
GAC had a Data and Safety Monitoring Plan/ Board commensurate with the study risk.  At the 
time of annual continuation she also reviewed protocol deviations and adverse events and 
communicated any concerns to GAC.
Ms. Salomone works closely with new investigators assisting them with the IRB application 
process and helping them develop Data and Safety Monitoring Plans appropriate to their 
protocol. She kept pertinent GCRC staff informed regarding lapses in IRB approval for GCRC 
supported protocols.
Ms. Salomone conducted random audits of protocols supported by GCRC resources.  The 
audits are a quality management tool providing a systematic internal process to oversee 
subject safety, ensure that monitoring is being conducted in accordance with the 
IRB-approved DSMP/B and increase compliance with federal, state and institutional 
requirements.  Within the GCRC, she participated in the GAC, Executive Committee and Project 
Review and Initiation Team (PRIT). Additionally, she attended quarterly meetings of the 
UConn Office of Audit, Compliance and Ethics and acts as a GCRC liaison with that office.
Ms. Salomone worked closely with the Human Subjects Protection Office (HSPO) in providing 
appropriate monitoring of GCRC supported studies, overseeing implementation of HSPO 
policy changes within the GCRC and for all GCRC supported protocols.  She represented 
GCRC concerns to the UCHC IRB chairs and to the IRB chairs at collaborating institutions.  
Ms. Salomone served on the HSPO Executive Council, which acts as an advisory board to the 
Director of the Human Subjects Protection Office on matters of policy, regulations and issues 
related to human subject protections.
Ms. Salomone also worked with research staff at the Connecticut Children's Medical Center 
(CCMC), a UCHC collaborating institution, and the UConn Storrs campus.  She assisted 
investigators with properly invoking the IRB Cooperative Agreements between UCHC and 
their respective institutions.
Finally, Ms. Salomone served on the Research Adverse Events Committee, a sub-committee of 
the HSPO.  This committee is charged with reviewing research-related serious adverse events 
(SAEs) with the mission of protection of research subjects.  She served as one of three primary 
reviewers of SAEs submitted via the mandatory UCHC on-line reporting system.
RESEARCH BIONUTRITION
Not applicable.
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